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 Abstract 
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Background 
Medication non-adherence has been described as a worldwide problem of striking 
magnitude yet a gold-standard adherence intervention remains elusive and current 
interventions elicit modest improvements at best.  Innovative, evidence-based 
approaches, grounded in theory and tailored to meet individual need are therefore 
required. 
Methods 
This thesis included four key elements: (1) a domiciliary medicines support service was 
evaluated to establish the effect of a pharmacy-led service targeting non-adherence of a 
primarily unintentional nature.  (2) A review of health psychology theory was undertaken to 
provide a theoretical basis for intervention design.  (3) A systematic review and meta-
analysis of ‘cognitive-based’ behaviour change techniques designed to improve 
medication adherence was undertaken to identify effective behaviour change techniques 
for intentional non-adherence.  (4) A theory-based questionnaire to identify barriers to 
medication adherence was developed as a precursor to an intervention to address patient 
identified barriers to medication adherence. 
Results 
Medication regimen simplification, provision of adherence support and implementation of 
care packages, appear to be effective in reducing patients’ medication related risk of harm 
and improving unintentional non-adherence in domiciliary support recipients.  However, 
these findings should be interpreted cautiously due to the ‘before-and-after’ study design.  
‘Cognitive-based’ interventions may be capable of eliciting improvements in adherence 
beyond those yielded with the behavioural and educational interventions that form the 
mainstay of current practice.  The theoretical domains framework has been used 
successfully to develop a questionnaire to identify medication adherence barriers.  
Conclusions 
At present, pharmacy-led adherence interventions tend to focus on resolving adherence 
difficulties of a practical nature.  Whilst these approaches are of some benefit to 
unintentional non-adherence, intentional non-adherence requires a different approach.  
‘Cognitive-based’ behaviour change techniques such as motivational interviewing could 
be delivered in routine pharmacy consultations to address adherence barriers identified 
using a theory-based questionnaire.  
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1.1 Chapter introduction 
This thesis seeks to explore the development and evaluation of interventions to 
improve medicine taking behaviours (adherence) by considering: 
• a home based medicines support service designed to improve how patients 
manage and use their medicines 
• a systematic review and meta-analysis of cognitive-based adherence interventions 
• the development of a novel questionnaire to identify barriers to medication 
adherence 
The aim of this chapter therefore is to describe: 
• the different terms used for medicines taking and related behaviours 
• the magnitude and potential causes of non-adherence 
• the complexity of the problem  
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1.2 Defining medication adherence 
At present, the most commonly used and widely accepted term to describe medication 
taking behaviours is adherence, but historically, the term compliance was preferred.  
Numerous definitions of compliance exist, and whilst there is no ‘official’ definition, all 
have the common theme of patient behaviour corresponding with the prescriber’s 
instruction.  Urquhart described drug regimen compliance as: 
‘the extent to which a patient’s actual history of drug administration corresponds with 
the prescribed regimen’1 
The more classically cited Haynes definition describes compliance as: 
‘the extent to which a person’s behaviour (taking medications, following a 
recommended diet or executing a lifestyle change) coincides with medical or 
healthcare advice’2 
Despite its widespread use, the term compliance has been criticised, predominantly 
because of the negative connotations evoked by the definition of the term as ‘the action 
or act of complying with a wish or demand’3.  This definition suggests a submissive, 
patriarchal relationship between the patient and their prescriber, whereby a patient 
must passively follow their doctors orders without any form of therapeutic alliance4.  
Furthermore, non-compliance can wrongly be interpreted as patient incompetence, or 
as a deliberate, self-sabotaging behaviour5. 
The term ‘adherence’ emerged in an attempt to resolve the negative connotations 
associated with the term compliance.  The Oxford English Dictionary defines the term 
adherence as a ‘steadfast commitment to a belief or practice’6.  With regard to 
medication taking, the term ‘adherence’ has been adopted to imply some form of 
negotiation between the patient and prescriber and the patient’s willingness to 
participate in the agreed regimen5.  The 2003 World Health Organisation (WHO) 
definition of adherence reflects the importance of implied agreement between the 
patient and healthcare provider7.  The WHO definition of adherence will be used 
throughout this thesis: 
 ‘the extent to which a person’s behaviour – taking medication, following a diet and/or 
executing lifestyle changes, corresponds with agreed recommendations from a 
healthcare provider’ 7.   
Despite the WHO definition, both compliance and adherence remain imperfect terms 
and are uninformative descriptions of medication taking behaviours4.  Adherence is 
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widely accepted as a less judgemental term than compliance, yet it still holds implicit 
assumptions of practitioner power and their better judgement.  Subsequently, in 1997, 
the Royal pharmaceutical Society of Great Britain (RPSGB) recommended a new term 
‘concordance’8, to describe the relationship between prescriber and patient.  When a 
prescriber and patient work together to reach a shared agreement and consider the 
beliefs and preferences of both parties, even when these may be opposing views, a 
concordant discussion has been achieved5.  Concordance is defined by the RPSGB 
as: 
‘an agreement between the patient and healthcare professional, reached after 
negotiation that respects the beliefs and wishes of the patient in determining whether, 
when and how their medicine is taken, and (in which) the primacy of the patient’s 
decision (is recognised)’ 8. 
The emergence of concordance in healthcare has been the subject of much debate 
and is still deemed to be a relatively novel concept.  Whilst research has emerged in 
examining the feasibility of delivering a concordant consultation and the implications of 
this, it is imperative to recognise that adherence and concordance are not synonymous 
terms.  Incorporation of concordance may be a fundamental aspect of improving 
medication adherence and the concept fits well with government objectives towards 
greater patient autonomy and choice.  However, the degree to which patients want to 
be involved in decision making about their care is variable and thus, not all patients are 
suitable or ready for shared decision making in their healthcare, preferring instead to 
be led by their doctor9.  
A fourth term, ‘non-persistence’ is also used in research, referring to patients who start 
taking their medicines but then stop, without advice to do so from their healthcare 
provider.  Cramer et al. suggest a definition for persistence as: 
“the duration of time from initiation to discontinuation of therapy”10 
The term non-persistence is commonly used for considering long term therapies such 
as tamoxifen, used in the treatment of breast cancer, where drop-out of the advised 
five year treatment course is common11. 
The extent to which medication taking behaviours can be deemed as ‘adherent’ or 
‘non-adherent’ is variable and dependent upon many factors such as the treatment 
type, disease state and adherence measurement.  Definitions of adherence in terms of 
percentages of patients forgetting their medicines or percentage of doses taken 
correctly are known as process-orientated outcomes; relating to the process of 
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adhering to prescribed medication regimens.  Alternatively, outcome-orientated 
definitions emphasise the end results of the medication taking behaviour such as 
decrease in blood pressure or frequency of infection resolution.  Whilst potentially 
useful in specific disease states, the generalisability of outcome-orientated definitions 
limits their widespread use.  Process orientated outcomes such as the percentage of 
doses taken correctly, are therefore the most frequent means to define a patients 
adherence, although for ease, researchers will often dichotomise this inherently 
continuous variable into ‘adherers’ or ‘non-adherers’.  Dichotomisation is an attractive 
option for convenience and simplicity, but details of adherence patterns and a depth of 
data is lost through this approach12.   
Consensus as to a gold-standard value for ‘good’ adherence has not been reached, 
though conventionally, adequate adherence has been considered as 80% of doses 
taken as prescribed2, 13.  The ‘cut-off point’ for ‘good’ and ‘poor’ adherence is however 
variable according to the medication taken and disease state.  In conditions such as 
HIV, near perfect adherence is necessary to ensure therapeutic goals are obtained.  
Chesney reports that at least 95% adherence to Highly Active Antiretroviral Therapy 
(HAART) is necessary for successful long term treatment of HIV and AIDS14.  Horne 
and colleagues suggest a more pragmatic definition of non-adherence, which supports 
the concept of clinically meaningful non-adherence as: 
‘the point below which desired preventative or therapeutic result is unlikely to be 
achieved’12 . 
Clear definitions of adherence are imperative to good research and an important 
consideration when comparing the outcomes of adherence studies.  
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1.3 The relevance and prevalence of medication non-adherence; why does it 
matter? 
Assuming a correct diagnosis and choice of treatment has been made, adherence to 
an agreed agenda for medication taking is the key link to successful outcomes in 
medical care.  Consequently, patient behaviours which lead to deviations from the 
prescribers intentions will inevitably lead to suboptimal treatment outcomes7, 12, 15.  The 
World Health Organisation (WHO), suggest that the magnitude and gravity of non-
adherence is such that greater worldwide health benefit could be gained through 
improving adherence to current medications than developing novel treatments7. 
1.3.1   The prevalence of non-adherence 
Whilst the potential implications of non-adherence are severe , it is the prevalence of 
non-adherence that causes greatest concern amongst healthcare professionals and 
policy makers15.  The cumulative findings of reviews and seminal reports have 
consistently concluded that between 30 and 50% of patients prescribed medication for 
chronic illnesses, do not take their medications as prescribed12, 16, 17, with other studies 
suggesting a third or more of patients comply poorly with prescribed drug regimens, 
irrespective of the disease state or prognosis1.   
Whilst the seminal World Health Organisation (WHO) report (2003) suggested that 
50% of patients with chronic diseases who live in the developed world are non-
adherent, it rightfully identified that in the developing world, non-adherence may 
threaten the management of chronic illness to an even greater extent, when coupled 
with poorer access to healthcare, diagnostics and medicines7.  Non-adherence was 
subsequently described by the WHO as “a worldwide problem of striking magnitude” 
and has been identified as a priority for healthcare researchers and policy makers7. 
1.3.2   The clinical consequences of non-adherence 
The clinical consequences of non-adherence will largely depend upon the medicines 
concerned and the disease state in question, but patient related factors including co-
morbidities can also be influential.  As such, non-adherence in one patient could have 
far greater clinical implications than in others, and the impact across different chronic 
illnesses can range from minimal to highly significant18.  
The dosage and timing of the medicine administered will influence both the therapeutic 
and adverse effects.  Taking a medicine at the wrong time of day may substantially 
reduce efficacy, for example, a 5mg dose of simvastatin has been shown to reduce 
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plasma cholesterol levels by 21% when taken in the evening, compared to 14% when 
taken in the morning, a difference that is significantly different (p = <0.05)19.  Whilst this 
study shows an interesting perspective, the limitation of using a 5mg dose, which is 
seldom used in routine practice, should be borne in mind.  Experience of side effects 
may also be increased by taking a medication at the wrong time of the day, for 
example, the diuretic effects of bendroflumethiazide, commonly prescribed for 
hypertension, will likely disrupt sleep if taken in the evening.  
Non-adherence through taking inadequate or excessive doses will also have clinical 
implications.  Taking too little medication may lead to treatment failure, for example 
inadequate adherence to immunosuppressive medications post organ transplant is 
likely to result in transplant rejection.  Conversely, taking too much medication, for 
example taking double doses, can cause serious adverse events, such as toxicity.  In 
addition, deviations in adherence by taking too much medication, or continuing with a 
therapy for longer than intended, can lead to problems with addiction, such as with 
opioid and benzodiazepines dependence.  
Intermittent adherence, where patients stop and start their medications may also have 
profound clinical consequences, especially for medicines with a ‘narrow therapeutic 
window’, such as lithium used in the treatment of bipolar affective disorder.  For these 
medicines, therapeutic and toxic blood plasma levels are very close to each other, 
therefore small deviations from complete adherence may have notable clinical effects.  
Sporadic adherence may also be hazardous in patients taking medications with 
substantial withdrawal or rebound effects. 
Undetected non-adherence may lead to unnecessary additional investigations and 
dose adjustments13 as the treatment may appear to be ineffective, incurring costs to 
both the patient and healthcare provider.  In extreme cases, for example insulin 
dependent diabetes, non-adherence can result in life threatening hypo or 
hyperglycaemia.  Increased morbidity and mortality have been observed in non-
adherent patients suffering with hypertension, diabetes and HIV18.  In 2006, Simpson et 
al. reported comprehensive meta-analytical evidence from 21 observational studies, to 
support the link between poor adherence and mortality; a mortality odds ratio (95% CI) 
of 0.56 (0.50, 0.63) was reported for ‘good’ adherence compared to ‘poor’ adherence20.  
The authors also report an association between good adherence to a placebo medicine 
and reduced mortality and so argue that this supports the notion of the “healthy 
adherer” effect, whereby adherence to a therapy may be a surrogate for overall healthy 
behaviours20.  Whilst this study is well regarded and has been heavily cited, the 
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potential limitations of drawing data from observational studies rather than RCTs 
should not be overlooked.  
Whilst the clinical consequences of non-adherence are important, it is worth noting that 
some medicines are more ‘forgiving’ than those with a narrow therapeutic window15.  
However, even when the clinical consequences of non-adherence to medicines may 
not be of notable concern, the financial implications of wasted medicines may still be 
apparent. 
1.3.3   The economic consequences of non-adherence 
The cost of wasted medicines; prescribed, dispensed and never used, poses a 
financial cost to the UK and worldwide healthcare systems.  A recent report 
commissioned by the Department of Health (DH) estimated the cost of wasted 
medicines in community and primary care in England to be in the region of £300 million 
annually21.  Although non-adherence may only account for a small proportion of this 
medicines wastage, the magnitude of medicines waste in the UK means that notable 
costs will still be incurred.  As with all interventions utilising NHS resources, strategies 
to reduce medicines waste must demonstrate cost effectiveness.  
Whilst medicines waste incurs some financial costs, it is the clinical consequences of 
non-adherence that contribute most heavily to the associated financial burden.  
Worsening health, failed therapy, unnecessary additional investigations or treatments, 
lost working days, increased hospital admissions or loss of treatment gain all contribute 
to notable financial costs.  Urquhart highlights that omission of just three consecutive 
doses of furosemide, when used to treat congestive heart failure (CHF), can result in 
fluid retention sufficient to precipitate acute fluid overload, with pulmonary oedema and 
associated breathing difficulties15.  The resulting hospital admission would have serious 
financial implications; O’Connell and Bristow report a cost of $10,400 US dollars for 
each CHF related hospital admission22 and more recently, Stewart et al. estimated the 
total direct cost of heart failure to the NHS to be £905 million, of which, hospitalisation 
was the predominant cost 23.   Although it is impossible to determine what proportion of 
CHF admissions result from poor medication adherence, given the documented 
adherence rates for other chronic conditions 12, 16, 17, and the need for good adherence 
to this medication, it is likely to be a notable number.  Whilst there is little evidence to 
support an association between disease severity and adherence, (as discussed in 
section 1.5.1) it is worth noting that the economic consequences of non-adherence 
may be greater for some medical conditions compared to others.  
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1.4 The nature of non-adherence 
Non-adherence may exist through errors of omission or addition or by taking medicines 
at the wrong time.  Incorrect administration of a medicine, for example poor inhaler 
technique, also constitutes non-adherence, as the patient will not be taking their 
medicines as agreed with their GP.  The nature of non-adherence and the reasoning 
behind these deviations is variable.  A patient who consciously chooses to omit doses 
of their medication is non-adherent for very different reasons to, for example, a patient 
with arthritis and insufficient manual dexterity to administer their medicines correctly.  
Adherence to medication is a complex, multi-stage process, and there are many points 
at which a patient may deviate from the initial agreement made with their GP.  For a 
patient to adhere to their prescribed medicine, pivotal processes must occur at key 
stages, the patient must therefore: 
• Collect their medication from their GP or pharmacy 
• Fully understand how and when to take it 
• Be motivated to take the medication and have the intention to follow the directions 
• Have the cognitive capacity to be able to remember to take the correct medication 
at the right time 
• Have sufficient physical dexterity to be able to manipulate the medicine packaging 
and administer the medicine 
Deviations in adherent behaviours at these key stages can therefore be classified in a 
number of ways.  Non-adherence may either be primary or secondary in nature and 
intentional or unintentional.  
 
1.4.1   Primary non-adherence 
Primary non-adherence occurs when a patient fails to redeem their prescription.  This 
may be an intentional decision or an unintentional memory failure whereby the patient 
simply forgets.  The majority of adherence studies focus on the use of medicines in the 
patient’s possession, therefore primary non-adherence is often overlooked.  This form 
of non-adherence is also termed ‘non fulfilment adherence’24. 
At present, UK based data on primary non-adherence relies heavily upon self-report 
measures and the numbers of prescriptions returned to the Prescription Pricing 
Authority (PPA) for verification of payment.  Both measures are flawed due to potential 
for inaccurate data.  However, the introduction of electronic prescribing has facilitated 
research to better identify the magnitude of primary non-adherence.  
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Early studies of primary non-adherence reported non-redemption rates of between 5 
and 20%25-28, however the methods used to provide the upper estimate of 20% have 
been criticised elsewhere for creating an overestimate26.  More recent studies have 
shown similar variations in estimates, with rates ranging from 2.4% to 21.6%29-31, 
though for the upper rate, a delay in filling a prescription was considered as primary 
non-adherence29.  The most recent and comprehensive data are provided by analysis 
of 195,930 electronic prescriptions; primary non-adherence was reported at a rate of 
22%32.  It is therefore reasonable to conclude that primary non-adherence exists in 
variable magnitudes, with numerous factors such as patient age 25, 29, 30, 32, 33, gender 25, 
30, 33
 and socio-economic status 29, 33 influencing the effect. 
In 2000, Matsui et al. studied primary non-adherence in parents of children who had 
attended a paediatric emergency department (n= 1222 children) and reported that 
7.3% of parents had failed to redeem the prescription issued to their child.  Reasons for 
this included believing the medicine was unnecessary, financial constraints and not 
having enough time31.   Similarly, Ekedahl and Mansson, report that 61% of patients 
who failed to collect a prescription transmitted from their GP to their pharmacy, did so 
because they felt it was not necessary30.  
Worthy of note when considering rates of primary non-adherence, is the increasing 
availability of Over the Counter (OTC) medicines, which can often be purchased for 
less than a prescription charge.   Primary non-adherence may therefore be a misnomer 
if a patient purchased an OTC equivalent instead of paying a prescription charge.  
Other factors which may lead to erroneous classifications of primary non-adherence or 
skew data collected on this matter include: 
• Prescriptions for emergency use or delayed antibiotics which may not be needed, 
non-redemption therefore reflects adherence by following the prescribers guidance, 
yet according to electronic data, may appear as primary non-adherence 
• Handwritten prescriptions are not recorded with electronic data and may therefore 
skew studies reliant on this measure  
1.4.2  Secondary non-adherence 
Secondary non-adherence occurs when a prescription is redeemed and the correct 
medicine is possessed but not taken as prescribed.  Contrary to primary non-
adherence, secondary non-adherence has been studied extensively, with a wealth of 
studies investigating both the magnitude and nature of secondary non-adherence.  
Monitoring of adherence to medication regimens dates back to as early as the time of 
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Hippocrates2, but widespread research interest in the field didn’t emerge until the 
1970’s34.  Reviews to estimate the extent of non-adherence generally tend to conclude 
that about 50% of patients do not take their medicines as intended, although this 
estimate can vary.  Such disparity reflects the complex nature of medication adherence 
but also the complexities of both defining and measuring it.  Patient populations and 
disease areas studied can also account for the variations in the extent of non-
adherence. 
Similar to primary non-adherence, secondary non-adherence may be intentional, when 
patients willingly choose not to use their medications as prescribed or unintentional 
when physical or cognitive barriers prevent adherence.  Irrespective of intentional or 
unintentional behaviours, most deviations in medicine taking occur as omissions of 
doses or delays in timing of doses rather than additional doses35, 36. 
1.4.3   Intentional non-adherence 
Intentional non-adherence occurs when a patient makes a conscious decision not to 
follow the agreed recommendations of their healthcare provider.  In 2005, Pound et al. 
reported that approximately half of all non-adherence is intentional 37 and that this can 
be both primary and secondary in nature. 
Factors precipitating primary intentional non-adherence include health beliefs such as 
feeling the medicines are not needed30, 31, lack of trust in the prescriber29, 32, lack of 
satisfaction with the healthcare received29, 31 and  financial constraints25, 26, 31, 33, 
although all of these reasons could also contribute to secondary non-adherence.  
Consistent evidence suggests that patient’s health beliefs and illness perceptions may 
be amongst the strongest predictors38, 39 of intentional non-adherence.  Illness 
perceptions and health beliefs are likely to inform a conscious, intentional decision to 
use prescribed medicines in a way that differs from the prescriber’s intentions, if they 
are used at all.  Psychological theories of health behaviours are useful in 
understanding the complex interaction between health beliefs, illness perceptions and 
non-adherent behaviours and will be discussed in depth in chapter three. 
Intentional non-adherence has also been displayed through strategic use of medicines 
to fit in with lifestyles.  Documented examples of such behaviour include skipping 
doses of antihypertensive medicines before drinking alcohol due to fear of 
interactions40 and moderating the dose of a Proton Pump Inhibitor (PPI) to manage 
acid reflux symptoms, after a ‘triggering’ meal such as heavily spiced foods41. 
 
 Chapter One                                                                                  Medication Adherence 
 
12 
1.4.4   Unintentional non-adherence 
Intentional non-adherence is an active process based around informed decision 
making.  Conversely, unintentional non-adherence is a passive process where specific 
barriers prohibit adherence in patients who would otherwise take their medicines. 
For primary non-adherence, two unintentional behaviours are likely dominant; 
difficulties in getting to a pharmacy29 and being unaware that an electronic prescription 
has been transmitted to a pharmacy30.  Cognitive deficits may also be implicated in 
primary unintentional non-adherence, whereby a patient simply forgets to redeem their 
prescription or loses it.  Language barriers, poor literacy or cognitive deficits may 
introduce another source of primary unintentional non-adherence, if a patient fails to 
understand the process of taking a prescription to a pharmacy for dispensing.  Whilst 
financial constraints are widely regarded as a source of intentional non-adherence 
(choosing not to spend the money on a prescription and spending it elsewhere 
instead), it could be argued that in cases of severe deprivation, insufficient funds could 
be classified as unintentional non-adherence.  The impact of financial constraints on 
medication adherence will vary according to the differing healthcare systems across 
different countries, as discussed in section 1.5.2. 
Secondary unintentional non-adherence, can be broadly categorised into two domains; 
physical and cognitive barriers to adherence.  Physical barriers to adherence describe 
functional limitations that prevent medication adherence and include swallowing 
difficulties and dexterity or visual problems.  Cognitive barriers to adherence concern 
impairments of memory or understanding, leading to non-adherence through 
‘forgetting’ or not understanding instructions.  
1.4.5   Overlap in the classification of non-adherence 
The complex multi-faceted nature of medication taking behaviours means that in most 
instances, non-adherence will have elements of both intentional and unintentional 
behaviours.  Despite the nature of non-adherence, the outcome is still the same; the 
patient fails to use their medicines as prescribed.  However, understanding the nature 
of non-adherent behaviours is imperative for formulating interventions to improve 
adherence.  Consider for example the case of a patient who reports non-adherence 
due to forgetting to take their medicines.  If the doses are forgotten due to genuine 
lapses in memory and the patient wishes to adhere but is struggling due to their 
memory deficits, an intervention such as reminder charts or alarms may be beneficial.  
Conversely, if the medicine is forgotten because the patient views it as unimportant and 
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does therefore not prioritise it in their mind, the same intervention is unlikely to yield 
benefit.   
  
 Chapter One                                                                                  Medication Adherence 
 
14 
1.5   Factors influencing medication adherence 
Reviews have identified more than 200 variables associated with medication non-
adherence34, 42 which can be broadly classified into three groups: 
• Treatment related factors such as experience of side effects or duration of therapy 
• Patient related factors such as motivation and health beliefs 
• Prescriber related factors such as the patients trust in their prescriber and their 
satisfaction with the information given to them 
Overlap between these classifications is evident, for example, oral chemotherapy is 
prescribed for life-threatening disease states but is associated with many side effects 
which may affect adherence (treatment related factors).  Consequently, patients may 
need more information about the treatment (patient related factor) which may not be 
provided (prescriber related factor) which could in turn influence patients health beliefs 
(patient related factor).  The existence of causal relationships must therefore not be 
overlooked.  
1.5.1   Treatment related factors 
The type of medicine prescribed, condition treated, duration of therapy, dosing regimen 
complexity and experience of side effects have all been identified as predictors of non-
adherence in varying magnitudes.  According to the WHO, experience of side effects 
and high dosage frequencies are the most prominent regimen related factors which 
impeded good medication adherence7.  
1.5.1.1  Disease area and type of medication 
In 2004, DiMatteo and Robin reported that adherence rates were highest in patients 
with HIV, arthritis, gasterointestinal disorders and cancer, and lowest in pulmonary 
disease, diabetes and sleep disorders43.  Similar results have been reported elsewhere 
by Fischer et al. who report that primary non-adherence to newly prescribed medicines 
was most common for hypertension, hyperlipideamia and diabetes32.  Ekedahl and 
Mansson also report that primary non-adherence rates vary according to the type of 
medication prescribed, with medicines acting on the musculoskeletal system having 
higher than expected non-redemption rates and antibiotics lower30.  Numerous inter-
relating factors are likely to account for these findings, but the patient’s perceived 
necessity of the medications and the weighted balance of perceived risks and benefits 
are likely notable. 
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The 2003 WHO report on medication adherence identified that the illness related 
demands of some conditions can strongly influence adherence, highlighting symptom 
severity, rate of progression, disease severity and availability of effective treatments as 
key determinants7.  These factors are likely to inform patient health beliefs and 
perceived medication necessity and will therefore either encourage or abate intentional 
non-adherence.  
Whilst the type of medication and condition treated can moderate adherence, the 
medicine dosage form can also be influential44.  A study of barriers to HIV medication 
adherence identified that the taste, smell, size and shape of medicines could impede 
adherence45.  The use of modified release formulations has been demonstrated to 
significantly improve adherence and reduce costs46 through reduced dosage regimen 
complexity.  Alternative dosage forms such as liquids, patches or suppositories can 
also aid adherence when physical barriers to adherence such as swallowing difficulties 
make more conventional dosage forms inappropriate.  Conversely, patient acceptability 
and preferences may mean that the use of less conventional dosage forms are of 
detriment to medication adherence, though the definitions of conventional and 
unconventional dosage forms may be geographically and culturally variable.  A recent 
questionnaire-based study (n= 485) which aimed to identify risk factors for non-
adherence to medication in inflammatory bowel disease reported that oral therapy was 
associated with a significantly better adherence than rectal therapy (60% vs. 32%, 
P = 0.001)47.  
The presentation of a medicine, in terms of its appearance and packaging can also 
influence adherence.  Solid dosage forms (tablets and capsules) are most frequently 
prescribed and will most commonly be packaged in either bottles with child resistant 
closures or blister packaging.  These apparently simple devices can pose notable 
barriers to adherence for certain patients, who have difficulty retrieving their medicines 
from their packaging.  Beckman et al. reported that 10% of patients were unable to 
access medication from a blister pack48 and  similar findings were reported by Nikolaus 
et al. with 10.1% of patients admitted to a geriatric ward being unable to open one of 
more medication container presented to them49.  Both studies report that an inability to 
manipulate medication packaging is directly related to visual, cognitive or physical 
deficits in the patient48, 49, therefore any patient, of any age may be affected if these 
difficulties prevail.   
Whilst difficulties with tablet packaging have reportedly caused problems for 
approximately 10% of patients, breaking scored tablets in half was found to be a 
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problem for 78.3% of older patients admitted to a geriatric ward.  The same study also 
reported that 41.4% of patients were unable to perform one or more tasks necessary to 
gain access to their own medications50.  Dexterity problems which prohibit access to 
medicines and administration problems are therefore notable barriers to adherence.  
1.5.1.2   Duration of therapy 
Patient persistence with therapy is known to decline dramatically after the first six 
months of therapy51, 52; adherence to medication for the treatment of chronic conditions 
is therefore likely to be poorer than that for acute conditions.  Benner et al. report that 
only 25% of older patients prescribed a statin to lower cholesterol maintained adequate 
adherence (defined as 80% of days covered) after five years52.  DiMatteo reports that 
non-persistence with a prescribed medication is most likely for asymptomatic 
conditions, prophylactic treatments or when the consequences of stopping treatment 
are delayed43.  This observation has important implications for long term adherence to 
medications such as anti-hypertensives and lipid regulating drugs, which are widely 
prescribed and constitute a notable proportion of UK prescriptions.  
1.5.1.3  Dosing regimen complexity 
The complexity of a medication regimen is defined by the number of medicines taken 
and the frequency of doses.  Additional requirements such as taking the medicines at 
specific times and in a specific way (e.g. with or without food) may augment the 
complexity.  Medication adherence has been shown to decline as the medication 
regimen complexity and number of different medicines increases18.  In part, this 
observation is related to the increased cognitive burden associated with more complex 
regimens.  However, accommodation of complex regimens requires greater lifestyle 
changes on the patient’s part and may be inconvenient, intentional elements of non-
adherence may therefore prevail in patients with low motivation, lack of support or 
disordered lifestyles.  Horne and colleague suggest that it is not the complexity of the 
regimen per se that influences adherence, but more how this fits with the patients 
routines, lifestyles and expectations12, making clear the potential for both intentional 
and unintentional behavioural influences.  
Evidence synthesis suggests that reducing the number of daily doses in a medication 
regimen should improve adherence42, 51, though individual studies have shown variation 
in the point at which further dose reduction continues to have an effect.  Claxton et al. 
report significantly greater adherence in patients taking once daily regimens compared 
to thrice daily or more frequently, though no differences were observed been once and 
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twice daily dosing regimens53.  This systematic review included 76 different studies and 
was restricted to studies that used electronic monitoring, the gold-standard, as the 
adherence measure.  The size and robust inclusion criteria therefore increase the 
confidence with which these findings can be regarded. Richter et al. report similar 
findings, though in this study, single doses were found to be preferable to multiple 
doses54.  However, the number of studies included in this review is not directly reported 
and the search strategy is comparatively less robust.  Further studies have also shown 
that simplifying a medication regimen can improve adherence with Fish and Lung 
reporting that once or twice daily dosing led to better adherence compared to regimens 
where doses were taken three or four times per day55.   
1.5.1.4  Experience of side effects 
Experience of side effects from a medicine is widely regarded as a predictor for non-
adherence56.  A US based cohort study (n=303) of tamoxifen discontinuation in women 
with breast cancer revealed that experience of side-effects increased the likelihood of 
tamoxifen discontinuation four-fold57.  However, tamoxifen therapy is indicated for five 
years following breast cancer as a prophylactic therapy, therefore the long therapy 
duration and prophylactic nature may be contributory factors to the non-adherence, in 
addition to the experience of side effects.  Experience of side effects has been 
significantly associated with non-adherence in HIV58 and interfered with medication 
adherence in diabetes, as adherence is significantly lower for medicines deemed 
problematic in causing side effects, compared to those which are not59.  Medication 
side effects are also a notable problem for adherence to medicines used in 
psychiatry60, especially antipsychotics where side effects are common and can have a 
durable negative impact on adherence61. 
Concerns about medicine side effects can also be influential in non-adherence; 
Gallagher et al. report a questionnaire based study where over two thirds of migraine 
sufferers (n = 2444) had delayed or avoided taking their prescription medicines due to 
concerns about adverse effects62.  General concerns about medicines will be 
discussed in greater depth in section 1.5.2.3. 
Whilst experience of side effects is a reliable predictor of non-adherence, inter-relating 
factors such as the patient’s coping skills, motivation and perceived necessity for the 
medicine will likely influence whether experience of side effects precipitates non-
adherence.  For example, experience of side effects to an antihypertensive medicine 
where the patient perhaps doubts the need for treatment may be more likely to cause 
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non-adherence than experience of side effects to life saving chemotherapy where the 
patient’s perceived necessity is likely higher.  
1.5.2   Patient related factors 
Medication taking is a patient determined event therefore many predictors of non-
adherence can be classed as patient related factors.  Illness perceptions and health 
beliefs have been identified as powerful predictors of adherence38, 39 whereas socio-
demographic factors are much weaker predictors34, 39.  Patient doubts as to the 
necessity of their medication and concerns about adverse effects have been shown to 
correlate with poor adherence across a wide range of diseases including asthma, 
diabetes, cancer and coronary heart disease38, hypertension63, renal disease64, 
depression65,  HIV/AIDS66 and haemophilia67.  Other patient related factors include their 
cognitive and physical capacity to adhere to medication regimens.  
1.5.2.1   Cognitive abilities 
Medicines’ taking requires an understanding and correct interpretation of directions 
plus the ability to remember to execute the behaviour; a patient’s cognitive capacity to 
undertake these processes will therefore influence adherence.  Forgetfulness is the 
most commonly cited reason for non-adherence4, even in patients without formally 
diagnosed memory problems.   
Notable research into non-adherence due to cognitive incapacity has been undertaken 
in the field of HIV medication adherence as low literacy levels and cognitive impairment 
are widely accepted as strong predictors of non-adherence in this domain68.  Becker et 
al. report that declining neuropsychological function in HIV patients correlates with 
worsening medication adherence69.  The extent of worsened adherence with cognitive 
impairment was elucidated by Hinkin et al. who report that neurocognitive impairment 
confers a 2.5 times greater risk of poor adherence70. 
Whilst the manifestation of cognitive impairments is frequently attributable to the HIV 
infection, the effect of the cognitive impairments described in HIV studies are 
generalisable to cognitive deficits in any population.   Wider conclusions about the 
impact of poor cognitive function on medication adherence can therefore be surmised 
and research in other conditions supports this.  Salas et al. report that mild cognitive 
impairment increases the risk of non-adherence to anti-hypertensive therapy and this 
risk increase is significant for patients living alone71.  
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Related to the concept of cognitive capacity, is that of health literacy, a relatively new 
concept in health promotion72.  Definitions of health literacy are widespread73, but the 
widely cited WHO definition is largely considered to be the broadest, defining health 
literacy as: 
“the cognitive and social skills which determine the motivation and ability of individuals 
to gain access to, understand and use information in ways which promote and maintain 
good health” 74 
In 2003, the ‘Skills for Life Survey’ was commissioned by the Department for Education 
and Skills to provide a national profile of adult literacy and numeracy across five broad 
levels of competence.  The literacy test was completed by 7873 randomly selected 
adults, residing in England and between the ages of 16 and 65; literacy levels were 
classified into three key groups; entry level (comprised of three subgroups), level one 
and level two.  The survey reported that 56% of the respondents (equating to 17.8 
million adults in England) had a literacy skills at level one or below, meaning their 
understanding was limited to short and straightforward texts at best.  The lowest 
possible grading (entry level one or below) was awarded to 3% of respondents 
(equivalent to 1.1million adults in England) meaning these people were classed as 
functionally illiterate75.  Patients with poor health literacy are at greater risk of non-
adherence, poor health and hospitalisations76 and health literacy has been identified as 
a predictor of adherence in cardiovascular disease77, 78, HIV79 and glaucoma80.   
The correlation between poor adherence and low health literacy is likely to manifest 
through poor understanding of dosing regimens.  A study of ethnic minority patients 
with low health literacy (n =87) reported that the inclusion of pictograms on medication 
labels improved understanding and adherence, with 18% more adherent patients in the 
intervention group compared to control81.  Kalichman et al. also suggest that patients 
with poor health literacy are more likely to hold health beliefs which impede 
adherence79. 
1.5.2.2  Illness perceptions 
The severity with which a patient perceives their illness and their experience of 
symptoms will influence both their perceived necessity of the medicine and interpreted 
sense of treatment efficacy.  Experience of symptoms can prompt adherence if the 
patient perceives the medicine as necessary and efficacious12.  However, symptom 
experience can also be detrimental to adherence if the patient wrongly attributes this to 
medication side effects82.  Non-adherence is particularly problematic in asymptomatic 
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chronic conditions, as an absence of symptoms may lead a patient to question the 
severity of their illness and necessity of their medicine83.  
Non-acceptance of illness is a known predictor of non-adherence84 as patients who do 
not believe themselves to be ill are unlikely to perceive their medicines as a necessity39.  
Patients’ ‘common sense beliefs’ are therefore pivotal in influencing their actions to 
cope with an illness12, 85.  ‘Downplaying’ of symptom severity and non-acceptance of 
illness has been noted as particularly relevant in asthma where adherence to 
prescribed regimens is notoriously problematic37.  Horne et al. report better adherence 
to inhaled corticosteroids in patients who perceive asthma as a chronic condition than 
those who understand asthma in a symptomatic sense and therefore do not perceive 
preventative therapy as necessary when symptoms are absent39.   
Illness perceptions can also be influenced by the social stigmas attached to certain 
illnesses such as depression, schizophrenia, HIV and epilepsy.  Patients with these 
conditions, especially HIV have reported a reluctance to take their medicines due to the 
fear of disclosing their illness12.  Rintamaki et al. report that HIV positive patients are 
3.3 times more likely to be non-adherent if they express high social stigma concerns 
and that patients will skip doses of their medicines due to fear that it would disclose 
their HIV status to friends and family86.  For epilepsy, lower levels of adherence with 
higher levels of perceived social stigma has been reported87, though Horne poses that 
stigmatisation could increase adherence in this condition as fear of seizures and the 
associated stigma may increases the perceived necessity of good adherence12.  In 
contrast to the concept of social stigmatisation, social factors such as the expression of 
positive attitudes by other members of the community, can improve adherence88. 
1.5.2.3  Health and medication beliefs 
Research suggests that people tend to view medicines as unnatural and harmful 
substances that are frequently over prescribed89, these negative beliefs may adversely 
affect adherence8.   In 2005, Pound et al. reported a synthesis of qualitative research 
which identified the main reason for non-adherence as concerns about medicines37.   
Horne’s seminal work in understanding the influence of medication beliefs in non-
adherence reveals that patients who hold negative beliefs about medicines tend to 
have greater concerns about taking them and are therefore less likely to be adherent12, 
38, 90
.  The original work conducted by Horne and colleagues considered medication 
beliefs in both general and specific contexts, and a questionnaire with well-regarded 
psychometrics was tested in over 800 patients across multiple disease areas38, 90.  In 
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December 2013, Horne et al. published a meta-analysis of studies which had utilised 
this questionnaire and included data from 94 different studies (n = 25,072)91.  Horne et 
al. report that across these studies, higher adherence was significantly associated with 
stronger perceptions of treatment necessity and fewer concerns.  
Negative beliefs about medicines have also been shown to affect interpretation of 
subsequent events, for example, experience of new symptoms are more likely to 
interpreted as side effects of the medicine rather than a worsening condition, in 
patients that hold preconceived negative beliefs92.  Public perceptions and media 
influences can also shape beliefs about medicines.  Media scares about, for example, 
anti-depressants being addictive, may feed in to a ‘general schema’ that assumes most 
medicines are addictive85, a belief which is likely to be of detriment to good medication 
adherence.    
Horne’s work has also identified that the balance between a patient’s perceived 
necessity of a medicine and their concerns about taking it predicts non-adherence to a 
greater extent than socio-demographic and clinical factors90.  Therefore, when a 
patient’s concerns about a medicine outweigh their perceived necessity for it, non-
adherence is more likely38.  Horne notes that the concept of medication efficacy is 
related to perceived necessity although the two concepts are not synonymous12.  
However, doubt over efficacy may evoke an evaluation of continued necessity and lead 
patients to ‘experiment’ with their medicine doses to ‘test’ whether they are still 
necessary37.  
Concerns about experiencing adverse effects from medicines are consistent across 
disease states, with evidence suggesting that a third of all patients hold such concerns 
38, 90
.  Other medicine related concerns may be more specific, such as concerns about 
weight gain with inhaled corticosteroid use93 or reduced efficacy and addiction with 
prolonged regular use of analgesics94.  However, concerns about addiction or 
dependence have been expressed by patients in many disease states including 
asthma95, 96, hypertension97, 98, epilepsy 99 and depression 100, 101.  Blenkinsopp et al. 
have identified that medicine related concerns include the fear of masking more sinister 
symptoms and fears of unknown cumulative effects with prolonged use102.  Such 
concerns are often based around ill-informed beliefs therefore educational interventions 
may be important in alleviating concerns and thus facilitating improved adherence. 
Another factor known to influence patient’s medication beliefs is the prescribing of 
generic rather than branded medicines and therapeutic substitutions to reduce 
prescribing costs103.  A recent qualitative study by Chambers et al. reported that some 
 Chapter One                                                                                  Medication Adherence 
 
22 
patients felt that generic medicines caused more side effects, whilst others doubted the 
therapeutic content of generic medicines which augmented their fear of side effects103.   
Such concerns may be of detriment to good adherence.  
1.5.2.4  Social and economic factors 
Socio-demographic factors such as age, gender, socio-economic status, marital status 
and ethnicity undoubtedly have the potential to influence medication adherence 
through various mechanisms, yet research has identified such factors as generally poor 
and inconsistent predictors of adherence39, 43.   
Age 
The WHO identify ‘age’ as a complex and unpredictable determinant of adherence7.   
Paediatric adherence is largely determined by the child’s primary caregivers and is 
subsequently often high, especially in the case of acute emergency prescriptions31.   
However,  in other paediatric conditions, adherence may be lower104, 105 and  as 
children age, they assume increasing responsibility for their own health106.  An 
influential report in 2004 concluded that adherence is generally lower in children than 
adults, especially in adolescents approaching independence, children with learning 
disabilities and infants107.  Numerous studies have therefore considered medication 
adherence in adolescent populations107-110 and specific guidelines to involve children in 
decisions about their care where possible, have been issued in the 2004 National 
Service Framework (NSF) for children111.  Policy guidance linked to the NSF has also 
been issued to facilitate medicines use in schools112.    
Medication non-adherence in older patients is also of concern.  Declining health, poor 
dexterity and cognitive capacity, co-morbidities and polypharmacy with complex 
regimens all contribute to the vulnerability of older people to medication non-
adherence13.   
Ethnicity and culture 
Ethnicity has been identified as an important predictor for non-adherence in numerous 
settings including hypertension113-115 and HIV 116, 117, with patients from ethnic minorities 
often being more susceptible to non-adherence118.  Monane et al. report significantly 
better adherence in patients of white race114 and similar findings have been reported 
elsewhere113.  Postulated reasons for this tend to focus on differing cultural beliefs 
although health inequalities may co-exist adding a further contributory factor114. 
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Differing cultural backgrounds have also been shown to influence medication beliefs.  
In 2004, Horne et al. reported that students of an Asian background were significantly 
more likely to hold negative beliefs about medicines, perceiving them as intrinsically 
harmful, addictive substances that are best avoided.  Conversely, students with 
European cultural backgrounds had significantly more experience with medicines and 
were more likely to endorse their benefits119.  
Social support  
DiMatteo’s meta-analysis of 122 studies identified a significant relationship between 
social support and adherence to medical treatments.  The analysis encompassed both 
emotional and practical support plus factors such as marital status and living 
arrangements.  The most notable correlation to adherence was practical support, with a 
3.6 fold increase in the likelihood of adherence for those patients receiving practical 
support compared to those who did not.  Correlates to other forms of support were also 
identified120.  Though influential, this report did not specifically focus on medication 
adherence and instead included adherence to other medical treatments and 
appointment keeping which may have biased the findings.  Based on this evidence, 
Horne concludes that social support may be an important factor in reducing barriers to 
adherence in some patients12.  Based on the best evidence available, Horne’s 
conclusions appear to be valid; social support should therefore be acknowledged as a 
potential moderator of medication adherence, though further work is needed to 
establish the circumstances in which this is most important.  
Whilst receipt of social support is commonly deemed to positively influence medication 
adherence, social pressure to adhere may induce ‘imposed compliance’ whereby 
patients feel forced to adhere to their medication regimens121.  This phenomenon is 
most prevalent in mental health, with schizophrenic patients reporting feelings of 
powerlessness with regard to their medicines due to the extreme pressures that they 
felt to adhere121.  Whilst contrary to the ideals of informed decision making and 
concordance, ‘imposed compliance’ may be a necessity in conditions such as a 
schizophrenia where adherence is frequently poor122.  
Medication costs 
The cost of medication has been identified as an important precipitator for primary non-
adherence, especially in countries where state-provision of healthcare is inadequate7, 
29, 33
.  In the UK, patients that pay a prescription charge are more likely to display non-
adherence compared to patients that are exempt from charges25, 27.  However, it is 
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worth noting that the cost of medicines may be secondary to the patient’s illness 
perceptions and medication beliefs.  Therefore, if a patient considers themselves 
gravely ill and that a medicine is necessary they are likely to find means to pay for the 
prescription as their perceived necessity for it will outweigh the financial sacrifice.  A 
patient in identical financial circumstances prescribed a medicine perceived by them as 
unnecessary to treat a condition they think not so serious may, however, be much less 
likely to pay the prescription charge.  
1.5.2.5  Patient co-morbidities 
Co-morbidities such as depression and anxiety or drug and alcohol abuse have been 
identified as important modifiers of medication adherence.  DiMatteo’s seminal meta-
analysis reported a threefold increase in the odds of non-adherence for patients 
suffering with depression compared to those who did not, an effect that was consistent 
across differencing disease states123.  Horne notes that the direction of causality with 
such observations remains unknown and so the mechanisms through which depressive 
symptoms moderate medication adherence are not fully understood12.   
Illicit drug use has also been linked to poor adherence, with a study of illicit drug use in 
HIV positive patients showing that individuals using illicit substances were over four 
times more likely to display suboptimal medication adherence compared to those with 
negative urine toxicology screenings124.  
Co-morbidities that engender visual, physical or cognitive deficiencies can also be 
detrimental to adherence, as mediated through administration difficulties. Reduced 
visual acuity will affect accuracy in reading prescription labels and identifying medicines 
whilst dexterity problems may impair manipulation of tablet packaging50.  Swallowing 
difficulties may also impede oral administration of medicines125 and mobility problems 
could prevent collection of medicines from a pharmacy and thus contribute to primary 
non-adherence.  
1.5.3   Prescriber and healthcare team related factors 
A good relationship with healthcare providers and trust in the prescribing practitioner 
are important moderators of medication adherence.  The trust that a patient has in the 
abilities of the person issuing their prescription can greatly influence the beliefs held 
about both their illness and medications, as can satisfaction with the consultation. 
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1.5.3.1  Patient and prescriber interaction 
In their seminal review of medication adherence, Vermeire et al. report that the quality, 
frequency and duration of interactions between the patient and prescriber will influence 
adherence34.  A prescriber’s attitude towards their patient, their ability to elicit and 
respect patient concerns, provide appropriate information and demonstrate empathy 
have been shown to be of utmost importance88.   
1.5.3.2  Provision of information 
Evidence suggests that better informed patients are more likely to be committed to their 
treatment regimens and adhere to decisions that they have been actively involved in126.  
To facilitate adherence, information regarding newly prescribed medicines must be 
delivered in a comprehendible manner that meets the patient’s information needs.  This 
approach should evoke patient satisfaction, which has been identified as an important 
predictor of medication adherence in numerous chronic conditions.  Satisfaction with 
information provision is linked to lower medication concerns and subsequent improved 
adherence127, 128.  
Poor communication can also make understanding of complex instructions difficult, 
especially in older patients129, leading to a lack of knowledge.  The role of patient 
knowledge in determining adherence, has been described as complex12 with some 
studies reporting a strong link, but many more studies failing to identify definitive 
causality130.  Discrepancies in the influence of patient knowledge on adherence may in 
part be accountable to conceptual and methodological disparities in the definition of 
patient knowledge.  Moreover, Horne et al. note that the cross sectional study designs 
assumed in this domain do not enable determination of a direction of causality.  It is 
therefore impossible to determine whether non-adherence is caused by a lack of 
knowledge or whether non-adherent patients are less interested in their medicines and 
do therefore not seek knowledge or pay attention when it is offered12.  Despite 
inconsistent evidence, a certain level of knowledge regarding a treatment and how to 
use it is a prerequisite for appropriate use131 and therefore relevant to adherence. 
Information delivery can also influence patient recall of instructions for taking 
medicines, another prerequisite for adherence132.  Evidence suggests that patients are 
able to recall less than 50% of prescription information presented to them133.  Whilst 
individual factors such as cognitive ability and intelligence have been shown to 
influence information recall134, the information delivery style, length and complexity all 
influence recall135. 
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The communication style assumed by a GP when prescribing a medicine has also 
been shown to influence adherence.  Barry et al.136 and Britten et al.137 have published 
qualitative work highlighting that when consultations are rushed, patients may leave 
their appointments with unmet concerns and feel worried and misguided; factors that 
may subsequently impede adherence.  A consultation style that involves patients in the 
decision making and where lay terminology is used is also known to improve 
adherence137, 138. 
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1.6 Measuring adherence 
Measurement of adherence is notoriously difficult and an important consideration in the 
evaluation of adherence research as differing methods can produce dissimilar results.  
Broadly speaking, adherence assessment methods can be grouped as direct and 
indirect measures.  Each method has advantages and disadvantages as summarised 
in table 1.1 and described in the following sections.  
1.6.1   Direct measures 
Direct measures of adherence commonly involve the measurement of a biological 
marker or drug metabolite in blood plasma or urine to detect the presence of a 
medicine in the body137.  Biological markers can be added to a formulation for this 
specific purpose.  Such techniques are expensive, labour intensive, invasive and 
susceptible to distortion by the patient4.  Direct measures of adherence are therefore 
an unpopular choice for many adherence studies, though for some medicines these 
approaches are widely used as an effective adherence measure.  Plasma lithium levels 
are routinely measured in primary care to avoid toxicity and medicines used in the 
treatment of epilepsy, such as phenytoin and valproic acid, are also amenable to 
plasma monitoring, with sub-therapeutic levels indicative of poor adherence4. 
Whilst monitoring of drug plasma levels provides an objective measure of adherence, 
few medicines are suitable for this approach as metabolism and other patient related 
factors may affect readings.  Moreover, patient behaviour may change if they know 
their plasma levels are soon to be monitored, sporadic non-adherence is therefore less 
likely to be detected.  
Direct measures of adherence also include the observation of medicines taking, 
commonly known as Directly Observed Therapy (DOT).  This technique is commonly 
used as an adherence assessment for conditions such as Tuberculosis (TB) where 
perfect adherence is essential yet commonly poor138 and is considered to be an 
accurate method of measuring adherence139 .  Patients are observed whilst taking their 
medication, which should ensure adherence, though patients have been known to 
retain the medicines in their mouth and then discard it surreptitiously post observation4.  
Whilst used in clinical practice to ensure adherence, DOT is seldom used as an 
adherence assessment tool in research studies.  It is worth noting that DOT is also 
used as an intervention to improve adherence, though evidence from a recent 
systematic review suggests the effectiveness of this approach may be limited138.  
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1.6.2  Indirect measures 
Whilst  direct measures of adherence are seldom used in research, the opposite is true 
for indirect measures, which tend to provide accurate and convenient adherence 
data34. 
1.6.2.1  Self-report 
Patients self-reports remain one of the simplest measures of adherence and can 
provide accurate data that correlates well with more precise measures such as 
electronic monitoring140.  Self-report measures include patient interviews, 
questionnaires and diaries which represent fast, flexible and inexpensive approaches 
that are generally acceptable to patients.  However, self-report can be subject to recall 
problems and social desirability bias, whereby a patient provides the ‘expected’ 
response of adherence, in order to please the researcher or their practitioner.  
Moreover, questionnaires assume patient understanding and honesty, which can be 
particularly problematic in patients who do not understand their regimen or are 
unaware of their non-adherence.  Good questionnaire design and administration are 
key to eliciting accurate adherence data and extensive guidelines have been issued on 
this topic141.  Patient interviews are more likely to overestimate adherence as social 
desirability biases are stronger, therefore postal questionnaire may provide greater 
accuracy142, 143. 
One of the most widely used self-report adherence questionnaires is the four item 
Medication Adherence Questionnaire (MAQ) developed by Morisky et al. in 1986 for 
use in antihypertensive therapy144.  The four non-adherent behaviours included in the 
questionnaire; forgetting, carelessness, stopping when feeling better and starting when 
feeling worse, were created using a theoretical approach.  The statements are phrased 
to minimise social desirability bias and good psychometrics properties have been 
established144.  The MAQ has been validated against a clinical outcome measure 
(blood pressure) and displays both concurrent and predictive reliability.  Despite these 
important credentials, the tool has been widely criticised as an overly simplistic 
assessment of an inherently complex behaviour.  This limitation is augmented by 
dichotomous response options which yield limited data and no indication of the 
frequency or magnitude of non-adherence. 
The Morisky Medication Adherence Scale (MMAS) evolved from the 4-item Morisky 
scale in response to its criticisms and has documented reliability, with greater 
sensitivity than the four-item scale used previously145.  MMAS considers seven non-
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adherent behaviours with dichotomous response options but also includes an 
additional item with a five-point Likert scale response, to establish the frequency with 
which the respondent has difficulties remembering to take all of their medicines.  
In 1999, Svarstad et al. developed the Brief Medication Questionnaire (BMQ) which 
utilised questionnaire development theory to specify a recall time period, thus 
increasing accuracy146.  The authors report specifically selected wording to reduce 
perceptions of threat or embarrassment and the tool has been validated using 
electronic monitoring.  The BMQ considers three different aspects of non-adherence 
relating to regimen, recall and beliefs and enables differentiation between sporadic and 
repeated non-adherence.  
Another commonly used self-report tool is the Medication Adherence Rating Scale 
(MARS) developed by Horne and Hankins147, 148.  Whilst formal validation of the tool 
remains unpublished, it has been reliably used to assess adherence across numerous 
domains90, 127, 149.  Similar to Morisky, MARS uses carefully selected wording to reduce 
social desirability pressures and assumes a non-judgemental and non-threatening 
stance127.  Respondents are asked to rate the frequency with which they engage in five 
non-adherent behaviours, using a five-point Likert scale ranging from ‘always’ to 
‘never’.  This continuous rather than dichotomous measure of adherence is widely 
regarded as a positive attribute150.  MARS has demonstrated good internal and test re-
test reliability when used to assess adherence across a variety of chronic conditions 
and has also shown good correlation to dosage unit counts151. 
Table 1.2 provides a summary of the overlapping constructs of these four most widely 
used self-report tools and highlights that ‘forgetting to take doses’ is the only non-
adherent behaviour common to all four tools. 
Less commonly used self-report adherence assessment tools include: 
• The Adult AIDS Clinical Trials Group (AACTG) Adherence Instrument152 – 
developed by Chesney et al. to identify non-adherence to medication for HIV  
• The Medication Adherence Self-Report Inventory (MASRI)140 - developed by Walsh 
et al. also in the domain of HIV, which incorporates a visual analogue scale to 
record adherence 
• The Medication Adherence Rating Scale (MARS)153 – developed by Thompson et 
al. for use in psychosis, specifically schizophrenia  
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• The Medication Adherence Reasons Scale (MARS)154 – developed by Unni and 
Farris in response to a literature review of reported reasons for non-adherence 
With numerous self-report adherence assessment tools, a synthesis of research was 
necessary to determine the suitability of these measures; this need was addressed with 
a systematic review in 2011155.  Garfield et al. identified 58 self-report adherence 
assessment tools suitable for use in primary care and 93% of these were reportedly 
validated.  Whilst a plethora of tools therefore exist, Garfield and colleagues note that 
few distinguish between intentional and unintentional behaviours, thus limiting their use 
in clinical practice.  Despite these limitations, self-report measures continue to be 
widely used in research.  
1.6.2.2  Patients’ clinical response 
The clinical correlates of non-adherence will depend upon the medication taken, 
disease state and severity plus patient co-morbidities15 and is therefore unlikely to 
represent a reliable adherence measure.  However, clinical response data such as 
blood pressure or blood cholesterol levels are commonly collected as part of routine 
care and may therefore represent an easily accessed ‘indicator’ of non-adherence 
rather than definitive measure4.  Clinical responses are not recommended as sole 
measures of adherence as they assume that the medicine is the only determinant of 
the outcome and do not account for the numerous confounders that may exist156.  
1.6.2.3  Pill counts 
Second to patient self-report questionnaires, pill counts are the most common method 
of adherence assessment4.  Prior to the emergence of electronic monitoring it was 
considered a gold-standard technique, but the method is not without flaws.  Whilst the 
process of counting the number of pills remaining in a patient’s bottle at the end of a 
designated time period (e.g. one month) is relatively simple it is time consuming and 
reliant on the patient retaining their medicines containers.  Moreover, the process 
assumes that uncounted pills have been ingested correctly.  Such assumptions are 
fallible as patients have been known to dispose of their unused medicines in an attempt 
to appear adherent4.  A comparison of pill count data to electronic monitoring, found pill 
counts to be unreliable157, detailed data of adherence patterns and dose timings are 
also unavailable using this technique.  Finally, pill counts are also subject to the 
Hawthorne effect, where patients change their behaviour when they know their 
adherence is being monitored158. 
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1.6.2.4  Prescription refills 
Prescription refill rates can be a reliable method of assessing adherence, in closed 
pharmacy systems whereby the patient can only obtain their medicines from one 
source.  In the UK, patients are free to obtain their prescription from any pharmacy; 
refill rates are therefore unlikely to be a reliable adherence measure.  In addition, refill 
rates only infer adherence as collection and possession of a medicine at the correct 
time points will not always equate to perfect adherence4.  Prescription refill data has 
been demonstrated to both under and overestimate adherence159. 
1.6.2.5  Electronic monitoring 
Electronic monitoring devices are available to record the time of opening a medicines 
bottle, dispensing eye drops (for glaucoma) or activation of a canister (for asthma) and 
are a reliable adherence assessment tool4.  Electronic monitoring avoids the notable 
biases introduced by tablet counts and other methods which enable the patient to 
disguise omitted doses by removing them prior to be counted15.  Precise and detailed 
insights into patients’ patterns of medicine taking are offered by this method, though 
the indirect method means details of whether the medicine was actually taken, or how 
many tablets were taken are still absent4.  Raynor reports that the use of electronic 
monitoring devices has been pivotal in furthering our understanding of non-adherent 
behaviours, leading to the discovery of ‘drug holidays’ and ‘white coat adherence’160.  
Whilst the costs associated with this method prohibit its routine use, electronic 
monitoring of adherence is widely considered as the ‘gold-standard’ approach161. 
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Table 1.1 Summary of adherence measures (based on Osterberg and Blaschke4) 
 
Test Advantages Disadvantages 
Direct measures of adherence 
Directly observed therapy (DOT) Generally considered as accurate method Impractical for routine use, patients can deceive observer 
Measurement of drug or metabolite 
blood plasma levels 
Objective measure Expensive process, variations in metabolism can give 
false readings, sensitive to Hawthorne effect 
Measurement of biological marker 
in blood 
Objective measure, can be used to assess 
placebo in clinical trials 
Expensive assays and sample collection 
Indirect measures of adherence 
Patient questionnaires and self-
report 
Simple and inexpensive measure, practical 
approach in clinical settings, good level of data 
can be elicited including differentiation between 
intentional and unintentional non-adherence  
Subject to self-report bias and Hawthorne effect 
Pill counts Objective, quantifiable and relatively easy to 
perform 
Patients can manipulate data (pill dumping), details of 
whether correct medicines were taken at correct time not 
captured  
Prescription refill rates Objective and relatively easy to obtain Assumes patient visits regular pharmacy and has not 
obtained medicines elsewhere, does not provide 
information on whether medicines were actually taken  
Assessment of patients clinical 
response 
Simple assessment, data often collected as part 
of routine care 
Non-response does not mean non-adherence as other 
factors may be causative 
Electronic monitoring (e.g. 
MEMS®) 
Provides detailed and precise data about 
timings, adherence tracked over period 
Expensive method, assumes opening and closing of bottle 
correlates with medicines taking, patients need to return 
packing to allow data download.  
Patient diaries Process of self-monitoring/recording adherence 
may improve it 
Easily falsified, may be subject to recall bias 
 
  
Table 1.2
 
 
Primary intentional non
Choosing not to redeem 
Choosing not to redeem 
Secondary intentional non
C
in prescriber
Choosing not to take 
Choosing to stop 
Choosing to stop a medicine due to perceived lack of efficacy
Choosing 
Choosing to take 
knowing best
Altering the dose
Stop taking for a while
Deciding to miss a dose
Taking less than instructed
Stopping medicine
Being c
Primary unintentional non
Forgetting to redeem 
Failure to redeem a prescription due to insufficient funds
Forgetting to order a medicine and running out of it
Forgetting to collect a dispensed prescription from the pharmacy/doctors surgery
 Summary of non
hoosing not to take a medicine
 
to increase the dose of a medicine
 
 
areless about taking medicines
Chapter One 
-adherent behaviours assessed by commonly used self
-adherence
a prescription 
a prescription 
-adherence
 or reducing
a medicine or reducing
a medicine or reducing
a medicine differently to prescribed because 
of a medicine 
 
 
 
 or reducing dose 
-adherence
a prescription
 
                                                                                 
 
due to not wanting to take medicine
due to unwillingness to pay 
 
 the dose because of health beliefs/illness perceptions/confidence 
 the dose 
 the dose 
 due to perceived lack of efficacy
due to feeling worse
 
 
 
due to experience or fear of side effects
due to feeling better
 
of increased convenience/fitting in with lifestyle/ 
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Table 1.2 (continued)
 
Secondary unintentional non
Not understanding the dosage instructions
Confusion in 
Forgetting doses
Forgetting to take medication with them when they stay away
Forgetting whether they have already taken a dose
Unable to administer medication due to dexterity problems
Unable to administer medication due to visual problems
Unable to take medication due to inappropriate formulations
Non
Not taking medication in last two weeks
Not taking medication yesterday
differentiation between different medications
 
-specific non
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-adherence
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1.7  Interventions to enhance medication adherence 
Widespread research interest in the most effective  interventions to improve medication 
adherence exists, yet no single method has been shown to be inherently superior162.  A 
series of highly influential systematic reviews have been conducted by Haynes et al. to 
explore the efficacy of Randomised Controlled Trials (RCTs) designed to increase 
medication adherence, the most recent being in 2008163.  Undertaken to Cochrane 
standards, this meticulous review identified 83 interventions to increase adherence for 
long term conditions, reported in 70 RCTs.  A mere 43% of these interventions 
improved adherence and only 30% led to an improvement in at least one treatment 
outcome.  Haynes et al. conclude that whilst these interventions are mostly complex, 
they are also largely ineffective and subsequently call for the prioritisation of innovative 
research in the field163. 
The studies included within the Haynes systematic reviews were deemed too disparate 
to warrant synthesis through meta-analytic techniques.  In 2003, Peterson et al. 
accommodated the disparity in studies by specifically focusing on educational and 
behavioural interventions164.  The resulting meta-analysis reported an overall effect size 
(95% confidence interval (CI)) of 0.07 (0.04 to 0.09), 0.11 (0.06 to 0.15) and 0.08 (0.04 
to 0.12) for behavioural, educational and combined interventions respectively.  Similar 
to the Haynes reviews, modest improvements in adherence were therefore reported, 
further highlighting the need for novel approaches in this domain.   
1.7.1    Educational strategies 
Educational interventions to improve medication adherence were defined by Peterson 
et al. as ‘those that taught the patient about the medication or disease through oral, 
written or audio-visual communication in an individual, one-to-one or group format’164.  
The focus on imparting knowledge to patients tends to yield conflicting effects, largely 
because patients’ information needs differ and untailored information delivery fails to 
consider individual attitudes and beliefs.  Provision of information may also be 
detrimental to adherence if negative aspects of therapy such as side effects are 
highlighted, which had not previously been considered165. 
Educational interventions are most likely to be efficacious in patients who are willing to 
take their medicines but who need information on how to do so, though it may also be 
of use in cases of intentional non-adherence, due to misunderstandings about 
medicines or ill-informed beliefs164. 
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In English community pharmacies, two nationally commissioned adherence 
intervention services are available, the New Medicines Service (NMS) and Medicines 
Use Reviews (MURs).  Whilst neither service is specifically classified as educational 
interventions, both have a fundamental element of increasing patient’s knowledge 
about their medicines.   MURs are not a clinical medication review but instead have the 
more modest aim of establishing a patient’s medication use and increasing patient 
knowledge and understanding of their medication166.  MURs have been a routinely 
delivered adherence intervention in community pharmacies nationwide since the 
inception of the new pharmacy contract in 2005 yet robust, comprehensive evidence to 
document their value remains elusive167.   
Despite the paucity of evidence in supporting the value of MURs, large amounts of 
NHS expenditure has been streamed into funding this intervention.  Data from the NHS 
prescription services showed that in the financial year, from April 2010 to March 2011, 
just over 2.1 million MURs were undertaken in community pharmacies in England 
alone which cost the NHS almost £58.9 million; a figure that continues to rise168.  Whilst 
the fundamental premise of a community pharmacy based medicines use review is 
intuitively useful and provides ample opportunity to identify, discuss and resolve 
adherence barriers, the outcome of these basic and limited techniques is unknown and 
the limited evidence available does not look promising.   
Contrary to MURs, the NMS service is theoretically based, with research evidence to 
support its design and rationale169, 170.   Designed to identify and resolve any adherence 
difficulties within the first few weeks of initiating a new therapy, promising early results 
from the service have been reported171.  A full economic evaluation and qualitative 
appraisal of the service is currently being undertaken172.  However, the NMS 
represents an educational intervention that is not targeted to meet individual needs and 
does not encompass a clear strategy for resolving adherence barriers, especially those 
of an intentional nature.  The deficit in community pharmacy based adherence 
interventions is therefore evident.  
1.7.2  Behavioural Strategies 
In the meta-analysis of adherence interventions reported by Peterson et al. behavioural 
interventions included the use of any tool or action that would change a patient’s skill 
level or normal routine, such as pillboxes, calendars, reminders and dose-schedule 
changes164.  Behavioural strategies are based on the assumption that medication 
taking behaviours can be learnt, modified and practised to improve medication 
adherence.  Provision of clear instructions as to how to adhere plus support strategies 
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such as provision of adherence aids and reminders are therefore commonly utilised in 
community pharmacy practices. 
1.7.2.1  Reminder charts 
Computer generated reminder charts are provided by community pharmacies as a 
prompt to encourage adherence, especially in patients with mild to moderate cognitive 
impairments.  Reminder charts commonly involve a list of the medicines prescribed in 
the left-hand column, with four daily time points (based around mealtimes) across the 
top of the chart, indicating the number of each medicine to be taken at each time point.  
An RCT reported by Raynor et al. demonstrated that recipients of a reminder chart 
were more likely to display adequate adherence compared to non-recipients (86% Vs 
63% p= <0.0001)131.  Reminder charts may therefore be a useful and relatively simple 
intervention in cases of unintentional non-adherence associated with cognitive 
impairment.  However, they are less likely to yield benefit in non-adherence of a more 
intentional nature. 
1.7.2.2  Simplification of dosing regimens 
Evidence, as described in section 1.5.1.3, demonstrates that as a patient’s dosing 
regimen increases, adherence is likely to decrease.  Interventions which aim to reduce 
the number and frequency of daily medicine doses are therefore an intuitive strategy to 
improve adherence.  Simplification of dosing regimens, in conjunction with the 
prescribing practitioner, is commonly deployed as a ‘first line tactic’ by community 
pharmacists wishing resolve identified adherence difficulties.  A meta-analysis of 
educational and behavioural interventions to improve medication adherence reported 
that dosage-schedule changes were the most frequently used behavioural type 
intervention164. 
1.7.2.3  Adherence aids 
When reminder charts and dose simplifications have failed to remedy adherence 
difficulties, adherence aids may be utilised and are often recommended by community 
pharmacists.  A wide range of devices are available and are designed to make it easier 
for patients to administer and remember their medicines.  Adherence aids may 
therefore be a useful strategy to overcome both cognitive and physical barriers to 
adherence. 
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Multi-compartment compliance aids (MCAs) 
MCAs assume many different designs but in essence comprise of a box divided into 
multiple compartments to represent the days of the week and differing times points 
during the day.  A patient’s medicines can be dispensed into the device, usually on a 
weekly basis, so that each tablet is set out at a specified time point.  Whilst most solid 
oral dosage forms (tablets) are suitable for inclusion in an MCA, many are not including 
those that are sublingual, dispersible or hydroscopic.  These medicines, along with 
non-oral formulations such as inhalers, creams or eye drops must therefore be 
supplied separately. 
MCAs are primarily designed to act as a reminder in cases of non-adherence due to 
memory impairment.  However, dispensing in an easily accessible device can also 
improve adherence for patients with dexterity problems that inhibit access to medicines 
in blister packs or with child resistant closures.  Though most commonly filled in 
community pharmacies, MCAs can also be purchased or supplied directly to patients or 
their carers/family members for self-filling with existing supplies of medicines.  
Evidence to support the use of MCAs is mixed but tends to acknowledge that these are 
costly interventions with limited evidence to support their use173.  In 2001 Nunney and 
Raynor conducted a questionnaire based study to evaluate the use of MCAs in primary 
care.  Responses from 123 pharmacies revealed that MCA use was common, but that 
initiation and supply were not always focussed towards the patient’s needs.  Interviews 
with 56 patients receiving an MCA revealed that 39% felt they would still be able to 
cope without their MCA and 18% had difficulty accessing their medicines from the 
device.  The authors conclude that MCAs should not always be the default option for 
support174.  Whilst this study provides valuable information, the limitations of 
questionnaire-based methods in just one UK region, must be considered.  Green and 
McCloskey also conducted a questionnaire based study, but focused on the provision 
of MCAs in UK hospitals rather than community dwelling patients.  This study was 
strengthened by the large number of UK hospitals contacted; a 74% response rate 
provided data from 160 acute hospitals across the UK, meaning the results from this 
study are likely generalisable to the wider UK population.  The authors report that whilst 
the majority of UK hospitals supply MCAs, only 16.3% reported use of a formal system 
to target MCA provision to the most suitable patients175.  
In 2005, Ryan-Woollley and Rees reported the use of MCAs in a more favourable light 
by focusing on reduced medicines waste and improvements in patient-prescriber 
communication following dispensing of medicines.  The authors report an ‘exploratory 
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controlled, matched study’ in which medicines wastage was reduced from 18.1% to pre 
study to 1% 12 months after a switch from conventional packaging to an MCA176.  
However, as medicines wastage data were not reported for the group of patients who 
continued to receive their medicines in conventional packaging, it is prudent to interpret 
these results with caution.  The study is further limited by the small sample size of 62 
sheltered housing residents from just one UK region.  
More recently, Nunney and colleagues reported a qualitative study using grounded 
theory to establish the attitudes and beliefs of 15 older people living independently and 
using MCAs and 17 HCPs from all sectors of care regarding the use of MCAs.  
Maintenance of independence was paramount to the older patients but there was 
mixed views on whether the use of MCAs supported this; patients largely agreed that 
the aids did not help with memory problems and the MCAs were often initiated without 
patient consultation which was viewed by the patients as paternalistic.  In their 
conclusion, the authors rightly call for further evidence for the use of MCAs in older 
patients and emphasise the importance of careful multi-disciplinary evaluations before 
an MCA is initiated and the need to consider and respect patients views177. 
Whilst there is a paucity of evidence regarding the use of MCAs, the evidence that is 
currently available has led to the recent issuing of guidance which advises that other 
avenues of support, such as reminder charts and dose simplification should be 
explored before considering an MCA178.  
Administration aids 
Specific aids to facilitate administration of medicines have been developed including 
the pill press® to facilitate de-blistering of tablets, the haleraid® to support co-
ordination of inhaler actuations with breathing and the auto-dropper® to aid 
administration of eye drops.  These devices are intended to address physical barriers 
to adherence where dexterity problems associated with conditions such as Parkinson’s 
disease or arthritis may be prohibitive.   
Salyani and Birt describe an evaluation of eye drop administration aids and conclude 
that whilst useful to some patients, some found them to be counterproductive179.  This 
evidence highlights the importance of rejecting a “one size fits all” approach to 
adherence interventions and the need to tailor support to meet the needs of an 
individual.  
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Modern technology 
In recent years, advances in technology have enabled internet and text message 
based reminded systems to be trialled and with smartphone use now common place, 
‘Apps’ to support adherence are also commonly available. Whilst formal evaluation of 
these techniques is still to be provided, indications show great promise and such 
techniques are likely to increase their precedence in the future180, 181. 
1.7.3  Cognitive based strategies 
In recent years, an interest in improving non-adherence using psychological based 
techniques has emerged.  Techniques to improve patients’ motivation to adhere, or 
address negative illness and medicines perceptions are likely to be more effective for 
intentional non-adherence.  The health psychology theory underpinning these 
techniques is considered in detail in chapter three of the thesis.  
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1.8  Chapter summary 
The WHO has summarised the consequences of non-adherence in simplistic terms as 
waste, morbidity and hospital admissions7.  Medication adherence is a complex and 
multifaceted process and a plethora of factors may determine patient behaviours in this 
domain.  Though research in this field is wide-spread, the deficit in effective 
interventions to improve adherence is well noted.   
Educational and behavioural techniques may have some effect and practical strategies 
such as reminders, adherence aids and dose regimen simplification may prove to be 
effective in cases of unintentional non-adherence where memory and dexterity 
problems prevail.  However, the efficacy of such interventions is likely modest and is 
not always predictable.  For intentional non-adherence, there is a deficit in an 
appropriate and effective armoury of interventional strategies to modify behaviour.  This 
deficit may be addressed by the emergence of newer ‘cognitive based techniques’ 
which employ psychological theory to modify patient behaviours.  The potential 
application of these newer techniques to pharmacy-led adherence intervention is 
considered in greater depth in chapters three, four and five.  However, before 
considering future adherence interventions, an evaluation of current practices was 
prudent.  Chapter two therefore describes the evaluation of a domiciliary medicines 
support service which is primarily designed to support unintentional non-adherence.   
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2.1 Introduction and background 
Non adherence to prescribed medicines is both complex and multifaceted, causing a 
notable problem in healthcare provision.  In chapter one, the nature of non-adherence 
and strategies to improve it were described.  This chapter evaluates a domiciliary 
medicines management service and its impact on non-adherence of a primarily 
unintentional nature. 
2.1.1 Cambridgeshire Community Services (CCS) NHS Trust Domiciliary 
Medicines Management Service 
Cambridgeshire Community Services (CCS) NHS Trust provides an established 
domiciliary medicines management service in the East Cambridgeshire and Fenland 
area, which is reportedly valued by both service users and healthcare professionals 
(HCPs).  The aim of the service is to provide support to patients having difficulties with 
the management of their medicines.  
The majority of patients visited are older and confused; however, any patient 
experiencing medicine related difficulties can be referred into the service, which is 
delivered by a specialist pharmacy technician (SPT).  The service takes a patient-
centred approach, tailoring resolution strategies to meet individual needs whilst 
considering the patient’s overall circumstances and views.  In light of the evidence for 
effective adherence interventions16, 173, a patient-centred service which is holistic in 
nature is appropriate.  Recommendations from The National Institute for Health and 
Clinical Excellence (NICE) relating to adherence support, namely that patients should 
be involved in decisions about their care182 are also complemented by the patient-
centred service design.  This approach differs from many medicines support services, 
which focus purely on provision of assistive technology such as reminder alarms or 
multi-compartment compliance aids (MCAs).  Such devices are often costly 
interventions with limited evidence of effectiveness173-176.   
Delivery by a SPT is relatively unique as domiciliary medicines support services are 
usually provided by pharmacists183, 184.  Using SPTs compared to pharmacists, plus 
implementation of support strategies other than assistive technology, are potentially 
effective approaches to reducing costs. 
Whilst numerous reports of successful outcomes from the CCS NHS Trust service are 
encouraging, anecdotal reports are insufficient to scientifically evaluate the efficacy and 
value of the service.  A rigorous service evaluation was therefore undertaken.  
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2.1.2  Pharmacy Technician led services 
To work as a pharmacy technician, a level three NVQ Diploma in Pharmacy Service 
Skills is required, taking approximately two years to complete185.  Senior technicians 
can specialise in areas such as medicines management, recording whether patients 
are adherent to their medicines and ensuring patients know how to take their medicines 
correctly186.  Accredited training to enable this specialisation, includes consultation 
skills, pharmaceutical care planning, adverse drug reactions, clinical topics and care of 
older people187.  Many Primary Care Organisations have employed specialist 
technicians to work alongside pharmacists in providing medicines support services188. 
Despite evidence of pharmacy technician involvement in current medicines support 
services, there are no published reports of domiciliary visiting services delivered solely 
by pharmacy technicians.  An evaluation of a technician led service, or at least 
description of activities undertaken, will enable comparisons to be made with previously 
reported pharmacist led services. 
2.1.3   Pharmacy domiciliary visiting services 
2.1.3.1  Definition 
Domiciliary visits provide an opportunity for a pharmacist or pharmacy technician to 
visit a patient in their own home and support their medication taking and 
pharmaceutical care needs.  
2.1.3.2  Context and background 
The premise of a domiciliary visit stems from the founding principles of the National 
Health Service (NHS), whereby a universal and comprehensive service should be 
provided with equal access to all189.  In an aging population, an ever growing number of 
older, frail or housebound patients are unable to receive the same pharmaceutical care 
as ambulatory patients who can easily visit their community pharmacy.  In 1999, Oxley 
reported that 58% of UK based older people receiving multiple medicines, were unable 
to collect their prescription in person, and were thus unable to directly access 
pharmaceutical care190.  It is often these patients, who may be vulnerable, confused 
and prescribed numerous medicines that need additional support to adhere.  A lack of 
direct contact with pharmacy services may lead to compounding of simple problems 
(such as misunderstandings) over time191, with a subsequent detrimental impact on 
medication adherence, efficacy and safety.  
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Domiciliary visits also enable assessment of medicines management practices in the 
patient’s own home.  This provides a broader perspective and allows detection of 
adherence related issues that may otherwise go unobserved such as inappropriate 
storage of medicines or hoarding192.  The increased privacy provided by home-based 
reviews may also encourage more honest and open adherence discussions193. 
2.1.3.3  Health policies and government guidelines 
In 2001, The Department of Health released The National Service Framework (NSF) 
for Older People, a key policy document outlining proposed objectives for improving the 
quality of care received by older people.  Recommendations included moving towards 
person-centred care, whereby all older people are treated as individuals and a range of 
medicines management interventions.  The most notable recommendation impacting 
on the provision of domiciliary services was the direction that all Primary Care Trusts 
(PCTs) should have schemes in place to allow older people to get more help from 
pharmacists with managing their medicines by April 2004194.  As a consequence, PCT 
pharmacists and technicians developed medicines support services to fulfil the 
requirements of the NSF, effectively providing an adherence intervention as a 
domiciliary visiting service.  Domiciliary services shifted from being novel, experimental, 
community pharmacy-led services towards PCT delivered services to target older 
patients with medicine management problems.  The NSF for older people also 
recommended regular medication reviews for older patients to maximise therapeutic 
benefits and minimise potential harm.  Pharmacy based domiciliary services therefore 
enable housebound patients to receive medication reviews and address other medicine 
related aspects of the NSF195. 
More recent publications and policy guidelines have maintained the move towards 
supporting older people to continue living in their home and with such changes, the 
need for domiciliary services is ever growing.  In 2004, The Public Service 
Agreement196 set targets for increasing the number of people aged over 65 living in 
their own homes, through supported care.  These targets were supported by the 
government White Paper, ‘Our health, our care, our say’, published in 2006197, which 
recommended changes that would lead to more integrated health and social care 
systems, enabling the delivery of services that better meet the needs of local 
populations.  Subsequently, the provision of care for older people increasingly shifted 
from secondary to primary care.  Further publications have reiterated the need for this 
shift195,196,198,199.  
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2.1.4  Research evidence relating to domiciliary visiting services 
Studies concerning domiciliary medicines support services and home-based 
medication reviews are predominantly UK based.  A mixture of Randomised Controlled 
Trials (RCTs), before and after studies and cohort studies provide insights into the 
medicines management problems encountered by patients, the types of interventions 
made and the associated health outcomes.  A brief summary of the current research 
base for domiciliary medicines support services is provided in table 2.1 and 
summarised in the subsequent sub-sections.    
2.1.4.1 Medicines management difficulties experienced by patients; the 
need for domiciliary services 
A small, UK based observational study (N=39), reported that 54% of participants had 
one or more medicine related problem which may lead to non-adherence and/or 
administration errors. The main reasons for non-adherence were forgetfulness, 
confusion, poor understanding and side effects200.  Whilst this study provides some 
useful insights, it is limited by the small sample size and study methods.  In a 
prospective cohort study of 100 patients visited at home by their community 
pharmacist, 160 interventions were made and later classified as medicines 
management issues (55%), health beliefs and concordance (26%) and therapeutic 
problems/adverse effects (19%)201. 
2.1.4.2  Nature and types of interventions made 
The interventions made in domiciliary visits are most frequently to facilitate improved 
medication adherence, commonly achieved via some form of medication review.  
Formats have included semi-structured interviews201-203, informal discussions200 or 
more structured, formal medication reviews204-207. 
In Schneider and Barber’s 2006 study, the majority of interventions focused on 
simplification and clarification of medication regimen, clarification of any medication 
ambiguities and implementation of adherence support such as provision of non-child 
resistant closures to reduce dexterity problems200.  Holland’s HOMER study, a large 
RCT of home-based medication reviews in older people, reported similar interventions 
including organising large print labels for the visually impaired, non-childproof closures 
for patients with dexterity problems and, as far as feasible, ensuring dosing regimens 
fitted with patients routines208.  However, the primary focus of the HOMER intervention 
was to provide medication review.  The intervention also aimed to provide education to 
patients and carers, remove out of date drugs, report possible drug reactions and the 
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need for compliance aids.  The interventions made in other studies tend to focus on 
similar support such as patient education about their medication202, 207 and assessing 
the need for adherence aids207.  Hawksworth and Chrystyn’s intervention focused on a 
more clinical design, including medication reviews, therapeutic drug monitoring and 
checking other biochemical parameters.  The service also assessed patients’ 
healthcare needs, checked medication adherence and examined excessive medication 
stocks, removing any unwanted medicines where necessary204. 
2.1.4.3 Position of services within the care pathway 
A proportion of research tends to focus on the period immediately following hospital 
discharge202, 205; a particularly hazardous time in terms of potential confusion and the 
risk of medication errors.  Other studies have focused on patients living in the 
community who were referred into the service by their GP191, 200 or other healthcare 
professionals191, identified by their pharmacist203 or who met predefined inclusion 
criteria204 201 207.  
2.1.4.4  Effect of domiciliary based interventions  
Reported benefits of pharmacist domiciliary visiting services include potential 
prevention of unplanned hospital readmissions204 and improved medication 
adherence191 202, 203.  Further benefits also include, improved clinical outcomes and cost 
reductions209 plus significant reductions in medicines related problems203.  The mean 
number of medicines prescribed has been significantly reduced following a pharmacy-
led medication review of older patients in their own homes207 and reductions in 
inappropriate medicines storage and hoarding also elicited208.  Recommended changes 
to therapy have also been deemed valuable by GP’s204.  A before and after study 
(N=143) of a tailored, pharmacist-led, home-based adherence intervention for older 
patients, reported significantly fewer medication related problems at follow up and 
significant improvements in adherence203. 
A large RCT of a home-based intervention delivered by both pharmacists and nurses 
(n= 762) reported a reduction in hospital admissions and deaths outside hospital210, 
however it is not possible to establish whether it was the pharmacist or nurse led 
components which were effective.  The follow-on study published by Stewart et al. a 
year later, did however only include nurse-led home visits211.  
A larger, UK based RCT (N=190), evaluated the impact of domiciliary visits on 
medication management in older patients who had recently been discharged from 
hospital202.  Patients in the intervention group received five domiciliary visits over a 
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twelve month period and demonstrated significantly better adherence, better medicine 
storage practices and a decreased tendency to hoard medicines.  They also required 
fewer GP visits or consultations than patients in the control group, who received 
standard care.  The authors concluded that the service was effective in detecting 
medicine related problems in a potentially high risk group.  In this, and all of the 
aforementioned studies, participants were identified by selecting patients matching pre-
defined inclusion criteria from either hospital or pharmacy records.  This method is not 
comparable to ‘real-life’ services where patients are identified by healthcare providers 
based on their individual need.  This limitation in the current body of knowledge is an 
important consideration, as this deficit could be addressed by formally evaluating a 
domiciliary service provided in a naturalistic setting.  
The HOMER trial (N= 872) was an RCT to determine whether a pharmacist-led home-
based medication review affected hospital readmission rates in older people205.  Older 
patients, recently discharged from hospital and who met broad pre-defined inclusion 
criteria were randomised to intervention or standard care.  Intervention group patients 
received two home visits to provide medicines education and remove any unwanted 
medicines.  Liaisons with the patients GP’s and community pharmacists were also 
made to rectify any medication related problems.  The intervention was associated with 
a significantly higher rate of hospital readmissions and did not significantly improve 
quality of life.  Although there were fewer deaths in the intervention group, this was also 
non-significant.  The authors of the HOMER study acknowledge that the reasons for 
these counter-intuitive findings are not known but suggest four possible explanations: 
1) The possibility of chance effects 
2) That the advice given enabled patients to present to their GP with problems earlier 
3) That the improved adherence increased previously avoided side effects/ adverse 
events 
4) That the intervention increased patient anxiety and confusion leading to greater 
dependence on health services 
A follow-on report to HOMER208, identified positive impacts from the pharmacists’ visits, 
including identification of adverse drug reactions (ADR’s) in 33% of patients and a 
significant reduction in inappropriate medicine storage and hoarding.  These findings, 
especially the detection of ADR’s may support Holland’s previously postulated notion205 
that the increase in hospital readmissions were actually warranted, to address issues 
such as ADR’s that may otherwise have gone undetected.  The economic evaluation of 
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the HOMER study reported a 25% probability of intervention cost effectiveness and 
therefore concluded that the likelihood of cost effectiveness is low212. 
A small number of other domiciliary medicines support studies have also included 
some form of simple cost analysis.  Hawksworth and Chrystyn’s clinical domiciliary 
pharmacy service (n=50) was crudely evaluated from a financial perspective by 
assessing the costs saved through avoided hospital admissions, based on data from a 
clinical panel that assessed the likelihood of readmissions.  The estimated cost saved, 
exceeded the remuneration necessary to fund the service and cost savings made 
through removal of excess, unwanted and out of date stock also inferred cost 
efficacy204.   Whilst the inclusion of an independent clinical panel to assess the 
importance of the interventions made, strengthens the study design, the conclusions 
made may have been premature generalisations based on a sample size of just fifty 
patients.  The subjective method of valuing the intervention also introduces a limitation. 
Removal of unwanted medicines and a reduction in the number of regularly prescribed 
medication, has also been used to demonstrate that such services represent a good 
use of NHS resources203.  More recently, Desborough et al. undertook a simple cost-
consequences analysis of the Norfolk Medicines Support Service; a pharmacist-led 
service based on provision of MCAs183.  The evaluation, which assumed a before and 
after study design and was based on 117 patients, reported a mean cost saving of 
£307 per patient following the intervention, plus reduced hospital admissions and 
improved medication adherence.  Whilst these studies provide a useful insight into the 
potential cost savings associated with domiciliary support services, the limitations of 
the before-and-after study design should be acknowledged.  
2.1.4.5  Outcome measures used to determine effect 
A common aim of pharmacy-led domiciliary services is to improve medication 
adherence, therefore, it is unsurprising that medication adherence is a commonly used 
outcome measure183, 200, 202, 203 as demonstrated in table 2.1.  Two of these studies 
assessed medication adherence via self-report183, 203, one used pill counts200 and one 
used both pill counts and patient interviews202.  Other outcome measures have 
included emergency hospital readmissions205-207, care home admissions207, healthcare 
utilisation data206, 209, medication related risks of harm213, patient deaths205-207 and 
patient quality of life183, 205, 207, 209. 
Whilst multiple studies provide evidence for improvements in outcome measures such 
as adherence, reducing medicine related problems and reducing inappropriate 
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medicine storage and hoarding, when outcome measures such as quality of life and 
hospital admissions are used, the evidence for positive effects becomes less clear.  It 
is therefore evident that no single, gold-standard outcome measure is available for 
evaluation of domiciliary medicines support services.   
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Table 2.1 Summary of research evidence relating to domiciliary medicines support services 
Paper Year Location Sample 
size 
Study 
type 
Intervention details Outcome measures Delivered by Delivered to Key results 
Begley et 
al.202 
1997 UK 190  RCT Assessment of  
knowledge, dexterity & 
cognitive functioning 
plus advice on storage 
& use of medicines  
Adherence (pill 
counts and 
interviews). GP 
consultations.  
Pharmacist Older patients 
recently 
discharged 
from hospital  
Significantly better 
adherence, better drug 
storage & decreased 
hoarding. Fewer GP 
consultations or visits. 
Coleman et 
al.201 
2001 UK 100 Cohort 
study 
3 home visits  Peer assessed 
impact on patient 
care 
Community 
pharmacist 
Older patients Favourable/ important 
impact on patient care 
in most cases. 
Desborough 
et al.183 
 
2012 UK 117 Before & 
after 
study 
Home-based 
medication review  
Self-reported 
adherence and 
quality of life 
Pharmacists Non-adherent  
patients aged 
>65 years 
Increased medication 
adherence. No 
significant changes in 
health-related QOL. 
Dilks184 2007 UK 468 Service 
evaluation 
General medication 
review, stock checks, 
counselling, 
adherence support & 
clinical monitoring 
None – 
characterisation of 
practice 
Domiciliary 
pharmacists 
At risk    
housebound or 
older patients 
Unnecessary 
medicines stopped, 
new medicines 
recommended & 
medicines synched 
Foulsham & 
Goodyer191 
1999 UK 90 Cohort 
study 
Semi-structured 
interview to assess 
medicines difficulties 
Appropriateness of 
referrals 
Pharmacist Community 
patients 
Little difference in 
appropriateness of  
referral between GP, 
nurse & social services 
Hawksworth 
& Chrstyn204 
1997 UK 50 Cohort 
study 
Medication review, 
TDM, adherence 
checks, removal of 
excessive stocks & 
unwanted medicines 
Patient risk of harm, 
unplanned hospital 
readmissions 
Community 
pharmacist 
Older patients  Prevention of 
unplanned hospital 
readmissions. 
Reduced likely harm to 
patients.  
Holland et 
al.205 
2005 UK 872 RCT Medication review, 
education & removal of 
unwanted drugs. 
Emergency hospital 
readmissions, death 
& QoL (EQ-5D) 
Community 
and hospital 
pharmacists 
Older patients 
recently 
discharged 
form hospital 
Significantly higher 
rate of hospital 
readmissions in 
intervention group. 
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Table 2.1 (continued)  Summary of research evidence relating to domiciliary medicines support services 
 
Paper Year Location Sample 
size 
Study 
type 
Intervention 
details 
Outcome 
measures 
Delivered by Delivered 
to 
Key results 
Lenaghan et 
al.207   
2007 UK 136 RCT Education, ID 
pharmaceutical care 
issues, assess need 
for adherence aids 
Admissions to 
hospital or care 
homes, deaths, 
& QoL (EQ-5D) 
Community 
pharmacists 
Patients 
aged >80 
years, living 
at home 
No difference in hospital 
admissions, care home 
admissions or death.  
Raynor et al. 203.   2000 UK 143 Before 
and after 
study 
ID of adherence 
problems. Individual 
action plans to revise 
medication regimens.  
Self-reported 
adherence 
Community 
pharmacists 
Patients 
aged >65 
years, living 
alone 
Significant reduction in 
medication problems 
and improved patient 
adherence 
Schneider & 
Barber200 
1996 UK 39 Cohort 
study 
ID adherence 
problems and 
hoarding 
Adherence (pill 
counts) 
Community 
pharmacists 
Housebound 
patients 
Non-adherence due to 
forgetfulness, confusion, 
poor understanding & 
side effects 
Sorensen et al. 
209
  
2004 Australia 400 RCT Education, 
medication review,  
multidisciplinary 
action plans  
Health-related 
QoL, ADRs, GP 
visits 
GPs and 
pharmacists 
At risk 
community 
based 
patients 
No differences in health 
related QoL. ADRs and 
GP visits reduced 
Stewart et al.211 1999 Australia 200 RCT Multidisciplinary, 
home-based 
intervention 
Unplanned 
hospital 
readmissions,  
out-of-hospital 
deaths 
Cardiac nurse Heart failure 
patients 
discharged 
from hospital 
Significant reduction in 
unplanned hospital 
readmissions and out-
of-hospital deaths in 
intervention group 
Waddingham213 2012 UK 50 Service 
evaluation 
Domiciliary 
medicines 
management service 
Patient risk of 
harm from 
medicines 
Specialist 
pharmacy 
technician 
Community 
based 
patients 
Reduction in risk of 
harm from medicines 
following intervention 
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2.1.5 The need for a service evaluation; application of background 
knowledge to research methods and study design  
The deficit in reports of pharmacy technician led domiciliary medicines support 
services, coupled with the need to provide more conclusive evidence of service benefit, 
beyond anecdotal reports, highlights the need for formal evaluation of such a service. 
In addition to providing evidence of service efficacy and patient value, this service 
evaluation will provide an opportunity to characterise service provision, and gather 
valuable data regarding the recipients of a technician-led service and the interventions 
utilised in supporting their adherence.   This will provide a ‘snap-shot’ assessment of 
community pharmacy-based services to improve non-adherence of a primarily 
unintentional nature.   
Outstanding methodological questions with regard to choice of outcomes measures in 
this domain can also be considered in undertaking the service evaluation.  
2.1.5.1  Selection of outcome measures 
The primary aim of the CCS NHS Trust domiciliary services is to improve medication 
adherence, therefore, inclusion of an adherence based outcome measure is necessary.  
Whilst electronic monitoring is the gold-standard approach, the frequent provision of 
MCAs in these services is problematic.  Technologies to enable electrionic monitoring 
with MCAs are available, but costly.  Moreover, changes to packaging to accommodate 
electronic monitoring had potential to confuse an already vulnerable population with 
cognitive impairments.  Electronic monitoring of medication adherence was therefore 
rejected as a feasible outcome measure.  Pill counts require multiple home visits thus 
are costly and as described in chapter one, the monitoring may alter patient 
behaviour158.  Whilst self-reported medication adherence has known problems of bias 
and recall difficulties, it is inexpensive and of low burden to participants and thus 
deemed to be an appropriate measure of medication adherence for this study.   
Table 2.2 summarises the desirable characteristics of the self-report adherence 
assessment tool which were carefully considered to ensure appropriate data collection 
and suitability for use in the population in question. 
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Characteristic  Rationale 
Simplicity and brevity of use To ensure a good response rate, especially in 
population with cognitive impairments  
Well designed and unambiguous To facilitate ease of use 
Assessment of adherence to all 
medicines prescribed, not individual 
medicines  
Replication of tool for each medicine would be 
unacceptably long and complex given the 
expected poly-pharmacy & cognitive impairments 
Continuous scale rather than 
dichotomous responses 
To ensure sufficient sensitivity for identification of 
changes in frequency of non-adherent behaviours 
Detection of broad range of non-
adherent behaviours  
To identify non-adherence of both an intentional 
and unintentional nature 
Non-threatening, non-judgemental 
and open phrasing of questions 
To encourage a good response rate and honesty 
Table 2.2 Desirable characteritsics for an adherence assessment tool 
The self-report adherence assessment tools identified in chapter one, were deemed 
too brief to elicit sufficiently detailed information144 or too complex and lengthy for the 
population in question146, 152, 154.  They were also rejected for their lack of relevance to 
this study153 and dichotomous type responses144, 145.  None of the tools evaluated were 
intended for use on generalised medication adherence rather than specific 
medications, therefore tools such as Horne’s Medication Adherence Rating Scale 
(MARS), were also rejected.  The deficit in appropriate, validated tools demonstrated a 
need to develop a novel adherence assessment tool for use within the population likely 
to receive a domiciliary visit. 
Previously reported outcome measures such as healthcare utilisation data, emergency 
hospital admissions and patient deaths were deemed unintuitive and potentially 
misleading in a population where progressive decline is anticipated.  Health-related 
quality of life was also rejected as an outcome measure, due to an anticipated lack of 
sensitivity for the intervention in question and general irrelevance which could confuse 
respondents.   
Beyond improving medication adherence, a key focus of the service is to improve 
patient safety and support patients to keep living in their own homes by reducing the 
risks associated with medicines mismanagement.  A means of detecting any reductions 
in the patient’s risk of harm following the intervention was therefore an intuitive 
outcome measure, in addition to self-reported medication adherence.  The National 
Patient Safety Agency (NPSA) have developed a commonly used risk matrix tool214, 
where risk scores are calculated by combining estimates of consequence (severity or 
outcome) and likelihood (frequency or probability) to produce an overall score ranging 
from 1 indicating rare negligible harm through to 25 indicating almost certain 
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catastrophic harm.  Although not validated for use in research, reports of the NPSA risk 
matrix’s use in assessing medication related risks of harm are available215, 216.  
However, the methods used to assign the risk scores in these studies are either not 
described215 or lacking in both rigour and detail216.  In this study, an indication of validity 
was obtained by comparison of the risk scores obtained with the NPSA risk matrix, to 
those obtained with the Fuller’s risk tool.  This tool was validated and refined for use in 
April 2004217, 218 to identify medicine related risks of harm and consists of seven 
domains.  The reliability of the NPSA risk tool, amongst multiple raters was also 
explored, representing a novel research application.  
Beyond self-reported medication adherence and patient’s risk of harm from their 
medicines, additional outcome measures included: 
• Patient satisfaction with the service – an intuitive outcome for a service evaluation, 
assessed via the Client Satisfaction Questionnaire (CSQ-8)219; a widely used a 
validated tool which is simply worded and easily understood220. 
• Patients’ perceived changes in confidence and ability to manage their medicines 
following the intervention – to assess the anecdotally reported additional benefits of 
the service, using an adaptation of a previously validated tool221. 
• Caregiver satisfaction with the service – using an adapted version of CSQ-8219 to 
enable alternate data collection where cognitive impairment is prohibitive of patient 
self-completion of the CSQ-8 questionnaire. 
• Changes to caregiver feelings following the intervention - to assess the anecdotally 
reported additional benefits of the service, using an adaptation of a previously 
validated tool221. 
The adaptations to the patient confidence221 and satisfaction tools219 are summarised in 
the methods section and table 2.3. 
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2.2 Service evaluation aims and study methods 
2.2.1  Aims  
To describe the interventions within a pharmacy technician-led domiciliary medicines 
management service and to assess service impact on patient adherence and 
medication related risk of harm. 
2.2.2  Objectives 
• To describe the nature of the pharmacist technician intervention, including visit, 
patient and medication details 
• To describe and quantify any changes in patient adherence and risk scores 
following intervention 
• To establish the level of agreement between healthcare professionals in assigning 
risk assessment scores to patients pre and post intervention 
• To explore agreement between the Fullers and NPSA risk assessment tools 
• To quantify patient satisfaction with the service and changes in patient ability and 
confidence with the management of their medicines 
• To quantify and describe patient caregiver satisfaction with the service and their 
feelings about providing care following the intervention 
2.2.3  Methods overview 
The UEA’s Faculty of Health Ethics Committee confirmed that as a service evaluation 
study, full NHS ethical approval was not necessary (appendix 2.1).  Given that the 
study involved an evaluation of a routinely provided service and would (primarily) 
involve analysis of existing data, the study was classified as a service evaluation 
according to the National Research Ethics Service (NRES) definitions222. 
A service evaluation of the CCS NHS Trust Domiciliary Medicines Management 
Service was undertaken using routinely collected and patient reported data.  Patients 
were referred into the service in the standard way and received the usual domiciliary 
visit, during which routine data were collected.  Additionally, pre-intervention self-
reported adherence was elicited using a patient questionnaire.  Following the 
intervention, patients and where appropriate patients’ caregivers, were posted a 
service evaluation questionnaire to determine service impact and satisfaction.  In 
addition to the data from the questionnaires, information gathered from the domiciliary 
visits was used to calculate each patient’s risk of harm from their medicines at both the 
pre and post intervention stage. 
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2.2.4  Patient identification and recruitment  
Patients could: 
• self-refer  
• be referred by a carer or relative 
• be referred by a healthcare professional such as a GP or district nurse 
• be referred by a paid carer, support worker or social services representative 
2.2.5  Inclusion criteria  
Patients referred into the CCS NHS Trust service and who received their initial visit 
during a four month recruitment period from February to June 2012.  
2.2.6  Exclusion criteria 
There were no exclusion criteria for study participation. 
2.2.7  Outcome measures 
Two primary outcome measures were used in the study: 
1. Change in patient adherence following the intervention 
2. Change in patient’s medication related risk of harm following the intervention 
Secondary outcome measures included: 
• Patient and patient caregiver satisfaction with the service 
• Changes in patients perceived confidence and ability to cope with medicines 
• Changes in patient caregiver feelings 
2.2.8  Domiciliary visiting process 
A flow chart summarising the study procedures and methods is provided in figure 2.1.   
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Figure 2.1 Data collection and analysis flow chart 
 
Initial contact with patient made by Specialist Pharmacy 
Technician (SPT) to arrange visit & usual pre-visit data 
collected.  All patients with initial visit booked during 
‘recruitment period’ included in study and assigned unique 
identification reference.  
Referral into service made in usual manner   
Database created of 
patient identification 
numbers, personal 
details & contact 
details.  Database 
remained secure at 
CCS.  All subsequent 
data used patient ID 
number 
Initial patient visit made to discuss medication related 
problems. Demographic, medication and adherence related 
problems elicited and recorded. Self-reported adherence 
assessment questionnaire collected and discussed and/or 
completed as part of visit. 
Implementation of intervention and support as necessary.  
Questionnaires 
returned to UEA for 
analysis by service 
evaluation team 
 
Assignment of pre-
intervention NPSA 
risk scores 
independently by four 
healthcare 
professionals.  Risk 
scores based on 
background and initial 
visit data on data 
collection forms 
Follow up patient visit arranged by SPT to assess efficacy 
of intervention & address any unresolved issues. 
Patient follow up visit made and copy of ‘follow up visit 
data collection form’ sent to Service Evaluation Team at UEA 
Post-intervention questionnaire sent to patients (or 
caregivers) with covering letter.  
Pre-visit adherence assessment questionnaire sent to 
patient with instructions to complete prior to initial visit. 
Adherence assessment questionnaire and initial visit data 
collection form sent to research team at UEA 
Assignment of post-
intervention NPSA 
risk scores 
independently by four 
healthcare 
professionals.  Risk 
scores based on 
information captured 
in follow up visit data 
collection forms 
Second mailing of post-intervention questionnaire to 
patients (or caregivers) with covering letter.  
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2.2.8.1  Patient referral into the service 
The Specialist Pharmacy Technician (SPT) prioritised referrals according to details of 
the medicine related problems provided at the point of referral.  Before visiting the 
patient, the SPT gathered the relevant information needed, such as details of 
prescribed medicines from the patient’s GP and frequency of prescription collection 
from the local pharmacy. 
2.2.8.2  Arranging the initial visit 
All patients were contacted via telephone to arrange an initial visit and asked to 
complete the adherence assessment questionnaire prior to the SPT’s visit to enable its 
discussion.  The adherence assessment questionnaire was posted to patients once the 
initial visit had been confirmed, with instructions for completion.  A unique patient 
identification reference was assigned to each patient to ensure all data were 
anonymous.  The corresponding patient details to identify the patient reference were 
securely stored at CCS NHS Trust. 
2.2.8.3  The initial visit 
During the visit the SPT elicited further details about the difficulties experienced by the 
patient in taking their medicines.  All potential avenues of support and assistance were 
fully explored, and the intervention provided was tailored to meet individual needs.  
Where possible, patients were involved in all decision making processes.  Detailed 
notes of the visit were recorded on a data collection form (appendix 2.2) which 
included: 
• Demographic data including patient age, gender and whether they lived alone or 
with a carer or relative 
• Number of regularly prescribed medicines  
• Details of the medicine related problems and likely risks 
• Details of any physical and cognitive difficulties experienced and their current level 
of support provision 
• Details of the intervention 
The design and content of the initial visit data collection form was informed by the 
Fuller’s risk screening tool (see figure 2.5), as this data would be used to assign risk 
scores later.  For details such as cognitive or physical difficulties, formal assessment 
tools were not used as this was deemed to be beyond the remit of the study and not 
advised for use with the Fuller’s risk tool223.  Instead a subjective assessment was 
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made by the SPT based on the patient and pre-visit data, for example, for a patient 
who appeared to be muddled with their medicines, confused by the days of the week 
and who confessed forgetting to take their medicines, the SPT would record this patient 
as ‘confused and forgetful’.  
The adherence assessment questionnaire was also, where possible, discussed during 
the initial visit to further clarify the nature and magnitude of patient non-adherence.  In 
instances where the patient had not completed the questionnaire in advance, where 
possible, the SPT administered the questionnaire verbally during the visit. 
After the initial visit, the SPT sent the anonymised ‘initial visit data collection form’ and 
adherence questionnaire to the UEA research team.   
2.2.8.4  Implementation of the interventions recommendations  
The processes of intervention implementation were variable according to the patient’s 
needs, for example, some patients needed their medication dispensed in a compliance 
aid, in which case the SPT liaised with the patient’s GP and local pharmacy to arrange 
for provision.  Alternatively, some patients needed simplification of their medication 
regimen, in which case the SPT liaised with the patient’s GP to suggest changes. 
2.2.8.5  Follow up visit 
Post intervention implementation, the SPT re-visited the patient to assess intervention 
effect and whether any further support was necessary.  The interval between the initial 
and follow up visit varied according to patient need.  Details of the follow up visit were 
recorded on a data collection form (appendix 2.3) and posted to the UEA service 
evaluation team for data extraction and the dissemination to the panel of risk scorers.  
2.2.9  Content and design of questionnaire based tools 
2.2.9.1  Pre-intervention adherence screen 
Figure 2.2 shows the adherence assessment tool that was developed by critique of 
pre-existing adherence assessment tools, (described in chapter one) and consideration 
of the study population.  The tool consisted of nine statements to represent commonly 
cited reasons for non-adherence, such as ‘I forget to take my medicines’ or ‘I have 
difficulty swallowing my medicines’.  For each statement, the patient was asked to 
indicate how often this led to them taking their medicines differently to prescribed, 
using a five point Likert scale ranging from always to never.  A five point scale 
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represented the best opportunity to capture meaningful data, without over burdening 
respondents with excessive options. 
The chosen ‘reasons’ for non-adherence covered both intentional and unintentional 
non-adherence, with both primary and secondary unintentional non-adherent 
behaviours gaining representation.  In any other population, more ‘reasons’ such as not 
taking medicines due to concerns over side effects or fear of embarrassment may have 
been included.  However, given the limitation of needing to keep this tool as simple and 
brief as possible, a maximum of nine ‘reasons’ was chosen as this was deemed to be a 
reasonable compromise between eliciting comprehensive information and not 
overburdening respondents.  Furthermore, by choosing a maximum of nine ‘reasons’, 
the tool could be kept to one side of A4 sized paper; a feature important to the overall 
questionnaire design and layout141, 150. 
Each statement on the questionnaire was scored on a five point scale with a response 
of ‘always’ scoring five points, through to a response of ‘never’ scoring one point.  The 
scores for each statement were then added together to give an overall score ranging 
from nine to 45 with higher scores indicative of greater non-adherence. 
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Domiciliary Medicines Management Service – Initial Assessment 
Medicines Management Service – Initial  
Many people have difficulty taking their medicines or find a way to use their 
medicines which best suits them. 
• The statements listed below are common situations that people 
experience. 
• For each statement, please tell us how often these lead to you taking 
your medicines differently to the instructions on the label or from your 
doctor. Please tick () the response that best reflects how you feel. 
 
Figure 2.2 Adherence assessment tool developed for use in study 
I take my medicines differently to 
instructed because: 
Always 
 
Often Some-
times 
Rarely Never 
I have difficulties opening medicine 
packaging, or using items such as 
inhalers or eye drops  
     
I have difficulties swallowing my 
medicines 
     
I struggle to read the instruction 
labels 
     
I have difficulties in remembering 
what time to take each medicine 
     
I forget to take my medicine 
 
     
I forget when to order or collect my 
medicines from the doctor or 
pharmacy 
     
I choose to alter the dose of my 
medicines if I feel better or worse 
     
I choose to miss out doses of my 
medicines if I feel better or worse 
     
I choose to stop taking my 
medicines for a while 
     
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2.2.9.2  Patient questionnaire  
The patient questionnaire (see appendix 2.4) was designed to elicit information that 
could not be gathered during the domiciliary visits and was posted to patients after their 
follow up visit, along with a covering letter (appendix 2.5).  Each questionnaire was re-
mailed two weeks after the original mailing with a slightly amended covering letter 
(appendix 2.6) explaining that the second mailing was a reminder in case the first 
questionnaire had been forgotten or misplaced.  Patients were advised to ignore the 
second mailing if they had already returned the first questionnaire. 
In recognition of the population in question and the possible levels of confusion, the 
salient points from a patient information sheet were incorporated into the covering 
letter.  Patients were therefore provided with all of the information needed to decide 
whether to complete the questionnaire, but paperwork was kept to a minimum to 
reduce the likelihood of confusion.  Patients were asked to complete the questionnaire 
and return it to the UEA using the pre-paid envelope provided.  Provision was also 
made for completion of the questionnaire over the telephone to accommodate potential 
visual, literacy or dexterity difficulties. 
The patient questionnaire comprised of three sections:  
1. Self-reported medication adherence – to elicit post-intervention medication 
adherence, using the same tool as the pre-intervention adherence screen.  
 
2. Patient confidence and ability to manage their medicines and health – to 
assess any changes in patients’ feelings towards managing their medicines and 
health following the intervention.  Based on a previously validated patient 
enablement tool221. 
 
3.  Patient satisfaction with the service – based on the Client Satisfaction 
Questionnaire (CSQ-8)219  
The second and third sections of the questionnaire were based on validated tools, but 
amended slightly to increase their relevance and to facilitate simplicity and brevity of 
use for the vulnerable questionnaire recipients.  A summary of the changes made to 
and the rationale for these changes is provided in table 2.3.   
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Questionnaire 
section 
Changes made Rationale for changes 
Patient 
confidence 
and ability 
Removal of two statements 
relating to coping with and 
understanding illness 
Deemed irrelevant to the purpose of 
the intervention 
Minor amendments to format 
and wording  
To improve consistency and patient 
acceptability 
Splitting and rewording the 
‘same or less’ response option 
To enable differentiation between no 
improvements and worsening ability 
and/or confidence 
Removal of ‘not applicable’ 
response option 
Deemed surplus to requirement as 
‘same’ option could be used when 
statement did not apply, plus 
improved ease of scoring  
Patient 
satisfaction 
Removal of ‘did you get the 
kind of service you wanted’ 
statement  
Considered irrelevant as majority of 
patients do not know what to expect 
Removal of ‘to what extent has 
the service met your needs’ 
statement 
Removed due to potential confusion 
of patients  
Removal of ‘if you were to seek 
help again would you choose 
the service again’ statement 
Removal due to irrelevance and 
potential confusion  
Changing response options to 
unidirectional format 
To facilitate simplicity of patient use 
and reduce cognitive burden 
Table 2.3 Summary of changes to validated tools used in patient 
questionnaire  
2.2.9.3  Patient caregiver questionnaire  
This questionnaire (appendix 2.7) was sent to patients’ informal caregivers following 
the intervention, where deemed appropriate by the SPT and/or requested by the 
caregivers.  A covering letter was mailed with the questionnaire (appendix 2.8).  Patient 
caregivers were provided with a pre-paid envelope to return the completed 
questionnaire directly to the research team at UEA.   
The caregiver’s questionnaire comprised of two sections: 
 
1. The carer’s feelings as a caregiver – designed to establish any effects of the 
service in terms of the caregiver’s anxiety, stress, confidence and time 
commitments.  This section was developed from the ‘confidence and ability’ 
sections of the patient questionnaire.  
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2. The carer’s satisfaction with the service - consisting of the same five 
questions used in the patient satisfaction questionnaire, with amended wording 
to reflect completion by the caregiver rather than patient.  
2.2.10 Public and patient involvement  
NHS Norfolk’s Patient and Public Involvement in Research (PPIRes) service224 was 
utilised to provide feedback on the questionnaires and study methods.  Feedback from 
a panel of ten members of the public, from diverse backgrounds, led to minor 
formatting and wording amendments in the questionnaires and covering letters to 
improve readability and clarity of instructions.  Changes to the questionnaire front page 
were also implemented to ensure that in the event of losing the covering letter, patients 
would still be able to complete and return the questionnaires.  
2.2.11  Piloting 
Data were collected for ten patients, prior to commencing full data collection to ensure 
feasibility of the data collection process and suitability of the questionnaires.  The data 
collection forms were subsequently amended to improve ease of use and ensure all 
data were captured unambiguously.   
Four patient questionnaires and five patient caregiver questionnaires were returned, 
with complete, accurate data and no suggestions for improvement, thus inferring 
questionnaire acceptability.  The only questionnaire change was therefore to remove 
the ‘not applicable’ option from the section on confidence, as detailed previously.  
The pilot phase also revealed that assignment of pre-intervention risk scores using 
both the NPSA and Fuller’s tools was excessively labour intensive.  As the Fuller’s tool 
was comparatively more objective and also previously validated, the lead researcher 
assigned risk scores using the Fuller’s tool, without the need to take a mean score from 
four HCPs.    
2.2.12  Data analysis 
2.2.12.1 Assignment of patient pre and post intervention risk scores using 
NPSA risk matrix214 
Risk assessment scores were calculated independently, by a panel of four healthcare 
professionals (HCPs) using the data collected on the initial and follow up visit data 
collection forms.  The panel of four HCPs comprised of a GP, nurse, community 
pharmacist and hospital pharmacist, selected from a convenience sample.  This 
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process was informed by the work of Dean and colleagues225, 226 who reported that only 
four HCPs comprised of; doctors nurses and pharmacists were needed to give high 
generalisability of hospital medication administration error scores.  A mean score from 
any four HCPs (ideally including a doctor, nurse and pharmacist) was both a reliable 
and valid approach 225. 
For each patient included in the service evaluation, the HCPs were asked to calculate a 
pre and post intervention risk score using the NPSA risk matrix as illustrated by figure 
2.3.  The risk scores assigned by each HCP were collated by the service evaluation 
team at UEA to determine the mean risk score pre and post intervention for each 
patient.  To allow for mean risk scores that did not fall within the NPSA’s specified 
ranges, the risk category boundaries were adjusted as detailed in figure 2.4.  The ‘low’ 
risk category remained unchanged, but the ‘medium’ risk group increased by one to 
include risk scores of 7.  The ‘high’ risk category was also extended by one to include 
risk scores up to 13 and the ‘extreme’ risk group was altered to include risk scores of 
14. 
In addition to the pre and post intervention risk scores assigned using the NPSA risk 
matrix, a pre-intervention risk score was also assigned using the Fuller’s risk screening 
tool, as detailed in section 2.2.12.2. 
 Likelihood  
Consequence 1  2  3  4  5  
 Rare  Unlikely  Possible  Likely  Almost certain  
5 Catastrophic  5 10 15 20 25 
4 Major  4 8 12 16 20 
3 Moderate  3 6 9 12 15 
2 Minor  2 4 6 8 10 
1 Negligible  1 2 3 4 5 
Risk scoring = consequence x likelihood (C x L)  
For grading risk, the scores obtained from the risk matrix are assigned grades as 
follows: 
 1 – 3 Low risk 
 4 – 6 Moderate risk 
 8 – 12 High risk  
 15 – 25 Extreme risk  
 
Figure 2.3 NPSA Risk matrix214 
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Figure 2.4 Risk score category boundaries for NPSA risk matrix (altered to 
accommodate for mean scores assuming full range of values) 
The use of the NPSA risk matrix can be exemplified by considering a hypothetical 
patient, typical of those evaluated in the service. The pre-intervention data could 
describe an 82 year old female living alone with moderate cognitive impairment who is 
prescribed multiple medicines including antihypertensives, opioid analgesics and 
warfarin.  This patient has formal carers who administer her medicines but the carers 
have noticed that the patient tampers with her medicines in between care calls and 
often takes additional doses or hides the medicines so that the carers can then not 
administer them.  Based on this pre-intervention data and using figure 2.2, a risk scorer 
may consider the consequence of harm to be ‘major’ (scoring 4) given the potential for 
under or overdosing on medicines such as opioids and warfarin and the likelihood of 
harm to be ‘possible’ (scoring 3) given the carers concerns.  This risk scorer would 
therefore assign a pre-intervention risk score of 12 (4x3).  However, based on the 
same data, another risk scorer may consider the consequence to be ‘catastrophic’ 
(scoring 5) given the risk of warfarin overdose and the likelihood to be ‘almost certain’ 
(scoring 5) given the additional doses known to be taken between care calls; this risk 
scorer would therefore assign a pre-intervention risk score of 25 (5x5).  The remaining 
two risk scorers may perhaps assign pre-intervention risk scores of, for example, 15 
and 16, therefore this patient’s mean pre-intervention risk score would be 17.  Figure 
2.3 shows that a risk score of 17 would be considered as ‘extreme risk’. 
At the post-intervention stage, the data provided to the risk scorers summarises the 
intervention.  Whilst there have been no changes in the patients cognitive state, 
prescribed medicines or social circumstances, the SPT intervened to provide a locked 
briefcase for storage of the medicines, to which only the carers had access.  This 
intervention meant that the patient could no longer tamper with their medicines in 
between care calls, could not take additional doses and all medicines were safely 
administered by the carers.  Based on this data, one of the risk scorers may now 
consider the likelihood of harm from medicines (in this instance taking additional doses) 
to be ‘rare’ (scoring 1) given the new intervention but, given the medicines prescribed, 
consider the consequence to still be major (scoring 4); this risk scorer would therefore 
 1-3 Low risk 
 4-7 Medium risk 
 8-13 High risk 
 14-25 Extreme risk 
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assign a post-intervention risk score of 4 (1x4).  A different risk scorer may however 
take a different stance and instead of focusing on the risk of overdose which has now 
been negated, question the clinical appropriateness of the medicines, given that a 
clinical review was not performed.  This risk scorer may consider that medicine related 
harm is ‘possible’ (scoring 3) which could have ‘moderate’ consequences (scoring 3) 
and therefore assign a post-intervention risk score of 9 (3x3).  If the remaining two risk 
scorers assigned risk scores of 5 and 6, then mean post-intervention risk score for this 
patient would be 6, placing them in the ‘medium’ risk category.  
2.2.12.2 Assignment of patient pre intervention risk scores using Fuller’s 
risk tool223 
Data collected during the initial visits were used by the principle investigator to assign 
pre intervention risk scores to all patients, using the Fuller’s risk scoring tool detailed in 
figure 2.5. 
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                                                                                                                        Score 
Number of 
prescribed 
medications 
1 
1 drug 
2 
2 drugs 
3 
3 drugs 
4 
4 or more 
drugs 
 
Mental state 1 
Alert and 
orientated 
 
4 
Orientated but 
sometimes 
forgetful 
8 
Confused, 
muddled/ 
disorientated/ 
very forgetful 
12 
Very confused/ 
forgetful 
 
Vision 1 
Can see to 
read with no 
aids 
2 
Needs 
glasses/aids to 
read print 
4 
Difficult to read 
print with 
glasses/ aids 
6 
Unable to see 
 
Social 
circum-
stances 
1 
Living with 
others who 
can fully 
support 
medication 
needs 
2 
Living with 
others who 
usually/ 
sometimes 
support 
medication 
administration 
3 
Living alone 
with some help 
from paid 
carers or 
family/ friend 
4 
Living alone 
with no help 
 
Physical 
condition 
1 
Can manage 
to open 
bottles/ 
packets 
independently 
2 
Weakness of 
hand/ poor co-
ordination, but 
can manage to 
open bottles/ 
packets with 
difficulty 
3 
Disabled. 
Requires 
some help to 
open bottles/ 
packages 
4 
Severely 
disabled 
unable to 
manage 
 
Attitude and 
knowledge 
about 
medicines 
1 
Interested 
about 
prescribed 
medicines and 
knows all 
about them, 
believes they 
are important 
2 
Fairly 
interested 
about 
prescribed 
medicines and 
knows enough 
about them to 
administer 
them safely/ 
believes they 
are important 
8 
Not very 
interested in 
prescribed 
medicines. 
Does not 
believe they 
are important/ 
unable to 
recall 
medicines 
regime 
12 
Disinterested 
and/or 
unwilling to 
take 
prescribed 
medication 
 
 
6-13 Low risk   14-16 Medium risk    17-22 High risk    23-42 Very high risk 
TOTAL  
 
 
Figure 2.5 Fuller’s self-medication risk assessment screening tool223  
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2.2.12.3 Statistical analysis and data manipulation 
Appropriate descriptive statistics were used to characterise the population in terms of 
demographics, medication related problems, types of intervention, patient risk 
assessment scores pre and post intervention, patient adherence pre and post 
intervention, patient and caregiver satisfaction with service, patient confidence with 
their medicines and health and patient caregiver feelings following the intervention. A 
summary of the statistical analyses undertaken is provided in table 2.4.   
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Table 2.4 Summary of statistical analyses undertaken 
Objective Variables Statistical test Rationale 
To determine significance of  changes in 
SPT reported adherence post intervention 
Proportion of patients categorised as 
fully adherent pre & post intervention  
McNemar’s chi-squared Dichotomised, nominal repeated 
measures data 
To determine significance of changes in 
patient reported adherence  
Median adherence score pre 
intervention and post intervention  
Wilcoxon Signed Ranks Repeated measures non-
parametric data 
To assess agreement between patient and 
SPT reported adherence problems 
All patient and SPT reported 
adherence problems 
Kappa co-efficients with average 
proportions of agreement for 
positive (Ppos) and negative 
responses (Pneg ).  
Kappa suitable for two raters, 
and nominal data.  High 
prevalence of negative 
responses (no adherence 
problems) meant Ppos and Pneg 
were needed to avoid biased  
interpretations of kappa 227, 228 
Adherence problems reported by 
patients ‘always’ 
Adherence problems  reported by  
patients ‘often’ 
Adherence problems reported  by 
patient ‘sometimes’ 
To determine significance of any changes  
in the ranking of NPSA risk score 
categories  post intervention  
Risk score categories pre and post 
intervention  
Wilcoxon matched pairs test Repeated measured ordinal data 
To establish inter-rater agreement for 
NPSA risk scores 
NPSA risk scores assigned by four 
different HCPs 
Kendall’s co-efficient of 
concordance (W) 
Literature recommended test for 
ordinal data and multiple 
raters229  
To establish inter-rater reliability between 
HCPs in assigning NPSA risk scores 
NPSA risk scores assigned by four 
different HCPs 
Two-way, random, consistency, 
average-measures Intra-Class 
Coefficient (ICC) 
Literature recommended 
assessment of inter-rater 
reliability230  
To establish agreement between risk 
scores assigned using two different risk 
assessment tools 
Pre-intervention risk scores assigned 
using NPSA risk matric and Fuller’s 
risk tool 
Two-way, random, absolute 
agreement, average-measures 
Intra-Class Coefficient (ICC) 
ICC equivalent to weighted 
kappa (for ordinal data) under 
general conditions231  
To compare degree of reported cognitive 
function between recipients and non-
recipients of the patient questionnaire  
Number of patients in each cognitive 
function category and whether or not 
they received a questionnaire 
Mann-Whitney U Two independent groups 
(recipients and non-recipients) 
with ordinal dependent variable 
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2.3 Results 
A flow diagram summarising the patients included and data collected is provided in 
figure 2.6.  Whilst the majority of patients provided both pre and post intervention data, 
post-intervention questionnaires from either the patient or their informal carers were 
only returned for 43.4% of patients. 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note all 99 patients receiving an initial visit had a pre-intervention risk score using the NPSA 
risk matrix and Fuller’s risk screening tool plus SPT adherence assessment 
All 95 patients receiving a follow up visit had a post-intervention risk score calculated using the 
NPSA risk matrix plus SPT adherence assessment 
Figure 2.6  Flow diagram to summarise patients included in the study and data 
collected 
Patients receiving initial 
visit (n=99) 
Patients receiving follow-
up visit (n=95) 
Follow-up visits 
Completed by telephone call (n=86) 
Completed by telephone call & in-person visit (n=7) 
Completed by in-person visit (n=2) 
Questionnaire sent to 
either patient or carer 
(n=64) 
Patient and caregiver questionnaires sent 
Patient questionnaire sent (n=37) 
Caregiver questionnaire sent (n=27) 
Patient or carer 
questionnaire returned 
(n=43) 
Patient and caregiver questionnaires returned 
Patient questionnaires returned (n=22) 
Carer questionnaires returned (n=21) 
Patients receiving an 
intervention (n=97) 
No intervention needed as patient managing well (n=2) 
Patient deceased (n=2) 
No questionnaire sent due to insufficient 
cognitive capacity and no informal carer (n=31) 
Patient questionnaires not returned (n=15) 
Carer questionnaires not returned (n=6) 
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Figure 2.7 shows the flow of data for patients’ self-reported adherence.  Loss to follow 
up caused a notable problem for this outcome measure as pre and post intervention 
data were only available for ten patients.  
       Pre-intervention       Post-intervention 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 Summary of data collection for patient reported adherence data 
2.3.1 Domiciliary support service recipients  
In total, 99 patients were included in the study; 69 (69.7%) of patients were female.  
Table 2.5 summarises the key patient characteristics, as captured on the data 
collection forms.  Patients were primarily older, with a median age (IQ range) of 82 (76 
to 86) years.  Of the 83 (83.8%) patients with some degree of cognitive impairments, 
47 (48.5%) were slightly confused and/or slightly forgetful, 12 (12.1%) were very 
confused and/or forgetful and 23 (23.2%) had a formal diagnosis of dementia (or under 
investigation).  
Patients tended to be living alone and this was the case for 63 (63.6%) patients; 22 of 
whom (34.9%) had no additional help or support in their medicines taking.  Whilst most 
Patients sent initial 
adherence 
assessment (n=99) 
Patients sent follow 
up questionnaire 
(n=37) 
Initial adherence 
assessment 
completed (n=48) 
Not completed: no 
reason given (n=51) 
Patients returning 
follow up 
questionnaire (n=22) 
Patient questionnaire 
not returned (n=15) 
Patients with fully 
complete adherence 
assessment (n=16) 
Adherence assessment 
section incomplete (n=6) 
Patients with complete adherence assessment data pre and post 
intervention (n=10) 
Patients did not complete initial 
adherence assessment (n=6) 
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patients could access their medicines independently and with ease, 14 (14.6%) 
patients reported struggling to do so and 22 (22.9%) required assistance with 
accessing or administering their medicines.  
The majority of patients were interested in their medicines, thought their medicines 
were important and were willing to take their medicines.  However, 53 patients (54.5%) 
were not knowledgeable about their prescribed medications and could not recall their 
regimens.  A majority of patients were reported as being unable to administer their 
medicines safely, and this was the case for 58 patients (59.8%). 
2.3.2 Prescribed medicines 
All patients were prescribed multiple medicines, with a median (IQR) of 9 (7 to 12) 
medicines per patient at the pre-intervention stage.  The median number (IQR) of 
doses taken daily, for regular use was 12 (7 to 19).   
The most commonly prescribed group of medicines, according to British National 
Formulary (BNF) chapter, were those affecting the cardiovascular system totalling 
35.4% of all prescriptions.  Medicines affecting the central nervous, endocrine and 
gastro-intestinal systems accounted for 19.1%, 15.7% and 11.2% of all prescriptions 
respectively.  Proton Pump Inhibitors (PPIs) were found to be the most commonly 
prescribed therapeutic group, accounting for 6.5% of all prescriptions.  The most 
commonly prescribed medicine was paracetamol; 39.4% of patients had this medicine 
on their repeat list. 
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Table 2.5      Summary of patient characteristics at pre-intervention stage  
Patient 
Characteristic  
Categories & number (%) of patients 
Co-habitation 
status 
Living alone 
63 (63.6%) 
Living with partner 
33 (33.3%) 
Living with family member 
1 (1.0%) 
Living in care home 
1 (1.0%) 
Other 
1 (1.0%) 
Mental state Alert and orientated 
17(17.2%) 
Slightly confused and/or 
slightly forgetful 
47 (48.5%) 
Very confused and/or very 
forgetful  
8 (8.2%) 
Dementia under 
investigation  
4 (4.1%) 
Formal diagnosis of 
dementia  
23 (23.7%) 
Vision Able to read without aids  
70 (75.3%) 
Needs glasses or aids to 
read print  
6 (6.5%) 
Struggles to read print even 
with aid or glasses  
9 (9.7%) 
Illiterate 
4 (4.3%) 
Registered blind  
3 (3.2%) 
Social 
circumstances 
Living alone but with help 
from friends, family or 
carers 
46 (47.4%) 
Living alone without any 
help 
22 (22.7%) 
Living with someone who 
supports their medication 
needs 
15 (15.4%) 
Living with someone 
who does not support 
their medicines needs 
9 (9.3%) 
Other 
5 (5.2%) 
Physical 
condition 
Can access all medicines 
independently and with 
ease  
60 (62.5%) 
Requires assistance with 
accessing or 
administering medicines 
17 (17.7%) 
Can manage to access all 
medicines but struggles  
14 (14.6%) 
Has difficulty 
swallowing medicines  
3 (3.1%) 
Severely disabled 
and unable to 
mange 
2 (2.0%)  
Attitude 
towards 
medicines 
Shows interest in 
medicines 
76 (79.2%) 
Believes medicines are 
important 
92 (95.8%) 
Willing to take medicines 
91 (93.8%) 
Able to administer 
medicines safely 
35 (35.6%) 
Able to recall 
medication regimen 
35 (36.5%) 
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2.3.3  Details of the domiciliary visits 
2.3.3.1  Referrals into the service  
Healthcare professionals (HCPs) accounted for 42 (42.9%) referrals.  Within this group, 
nurses accounted for 19 referrals (45.2%) and there were 11 GP referrals (26.2%).  
Other sources of referral within the group of HCPs included psychiatrists, occupational 
therapists and speech and language therapists.  
Referrals from ‘social’ based sources, such as care-agency co-ordinators and housing 
scheme managers, accounted for 27 (27.6%) referrals in total.  Friends and family 
members accounted for 12 (12.2%) referrals and there were six (6.1%) self-referrals.  
The remaining 11 referrals (11.2%) came from pharmacy staff or prescription clerks at 
the local surgery.  
2.3.3.2  Reasons for referral into the service 
Figure 2.8 provides a summary of the reasons for referral into the service.  The majority 
of referrals related to some kind of cognitive impairment with 39 referrals (39.4%) made 
due to concerns over the patient’s failing memory, confusion, being known to forget to 
take their medicines or because of a recent diagnosis of dementia.  
 
Figure 2.8 Summary of reasons for patient referral into service 
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2.3.4  Identification and management of medication difficulties  
A wide range of medication related difficulties were identified, with all bar two patients 
experiencing some form of difficulty which required intervention.  The vast majority of 
medication related difficulties were associated with non-adherence, as reported in 
section 2.3.5.1. 
2.3.4.1  Medication difficulties unrelated to adherence 
In addition to the medication difficulties associated with non-adherence, 29 patients 
(29.3%) also experienced difficulties which were not specifically associated with 
adherence such as excessive stock holding and inaccurate repeat medication lists.  
Table 2.6 provides a summary of the medication difficulties experienced that were 
unrelated to adherence and the resolution strategies deployed by the SPT to overcome 
these.  The most common medication difficulty that was not directly related to 
adherence was the presence of discontinued medicines on the patient’s medication 
repeat list, followed by the presence of excessive stocks of medicines in the patient’s 
home.  On four occasions, the build-up of excessive medication was due to community 
pharmacies automatically reordering all of the patient’s medicines each month, without 
checking what was required first.  For the 29 patients that had medication problems 
unrelated to non-adherence at the initial visit stage, 89.7% had these problems 
resolved by the follow up stage. 
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Medication 
difficulty 
No. (%) 
patients 
affected 
Resolution strategy 
utilised by SPT 
Outcome 
Discontinued 
medicines on  
repeat list  
10 
(10.1%) 
Query need for medication 
at GP surgery (n=10) 
Re-initiation of medication 
considered necessary (n=4) 
Redundant medicines 
removed from repeat list (n=6) 
Excessive 
medication 
stocks in 
patients home 
8 (8.1%) Removal of excess 
medicines (n=8) 
Excessive medicines stocks 
avoided (n=8) 
Patient counselled not to 
order each month (n=1) 
Prevention of recurrence of 
excessive stock build up (n=1) 
Medication added to an 
MCA (n=2) 
Prevention of recurrence of 
excessive stock build up (n=1) 
Locked box provided to 
stop patient access to 
medicines (n=1) 
Only carers can access 
medicines so patient cannot 
interfere or stockpile (n=1) 
Community pharmacy 
based automatic 
reordering stopped (n=4) 
Prevention of recurrence of 
excessive stock build-up of 
unwanted items (n=4)  
Packaging 
difficulties  
2 (2.0%) De-blistering device 
provided (n=1)* 
Improved access to medicines 
(n=1) 
Sight 
impairment 
2 (2.0%) Provision of a filled MCA 
(n=1) 
Patient able to take medicines 
safely (n=1) 
District nurse to visit and 
monitor blood glucose 
levels (n=1)  
Blood glucose monitoring 
could resume safely (n=1) 
Experience of 
side effects 
2 (2.0%) Discuss problem with 
patient’s GP 
Patient switched to an 
alternative without side effect 
Swallowing 
problems 
1 (1.0%) Discuss problem with 
patient’s GP 
Patient switched to liquid 
formulation 
Inappropriate 
prescribing 
1 (1.0%) Discuss problem with 
patient’s GP 
Patient switched to an 
alternative medicine 
Medication 
not on repeat  
1 (1.0%) Discuss problem with 
patient’s GP 
Medication added to patient’s 
repeat list 
* The other patient with difficulties accessing their packaging had passed away by the 
follow up visit 
Table 2.6  Summary of medication difficulties experienced by patients 
(unrelated to adherence), resolution strategies deployed by the 
SPT and outcomes 
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2.3.4.2  Interventions recommended for medication related difficulties 
Table 2.7 provides a summary of all interventions recommended following the initial 
visit.  Of the 190 recommended interventions, the two most common types were 
provision of some form of MCA and provision of some form of advice to patients.  
Intervention delivered No (%) patients 
receiving 
intervention 
% of total 
interventions 
delivered 
Provision of advice to patient 43 (43.4%) 22.6% 
Provision of an MCA 43 (43.4%) 22.6% 
Liaison with other parties to resolve issues  34 (34.3%) 17.9% 
Provision of a locked box/briefcase for storage of 
medicines in patients’ home 
23 (23.2%) 12.1% 
Removal of unnecessary/inappropriate/unused 
medicines from repeat medication list 
12 (12.1%) 6.3% 
Provision of an adherence aid (reminder watch or 
chart, de-blistering device or Haleraid®) 
9 (9.1%) 4.7% 
Removal of unused/excess medication from 
patient home 
8 (8.1%) 4.2% 
Stopping unnecessary/confusing systems e.g. 
pharmacy filled MCA or repeat ordering system 
6 (6.1%) 3.2% 
No intervention needed 5 (5.1%) 2.6% 
Other practical solutions e.g. synchronisation of  
medication or switching pharmacy 
4 (4.0%) 2.1% 
Arranging a second follow up visit to check on 
patient progress 
2 (2.0%) 1.1% 
Table 2.7 Summary of interventions delivered 
 
Of the 43 MCAs supplied as an intervention, 22 (51.2%) were standard devices, 
without reminder technology, and were filled in a community pharmacy.  A further six 
(14.0%) ‘standard’ MCAs were supplied to willing informal carers (patients friends or 
family) for self-filling rather than being filled in a pharmacy.  The remaining MCA 
recommendations were for the Pivotell® device; there were seven (16.3%) 
recommendations for a pharmacy filled device and eight (18.6%) recommendations to 
loan a Pivotell® to willing informal carers to fill. 
Patient advice included demonstration of how to use inhalers and compliance aids plus 
advice regarding the importance of taking medicines as prescribed and appropriate 
dosing regimens.  Another common intervention was provision of a locked 
box/briefcase for storage of medicines in the patient’s home so that only the carers 
could access the medicines, preventing the patient from accessing additional doses 
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between care calls or tampering with the medicines.  This intervention occurred on 23 
occasions, accounting for 12.1% of all interventions. 
2.3.5  Patient adherence 
2.3.5.1  SPT reported adherence at the initial visit stage  
The majority of patients (66.7%) were recorded as either fully or partially non-adherent.  
Although almost a quarter of patients (24.2%) were classified as ‘fully adherent’, 14 of 
these patients (58.3%) still had problems to resolve, including patient worries about 
excessive medicines stocks and difficulties with local pharmacies.  Fully adherent 
patients had also requested support because they wanted to manage their medicines 
independently without need for carers or were referred by family members who could 
no longer cope with providing the level of support necessary to facilitate adherence.  
Twenty-two patients were classified as ‘partially adherent’ with deviations including 
taking some medicines at an incorrect dose or time, forgetting to take some medicines 
and failing to take medicines (e.g. eye drops) that were not in a Pivotell® device. 
Of the 44 patients classified as ‘non-adherent’ 13 patients (29.5%) were identified as 
‘forgetting’.  Non-adherence was also attributed to taking additional doses of medicines 
in between carer visits, which affected 11 patients (25.0%).  Patients were also 
reported as being too confused to take their medicines, hiding their medicines from 
their carer so that they could not be administered and refusing to take their medicines 
in four (9.1%), three (6.8%) and two (4.5%) instances respectively.  There were 
individual cases of swallowing difficulties, packaging problems, taking the wrong dose, 
forgetting and taking excessive doses and forgetting if medicines have been taken.  
2.3.5.2 SPT reported adherence at the follow up visit stage 
At the follow up visit stage, 88 patients (88.9%) were classified as fully adherent.  All 24 
patients reported as being ‘fully adherent’ at the initial visit stage were still fully 
adherent at follow up.  Although all of these patients had maintained full adherence 
throughout the study, 15 patients (62.5%) had gained benefit from the SPT’s visit, 
beyond confirming that they were taking their medicines correctly.   
Improvements in medication adherence were also reported for the group of patients 
classified as ‘partially adherent’ at the initial visit stage with 17 of these patients 
(77.3%) recorded as fully adherent by the follow up visit.   
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At the initial visit stage, the SPT reported that it was unclear whether or not eight 
patients were adherent.  At the follow up visit stage, seven of these patients (87.5%) 
were classified as fully adherent.   
Of the 44 patients initially recorded as non-adherent, 35 (79.5%) had become fully 
adherent by the follow up visit, however, two patients (4.5%) remained non-adherent as 
they openly declared that they ‘wished to die’.  The remaining seven initially non-
adherent patients included two patients (4.5%) who moved into residential care 
(becoming fully adherent though this was not directly related to the SPT’s intervention) 
and two patients (4.5%) where their adherence remained unclear.  Finally, one patient 
was deceased, one patient had their medicines administered via GP authorised covert 
administration and one patient was partially adherent as they took all of their medicines 
bar one from a Pivotell® device. 
2.3.5.3 Comparisons between SPT reported adherence at pre and post 
intervention stage  
Table 2.8 summarises the proportion of patients classified into each adherence 
category at the pre and post intervention stage, exemplifying the clear trend towards 
increased adherence following the intervention.  With exclusion of cases where 
adherence was ‘unclear’ or the patient had died, 21 patients (25.0%) were fully 
adherent at the pre intervention stage, compared to 81 patients (96.4%) at the post 
intervention stage.  This difference was statistically significant (McNemar’s Χ2 = 58.02, 
1df, p-value of <0.001). 
Adherence category No. (%) patients at pre-
intervention stage 
No. (%) patients at post-
intervention stage 
Fully adherent 24 (24.2%) 88 (88.9%) 
Partially adherent 22 (22.2%) 1 (1.0%) 
Non adherent 44 (44.3%) 2 (2.0%) 
Unclear/uncertain 8 (8.1%) 6 (6.1%) 
Unreported 1 (1.0%) 0 (0.0%) 
Deceased 0 (0.0%) 2 (2.0%) 
Table 2.8 Patient adherence at the pre and post intervention stages  
2.3.5.4  Patient self-reported adherence at the initial visit stage 
Of the 99 patients receiving an initial visit, 48 initial adherence screens were completed 
(48.5%), of which 18 (37.5%) were completed by the patient prior to the visit and five 
(10.4%) were completed by a patient caregiver.  Twenty patients (41.7%) completed 
 Chapter Two                    Domiciliary Medicines Management Service Evaluation Study 
 
82 
the adherence screen with the SPT’s assistance during the initial visit.  For five 
patients, the person completing the adherence screen (10.4%) was not recorded.  
Figure 2.9 summarises the patient responses to the adherence statements, highlighting 
the variation in adherence difficulties causing non-adherence.  The most common 
cause of non-adherence was ‘struggling to read the instruction labels’ with 14 patients 
(33.3%) stating that they ‘always’ or ‘often’ experienced this problem.  
The mean (95% CI) medication adherence score pre intervention could be calculated 
from 42 (87.5%) questionnaires with complete data and was 37.3 (35.5 to 39.1) out of a 
possible 45 with higher scores indicating better adherence.  Only two patients (4.8%) 
reported being perfectly adherent.  
2.3.5.5  Patient self-reported adherence at the follow up visit stage 
In total, 22 (59.5%) patient questionnaires were returned providing self-reported 
adherence data at the post-intervention stage of which 14 (63.6%) were completed by 
the patient themselves.  A family member was responsible for the completion of four 
patient questionnaires (18.2%) with a friend/carer or somebody else each completing 2 
of the returned patient questionnaires (9.1%). 
The adherence assessment section was fully completed by 16 patients (72.7%), 
providing a mean (95% CI) total adherence score was 38.3 (36.0 to 40.6) out of a 
possible score of 45, with higher scores indicative of better adherence.  
A summary of the patient responses is provided in figure 2.10 which highlights patients’ 
tendency to report ‘rarely’ or ‘never’ engaging in the non-adherent behaviours 
represented by the questionnaire statements; this was the case for 79.6% of 
responses.  Struggling to read instruction labels was the most frequent cause of non-
adherence, with 10 patients (45.5%) reporting ‘always’, ‘often’ or ‘sometimes’ 
experiencing this problem.   
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Figure 2.9 Summary of patient self-reported adherence pre-intervention  
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Figure 2.10 Summary of patient self-reported adherence post-intervention  
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2.3.5.6 Comparisons between patient self-reported adherence pre and 
post intervention 
Due to the limitations of the questionnaire distribution process at the post-intervention 
stage, pre and post intervention self-reported adherence data were only available for 
ten patients.  The data for these ten patients are summarised in table 2.9 and are 
consistent with the strong overall tendency for adherence at both the pre and post 
intervention stage and a lack of notable difference between the pre and post 
intervention data.  The median (Interquartile range (IQR)) adherence score for these 
ten patients pre-intervention was 38.0 (36.0 to 40.6) with a post-intervention median 
(IQR) adherence score of 40.0 (34.5 to 44.0).  This difference was not statistically 
significant (P= 0.735, Wilcoxon signed ranks).  
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 % of patients responding… 
Always Often Sometimes Rarely Never 
Adherence statement (n=10) Pre Post Pre Post Pre Post Pre Post Pre Post 
I have difficulties opening medicines packaging or using 
items such as eye drops  
0.0% 10.0% 0.0% 0.0% 40.0% 20.0% 10.0% 40.0% 50.0% 30.0% 
I have difficulties swallowing my medicines  
 
20.0%  0.0% 0.0%  0.0% 20.0% 20.0% 10.0% 20.0% 50.0% 60.0% 
I struggle to read the instructions label  
 
20.0% 30.0% 0.0% 10.0% 20.0% 0.0% 0.0% 10.0% 60.0% 50.0% 
I have difficulties in remembering what time to take each 
medicine  
0.0% 0.0% 0.0% 10.0% 20.0% 20.0% 30.0% 20.0% 50.0% 50.0% 
I forget to take my medicines  
 
0.0% 0.0% 0.0% 10.0% 20.0% 10.0% 20.0% 30.0% 60.0% 50.0% 
I forget to order or collect my medicines from the doctor or 
pharmacy  
0.0% 0.0% 0.0% 0.0% 0.0% 10.0% 30.0% 10.0% 70.0% 
 
80.0% 
I choose to alter the dose of my medicines if I feel better or 
worse  
0.0% 0.0% 0.0% 0.0% 30.0% 10.0% 0.0% 10.0% 70.0% 80.0% 
I choose to miss out doses of my medicines if I feel better or 
worse  
0.0% 0.0% 0.0% 0.0% 10.0% 0.0% 0.0% 10.0% 90.0% 90.0% 
I choose to stop taking my medicines for a while  
 
0.0% 0.0% 0.0% 0.0% 10.0% 10.0% 0.0% 10.0% 90.0% 80.0% 
Table 2.9 Pre and post intervention self-reported adherence (n=10) 
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2.3.5.7 Agreement between SPT and patient reported adherence problems 
at the initial visit stage 
Table 2.10 summarises the agreement between the SPT and patient reported 
adherence problems at the pre-intervention stage.  Multiple problems were frequently 
reported by both the SPT and patients. There were 11 cases where the SPT reported a 
problem that the patient did not, 59 cases where the patient reported a problem that the 
SPT did not and 64 cases where both the SPT and the patient reported a problem. 
Whilst there was ‘moderate’ agreement between the SPT and patients for ‘all cases’, 
agreement was more likely on negative reports (no adherence problems) compared to 
positive reports (adherence problems) as highlighted by the Pneg and Ppos values 
respectively, though this difference is not vast.  Moreover, with a narrow confidence 
interval around the kappa value, it is reasonable to conclude that agreement overall 
was ‘moderate’. 
For patients who reported ‘always’ experiencing an adherence difficulty, this problem 
was, in the majority of cases, also reported by the SPT, providing ‘substantial’ 
agreement that was statistically significant.  Patients reported three cases of ‘always 
having difficulties reading medicines instructions labels’ and four cases of ‘always 
having difficulties with medicines packaging or devices’ that were not recorded as 
difficulties by the SPT.   
Instances of patients reporting ‘often’ experiencing adherence difficulties were reported 
by the SPT less frequently, yielding a lower kappa value in the ‘fair’ range.  The 
imbalance of agreement between negative reports and positive reports is also more 
notable at this stage, reducing the confidence with which the Kappa value is trusted, as 
reflected in the wider confidence interval.  The favouring of agreement in negative 
cases over positive may infer that the kappa value is exaggerated.  
Instances of a patient reporting ‘sometimes’ experiencing an adherence problem were 
also commonly not recorded by the SPT, though the Kappa value falls in the ‘moderate’ 
range.  This could however be elevated by the higher proportion of agreement on 
negative ratings compared to positive.  The adherence difficulty of ‘sometimes 
struggling to swallow medicines’ was the most commonly reported problem that the 
SPT had not recorded with all seven patient reported cases not having this 
documented in the patients notes. 
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Patient 
reported 
adherence 
problems 
No. 
problems 
reported by 
patients 
No. (%) 
also 
reported 
by SPT 
Kappa  
(95% CI) 
P-
value 
Agreement
* 
Ppos Pneg 
All cases 123 64 
(52.0%) 
0.55 
(0.46 to 0.64) 
<0.001 Moderate 0.65 0.89 
‘Always’ 26 19 
(73.1%) 
0.66 
(0.51 to 0.80) 
<0.001 Substantial 0.68 0.98 
‘Often’ 17 7  
(41.2%) 
0.37 
(0.16 to 0.59) 
<0.001 Fair 0.40 0.97 
‘Sometimes
’ 
77 37 
(48.1%) 
0.53 
(0.41 to 0.64) 
<0.001 Moderate 0.59 0.93 
*Landis and Koch scale232 
Table 2.10 Agreement between patient and SPT reported adherence problems 
at the pre- intervention stage 
Figure 2.11 summarises the percentage of patient reported adherence problems that 
were not documented by the SPT.  ‘Struggling to swallow tablets’ was the most 
common patient reported adherence difficulty that was not documented by the SPT 
accounting for 15.5% of all cases.  
 
Figure 2.11 Patient reported adherence problems not recorded by the SPT 
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2.3.5.8 Agreement between SPT and patient reported adherence problems 
at the post intervention stage 
Table 2.11 summarises the agreement between patient and SPT reported adherence 
at the post-intervention stage.  The majority of adherence problems reported by 
patients at the post-intervention stage were not recorded by the SPT, yielding low 
agreement.  In all cases bar those reported as ‘always’ causing an adherence problem, 
the SPT and patients agreed on negative cases (no adherence problems) far more 
frequently than positive cases (adherence problems) meaning the calculated kappa 
values are subject to notable bias.  Whilst ‘moderate’ agreement was obtained when 
patients ‘always’ experienced an adherence problem, the 95% confidence interval 
associated with the kappa statistic is very wide, making meaningful interpretations 
problematic. 
Despite the limitations of interpretation of these data, it is reasonable to infer that 
agreement between patient and SPT reported adherence was negligible, and unlikely 
to exceed that which would have occurred by chance. 
Patient 
reported 
adherence 
problems 
No. 
problems 
reported 
by 
patients 
No. (%) 
also 
reported 
by SPT 
Kappa  
(95% CI) 
P-
value 
Agree-
ment* 
Ppos Pneg 
All cases  35 3 (8.6%) 0.12  
(-0.02 to 0.25) 
0.005 Slight 0.15 0.90 
‘Always’  6 2 (33.3%) 0.43  
(0.02 to 0.84) 
<0.001 Moderate 0.44 0.99 
‘Often’ 4 0 (0.0%) -0.01 
 (-0.02 to 0.00) 
0.879 Poor 0.00 0.97 
‘Sometimes’ 26 1 (3.8%) 0.05 
 (-0.07 to 0.17) 
0.152 Slight 0.07 0.92 
 
 
*Based on Landis and Koch scale232 
Table 2.11 Agreement between patient and SPT reported adherence problems 
at the post- intervention stage 
 
2.3.6  Patients’ risk of harm from their medicines  
A summary of the mean risk scores calculated pre and post intervention for each 
patient, using the NPSA risk matrix is provided as appendix 2.11.  
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2.3.6.1  Pre-intervention risk scores using the NPSA risk matrix 
Pre-intervention risk scores (mean of four HCPs for each patient) ranged from 2 to 21 
with higher scores indicative of a greater risk of harm.  The group median (IQR) was 
12.0 (9.0 to 15.0) indicating that on average, patients receiving their initial visit were 
considered to be at a ‘high’ risk of harm from their medicines.  According to the NPSA 
risk categories, the majority of patients (82.8%) were considered to be at either a ‘high’ 
or ‘extreme’ risk of harm from their medicines.  
2.3.6.2  Post-intervention risk scores using the NPSA risk matrix 
Post-intervention risk scores (mean of four HCPs for each patient) ranged from 2 to 16 
and the group median (IQR) was 5.0 (3.0 to 6.0); a ‘medium’ risk of harm.  The majority 
of patients (92.9%) had either a ‘low’ or ‘medium’ risk of harm from their medicines.  
2.3.6.3 Comparison between pre and post intervention risk scores using 
the NPSA risk matrix 
A reduction in risk score following the intervention was achieved for 92 patients 
(92.9%).  The median risk scores were significantly lower post intervention (P= <0.001, 
Wilcoxon matched pairs test) with a median (IQR) change of -7.0 (-3 to -10) points 
following receipt of the domiciliary medicines support service.  For 83 patients (83.8%) 
the reduction in risk score following the intervention was sufficient to also reduce their 
risk score category. 
Figure 2.12 provides a comparison between the percentage of patients falling into each 
risk score category at the pre and post intervention stages and highlights the switch of 
patients from ‘high and extreme’ risk at the pre-intervention stage to ‘medium and low’ 
at the post-intervention stage.  The error bars representing the 95% CI around each 
point estimate highlight that true differences between the proportion of patients in each 
category pre and post intervention are likely, given that the confidence intervals do not 
overlap in all cases.  For all four HCPs, risk score categories were ranked significantly 
lower following the intervention (p = <0.001, Wilcoxon matched pairs). 
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Figure 2.12 Comparison of percentage of patients in each risk score category 
at the pre and post intervention stage 
 
2.3.6.4 Agreement in NPSA risk scores assigned by different healthcare 
professionals 
Pre-intervention risk scores 
For inter-rater agreement, a Kendall’s W statistic of 0.67 indicated good agreement and 
this was statistically significant (p = <0.001).  For the measure of inter-rater reliability 
(IRR), an ICC value (95% CI) of 0.83 (0.77 to 0.88) was calculated, representing 
excellent IRR233.  This average measure of reliability notably exceeded the single 
measure (95% CI) of 0.55 (0.46 and 0.65), highlighting the improved reliability achieved 
by taking an average of the risk scores assigned by four different HCPs. 
Post-intervention risk scores 
There was significant agreement between the risks scores assigned by the four HCPs 
(p = <0.001) and according to the Kendall’s W statistic of 0.56, this agreement was 
considered to be ‘reasonable’.  For the inter-rater reliability measure, an ICC value 
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(95% CI) of 0.78 (0.70 to 0.84) was calculated, representing excellent IRR233.  As with 
the pre-intervention stage, this average measure of reliability notably exceeded the 
single measure (95% CI) of 0.47 (0.37 and 0.58), highlighting the improved reliability 
achieved by taking an average of the risk scores assigned by four different HCPs. 
2.3.6.5  Pre-intervention risk scores using Fuller’s risk assessment tool 
Difficulty with the use of the Fuller’s tool was reported, as patients frequently fell in 
between the category boundaries, especially for the ‘patient’s attitude towards their 
medicines’ section.  The tool was therefore adapted so that data could be recorded in a 
consistent manner, for example, where a patient was interested in and willing to take 
their medicines but unable to recall their regimen, a score of ‘6’ was assigned. 
A pre-intervention risk score was calculated for 92 patients where sufficient data were 
provided.  The median (IQR) risk score was 18.5 (13.0 to 23.0) and so on average, 
patients were considered to have a ‘high’ risk of harm.  The percentage of patients 
categorised as ‘low’ and ‘very high’ risk was equal, with each category accounting for 
24 patients (26.1%).  Eight patients (8.7%) were classified as having a ‘medium’ risk of 
harm from their medicines and the remaining 36 patients (39.1%) were classified as 
having a ‘high’ risk of harm. 
2.3.6.6   Comparison between risk score categorisation using the NPSA and       
Fuller’s risk tools  
Figure 2.13 compares the percentage of patients assigned to each risk score category 
at the pre-intervention stage, using the NPSA and Fuller’s risk tools.  The percentage 
of patients classified as low risk using the Fuller’s risk tool is notably higher than that 
for the NPSA risk tool.  Likewise, the proportion of patients classified as ‘high’ or ‘very 
high’ are lower for the Fuller’s risk score compared to the NPSA risk score.   
The 95% CI around each point estimate (represented by error bars) highlight that whilst 
there may be differences in the proportions of patients in each category using the two 
tools, it is only the ‘low’ risk category where true differences are likely to exist.  
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Figure 2.13  Percentage of patients in each risk score category using NPSA and 
Fuller’s risk tools 
The ICC (95% CI) value calculated to assess agreement between the two tools was 
0.36 (0.05 to 0.57).  The equivalence of the ICC value to weighted kappa means that 
agreement between the two tools can be considered as ‘fair’.  The associated p-value 
of 0.008 confirmed significant agreement between the two tools.  
2.3.7 Patient questionnaires 
Thirty-six questionnaires were sent directly to patients, of which 22 (61.1%) were 
returned.  Twenty-seven questionnaires were sent to a patient’s caregiver and the 
remaining 31 patients were not eligible for either questionnaire due to poor cognitive 
function and receipt of formal rather than informal care.  
Table 2.12 provides a comparison of questionnaire recipients and non-recipients, 
according to their SPT reported cognitive state.  This comparison was made to 
determine whether, as per protocol, the SPT had only sent the questionnaires to 
patients deemed to have sufficient cognitive capacity for completion.  
In the group of patients who received a questionnaire, 2 (5.6%) had notable cognitive 
impairment, as defined as being ‘very confused, ‘very forgetful’ or having a formal 
diagnosis of dementia.  Comparatively, for the group of patients who were not sent a 
questionnaire, 38 (65.5%) had notable cognitive impairments.  Differences in the mean 
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rankings of cognitive impairment for questionnaire recipients and non-recipients was 
significantly different (MWU P=<0.001); non-recipients of the questionnaire therefore 
had significantly poorer cognitive function.  
SPT reported cognitive state No. (%) patients 
sent a questionnaire 
No. (%) patients NOT 
sent a questionnaire 
Alert and orientated 15 (41.7%) 0 (0.0%) 
Slightly confused and/or slightly 
forgetful  
18 (50.0%) 21 (36.2%) 
Slightly confused AND very forgetful 0 (0.0%) 6 (10.3%) 
Very confused and/or very forgetful 1 (2.8%) 9 (15.5%) 
Formal diagnosis of dementia or 
awaiting tests 
1 (2.8%) 23 (39.7%) 
Table 2.12 Questionnaire distribution according to patients’ cognitive state 
The data concerning patient reported adherence is reported in section 2.3.4.5 with the 
rest of the adherence related data. 
2.3.7.1  Patient confidence with managing their medicines and health  
Table 2.13 summarises the patient responses to the six questionnaire statements 
relating to the patient’s confidence with managing their medicines and health after 
receiving the intervention.  
An overall section score could be calculated for 19 patients (86.4%) with fully 
completed data for this section.  The mean (SD) total confidence score was 17.3 (4.9) 
out of a possible 24, with higher scores indicating greater improvements in confidence 
and perceived ability post intervention.  Cumulatively, 60.2% of patients reported an 
improvement in their overall confidence and ability to manage their medicines and 
health.   
The majority of responding patients thought that their confidence in taking their 
medicines correctly had improved following the intervention and this was the case for 
81.0% of respondents.  In a similar vein, 66.7% of responding patients thought that 
their ability to take their medicines correctly had improved following the intervention.  A 
majority of patients also reported that their ability to cope with life had improved 
following the intervention. 
In relation to the patient’s perceived ability to keep themselves healthy, a smaller 
margin of 42.8% of responding patients reported an improvement, with a majority of 
patients reporting that their ability to keep themselves healthy had stayed the same.  
An improvement in the patient’s ability to help themselves was reported by 60.0% of 
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patients and 55.0% of patients thought their confidence in managing their health had 
improved.  
Confidence/ability statement: 
As a result of my recent home visit to 
help me with my medicines, I feel: 
No. (%) of participants giving a 
response of… 
Much 
better 
Better The 
same 
Worse  
My confidence in taking my medicines 
correctly is… 
8 
(38.1%) 
9 
(42.9%) 
4 
(19.0%) 
0 
(0.0%) 
My ability to take my medicines correctly is… 8 
(38.1%) 
6 
(28.6%) 
7 
(33.3%) 
0 
(0.0%) 
My ability to cope with life is… 7 
(35.0%) 
4 
(20.0%) 
8 
(40.0%) 
1 
(5.0%) 
My ability to keep myself healthy is… 5 
(23.8%) 
4 
(19.0%) 
11 
(52.4%) 
1 
(4.8%) 
My ability to help myself is… 4 
(20.0%) 
8 
(40.0%) 
8 
(40.0%) 
0 
(0.0%) 
My confidence in managing my health is… 6 
(30.0%) 
5 
(25.0%) 
8 
(40.0%) 
1 
(5.0%) 
Overall response (n=123) 38 
(30.9%) 
36 
(29.3%) 
46 
(37.4%) 
3 
(2.4%) 
Table 2.13 Summary of patient responses to confidence with managing 
medicines and health section of questionnaire 
 
2.3.7.2  Patient satisfaction with the service received 
All 22 of the returned patient questionnaires had complete satisfaction data and could 
therefore be used to calculate the average overall satisfaction score.  The median 
(IQR) total satisfaction score was 19 (16 to 20) out of 20, with higher scores indicating 
greater satisfaction.   
Table 2.14 summarises the patient responses to each of the satisfaction statements 
and highlights the positive trend towards satisfaction with the service.  The quality of 
the service received was rated as good or excellent by 90.0% of responding patients.  
In addition, 100% of responding participants:  
• Would recommend the service to a friend in need of similar help  
• Were satisfied with the amount of help they had received 
• Reported that the services they had received had helped to deal with their 
medicines more effectively  
• Reported that overall, they were satisfied with the service they had received 
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Satisfaction statement  Questionnaire responses 
Number (%) of patient responses 
How would you rate the 
quality of the service you 
have received? 
 Excellent 
11 (50.0%) 
 
Good 
9 (40.9%) 
 
Fair 
2 (9.1%) 
Poor 
0 (0.0%) 
 
If a friend were in need of 
similar help, would you 
recommend the same 
service you received? 
 Yes, 
definitely 
16 (72.7%) 
 
Yes, I think 
so 
6 (27.3%) 
 
No, I don’t 
think so 
0 (0.0%) 
No, definitely 
not 
0 (0.0%) 
How satisfied are you 
with the amount of help 
you received? 
 Very 
satisfied 
13 (59.1%) 
 
Mostly 
satisfied 
9 (40.9%) 
 
Indifferent or 
mildly 
dissatisfied 
0 (0.0%) 
Quite 
dissatisfied 
0 (0.0%) 
 
Have the services you 
received helped you to 
deal more effectively with 
your medicines? 
 
 Yes, they 
have helped 
a great deal 
13 (59.1%) 
Yes, they 
helped 
somewhat 
9 (40.9%) 
No, they 
didn’t really 
help 
0 (0.0%) 
No, they 
seemed to 
make things 
worse 
0 (0.0%) 
In an overall, general 
sense, how satisfied are 
you with the service you 
have received? 
 Very 
satisfied 
14 (63.6%) 
Mostly 
satisfied 
8 (36.8%) 
Indifferent or 
mildly 
dissatisfied 
0 (0.0%) 
Quite 
dissatisfied 
0 (0.0%) 
Table 2.14 Summary of patient responses to satisfaction section of 
questionnaire 
2.3.7.3  Comments provided in patient questionnaires 
Ten (45.5%) questionnaires were returned with additional written comments.  Eight of 
these comments (80.0%) were positive, describing the effectiveness of the service and 
the patient’s satisfaction with the SPT delivering the service.  One comment was 
neither positive nor negative, and one comment related to unresolved problems.  A 
selection of statements to support these findings are provided in appendix 2.12.  
2.3.8   Patient caregiver questionnaires 
Questionnaires were returned by 21 caregivers giving a response rate of 77.8%.  
Twelve caregiver questionnaires (57.4%) were completed by the offspring of a patient 
and five (23.8%) were completed by the patients spouse.  For four caregiver 
questionnaires (19.0%) the caregivers relationship to the patient was not recorded. 
2.3.8.1  Caregiver feelings following the intervention 
Complete data for this section were available for 20 (95.2%) of the returned caregiver 
questionnaires.  The median (IQR) overall score for the caregiver’s feelings post 
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intervention was 27 (22 to 30) out a possible 32 with higher scores indicating greater 
confidence and lower concerns following the intervention.   
A summary of the caregiver responses to each statement in this section is provided in 
table 2.15.  An increase in the caregiver’s confidence in the ability of the patient to take 
their medicines as prescribed was reported by 95.2% of responding caregivers.  A 
large majority (85.7%) of caregivers also felt more confident in the patient’s ability to 
manage their medicines independently.  An improvement in the patient’s ability to 
manage their health and well-being was reported by 60.0% of responding caregivers 
and 95.2% of responding caregivers reported a reduction in the patient’s difficulties 
with taking their medicines.  
In terms of the caregiver’s own feelings, 90.4% reported reduced levels of anxiety and 
81.0% reported a reduction in the amount of time that spent worrying about medicines 
taking.  The majority of caregivers also reported a reduction in the amount of time the 
spent helping the patient with their medicines and this was the case for 76.2% of 
responding caregivers.  Just over half of the responding caregivers (52.4%) reported a 
reduction in the level of reliance that the patient had on them.  
As a result of the recent Medicines 
Management visit received by the 
person that I care for, I feel : 
No. (%) of patient caregivers giving a 
response of… 
Much 
better 
Better  The same Worse  
My confidence in their ability to take their 
medicines correctly is… 
12 
(57.1%) 
8 
(38.1%) 
1  
(4.8%) 
0 
(0.0%) 
My confidence in their ability to manage 
their medicines independently is… 
12 
(57.1%) 
6 
(28.6%) 
3  
(14.3%) 
0 
(0.0%) 
My confidence in their ability to manage 
their health and well-being is… 
6 
(30.0%) 
6 
(30.0%) 
8 
 (40.0%) 
0 
(0.0%) 
 Much 
less 
Less  The same  More 
My level of anxiety about them taking their 
medicines wrongly is… 
12 
(57.1%) 
7 
(33.3%) 
2  
(9.5%) 
0 
(0.0%) 
The difficulties that they had in taking their 
medicines are… 
12 
(57.1%) 
8 
(38.1%) 
1  
(4.8%) 
0 
(0.0%) 
The amount of time I have to spend 
helping them with their medicines is… 
9 
(42.9%) 
7 
(33.3%) 
3  
(14.3%) 
2 
(9.5%) 
The amount of time I spend worrying about 
them taking their medicines is… 
11 
(52.4%) 
6 
(28.6%) 
4  
(19.0%) 
0 
(0.0%) 
The level of reliance that they have on me 
is… 
3 
(14.3%) 
8 
(38.1%) 
9 
 (42.9%) 
1 
(4.8%) 
Total no. (%) of responses given 77 
(46.1%) 
56 
(33.5%) 
31 
(18.6%) 
3 
(1.8%) 
Table 2.15 Caregiver feelings and confidence following the intervention 
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2.3.8.2  Caregiver satisfaction with the service 
All 21 returned questionnaires were fully complete for this section and therefore used to 
calculate the average overall satisfaction scores.  The median (IQR) total satisfaction 
score for caregivers was 20 (19 to 20) out of a possible score of 20 with higher scores 
representing greater satisfaction.   Table 2.16 summarises the caregiver responses to 
the satisfaction section of the questionnaire and highlights a positive response to the 
service, with 100% of caregivers rating the service as ‘good’ or ‘excellent’ and 
recommending the service.  100% of caregivers also thought that the service had 
helped the patient to deal with their medicines more effectively and were satisfied with 
the overall service.  95.2% of caregivers were happy with the amount of support 
received. 
Satisfaction statement  Questionnaire responses  
Number (%) of patient responses 
How would you rate the 
quality of the service 
received? 
 Excellent 
18 (85.7%) 
 
Good 
3 (14.3%) 
 
Fair 
0 (0.0%) 
Poor 
0 (0.0%) 
 
If a friend were in need of 
similar help, would you 
recommend the same 
service to them? 
 Yes, 
definitely 
20 (95.2%) 
 
Yes, I think 
so 
1 (4.8%) 
 
No, I don’t 
think so 
0 (0.0%) 
No, definitely 
not 
0 (0.0%) 
How satisfied are you 
with the amount of help 
received by the person 
that you care for? 
 Very 
satisfied 
18 (85.7%) 
 
Mostly 
satisfied 
2 (9.5%) 
 
Indifferent or 
mildly 
dissatisfied 
1 (4.8%) 
Quite 
dissatisfied 
0 (0.0%) 
 
Have the services 
received by the person 
that you care for, helped 
them to deal more 
effectively with their 
medicines? 
 Yes, they 
have helped 
a great deal 
15 (71.4%) 
Yes, they 
helped 
somewhat 
6 (28.6%) 
No, they 
didn’t really 
help 
0 (0.0%) 
No, they 
seemed to 
make things 
worse 
0 (0.0%) 
In an overall, general 
sense, how satisfied are 
you with the service 
received by the person 
that you care for? 
 Very 
satisfied 
17 (81.0%) 
Mostly 
satisfied 
4 (19.0%) 
Indifferent or 
mildly 
dissatisfied 
0 (0.0%) 
Quite 
dissatisfied 
0 (0.0%) 
Table 2.16 Caregiver responses to satisfaction section of questionnaire 
 
 
 
 Chapter Two                    Domiciliary Medicines Management Service Evaluation Study 
 
99 
2.3.8.3  Caregiver comments from returned questionnaires 
Ten (47.6%) of the returned caregiver questionnaires had additional written comments.  
Eight of the comments were positive (80.0%) and two comments (20.0%) detailed 
problems that were still occurring.   
Comments focused on feelings of less worry and greater confidence about correct 
medicines taking  plus general satisfaction and the personable approach and care 
offered by the SPT.  A selection of statements to support these findings are provided in 
appendix 2.13.  
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2.4 Discussion 
The service evaluation was focused around describing the effects of the CCS NHS 
Trust Domiciliary Medicines Management Service on medication adherence and 
patients’ risk of harm from their medicines.  The results have highlighted that the 
service yields significant improvements in patient adherence and significant reductions 
in the patients’ risk of harm.  Whilst this observation is seemingly positive, limitations 
must be considered when appraising this study, these limitations are discussed within 
the relevant sections below and can be summarised as: 
• The omission of the patients clinical details means that full characterisation of the 
service recipients is not possible 
• The study design means that we have no way of knowing how the patients may 
have progressed without intervention 
• The lack of outcome measures beyond adherence and risk means that limited data 
is portrayed; the intervention could have conceivably increased healthcare 
utilisation and decreased quality of life but this is unknown.  
• Poor follow up with self-reported adherence prohibits the utility of this data in 
drawing meaningful conclusions 
• The study is limited by notable risk of bias, namely: 
o The risk scores were assigned using data provided by the SPT who delivers 
the service 
o The SPT adherence data should be interpreted with caution as this is also 
directly provided by the SPT delivering the service 
o There is potential for bias in the questionnaire distribution process which 
was co-ordinated by the SPT delivering the service.  
• The omission of long-term follow up data means that the duration of effect from the 
intervention is unknown 
2.4.1  The nature of the pharmacist technician intervention, including 
patient, medication and visit details 
2.4.1.1  Patient details 
Service recipients were primarily of an older age, experiencing some degree of 
cognitive impairment, living alone and unable to administer their medicines safely.  In 
comparison to national statistics, recipients of this service were: 
• Older - 31.2% were aged over 85 years compared to 2.0% in the wider 
population234 
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• Had a greater degree and prevalence of cognitive impairment – 23.2% had a formal 
diagnosis of dementia compared to 12.1% and 13.5% of males and females in this 
age range respectively235, 236 
• More likely to be living alone – 63.6% compared to 49.0% of patients of a similar 
age in the wider population237. 
Numerous factors associated with increasing age, such as declining cognitive and 
physical capacity plus a lack of social support have been reliably associated with 
medication difficulties and non-adherence4, 238.  As such, it is reasonable to infer that 
the service was targeted towards those at greatest risk of non-adherence and other 
medication related difficulties.  This is supported by the high risk scores observed in the 
majority of patients at the initial visit and serves to communicate the potential fragility 
and vulnerability of the population receiving this service and the need to intervene. 
Although the majority of patients were unable to administer their medicines safely, 
many were considered competent, which may cause question as to the need for 
intervention.  It is however, important to note that an ability to take medicines safely 
does not necessarily equate to execution of the behaviour and thus, patients with an 
ability to take their medicines as prescribed were not necessarily doing so.  This 
implies that there were elements of intentional non-adherence amongst the population. 
2.4.1.2  Medication details 
Patients were taking a median of nine medicines per day and multiple daily doses, 
inferring complexity of regimens.  This is unsurprising given the evidence to support an 
association between regimen complexity and non-adherence18, 53. 
In 1999, Golden et al. reviewed prescribing of medicines in homebound older adults in 
the USA239.  The large cohort, whose mean age was comparable to the patients in this 
service evaluation, were on average prescribed 5.3 +/- 2.9 drugs (range 0-22), which is 
notably less than the recipients of this service.  Data from other studies, including the 
HOMER trial205 and Hawksworth and Chrystyn’s study204 report similar numbers of 
medicines per patient.  Recipients of the CCS NHS Trust service were therefore taking 
more medicines on average, highlighting their increased vulnerability and need for 
support.  
Whilst details of the medicines taken were essential for calculating the risk scores and 
provide useful data to characterise the recipients, it would also have been useful to 
collect clinical data to establish for which conditions the medicines were taken for.  The 
absence of this data therefore marks a study limitation. 
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2.4.1.3  Visit details 
Referrals into the service were from a diverse range of sources with a variety of 
different referral reasons.  The volume of patients visited per month appears to be 
admirable for a sole full-time technician, given that follow up visits and intervention 
implementations for patients already in the system, but not included in this evaluation 
would also be necessary during this time.  The number of patient visits is also 
comparable to that described in a similar study184 over a similar time period, supporting 
the idea that patient turnover in this service is appropriate.  
The number of patients visited during the data collection period also implies that this is 
a well utilised service, as does the diversity of referral sources.  It is unsurprising that 
almost all referrals came from primary care, as it would be expected that patients 
experiencing problems with their medicines would be in their own homes.  However, it 
is interesting to note that there were also referrals from secondary care.  In both cases 
these referrals concerned patients currently in hospital but who were soon to be 
discharged.  This cross-setting referral system is encouraging as recent government 
policies have encouraged improved hospital discharge processes to ensure continuity 
of care and reduce the risk of harm at the healthcare interface199, 240.  The SPT is 
ideally placed to liaise between primary and secondary care services.  Assuming the 
SPTs capacity was allowing, greater referrals from secondary care, in instances of 
patient discharge could be an intuitive means for expansion of the service. 
The list of referral sources includes almost all healthcare providers involved in primary 
care.  Family members, friends and the patients themselves were also represented as 
sources of referral.  In 2007, Bhattacharya et al. reported that services with more 
referral sources were more likely to remain operational beyond a year of initiation189.  
The wide range of referral sources for this service is therefore a likely contributory 
factor to its continued service provision.  
The only referral source that is potentially under represented is community 
pharmacists, who are ideally placed to identify patients experiencing adherence 
problems.  Whilst implementation of interventions requires considerable liaison 
between the SPT and community pharmacists, exploration of increased referrals from 
this source may also be an intuitive route to expansion of the service.  
In 1999, Foulsham and Goodyer reported that referrals made into a new domiciliary 
medicines support service were predominated by GPs and nurses, with far fewer 
referrals from social services191.  Comparatively, for the referrals made via this service 
 Chapter Two                    Domiciliary Medicines Management Service Evaluation Study 
 
103 
evaluation, the relative proportion of referrals made by these three sources was more 
alike.  It encouraging to see that the SPT has forged good interdisciplinary relationships 
and that social services are closely involved, as this agency is likely to most frequently 
see how patients are coping in their own homes.  
The prevalence of referrals from care agency co-ordinators and housing scheme 
managers reflects the difficulties experienced by paid caregivers in administering 
patients’ medicines.  Patients were tampering with their medicines, hiding them from 
their carers or taking inappropriate additional doses between care calls which triggered 
the referrals.  It is encouraging to see that carers made referrals to the SPT in these 
circumstances and positive that additional referrals were made for patients where there 
were concerns about coping and declining memory.  This infers that patients in receipt 
of paid care or who were living in sheltered housing were well monitored, with efficient 
referral systems in place to address any concerns. 
The reason for referral related to cognitive impairments in a majority of cases which is 
unsurprising given the prevalence of cognitive deficits in the sample population.  
Dexterity or swallowing problems, excess stock build ups and requests for MCA all also 
accounted for multiple referrals, though the proportion of referrals attributed to dexterity 
problems may have been expected to be higher, given the age of the sample 
populations.  It is interesting that multiple referrals were made to request an MCA as 
this suggests that some referrers had preconceived ideas about an appropriate 
intervention.  This may be an artefact of the many domiciliary medicines support 
services that are primarily focused on provision of an MCA. 
At the initial visit stage, a range of problems, unrelated to medication adherence were 
identified, further highlighting the diversity of problems experienced and range of 
referral reasons.  Whilst problems such as difficulties with tablet packaging, out-dated 
repeat medication slips and excess medication stocks were identified, such difficulties 
were only reported for a minority of patients, meaning the majority of patient’s problems 
were more directly associated with medication adherence.  This supports the concept 
that the medicines management service is primarily, but not exclusively a medication 
adherence intervention.  
Provision of some form of MCA or advice were the most common interventions, 
however each only accounted for just under a quarter of all interventions respectively.  
A wide range of interventions were therefore recommended which is encouraging and 
likely a reflection of the holistic, patient-centred approach adopted.  Moreover, the 
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range of interventions recommended and consideration of alternate options supports 
the SPT’s ethos that supply of an MCA should not be a default option. 
The utility and necessity of MCAs has long been disputed and recent guidelines have 
emphasised the importance of only using MCA where necessary and exploring all 
avenues of support rather than assuming the use of an MCA as a default resolution 
strategy178.  Whilst many patients received some form of MCA, given the frequency of 
cognitive impairments, it is likely that in the vast majority of cases, this represented an 
appropriate intervention.  Furthermore, the data collected suggests the SPT considered 
other avenues of support as over a third of the MCAs provided were to be filled by 
either a friend or family member.  This demonstrates that alternate sources of support 
were utilised where possible, tailoring the intervention to meet the individual’s need and 
adjusting it to individual circumstances.   
Though the initiation of an MCA is seemingly appropriate for the patients reviewed in 
this service, a lack of detail as to how these MCAs were implemented may be cause for 
concern.  It is important to consider the clinical safety of initiating MCAs in instances 
where patients’ medicines may not have been fully reviewed or optimised.  For 
example, a patient may have been prescribed a 10mg dose of Ramipril and been non-
adherent for some time, meaning their blood pressure would need to be reviewed and 
dose titration of the Ramipril, as if the patient was treatment naïve, would be 
necessary.  However, if this 10mg dose was added to an MCA, without review and 
without dose titration, adverse effects such as postural hypotension are probable, 
which would significantly increase the patient’s risk of falls.  Given that patients in 
receipt of this service were predominantly frail and older, such risk increases are 
unacceptable.  In the absence of details regarding the review processes before 
initiation of an MCA and more importantly without long-term follow up details of adverse 
effects, it is not possible to establish whether such problems occurred.  These deficits 
therefore mark further study limitations.  
In 2012, Desborough et al. reported an economic evaluation of the Norfolk Medicines 
Support Service (NMSS) as a before and after study183.  The recommended 
intervention was dispensing of medicines in an MCA for 90 patients (76.9%); a notably 
greater proportion than the 43.4% of patients in the CCS NHS Trust service.  In 
addition, 32.6% of the MCAs supplied as an intervention in the CCS NHS Trust service, 
were supplied to be filled by friends or family members rather than the pharmacy.  
Desborough et al. reported that in 2007, the unit cost of filling an MCA was £78 per 
patient, for six months.  In the CCS NHS Trust service, there were therefore 14 
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patients, who could have had an MCA filled in a pharmacy, but instead friends or family 
members were utilised.  This represents a potential cost saving of £1092 over six 
months, however, there is little comparative evidence regarding the safety of MCA 
filling by non-pharmacy staff.  Such costs savings and utilisation of alternate sources 
are important credentials for the CCS NHS Trust service.  However, without formal 
economic evaluation, inferences with regard to cost effectiveness of the service must 
be drawn with caution.  
The interventions recommended also highlight that, in almost all cases, referral into the 
service was appropriate as some form of intervention was needed.  Only two patients 
did not receive a follow up visit as no intervention was necessary.   
Problems identified at the initial visit stage that were not specifically related to non-
adherence, had, in the main part been resolved following the intervention, highlighting 
the benefits of the service, beyond improvements in adherence.  All patients with an 
outdated medication repeat list had this problem resolved by the follow-up stage, either 
by removal of the redundant medicine or re-initiation where appropriate.  An accurate 
repeat medication list is an important aspect of patient safety, especially at the 
healthcare interface as they are routinely used as a primary resource upon hospital 
admission.  In the instances of removing a medication that was no longer needed, this 
may have saved a medication being erroneously administered if the patient was 
admitted to hospital.  Conversely, in instances of a medication that was thought to be 
redundant (by the patient) but that was reinitiated following the intervention, the SPT 
had resolved confusion and ensured continuation of appropriate medicines. 
The SPT’s intervention also resolved instances of excessive stock build ups and in all 
cases, additional measures were taken to prevent reoccurrence of this.  Interestingly, in 
three cases of excessive stock build-ups (37.5%), the problem had occurred due to 
poorly managed pharmacy repeat ordering services.  These services are intended to 
improve medication adherence and reduce medicines waste by a nominated 
community pharmacy contacting the patient each month to see which items they would 
like to order.  It would seem however, that for some patients, all items were 
automatically ordered each month, irrespective of whether or not they were needed.  
This not only represents poor professional practice, but also a notable waste of 
resources; these cases were reported back to the SPT for further investigation. One 
specific case in this service evaluation related to a patient who was sent all of their 
diabetic blood testing strips and associated paraphernalia each month, despite visual 
impairments which precluded the use of these items.  The cumulative cost of lancets, 
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test strips, monitoring devices and waste disposal units for this patient would amount to 
substantial costs.  Whilst the SPT’s intervention of stopping all of these items and 
arranging for a district nurse to test the patient’s blood sugar regularly is, in itself a 
costly intervention, it is likely to be more cost efficient and certainly far safer than 
wasting the supply of these valuable resources each month.  
Beyond reducing medicines waste and ensuring safety with accurate medication repeat 
lists, the SPT’s intervention also resolved patient side effects, packaging problems and 
inappropriate prescribing, plus improved medication access for patients with sight 
impairments.  This demonstrates the wide range of benefits associated with the 
service, though the long-term benefits elicited are unknown.  
2.4.2 The development and acceptability of a new adherence 
assessment tool 
The first draft of a novel adherence assessment tool, for use in this specific population 
was developed and tested.  The potential adherence problems represented in the tool 
were selected with the population in mind and are based on the plethora of existing 
validated adherence assessment tools which increases confidence in content validity. 
Assessment of face validity in the target population, was however, more problematic.  
Less than a quarter of the patients receiving an initial visit completed the adherence 
assessment questionnaire prior to the SPT’s visit.  This observation could be indicative 
of poor face validity (the patient’s did not understand what they had to do or could not 
answer the questions).  However, given the magnitude of cognitive impairment in the 
service recipients, forgetfulness and confusion may have been more likely contributory 
factors.  Of the questionnaires completed, high proportions were completed fully, 
indicating that the patients were able to understand the instructions and questions.  
However, it is important not to overlook the possibility that those who did not 
understand the instructions and questions simply did not complete the questionnaire 
and were therefore ‘non-responders’.  
Post intervention data on the adherence assessment tool was captured for roughly a 
quarter of all patients receiving the service, augmenting the difficulty in establishing the 
face validity of the tool in the full sample.  However, there was a good response rate for 
the limited number of patients who were sent a questionnaire and high proportions 
were completed in full.  This suggests that in patients with sufficient cognitive capacity, 
the face validity of the questionnaire was adequate. 
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Whilst patient responses were predominantly ‘rarely’ or ‘never’ as is often found with 
medication adherence self-reports, there were a notable number of patients reporting 
adherence problems.  This suggests that the adherence assessment tool was capable 
of detecting adherence related difficulties.  The choice of a continuous rather than 
dichotomous scale may have facilitated these detections.  
The comparison between the patient and SPT reported adherence sheds an interesting 
light on the questionnaire and brings into question whether the patients completed the 
questionnaires appropriately.  There are however, multiple possible explanations for 
these discrepancies: 
1. That the SPT did not feel it pertinent to record problems that occurred ‘often’ or 
‘sometimes’, especially if there were more pressing issues that occurred ‘always’ 
2. That the SPT did not check experience of certain adherence barriers with patients 
and therefore failed to establish some adherence difficulties 
3. That the patients felt more confident in reporting adherence problems on the self-
report questionnaire than in discussing them in person with the SPT 
4. That patients filled in the questionnaires inaccurately 
It is likely, that the disagreement between the patient and SPT reported adherence is 
an amalgam of the four outlined explanations.  The data collected offers some support 
for the second proposed explanation, as a very high proportion of patients reporting 
swallowing difficulties did not have this problem documented by the SPT, yet a notably 
lower proportion of patients reporting ‘stopping their medicines for a while’ did not have 
this problem documented by the SPT.  These data suggest that adherence barriers 
such as swallowing difficulties, altering doses of medicines and difficulties reading the 
instructions labels were overlooked more commonly than others such as forgetting to 
take or order medicines, especially when the problems occurred ‘often’ or ‘sometimes’.   
Whilst it may be worth reviewing the procedures undertaken by the SPT for adherence 
problems that ‘often’ or ‘sometimes’ cause difficulties, it is worth considering the 
potential of the fourth explanation too; that the questionnaires were not completed as 
intended.  Agreement between the SPT and patients was lower at the post-intervention 
stage compared to the pre-intervention stage, which supports the proposal of 
insufficient questionnaire sensitivity to detect change.  This may also be augmented by 
the subjective nature of the response options on the questionnaire, as ‘sometimes’ may 
be interpreted differently by different people.   
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Some adherence tools140, 146, 152 have attempted to overcome the problem of subjective 
response options by asking how often each adherence difficulty has caused non-
adherence over, for example, the last three or seven days.  Whilst these approaches 
have proved to be appropriate in their target populations, it is likely that such specific 
recall may increase the cognitive burden of completion and thus be inappropriate for 
the population in this study.  
At the post-intervention stage, the adherence questionnaire was identical to that given 
to patients at the pre-intervention stage.  Therefore, a patient with, for example, 
swallowing difficulties, may still report that they ‘always’ or ‘often’ have difficulties 
swallowing their medicines, despite receiving an intervention whereby their medicines 
were all switched to liquid forms.  From the patient’s perspective, they have difficulties 
swallowing their medicines and therefore need to have them in an alternate form.  For 
all other statements, an ambiguity of interpreting the situation, as described above may 
be possible.  An alternate form of the questionnaire, focussing on changes in 
medicines taking since the initial visit may therefore have been more appropriate, 
although it is common practice to use standardised self-report measures pre and post 
intervention without changes. 
Overall, it would seem that the questionnaire can identify adherence related difficulties 
and is acceptable to patients with sufficient cognitive capacity to allow questionnaire 
completion.  The acceptability and utility of the questionnaire in patients with cognitive 
deficits remains unestablished.  However, it is worth considering whether any 
questionnaire based tool, no matter how simple would be acceptable to patients with 
notable cognitive impairments.  
2.4.3  Changes in patient adherence following the intervention 
The SPT reported that the majority of patients were either fully or partially non-adherent 
at the initial visit stage, highlighting the need for the service.  This need is augmented 
by the data which demonstrated that over half of the patients deemed to be fully 
adherent, required some form of intervention to ensure their adherence could be safely 
maintained.  The proportion of patients classified as partially adherent at the initial visit 
stage reflects the variable nature of non-adherence.  
The most common cause of non-adherence was ‘forgetting’ which is expected given 
the cognitive impairments of the service recipients and is similar to the findings of a 
comparable study200.  The notable proportion of non-adherence that was attributable to 
patients taking additional doses in between care calls is also likely to reflect the 
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documented cognitive impairments in the sample population.  However, it is worth 
considering that there could also be elements of intentional non-adherence, especially 
in taking additional doses.  The cases of hiding medicines from carers may also reflect 
intentional non-adherence, although this may be more likely to be a facet of altered 
behaviours arising from dementia or other cognitive impairments. 
With consideration of the intentional or unintentional nature of the adherence 
behaviours encountered, there is a strong likelihood that the non-adherence observed 
was dominated by unintentional factors.  Both cases of ‘refusing to take medicines’ 
were likely intentional and for some behaviours such as hiding medicines and taking 
additional doses it is unclear whether such behaviour is intentional in nature.  More 
likely, as discussed previously, is that such behaviours are related to the high 
prevalence cognitive impairments which may account for such behaviours.  ‘Forgetting’ 
was, in all likelihood an unintentional behaviour, especially given the prevalence of 
known cognitive impairments.  However, as highlighted in chapter one, ‘forgetting’ can, 
in some circumstances be defined as an intentional behaviour.  Despite clearly defined 
classifications, it is reasonable to conclude that the medication non-adherence 
encountered in this evaluation was almost exclusively unintentional in nature.  
The SPT reported a statistically significant increase in the proportion of adherent 
patients following the intervention.  This data is encouraging for the service as it 
portrays its efficacy favourably.  However, two important limitations must be 
considered.  Firstly, these data were gathered by the SPT providing the service and 
may thus be subject to strong potential reporting bias.  Secondly, whilst the SPT 
reported that patients had become adherent following the intervention, the longevity of 
these adherence improvements is unknown.  A further follow up of patients at, for 
example, a six month or one year time point post intervention would therefore be useful 
to establish whether the intervention achieved long term adherence improvements.  
Whilst the potential for reporting bias in SPT gathered data should not be overlooked, 
there is evidence to suggest this is unlikely.  In many cases, for example those 
involving patients that were tampering with their medicines in between care calls, the 
SPT intervention of providing a locked box for medicines storage that only the carers 
can access, prohibited the patient’s non-adherent behaviour thus a genuine positive 
outcome is extremely likely.  Furthermore, the magnitude of the adherence 
improvements, coupled with the supporting descriptive data and information on the 
interventions recommended cumulatively suggest that the intervention truly did improve 
adherence.  
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Beyond improving adherence for those classed as non-adherent or partially adherent at 
the initial visit stage, patients who were adherent but who were experiencing medicines 
related difficulties also received benefit from the service.  This inclusivity and 
commitment to supporting all patients in need also represents the service favourably. 
Whilst the SPT reported data showed large and statistically significant improvements in 
medication adherence following the intervention, this was not so for the patient 
reported data.  However, pre and post intervention self-reported adherence data were 
only available for ten patients, meaning the value of the statistical test is questionable 
due to insufficient power.  With greater numbers, the improvement in median 
adherence score following the intervention may have been significant.  In addition, the 
adherence tool may not have been sufficiently sensitive to detect changes in 
adherence, as discussed previously.   
A further point of consideration with the patient reported adherence data is that the 
person completing the pre-intervention adherence screen may not have been the same 
as the person completing the questionnaire at the post-intervention stage.  Patients 
were frequently supported by the technician at the pre-intervention stage, and many 
returned questionnaires at the post-intervention stage had been completed by a 
caregiver rather than the patient themselves.  It is therefore difficult to draw meaningful 
conclusions from the patients’ self-reported adherence data and this is a notable 
limitation of the study.  
The questionnaire dissemination process, whereby the SPT decided which patients 
received a questionnaire based on their cognitive capacity also introduces potential 
selection biases.  However, statistical tests confirmed that significantly more patients 
had poorer cognitive function in the group on non-recipients.  Whilst this observation 
cannot exclude the potential of selection bias, it does increase our confidence that 
questionnaire distribution procedures were followed correctly, whereby questionnaires 
were not sent to patients considered to have insufficient cognitive function.  A 
dissemination process whereby all patients were sent a questionnaire would overcome 
this potential bias, however the ethical implications of potentially confusing vulnerable 
older adults with known cognitive impairments would have to be considered.  In a 
similar vein, there is also potential selection bias in the questionnaire distribution 
process for caregivers.  Whilst it is assumed that all eligible caregivers received a 
questionnaire, data to support this assumption was not collected.  An auditable, more 
robust caregiver questionnaire dissemination process is therefore recommended to 
alleviate the potential for this source of bias.   
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2.4.4 Changes in patient risk assessment scores following the 
intervention 
Pre and post intervention risk scores were successfully assigned to each patient by 
four different health care professionals (HCPs) using the NPSA risk matrix, 
representing novel utilisation of the risk matrix tool.  Whilst the tool has been reported 
for use in assigning medication related risks of harm, this is, to the best of our 
knowledge the first time that a multiple-rater approach has been utilised. 
The variation in risk scores across patients both pre and post intervention reflects the 
diversity of patients receiving this service and their complex and varying healthcare 
needs.  On average, the patients’ risk of harm at the pre-intervention stage was ‘high’, 
indicating the need to intervene and appropriateness of referral.  Following the 
intervention, the vast majority of patients achieved a reduction in their risk score and 
the average risk score was reduced to ‘medium’.  The difference in median risk scores 
pre and post intervention was statistically significant, and thus suggests beneficial 
effects of the service.  There was also a significant reduction in the proportion of 
patients categorised as ‘high or extreme’ risk following the intervention, adding further 
weight to the evidence of beneficial service effect.   
In cases where reductions in risk scores were not achieved, consideration of the 
circumstances surrounding these patients makes a strong case for understanding the 
limitations of the SPTs capacity to make changes.   Overall therefore, there is strong 
evidence for the efficacy of the service in reducing the patients’ risk of harm.  Whilst 
there is statistical evidence to suggest service benefit in terms of risk reduction, it is 
essential to consider how meaningful the data were, given that the risk scores are 
based on data provided by the SPT delivering the service. The limitations of the before 
and after study design must also be considered.  
2.4.5 Agreement between healthcare professionals in assigning NPSA risk 
assessment scores to patients’ pre and post intervention 
The measures of inter-rater agreement (IRA) and inter-rater reliability (IRR) for the risk 
scores assigned by the four HCPs demonstrate that overall, HCPs were able to 
consistently differentiate between different risks of harm (IRR), even if they didn’t 
always agree of the severity of the risk (IRA).  The high ICC values suggest that, whilst 
the coders did not always reach perfect agreement in their risk scores, the process of 
assigning risk scores was undertaken in a consistent manner and that a minimal 
amount of measurement error was therefore introduced by the independent coders 
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(HCPs)241.  Whilst inter-rater reliability was considered excellent at both stages, inter-
rater agreement was less impressive, although still at an acceptable level and of 
statistical significance.   
The comparison between single and average measures of ICC at both the pre and post 
intervention stage highlights that reliability of risk score assignment is greatly improved 
by taking an average of the scores provided by four different HCPs than a single risk 
scorer.  This observation supports the selected method of taking an average of four 
different risk scores and adds confidence to the interpretation of a reduction in risk 
score following intervention.  
The statistically significant and (moderately) high statistics for Kendall’s W mean that 
the four different HCPs were essentially applying the same standard of rankings for the 
patients included in the study229.  Agreement was slightly poorer at the post-
intervention stage compared to the pre-intervention stage which may suggest that the 
HCPs struggled to agree on the value of the intervention and the extent to which it had 
reduced the risk of harm.  However, closer analysis of the data may also account for 
this observation.  At the pre-intervention stage the risk scores assigned by the HCPs 
were clustered around the midpoint of the scale without substantial variance.  
Comparatively, there was less clustering of data around a central point at the post-
intervention stage, with a greater range of risk scores across patients.  The slightly 
higher value for Kendall’s W at the pre-intervention stage may therefore be an artefact 
of an overall narrower range of scores between different patients.  This being so, a 
clustering of scores around the central point of the scale could imply that the HCPs felt 
uncertain of their risk score assignments and had a tendency to ‘hedge their bets’ 
around the central point.  
Qualitative interviews with the HCPs who assigned the risk scores would have been a 
useful addition to the data, to inform an understanding of how decisions about risk 
scores were made and whether there were any differences in the perceived ease of 
assigning risk scores at the pre and post intervention stage. 
Whilst the method of taking an average risk score from four HCPs has been shown to 
improve the reliability of the measure, the implications for future use of this method 
must be considered as it is a labour intensive approach.  In terms of the sole technician 
model utilised in this study, if utilisation of this measure were to continue, the reliability 
of risk scores being assigned by one individual alone must be questioned, or at least 
be carefully assessed before conclusions about risk reductions are drawn.  For teams 
of technicians or other HCPs utilising the NPSA risk matrix in their practice, robust 
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training must be provided and assessments of inter-rater agreement and reliability 
should be undertaken before assuming the team will utilise the tool in comparable 
ways242 .  
One important note of consideration is that the high and statistically significant value of 
Kendall’s W simply shows that there was good agreement between the HCPs in the 
risk scores assigned.  It does not infer that the risk scores assigned were accurate 
‘predictors’ of the patient’s risk of harm.229  Further work to establish the validity of this 
method in accurately predicting a patient’s risk of harm is therefore recommended.  
Additional data such as mortality or hospital admissions would be necessary to 
establish a relationship between risk and outcome, although the ethical implications of 
such work may be prohibitive. 
2.4.6 Agreement between the NPSA and Fuller’s risk assessment tools 
when used to calculate pre-intervention risk scores 
Overall, the Fuller’s risk tool offered a more conservative estimate of patients’ risk of 
harm from their medicines compared to the NPSA risk matrix.  Whilst there was 
significant agreement between the two tools, the magnitude of agreement may be 
cause for concern and further investigation is warranted to establish why agreement 
between the two tools was not greater. 
The ‘fair’ agreement between the two tools may therefore leave the validity of the 
NPSA risk matrix in question, as the Fuller’s risk tool is reported as being validated for 
use in identifying a patients’ risk of harm associated with medicines.  However, upon 
closer inspection, the validation process for the Fuller’s tool comprised only of 
establishing inter- and intra-rater reliability.  It’s content and criterion validity and hence 
the extent to which the tool actually predicts patient harm therefore remains unknown.  
For both tools, further research is therefore necessary, to establish whether the risk 
scores calculated are indicative of actual harm, such as hospital admissions, increased 
healthcare utilisation, mortality or adverse drug reactions.  The ethical implications of 
such research may however, as previously noted, make such data collection 
problematic. 
2.4.7 Patient satisfaction with the service plus changes in ability and 
confidence to manage their medicines 
Patient satisfaction with the service was captured from approximately a quarter of the 
service recipients.  Whilst this is lower than ideal and may therefore not reflect a 
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representative sample of the service recipients, it is an artefact of the difficulties 
associated with capturing questionnaire based data in a population where cognitive 
impairments are so prevalent.  A potential source of bias with this data could be that 
the SPT delivering the service, decided which patients would receive a patient 
questionnaire, based on their known levels of cognitive capacity.  This was an intuitive 
approach to overcoming the ethical concern of confusing patients with known cognitive 
deficits by sending them a questionnaire.  However, the SPTs ‘selection’ process has 
potential to introduce bias via preferential selection of patients who were expected to 
give favourable responses.  Whilst it is important to acknowledge these potential biases 
and study limitations, analysis of the data gathered suggests such bias was unlikely as 
the patients who were sent a questionnaire were significantly less likely to have notable 
cognitive impairments compared to those who were not sent a questionnaire.  
The patient reported satisfaction highlights the quality of the service, with almost all 
patients rating the service as good or excellent.  The comments provided by patients 
also highlight this satisfaction and proved to document that the humility, compassion 
and generosity with time provided by the SPT were pivotal to its success and the 
patients’ satisfaction.  This overwhelming positive response suggests that the continuity 
of care and expertise of a sole SPT model are important attributes.  
Positive effects of the service were also communicated by the favourable 
improvements in the patients confidence and ability to adhere and manage their health.  
This data has added a valuable depth of information to the service evaluation and has 
enabled realisation of improvements beyond reduced risks and improved adherence.  
Empowering patients to manage their own health and well-being is an important priority 
for healthcare and thus, the service is again represented favourably.    
2.4.8 Patient carergivers’ satisfaction with the service and their feelings 
about providing care following the intervention 
The high caregiver questionnaire response rate (77.8%) and excellent completion rates 
(only one questionnaire had one section that was not fully complete) imply adequate 
face validity.  Almost all caregivers reported an increased confidence in the patient’s 
ability to take their medicines as prescribed and manage their medicines independently 
plus reduced difficulties with taking their medicines, highlighting the benefits of the 
service.  The questionnaire also captured the positive influence of the service on the 
caregiver’s own feelings, with a large majority of patients reporting reduced anxiety 
levels and less time spent worrying about medicines taking.  Whilst these positive 
effects are laudable, it is worth noting that only half of the caregivers reported a 
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reduction in the level of reliance that the patient had on them.  This observation may be 
worthy of further investigation as it implies that caregivers still felt relied upon for 
medicines support.  Whilst this reliance may intuitively be perceived negatively, 
involving informal caregivers in the continuation of patient care may have benefits and 
it is known that some caregivers struggle to relinquish all responsibility243.  
The median satisfaction score for caregivers was 20, indicating that on average, 
caregivers expressed complete satisfaction with the service and could not have rated it 
more highly; this observation portrays the service auspiciously.  This satisfaction is also 
portrayed in the caregiver comments, which, as with the patient comments, are focused 
around the personable and supportive nature of the SPT.  Caregiver comments also 
captured the reduced levels or anxiety associated with being a caregiver confirming the 
all-round benefits of receipt from this service.  
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2.5 Conclusion 
An evaluation of the CCS NHS Trust Domiciliary Medicines Support Service has 
highlighted that the service is capable of improving medication adherence and reducing 
patient’s risk of harm from their medicines.  However, there are substantial limitations 
to this data, most notably that both primary outcome measures were informed by data 
supplied by the SPT delivering the service. These findings must therefore be 
interpreted with caution.  Further to these potential biases, the overall method imposes 
a limitation in so much as we cannot be sure how the patients would have progressed 
without intervention.  A follow-on RCT study would enable this data to be captured, 
offering a more robust evaluation of service effect.  However important ethical concerns 
(i.e. not intervening to resolve identified difficulties in the control arm) would need to be 
carefully considered.    
Despite numerous study limitations, high levels of patient and patient caregiver 
satisfaction were reported, plus improvements in the patient’s confidence and ability to 
manage their medicines and health.  The possibility of selection bias with the 
questionnaires must however be considered though additional analyses suggests this 
is unlikely.  
Based on the data gathered (whilst acknowledging the aforementioned limitations), this 
service may seemingly be providing effective domiciliary medicines support to its 
recipients.  However, the longevity of these positive effects is unknown and further 
work is therefore recommended.  Establishing the prolonged effects of this service may 
however be difficult in a population prone to natural declines in their ability to manage, 
especially those with cognitive impairment.  The cost-effectiveness of the intervention 
has also not been established, which, given the reduced use of MCAs and technician 
led basis compared to pharmacists, may be useful.  Further inferences of service 
efficacy could also have been captured through additional data such as health related 
quality of life, healthcare utilisation data and adverse events.  Whilst the rationale for 
not eliciting this data is provided, its absence represents a further study limitation. 
The work undertaken posed numerous methodological concerns and further work is 
necessary to continue resolving these.  Self-reported adherence in a population with 
known cognitive impairment remains problematic, although the tool developed for this 
study shows promise in those patients with sufficient cognitive capacity.  Further 
exploration the utility of this new adherence assessment tool and validation by 
comparison to electronic measurements of adherence such as the Medication Event 
Monitoring System (MEMS®) devices is therefore recommended.  For patients with 
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cognitive impairments, self-report is unlikely to be an appropriate measure of 
adherence, even when bespoke assessment tools are used.  Alternatives measures 
such as pill counts and MEMS® devices should therefore be explored.  In relation to the 
assessment of a patient’s risk of harm from their medicines, neither tool used was 
without limitations.  The subjective nature of risk assessment and the difficulties in 
establishing validity of the processes leaves the utility of such approaches in question.  
At best, the NPSA tool may be a brief and easily utilised means of capturing a patients 
risk and comparing this at different time points to establish intervention effects.  It 
should not however, be seen as an absolute proxy for risk and the scores produced 
from its use should therefore be interpreted with caution.  
The work undertaken has contributed to the deficits in knowledge regarding domiciliary 
support services by providing a wealth of data to characterise service recipients, their 
adherence difficulties and the interventions recommended to resolve these.  Such data 
has not been widely reported and, whilst possibly collected via audits and service 
evaluations for each individual service offered in the UK, is rarely shared amongst 
service providers to establish best practice.  Dissemination of this work to providers of 
similar services may therefore facilitate shared knowledge and best practices.  
However, this data could have been supplemented by information regarding the 
patients’ clinical conditions.  
The service provision model utilised in this evaluation has demonstrated positive effect 
and is clearly well regarded by its recipients and their caregivers, however it is not 
known whether this model is optimal.  Provision of the service by a sole SPT appeared 
to have benefits, as supported by the questionnaire comments which focused on the 
specialist expertise, generosity with time and attention plus continued support enabled 
by this model.  It is clear therefore, that, with the right personnel, a sole SPT model can 
work well.  However, the limitations of this model and risk of dependence on one 
individual should be borne in mind.  Further collaborative practice and sharing of 
knowledge amongst providers of domiciliary support services, via forums and 
dissemination of research may help to establish the optimal model for service delivery. 
The contribution of this chapter to the overall thesis is centred on understanding the 
role of community pharmacy based adherence services in addressing non-adherence 
that was almost exclusively of an unintentional nature.  The evidence highlights that, 
with this particular service, non-adherence can seemingly be managed effectively, with 
a range of interventions utilised to address these deficits.  Whilst the strength of this 
service was its holistic focus and commitment to ensuring all avenues of support were 
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considered it is reasonable to conclude that as a profession, pharmacists and 
pharmacy technicians are well equipped to address non-adherence of an unintentional 
nature.  Memory and physical impairments can be remedied with assistive techniques 
such as reminders and devices, and advice with regard to appropriate dosing and 
administration can be offered with expertise.  Overall, community pharmacies are well 
equipped to support their patients in overcoming intentional non-adherence, although 
such services may be further improved by sharing of knowledge and best practice.    
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3.1 Chapter introduction 
Chapter two focused on a domiciliary support service to resolve adherence difficulties 
of a primarily unintentional nature.  In this service, patients experiencing cognitive 
and/or physical deficits were supported via a variety of resolution strategies including 
additional support plus provision of advice and adherence aids.  Whilst improvements 
can still be made, in the main part, pharmacy services appear to be reasonably well 
equipped to resolve non-adherence that assumes this unintentional nature. 
The remainder of this thesis will therefore concern strategies to resolve intentional non-
adherence.  The adherence interventions routinely delivered in community pharmacies 
such as Medicines Use Reviews (MURs) are not well designed to challenge complex 
patient preferences to intentionally deviate from their prescriber’s intentions.  
Encouraging adherence in these situations is likely to need a different approach, 
capable of facilitating behaviour change.  In this chapter, different techniques to change 
behaviour will be explored.  However, to understand the techniques that can be used to 
resolve intentional non-adherence, we must first consider the psychology underpinning 
these behaviours. 
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3.2 Health psychology and its application to medication adherence 
 
Health behaviours can be thought of as actions that we engage in with the intention of 
maintaining, attaining or regaining good health, or actions taken in order to prevent 
illness244.  By this definition, the action of taking a medicine as prescribed is a health 
behaviour.  In 1980, the biopsychosocial model of health behaviour was first proposed 
by Engel, who suggested that biological, psychological and social factors interact245.  
This model therefore accounts for the potential impact of thoughts, feelings, culture and 
environment on a person’s behaviour and can be used as a framework to ‘understand 
the person in the context of their life’246.  The biopsychosocial model is therefore 
essential for understanding the plethora of factors that may influence a patient’s 
medication taking behaviours. 
In chapter one, the importance of a patient’s health beliefs to medication adherence 
were described.  Health beliefs can be considered in four different ways247: 
1) Attribution theory – individuals need to view their world as predictable and 
controllable; an individual’s level of perceived control over their illness may 
therefore influence health behaviours such as adherence to medications.  
 
2) Risk perception – individuals will develop a sense of whether or not they are 
susceptible to a given health problem.  Continuation of unhealthy behaviours 
may be explained by unrealistic optimism where an individual feels confident 
that they are not susceptible to the risks associated with the behaviour.  In a 
similar way, risk compensation frameworks suggest that an individual may 
engage in one set of risky behaviours (for example medication non-adherence) 
as they perceive that this can be compensated for by an alternate healthy 
behaviour (such as eating fruit).  
 
3) Motivation and self-determination theory – autonomous motivations drive 
personally relevant goals and convey a sense of wellbeing and persistence with 
health behaviours.  Controlled motivations are driven by external factors such 
as pressure to please peers and may be associated less personal satisfaction 
and subsequent avoidance of health behaviours.  
 
4) Self-efficacy – describes an individual’s sense of belief and confidence in their 
abilities; a deficit in self-efficacy may prevent engagement with health related 
behaviour change such as implementing a new medicines regimen. 
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The application of health psychology theory to medication adherence is apparent as 
patient behaviour (taking medicines as prescribed) is the pivotal link between effective 
prescribing and achieving a therapeutic outcome.  In an attempt to understand and 
predict the complexities of human behaviour, several psychological theories have 
emerged to integrate these four key aspects of health beliefs and behaviour.  Whilst the 
theories tend to have similarities and overlapping components, differences also prevail. 
3.2.1 Leventhal’s Self-Regulatory Model (SRM)248 
Leventhal’s Self-regulatory Model (SRM) describes the key factors which influence 
health behaviours when an individual encounters ill-health, by assuming a problem-
solving approach248.  The model suggests that individuals deal with illness and illness 
symptoms in the same way as any other problem; by maintaining an equilibrium.  In the 
presence of a threat to psychological or physical being (an illness), individuals will be 
motivated to engage in activities to resolve this so that an equilibrium is restored244.   
Illness representations, defined by Leventhal and colleagues as ‘a person’s own 
common-sense belief about their illness’248 provide a framework of five dimensions for 
coping with and understanding an illness, as described in figure 3.1. 
 
 
 
 
 
 
 
Figure 3.1 Illness representations included in Leventhal’s SRM 
The SRM is divided into three stages; interpretation, coping and appraisal.  During the 
interpretation phase, the five dimensions (detailed in figure 3.1) are assessed to create 
an illness representation.  An emotional response may also be evoked during the 
interpretation phase as the implications of an illness may lead to anxiety, stress and 
fear.  The second phase, coping, is the point at which an individual will begin to act 
upon their interpretation of the illness, this may involve advice seeking from friends, 
family or healthcare providers, or for example, taking time off of work.  In the third stage, 
appraisal, the individual will assess their chosen coping strategies and decide whether 
Identity – the label given 
to an illness, either via a 
practitioner’s diagnosis 
or self-diagnosis, which 
can be influenced by 
prior experiences.  
Perceived cause – 
personal beliefs about 
what may have 
caused the illness, 
may also be based on 
personal experience. 
Timeline – individual’s 
perception of how long 
an illness will last, based 
on own assumptions or 
information from health 
professionals  
Consequences – 
how an individual 
thinks the illness will 
impact on their life. 
Curability and controllability – 
whether the individual believes their 
illness can be treated and the outcome 
of their illness can be controlled.  
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to continue with this or adopt an alternative strategy.  Some individuals may not reach 
the appraisal stage, especially if they opt for an avoidant strategy or only know of one 
coping strategy246. 
The SRM has been widely used to understand how people respond to the threat of 
illness and is useful in its acknowledgement of the dynamic interaction between the 
way an individual thinks, experiences and copes with an illness.  Illness responses will 
commonly involve consultation with a healthcare provider, which in turn will often yield 
a prescription.  An individual’s illness representations may therefore be pivotal to their 
decision whether to adhere to their prescribed medicine and heavily influenced by 
previous experiences and lay health beliefs.   
In more recent years, the SRM has been reviewed, with new research identifying that 
treatment beliefs are more strongly associated with behaviour than illness beliefs249.  
This self-regulatory approach to treatment beliefs is supported by recent work, relating 
to predictors of adherence to preventative medicines for patients who have 
experienced a stroke250. It was reported that whilst illness perceptions were not 
predictors of poor adherence to preventative medicines, high specific concerns and low 
perceived benefits of medicines were strongly associated with poor adherence. 
3.2.2 Social Cognition Models (SCMs)  
 
Social cognitive approaches to behaviour emphasise that individuals play an active role 
in interpreting the information around them, focusing on the social context of behaviour 
change and the cognitive processes that determine whether or not an individual 
engages with behaviour change244.  Fiske and Taylor defined social cognitions as 
‘individual cognitions or thoughts which intervene between observable stimuli and 
responses’251.  They therefore represent modifiable determinants of health behaviour 
and have attracted interest in the fields of health psychology and behaviour change.  
Social Cognition Models (SCMs) assume that the major determinants of behaviour are 
an individual’s attitudes and beliefs, which in turn influence the interpretation of 
experiences and information, which guide behaviour.  Many models have emerged and 
new theories continue to be presented, however, the three most commonly applied 
social cognitive models are described in the following sections. 
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3.2.2.1  The Health Belief Model (HBM)252 
The Health Belief Model was one of the first SCMs and remains one of the best known 
health behaviour change models253, despite almost forty years passing since its original 
conception by Rosenstock252.  Later elaborations developed the model further253, 254, 
maintaining its position as a core model of health behaviour.  Rosenstock and 
colleagues worked as a small team of social psychologists during the 1950’s as part of 
the US Public Health Service, where they were tasked with developing a theoretical 
model to better understand the widespread failure of screening programmes for 
tuberculosis255.  The HBM model was therefore developed in the context of 
understanding preventative health behaviours.  Central to the underpinning of this 
model, is the importance of health beliefs in determining whether or not an individual 
engages with protective health behaviours.  
According to the HBM, the likelihood of an individual engaging in a health behaviour 
(for example taking a prescribed medication) is determined by the perceived health 
threat and an evaluation of the recommended action.  Figure 3.2 provides a summary 
of the Health Belief Model, and highlights that the core elements of the model are: 
• Perceived susceptibility - an individual’s assessment of the likelihood of 
succumbing to the illness in question 
• Perceived severity - an individual’s assessment of the severity of a condition and 
its consequences 
• Perceived barriers/costs - an individual’s assessment of likely influences that may 
discourage adoption of the health behaviour and the implications of adopting (or not 
adopting) the behaviour 
• Perceived benefits – an individual’s assessment of the positive consequences of 
adopting the behaviour 
• Cues to action – prompts that trigger the behaviour, including internal cues (such 
as symptoms of illness) and external cues (such as health promotion) 
• Health motivation – the value that an individual attaches to their health and their 
willingness to take part in health promoting activities 
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Figure 3.2
Figure sourced from 
and Practice with Social Cognition Models. Oxfor
The perceived susceptibility and seriousness of a condition feed into a cog
perceived threat, whereas the perceived benefits and barriers of an action feed into a 
cognition of outcome expectation.  In essence, the HBM explains that people create a 
risk/benefit analysis of perceived threat and balance this against their o
expectations.  The balance between these two factors will determine behaviour. 
With regard to medication adherence, for
are susceptible to an illness and that they will become unwell if they do not adhere 
their prescribed therapy.  They must also believe that taking the medicine will infer 
benefits, that there are few personal costs resulting from adherence and that any 
barriers to non
engage in the necessary behaviours
prevent symptoms (for example beta
for asthma) and protect against disease manifestation (for example statins to protect 
against cardiovascular disease), patients must always believe that they are susceptible 
to the illness and that treatment will confer greater benefits than costs, plus have 
sufficient motivation in order to adhere
patient behaviour in relation to medication adherence. 
Demographics 
(age, gender, 
socioeconomic 
         
 The Health Belief Model (HBM)
Conner, M. and P. Norman (2005). Predicting Health Behaviour: Research 
-adherence are not insurmountable.  They must also be motivated to 
         Theoretical models 
Perceived 
susceptibility
Perceived 
Perceived 
motivation
Perceived 
barriers/costs
125
 
.  Whilst medicines can be used to both treat and 
-agonist inhalers and steroid inhalers respectively 
. The HBM is therefore useful in understanding
 
severity 
benefits 
Health 
 
 
and behaviour change techniques
 
 
d University Press
a patient to adhere they must believe they 
256
.  
 
Cues to action
Behaviour
 
 
 
nition of 
utcome 
 
to 
 
Chapter Three                  Theoretical models and behaviour change techniques 
 
126 
The HBM has been applied to a wide range of health behaviours257 though conflicting 
findings have been reported244.  Criticisms of the HBM have focused on its emphasis 
on individual rather than social and environmental factors plus the assumption that 
individuals are rational processors of information, which does not account for the 
influence of emotions such as fear.  Despite these criticisms, the HBM remains the 
most cited and researched of the SCMs.  
3.2.2.2  Protection Motivation Theory (PMT)258 
The PMT model was originally conceived to explain the effects of ‘fear appeals’ on 
health attitudes and behaviours258.  Whilst this theory builds upon the HBM, PMT 
includes ‘fear’ and thus attempts to incorporate an emotional component within the 
understanding of health behaviours.  The components of the PMT (as depicted in figure 
3.3) predict behavioural intentions which are closely related to behaviour. 
PMT postulates that when an individual is confronted with a threat (for example ill 
health), two mediating cognitive processes are stimulated; threat appraisal and coping 
appraisal259.  Threat appraisal is influenced by an individual’s perceived severity of a 
threat, their perceived susceptibility to it and their fear.  Coping appraisals combine the 
individuals assessment of the efficacy of the threat responses (actions), and their 
perceived sense of self-efficacy in executing these threat responses258.  Environmental 
and intrapersonal information influence the core components of the PMT, which then 
elicit either an adaptive or maladaptive coping response.  For an adaptive behaviour to 
be performed an individual must perceive the threat to be severe, something they are 
susceptible to and that there is an effective response (behaviour) that will negate the 
threat and which they are confident they will be able to execute.   
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Figure 3.3
Figure sourced from Lee et al.
In the application of PMT to, for example, adherence to medication for the prevention of 
cardiovascular disease, PMT would predict that information about the role of medicines 
in preventing cardiovascular disease would increase the individual’s fear and pe
severity of the disease, as well as their belief regarding how susceptible they are to 
experiencing adverse cardiovascular events.  If the individual felt confident that they 
could adhere to their medicines (self
reduce their risk of cardiovascular disease (response effectiveness), then high 
intentions to change their behaviour and adhere to their regimen will prevail, yielding an 
adaptive coping response.   
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unlikely to provide the best explanation of medication taking behaviours.
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medication taking behaviours and thus the TRA is relevant to this domain.  The 
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An adherence study to psychiatric medication, using the TPB to aid understanding, 
reported that perceived behavioural control and intentions to adhere both significantly 
predicted adherence, accounting for 38.1% of the variance in adherence264.  These 
research findings, amongst others support the application of the TPB to understanding 
medication adherence.  As such, it is clear to see that interventions seeking to change 
a patient’s beliefs about taking their medicines or enhance their motivation to do so are 
likely to yield changes in behaviour.  If an individual believed that adhering to their 
medication would be beneficial to their health (attitude towards the behaviour) and 
believed that other people thought they should take their medicine (subjective norm), 
plus, if they believed that they were capable of adhering to their prescribed medication 
regimen (behavioural control) then this would predict high intentions to adhere 
(behavioural intention).  The TPB also predicts that perceived behavioural control can 
directly influence behaviour without influencing intentions, for example, in instances 
where deficits in manual dexterity affect a person’s ability to access or administer their 
medicines (behavioural control), this is a better predictor of adherence than whether or 
not they intended to adhere.  
Whilst the positive aspects of the TPB, especially with regard to medication adherence 
are apparent, limitations have also been suggested.  Most notably, the intention-
behaviour gap is of concern, as intentions are not always translated into behaviours244.  
3.2.2.4  Summary of Social Cognition Models  
All of the models of behaviour proposed are based on cognitions that are consciously 
thought out before the behaviour occurs.  Whilst useful in allowing an understanding of 
conscious behaviours, habitual or irrational behaviours which do not involve conscious 
pre-emptive thoughts cannot be explained by these theories.  The theories therefore 
provide a foundation point from which we can begin to understanding the complexity of 
explaining medication taking behaviours.  Rather than being a definitive explanation of 
human behaviour, SCMs represent a tool to facilitate our understanding, providing a 
structured approach to understanding health beliefs and predicting health behaviours.  
In light of the limitations of the SCMs, suggestions for the addition of further variables 
have been posed, including247: 
1) Expanded norms – such as moral norms, descriptive norms (perceptions of 
whether other people carry out the behaviour) and injunctive norms (whether 
other people may approve or disapprove of the behaviour) 
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2) Affective beliefs – to include the influence of emotions and their affect upon 
behaviour, beyond the inclusion of ‘fear’ in PMT 
3) Anticipated regret – as an alternative approach to emotions 
4) Self-identity – as individuals will only intend to perform a behaviour if it fits with 
their own image of themselves 
5) Ambivalence – to accommodate for behavioural attitudes that are indifferent 
rather than positive or negative  
6) Personality – certain aspects of personality are associated with health 
behaviours and may influence motivation  
 
3.2.3  Stage models 
A notable limitation of the Social Cognition Models is that cognitions and behaviours 
change over time.  Stage models attempt to address this problem by considering health 
behaviours as processes which occur in a series of stages. 
3.2.3.1  The stages of change model 
The stages of change model, also known as the Transtheoretical Model of behaviour 
change (TTM) is the most widely applied stage model and assumes that different 
cognitions take precedence at different stages of change.  Developed in 1983 by 
Prochaska and DiClemente265 and based on the analysis of different theories of 
psychotherapy266 the TTM recognises that individuals change their behaviour in 
gradual and often non-linear fashion.   
The TTM proposes five key stages of change: 
1. Pre-contemplation – an individual is unaware of the need to change or unwilling to 
do so, they will not be thinking about changing their behaviour and will not be 
interested in any help to do so. 
2. Contemplation – the individual becomes aware of the consequences of their 
current behaviour and their personal susceptibility and begin to weigh up the costs 
and benefits of changing the behaviour.  Whilst thinking about the behaviour, they 
are not as yet fully committed to changing it. 
3. Preparation – the individual has made the decision to change their behaviour and 
intends to do so in the near future. This is the period of psychological preparation 
for change, small changes may be tried first to ease the behavioural transition. 
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4. Action – the individual implements the plans made in the preparation stage and 
attempts to change their behaviour, though the risk of relapse is high. 
5. Maintenance – the individual develops strategies to maintain their new behaviour 
and resist temptations which would prompt relapse. 
 
Ideally, relapse will be avoided and the new ‘healthier’ behaviour will be maintained.  
However, in reality, it may take several attempts before a patient is able to fully 
maintain their new behaviour.  Decisional balance, the way in which an individual 
weighs up the costs and benefits of a behaviour is also key to the TTM, as an 
individual’s focus will shift according to the different stages of change.  For example, an 
individual who has stopped smoking is likely to focus on the benefits of this behaviour 
at the action and maintenance stages, but comparatively, at the pre-contemplation 
stage, they are more likely to focus on the costs.   
In relation to medication adherence, the TTM is useful in understanding the processes 
necessary to convert a non-adherent patient into an adherent one.  Moreover, it is 
useful in prioritising service delivery so that interventions to support behaviour change 
are delivered at the appropriate stage, when a patient feels ready and is a willing 
recipient of support and help. 
3.2.3.2  The Health Action Process Approach (HAPA) 
Developed by Schwazer in 1992267, the HAPA stage model of health beliefs and health 
behaviours, emerged following a review of literature in an attempt to address 
recognised deficits.  The model emphasises the importance of self-efficacy and shares 
many constructs with the SCMs described earlier.  The HAPA differs from other models 
in its distinction between a decision making/motivation stage and an 
action/maintenance stage.  In the motivation stage, an individual decides whether or 
not to carry out a behaviour and then makes plans to initiate and maintain the 
behaviour in the action phase.  Figure 3.5 summarises the HAPA. 
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Figure 3.5
Figure sourced from 
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3.2.4 Summary of theories of behaviour 
Considering medication adherence in the context of health behaviour theories is a 
useful tool in understanding how to modify patient behaviour by supporting adherence.  
The SCMs and stage models have shown that social cognitions predict behaviour, 
therefore, if practitioners wish to influence patient behaviour, aiming to amend these 
social cognitions, where possible, is intuitive.    
Interventions grounded in psychological theory have also been shown to elicit larger 
behavioural effects than interventions that are not designed with a theoretical basis.  In 
their systematic review and meta-analysis of internet based health promotion strategies, 
Webb et al. reported that more extensive use of theory was associated with statistically 
significant increases in effect size (p= 0.049).  In particular, Webb and colleagues 
report that interventions based on the theory of planned behaviour tended to elicit the 
most substantial effects on behaviour269.  Similarly, Taylor et al. have recently 
published a meta-analysis of worksite physical activity programmes and reported that 
interventions which explicitly used more theory, elicited larger effects270.  
Whilst the most commonly and widely accepted theories of behaviour have been 
considered, there are many other models, each focusing on slightly different or 
overlapping constructs.  The complexities of the different models and their overlapping 
concepts, limit their use in the wider field outside of theoretical psychology.  Moreover, 
the different models place precedence on different cognitions, therefore it can be 
difficult to know which cognitions are priorities for intervention targeting.  Many models 
(including the TPB) also explain and predict behaviour rather than providing information 
on how best to modify it which augments the usability difficulties.  Given these 
problems, it is not surprising that so few interventions have a strong grounding in 
theory; the complexities, poor accessibility and confusing overlaps of the theoretical 
models act as a barrier to their efficient incorporation in intervention design.  
In order for behaviour change interventions to be theoretically based and therefore 
better designed, the psychological models of behaviour which underpin the theory need 
to become more accessible.  In recent years, novel work has emerged which aims to 
address these deficits and provide a theoretical framework for the models of behaviour 
and integrate the models to form a singular, definitive model comprised of the core 
constructs of behaviour.  
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3.2.5  Integrated models of behaviour  
Integrated models of health behaviour have included Lippke and Plotnikoff’s integration 
of PMT with the SOC to predict exercise271 and the work of Jacobs et al. who 
integrated the TPB with self-determination theory in the context of diet and physical 
activity272.  Whilst these approaches have generated research interest, the most 
notable integrative model to emerge in recent years, ‘the major theorist’s model’ 
emerged from a workshop attended by prominent psychologists who identified eight 
key variables which they believed to account for variance in any given behaviour273.  
These variables were divided into those directly impacting upon behaviour 
(environmental constraints, skills and intentions) and those relating to intentions (self-
discrepancy, self-efficacy, social pressure, advantages/disadvantages, emotional 
reactions).   
Conner and Norman note that although this model is logical and includes well-tested 
constructs from the SCMs, it also contains new, untested constructs and those which 
have previously shown poor predictive validity such as self-discrepancy256.  Further 
criticisms of the model extend to the omission of variables such as risk perception and 
perceived severity, which are known predictors of behaviour plus a failure to bridge to 
intention-behaviour gap256.  Fishbein and colleagues’ work with the ‘major theorist’s 
model’ did however represent the first theoretical framework of individual behaviour 
change, from which notable research has stemmed.  
3.2.6  Theoretical frameworks of individual behaviour change 
In recent years, two theoretical frameworks have emerged274, 275, pooling the different 
models of behaviour and identifying common domains to form a scaffold for identifying 
individual patient barriers to behaviour change. These frameworks are therefore the 
logical mediator between understanding theories of behaviour and developing a theory 
based novel adherence intervention.   
The frameworks have been designed to have high usability and an accessible nature, 
to facilitate the incorporation of health psychology theory into intervention design in a 
robust, but far simpler way. 
3.2.6.1  The ‘Fishbein Framework’274 
Fishbein’s framework for individual behaviour change was developed in the context of 
health promotion, with specific relation to HIV preventative behaviours.  The framework 
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consists of eight domains, which have been identified as the key moderators of patient 
behaviour, as shown in figure 3.6. 
 
 
 
Figure 3.6 Domains of the ‘Fishbein Framework’ 
In order to adhere, a patient requires practical skills to be able to take their medicines 
(skills) plus confidence in their ability to do so (self-efficacy).  They also need to be 
motivated to adhere and intend to take their medicines (intention) and they must not be 
hindered by difficulties such as being unable to collect their medicines (environmental 
constraints).  Adherence will also be supported by a positive attitude towards taking the 
medicine (attitude), positive social influences (norms) and placing importance on 
undertaking the behaviour (self-standards).  Experience of stress and anxiety 
associated with medicines taking may hinder adherence (emotions).  
Fishbein et al. suggested that just three domains were necessary and sufficient 
prerequisites for performing a specified behaviour; a strong intention to perform the 
behaviour, no environmental constraints that would make performing the behaviour 
impossible and the skills necessary to perform the behaviour.  The remaining domains 
are considered to be determinants of intention strength.  Fishbein and colleagues used 
a consensus approach to arrive at these domains, but precise methodological details 
are absent.  The framework was also published for psychological readership, which 
may limit its accessibility to non-psychologists, responsible for research on the 
implementation of evidence based practice.  The Fishbein Framework therefore 
represents a useful foundation for collating health behaviour models, but may not be 
sufficient to provide a fully accessible and widely used tool.  
3.2.6.2  The Theoretical Domains Framework (TDF) 275 
Unlike Fishbein’s work, the Theoretical Domains Framework (TDF) was developed in 
the context of professional behaviour change, but has later been adapted for patient 
health behaviours.  This seminal work was undertaken in 2005 by Michie et al. on 
behalf of the Psychological Theory Group and was later adopted as the British 
Psychological Society’s (BPS) Framework.  Michie and colleagues used a multi-stage 
consensus approach over a 14 month period to develop a theoretical framework that 
could be used in implementation research.  The multiple stages included work with 18 
Skills 
Self-efficacy 
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Intention 
(motivation) 
Environmental 
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Attitude Emotion Norms Self-standards 
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experts in health psychology theory, 16 international health service researchers with 
expertise in implementation research and 30 delegates at a health psychology 
conference.
Figure 3.7 summarises the final 12 
Fishbein’s framework
are provided in appendix 3.1.  Given that consensus for
independently of the Fishbein Framework and in the context of different behaviours, the 
similarity between the two frameworks can be argued to further validate the work of 
Michie et al
additional domains: ‘knowledge’, ‘memory, attention and decision processes’, 
‘behavioural regulation’ and ‘nature of the behaviour’.  Michie 
inclusion of four additional domains may be reflective of the wider g
employed, but also developments in the research field since Fishbein’s work
 
 
  
 
 
 
 
 
 
 
* Domains in parenthesis show corresponding domains of ‘Fishbein framework’
Figure 3.7
In 2012 the TDF was refined following a comprehensive three
process276
framework provides explicit behavioural domain definitions, informed by the use of the 
American Psychological Associations’ Dictionary of Psychology
appendix 3.2.  Further refinements to the TDF are summarised in table 3.1.
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Nature of change Rationale 
‘Motivation and goals’ domain 
separated into ‘intentions’ and ‘goals’ 
Domain split to differentiate between ‘goals’ 
which focus on a preferred outcome or end 
state and ‘intentions’ which concern the resolve 
to initiate or terminate a behaviour. 
‘Beliefs about consequences’ domain 
split into two domains, one retaining 
the original name and one termed 
‘reinforcement’ 
Domain split to differentiate between 
‘reinforcement’ which focuses on the constructs 
of associative learning and ‘beliefs about 
consequences’ which focuses purely on beliefs.  
‘Beliefs about capabilities’ domain split 
into two domains, one retaining the 
original name and one termed 
‘optimism’ 
Domain split to differentiate between ‘optimism’ 
which concerns a general disposition and 
‘beliefs about capabilities’ which focuses on 
specific capabilities 
‘Behavioural regulation’ domain 
clarified 
Clarification enables focus on self-regulatory 
processes 
‘Nature of the behaviours’ domain 
removed 
Analysing the nature and influences of 
behaviour are two distinct processes 
Table 3.1 Summary of key changes to updated TDF276 
3.2.6.3  Research applications of the TDF 
Whilst the refined TDF is yet to be widely used in research, the original TDF has 
generated marked research interest.  In their 2012 commentary, Francis et al. identify 
133 papers which cite the TDF, including 17 studies which have used the TDF to 
explore health professionals’ behaviours278.  The TDF has been used successfully to 
develop theoretically derived behaviour change interventions for the management of 
acute low back pain in primary care279 and to identify barriers to the implementation of 
best practice guidelines in schizophrenia280.  Further uses of the TDF include the 
identification of enablers and barriers to incorporation of evidence based guidelines, in 
acute low back pain281, 282 and to classify the behavioural determinants of clinicians’ 
blood transfusion practices283, 284 .    
Whilst these qualitative studies highlight the variety of health behaviours to which the 
TDF is applicable, interesting work has also emerged from the application of the TDF to 
the development of health related questionnaires.  Questionnaires have emerged to 
identify barriers and promoters to behaviours such as the implementation of smoking 
cessation guidelines in midwives285 and dentists286, following hand hygiene behaviours 
in hospital workers287 and following guidelines the positioning of nasogastric (NG) tubes 
in healthcare providers288.  The questionnaire relating to positioning of NG tubes was 
later used to highlight the feasibility of using the TDF as a framework to guide the 
implementation of patient safety interventions289.  
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More recently, a patient based questionnaire, grounded in the TDF and designed to 
identify determinants of physical activity has been reported290.  In this work, previously 
identified barriers to physical activity were mapped to the behavioural domains of the 
TDF then questionnaire statements developed to reflect these barriers.  Psychometric 
testing of the questionnaire, following its completion by 832 UK based university staff 
and students highlight the promising credentials of this tool.  
3.2.6.4  Strengths and limitations of the TDF 
The theoretical domains framework has assimilated common and overlapping 
constructs of the plethora of health behaviour and social cognition models, into a 
simple framework to identify key determinants and constructs of health related 
behaviours.  This approach, which aims to provide easier access to health psychology 
theory, has been applied to a variety of health behaviours and in many different ways.  
Michie et al. comment that the TDF is intended for use by health services researchers 
and other practitioners, without expertise in health psychology and note that this is a 
key point of differentiation from other theoretical models which tend to be intended for 
use by psychologists275.  Whether or not the aim of improving access to psychological 
theory has been realised is yet to be established as to date, publications reporting the 
use of the TDF are still predominated by psychologists278.  However, by providing a 
singular and comprehensive framework, covering multiple overlapping theories, it is 
feasible that the TDF could be utilised more easily by non-psychologists.  If nothing 
else, use of the TDF has the potential to remove the complex decision of identifying 
which theory of behaviour should be used as a model.  The utility of the TDF by 
pharmacists rather than psychologists is explored in chapter five.  
Taylor et al. have highlighted that the TDF is also amenable to adaptation for specific 
behaviours offering a degree of flexibility to its application290.  The original TDF and its 
later update are therefore promising tools both in behaviour change and 
implementation research.  However, the TDF is not without limitations.  Whilst 
approaches such as the theory of planned behaviour specify relationships between the 
detriment areas, such as the link between intention and behaviour, the TDF does not 
specify such relationships.  The TDF does therefore not attempt to replace such 
theories283 but instead offers an alternate approach.  
3.2.6.5  Applying the TDF to the design of a novel adherence intervention 
In their hand hygiene behaviours work, Dyson et al. comment that identification of the 
barriers to behaviour change is a significant step forward in designing targeted and 
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effective interventions to modify behaviour287.  More recently, in their physical activity 
questionnaire, Taylor et al. note that their questionnaire has the potential to be adapted 
to other health domains to facilitate tailoring of interventions to meet individual needs290. 
Whilst the TDF has been applied to numerous health behaviours and promising work 
has emerged to utilise the TDF to identify barriers to behaviour change, to date, the 
TDF has not been applied to medication adherence.  If the barriers to medication 
adherence could be identified and mapped to the behavioural domains of the TDF, a 
questionnaire to represent these barriers could be developed, similar to that developed 
by Taylor et al.  Such a questionnaire, enabling identification of an individual’s barriers 
to medication adherence could be a pivotal precursor to delivery of a theory-based 
adherence intervention targeted to meet individual needs by resolving their identified 
adherence barriers.  The notion of developing an Identification of Medication 
Adherence Barriers Questionnaire (IMAB-Q) was therefore conceived, as described in 
chapter five of this thesis.  
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3.3 Facilitating behaviour change; a taxonomy of behaviour change 
techniques 
Whilst understanding that the theories of medication taking behaviours are fundamental 
in designing adherence interventions, the primary aim of such interventions will be to 
improve medication adherence by changing patient behaviours.  As such, the 
challenge in designing effective adherence interventions is in understanding how to 
influence and change patient behaviour12.  Behaviour change is notoriously difficult, 
requiring considerable time, effort and motivation on the patient’s part.   
In 2011, the term Behaviour Change Technique (BCT) was defined as: 
“an observable, replicable and irreducible component of an intervention designed to 
alter or redirect causal processes that regulate behaviour”291 
BCTs can therefore be thought of as the ‘active ingredients’ of an intervention and the 
components that yield behaviour change.  A plethora of BCTs to change health 
behaviours are available and many of these, such as provision of education and 
demonstrating the behaviour, are routinely used in community pharmacy consultations 
to support medication adherence.   
One of the most widely cited criticisms of health behaviour change research is the lack 
of a ‘common language’ to describe intervention components292, 293.  As such, similar 
terms may be used for very different techniques or different terms used for identical 
techniques.  An example of ambiguous terminology, applicable to medication 
adherence is that of the term ‘self-monitoring’ which could refer to diary keeping to 
record medicines taken.  However, the term could also refer to monitoring the benefits 
of medication adherence by recording, for example, home monitored blood pressure or 
blood glucose readings.  
Guidance for the development and evaluation of complex interventions, issued by the 
Medical Research Council (MRC), has called for improved methods for specifying and 
reporting intervention content294.  Developing a common vocabulary for intervention 
components, as a taxonomy of behaviour change techniques was an intuitive approach 
to addressing this problem.  In 2008, Abraham and Michie developed the first cross 
disciplinary behaviour change technique taxonomy, comprised of 26 BCTs as detailed 
in appendix 3.3.  In the same year, Michie et al. linked 35 defined BCTs to the 
behavioural domains of the TDF295, as summarised in appendix 3.4.  This mapping 
work represents the first steps towards practitioners being able to select a behaviour 
change technique according to the problem that they are trying to address and thus 
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represents an important milestone in health behaviour change research.  With 
application to medication adherence this preliminary work poses that, for example, if a 
patient was known to be non-adherent due to a deficit in their skills such as an inability 
to correctly use their inhaler, the BCT termed ‘modelling/demonstrating the behaviour’ 
would be appropriate as the patient would likely benefit from being shown how to use 
the inhaler correctly.  Conversely, BCTs such as motivational interviewing have been 
mapped to the TDF behavioural domain of ‘motivation and goals’ which is intuitive as 
motivational interviewing is known to be an effective approach to increasing a patient’s 
motivation.  For some behavioural domains such as ‘skills’ and ‘beliefs about 
capabilities’, numerous BCTs were identified as potential tools for behaviour 
modification.  Conversely, for other behavioural domains such as ‘knowledge’ and 
‘emotions’, far fewer BCTs were identified.  These differences are likely influenced by 
the type of behaviour to be targeted.  For example, in order to increase a patients 
knowledge, there is little more to be done other than to provide education.  Similarly, to 
overcome emotional barriers to behaviour change such as feeling negative, few BCTs 
are readily available; Michie and colleagues suggest BCTs termed ‘stress management’ 
and ‘coping skills’ as effective techniques295. 
Whilst this work was intended as a preliminary taxonomy and mapping exercise it 
represents a pivotal progression in the quest for well defined, theory based behaviour 
change interventions.  For the interventions grounded in the TDF, such as the barriers 
to physical activity questionnaire designed by Taylor et al. an opportunity to select 
BCTs according the behavioural domain containing the greatest prominence of barriers 
is created.  This approach is also applicable to the proposed questionnaire that will be 
developed to identify barriers to medication adherence, representing an exciting 
opportunity to develop an evidence and theory based intervention tailored to meet 
individual need.  
The preliminary nature of the work presented with Abraham, Michie and colleagues is 
represented by the notable developments and refinements that have emerged in recent 
years.  The original BCT Taxonomy has been applied to behaviours such as physical 
activity and healthy eating296, smoking cessation297 and excessive alcohol use298. In 
2013 the first full BCT Taxonomy was published, comprised of 93 BCTs clustered in 16 
groups293.  Work to map the new 93 BCT taxonomy to the behavioural domains of the 
TDF is due for publication imminently299 and will provide explicit detail of interventions 
appropriate for moderating barriers to behaviour change in the domains of the TDF.  As 
the taxonomy continues to be refined, its potential application to medication adherence 
research should therefore be borne in mind.   
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3.4 Behaviour change techniques to resolve intentional non-adherence 
The 26 BCTs defined by Abraham and Michie292 and detailed in appendix 3.3 highlight 
that the nature of the BCTs and the behaviours for which they may be useful in 
moderating are variable.  BCTs such as ‘providing instructions’ would be useful in 
cases of unintentional non-adherence, where a patient does not know how to adhere to 
their medicines.  Similarly, BCTs such as ‘teach to use prompts or cues’ would also be 
useful to address barriers to adherence such as forgetfulness which often assumes an 
unintentional nature.  Conversley, BCTs such as ‘motivational interviewing’, ‘prompting 
intention formation’ and ‘prompting barrier identification’ may be more useful in 
intentional non-adherence, whereby an individual’s, motivations and intentions may 
need to be altered.  As the remainder of this thesis concerns strategies to resolve 
intentional non-adherence, BCTs that may be applicable to the endeavour will be 
considered in greater depth.  Firstly, consideration is given to the intervention approach 
that may be needed to facilitate change of intentional behaviours.  
3.4.1  A patient centred approach to behaviour change 
Substantial developments in understanding health related behaviour changes came 
with the seminal work of Rollnick who identified that the challenging nature of 
behaviour change is augmented by patient ambivalence towards making the 
changes300. 
For many years, healthcare practitioners’ attempts to encourage lifestyle changes, 
such as those needed to adhere to medication regimens, were heavily focused around 
the provision of persuasive advice, which whilst beneficial for some patients, tended to 
demonstrate poor efficacy301.  These poor results may be a reflection of the 
ambivalence experienced by patients contemplating change and their lack of readiness 
to do so.  Consequently, provision of advice when it has not been requested, in 
patients who are not ready to receive it is likely to have detrimental effects by 
instigating or increasing a patient’s resistance to change302.  In the BCT Taxonomy, 
techniques such as ‘providing information on consequences’ and ‘providing information 
about behaviour-health link’ have the potential to evoke resistance, if delivered to 
patients who are unwilling recipients of such information.  In contrast to the patriarchal 
perceptions evoked through unwanted advice from health care professionals wishing to 
instigate behavioural changes in their patients, the move towards more patient-centred 
approaches produced far better outcomes301.  
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Despite the move towards patient centred care, routine community pharmacy services, 
such as MURs and the NMS are still heavily focused on the provision of advice and 
education.  For patients who, for reasons of health beliefs, illness perceptions or lack of 
motivation have willingly chosen to not take their medicines as prescribed, education 
as to why they ‘should’ take their medicines is unlikely to evoke behaviour change.  
Included within the aforementioned behaviour change taxonomy, are a number of 
behaviour change techniques, such as Motivational Interviewing (MI) which are 
targeted towards behaviour change using a psychological or cognitive based approach.  
These techniques are of particular interest for resolving non-adherence of an 
intentional nature as they are designed to change the way individual thinks and feels 
about the behaviour and their motivation to do so.  
3.4.2  Motivational Interviewing (MI) 
Motivational interviewing (MI) is a patient-centred technique that has gathered 
increasing interest in health care settings303 since its conception by Miller in 1983304 
and subsequent elaborations302.  Rollnick and Miller describe the main focus of MI as 
the facilitation of behaviour change by enabling patients to resolve and explore their 
ambivalence related to the behaviour305.  MI is a directed technique with clear goal 
setting and deployment of systematic strategies to guide the patient towards choosing 
to change their behaviour in the desired direction302. A supportive rather than 
argumentative approach is imperative, with a persuasive rather than coercive stance 
enabling an increase in the patient’s intrinsic motivation306. 
Miller and Rollnick describe the five clinical principles upon which MI is based as 
expressing empathy, developing discrepancy, avoiding argumentation, rolling with 
resistance and supporting self-efficacy302. Without empathy, rapport may be low and 
clients may be resistant to change and less likely to explore their inner thoughts and 
motivations. Likewise, developing discrepancy is essential in exploring the patient’s 
ambivalence and formulating arguments for and against their problematic behaviours 
with avoidance of argument and rolling with resistance imperative in ensuring 
ambivalence and reluctance is respected and that defensive or resistant behaviours 
are avoided.  Finally, supporting the patients self-efficacy is essential in building upon 
their confidence in their ability to change, without which, change cannot be elicited307.  
Miller and Rollnick describe rolling with resistance metaphorically as ‘dancing’ with the 
patient rather than ‘wrestling’ with them, and note that by de-escalating expressed 
resistance rather than challenging it, further resistance to change may be avoided302.  
Additional strategies, such as listing the positive and negative points of both current 
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behaviour and changed behaviour can be used within this framework to tailor the 
intervention towards an individual’s needs301.  Through accumulation of these five 
clinical principles and utilisation of additional strategies, two core phases of MI can be 
differentiated; the first being increasing motivation to change, the second, consolidating 
a verbalised commitment to make the change306.  
3.4.2.1  The theoretical basis of MI 
The conception of MI was heavily based on Miller’s experience of treatments for 
problem drinkers304 rather than being grounded in any one specific theory of behaviour.  
However, the interest generated from his early work and subsequent modifications with 
Rollnick302 have facilitated the linking of MI to the trans-theoretical model of change301.  
MI can also be linked to the core themes of other theories of behaviour, such as the 
health belief model, where MI can influence a patients perceptions about their health 
behaviour301.  As such, MI draws upon several other theories in order to understand 
motivation, the most essential component of the behaviour change process307.  Miller’s 
and Rollnick’s MI theories are also inspired by Carl Roger’s work on non-directive 
counselling308, where examination and resolution of ambivalence are core.  MI also 
builds on Festinger’s cognitive dissonance theory309 and Bem’s self-perception 
theory310 which both describe the processes involved with attitudinal changes.   
3.4.2.2 Evidence for MI in health related behaviour change; systematic 
reviews and meta-analyses  
Comprehensive evidence for the efficacy of MI in healthcare is provided by reviews311, 
312
 systematic reviews313, 314 and meta analyses307, 315-318, as summarised in table 3.2.  
From the wealth of evidence presented it is clear that a large and growing body of 
research has examined the effectiveness of MI, across a range of different healthcare 
settings.  The earliest studies are predominated by small reviews of non-randomised 
studies; conclusions should therefore be drawn with caution.  However, as the body of 
evidence has grown, comprehensive and well conduced systematic reviews and meta-
analyses of RCTs have been provided, offering high quality evidence.  
The reviews summarised in table 3.2 highlight that MI consistently yields statistically 
significant positive effects in the small to medium effect size range.  Whilst the reviews 
provide conflicting evidence as to the longevity of MI effects, the effects appear to be 
maintained up to at least one year beyond treatment.  Beyond establishing the efficacy 
of MI, the reviews also provide insights into the optimal means of MI based intervention 
delivery.  Evidence suggests that MI is less effective when delivered in group sessions 
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compared to one-to-one and that better outcomes are achieved through greater 
exposure to MI.  In terms of the wider application of MI and scope for its routine use, 
the evidence has shown that MI is not solely indicated for substance abuse problems 
or very troubled clients.  It is successful in motivating clients to change, across of range 
of health behaviours, from various different groups and backgrounds and with delivery 
from practitioners of differing levels of experience and training.    
Whilst these reviews describe the evidence for MI in facilitating healthcare related 
behaviour change, no reviews have specifically focused on the domain of medication 
adherence. 
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Table 3.2  Summary of evidence for the use of MI in healthcare settings  
Author Type of evidence Setting Evidence for efficacy Other key findings 
Noonan and 
Moyers 
(1997)311 
Review article of 11 clinical 
trials  
Problem drinking and 
substance abuse 
Over 80% of studies 
demonstrated efficacy in 
addictive behaviours 
MI worthy of further development in 
healthcare settings 
Dunn et al. 
(2001)313 
Systematic review of 29 
studies 
Focus on brief interventions 
adapted from MI across four 
behavioural domains; 
substance abuse, smoking, 
HIV risk and diet and exercise 
60% of studies 
demonstrated at least one  
significant behaviour 
change effect size 
MI particularly useful to enhance entry 
into and engagement with intensive 
substance abuse treatment programmes.  
Positive effects did not diminish over time 
Burke 
(2003)315 
Meta-analysis of 30 studies Adaptations of MI (AMI) for 
alcohol, drugs and 
diet/exercise 
AMIs equivalent to other 
active treatments and 
yield moderate, sustained 
effects (0.25 to 0.57) 
MI effects equivalent to other active 
treatments and achieved in considerably 
less time; cost effectiveness therefore 
likely 
Britt et al. 
(2004)301 
Review article MI use in healthcare settings Individual studies 
described no research 
synthesis 
Paucity of information describing MI 
interventions noted as problematic 
Rubak et al. 
(2005)316  
Systematic review and meta-
analysis of RCT’s using MI 
(72 methodologically sound 
studies) 
Various healthcare settings 74% of RCTs reviewed 
had a positive effect 
Individual support superior to group 
support. 81% efficacy for interventions 
lasting 60 minutes or more compared to 
61% efficacy for interventions lasting 20 
minutes or less.  40% of RCTs with only 
one session were effective, compared to 
87% with 5 or more sessions 
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Table 3.2 (continued) Summary of evidence for the use of MI in healthcare settings  
Author Type of evidence Setting Evidence for efficacy Other key findings 
Hettema et al. 
(2005)317 
Meta-analysis of 72 
clinical trials 
A range of healthcare 
problems across ten 
different behaviours 
Small to medium effect sizes 
achieved via MI 
Greater effects in ethnic minorities and 
when interventions are not manual 
guided.  Efficacy not influenced by MI 
purity or methodological quality.  Effects 
established early and diminish over time 
Knight et al. 
(2006)314 
Systematic review MI in physical healthcare 
settings including asthma, 
hypertension, heart 
disease & hyperlipidaemia  
Physiological and psychological 
positive lifestyle changes elicited 
Generally poor quality trials; better 
research needed 
Lundahl and Burke 
(2009)307 
Practice friendly 
synthesis of 
prominent meta-
analyses 
Variety of health 
behaviours including 
problem drinking 
MI significantly (10-20%) more 
effective than no treatment and 
generally as effective as other 
active treatments but with 
results achieved in less time 
than comparators. 
Client related variables unrelated to 
treatment outcomes.  Group based 
interventions less effective than one-to-
one sessions.  Durability of MI effects is 
variable but on average, durable for at 
least one year beyond treatment.  
Lundahl (2010)318 Meta-analysis of 119 
studies over 25 years 
Various health behaviours  Average effect size (95% CI) = 
0.22 (0.17 to 0.27); small but 
statistically meaningful effect 
Effect size greater when compared to 
weak comparison groups rather than 
specific treatments 
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3.4.2.3  Adaptations of motivational interviewing 
MI can be delivered as a stand-alone intervention or motivational prelude to other 
cognitive based interventions317.  When MI in its purest form is combined with elements 
of other therapeutic interventions, the term adaptations of MI (AMIs) is commonly used, 
a term first coined in Burke’s meta-analysis in 2003315.   
Behaviour Change Counselling (BCC) is an adaptation of MI, suitable for brief 
consultations in healthcare settings319.  Although derived from MI, the brevity of the 
consultations, intervention aims and information exchange style are all pertinent to the 
distinct classification of BCC away from MI, as described by Rollnick’s taxonomy320.  
Whilst the fundamental aim of MI is to elicit ‘change talk’ and develop discrepancy, the 
aims of BCC are more modest, and hence more fitting for brief interventions.  BCC 
simply aims to provide a patient with the opportunity to talk through the why and how of 
change and for the practitioner to understand how the patient is feeling and what plans 
they have for change320.  Although well described in the work of both Rollnick et al.320 
and Broer et al321, literature searching revealed a substantial paucity of evidence for 
BCC in any health domains including medication adherence.  Instead, published work 
has tended to focus on the practicality of training GPs to use BCC to improve asthma 
medication adherence321 and the development of a tool to assess changes in 
practitioner behaviour before, after and during BCC training319.  Whilst BCC appears to 
be an interesting and relevant modification of MI, evidence is therefore needed to 
assess its efficacy as a stand-alone intervention to facilitate behaviour changes such 
as improved medication adherence.  
3.4.2.4  Other ‘cognitive-based’ techniques 
Whilst the Behaviour Change Taxonomy specifically refers to MI, other cognitive based 
techniques include many of the behaviour change techniques included in the taxonomy.  
Whilst MI focuses on the readiness for change, other cognitive based techniques 
explore and enhance a patient’s ability to change317.  
Problem solving treatment (PST) is a brief psychological intervention derived from 
cognitive behavioural principles.  Designed to increase a patient’s ability to solve their 
problems in a structured way, PSTs also improve patient confidence in dealing with 
future problems and encourage realistic and specific goal setting322, 323.  To date, the 
evidence base for PST efficacy is centred in the treatment of major depression and a 
wide range of emotional disorders323.  More recently, an RCT of community pharmacy 
based interventions to reduce drug related problems and increase medication 
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adherence has combined PST with MI during a community pharmacy based 
medication review324.  The application of these techniques to improving medication 
adherence and for use in community pharmacies highlights that such techniques are 
amenable to use in a variety of settings.  Ahmad et al. report that whilst MI was used to 
increase a patients motivation towards better medication adherence, PST was used to 
address difficulties in achieving adherence, and equip patient with the tools to 
overcome adherence barriers324.  Whilst data from this study is, as yet limited to 
publication of the study protocol, this work represents the potential to apply PSTs to 
health scenarios beyond treatment of emotional disorders.  
In a similar way to PST, the technique of forming implementation intentions, otherwise 
known as ‘if-then planning’ has been used to improve goal attainment and change 
individual behaviours325, 326.  Implementation intentions interventions (III) recognise that 
self-regulatory problems may impede goal achievement, even when goal intentions are 
strong326.  As such, a patient may have, for example, a strong intention to take their 
medicine as prescribed, but self-regulatory problems such as time-management or 
forgetfulness may mean that non-adherence prevails.  
The formation of an implementation intention provides a preconceived ‘action-plan’ to 
link anticipated critical situations to goal directed responses which ensure goals are still 
attained327.  With regard to medication adherence, the ‘chosen critical situation’ could 
be, for example, consuming a cup of tea in the morning.  If the ‘goal directed response’ 
is taking medication at an appropriate time then the ‘preconceived action-plan’ (the if-
then plan) could be ‘If I have my morning cup of tea, and I’ve not taken my medicines 
then I must do so’. Formation of an implementation intention therefore encompasses 
specifying exactly when, where and how a goal will be obtained so that encountering 
specific situations automatically triggers behaviours, thus avoiding the need for further 
decision making328.  Meta-analytical evidence has demonstrated that ‘if-then-planning’ 
has beneficial effects in a wide range of health behaviours 326.   
In recent years, literature reporting the use of III to improve medication adherence has 
emerged.  A recent UK based study utilised ‘if-then planning techniques’ to improve 
adherence to contraceptive use in teenagers and reported that consultations for 
emergency contraception and pregnancy testing reducing by 15% after ‘if- then plans’ 
had been made329.  Also based in the UK, Jackson et al. aimed to increase adherence 
to short-term antibiotics via formation of implementation intentions at the point of 
prescribing.  Although no significant improvements in adherence were reported, the 
authors identify methodological limitations and recognise the potential of III as a simple 
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strategy to promote medication adherence that can easily be deployed by pharmacists 
and other healthcare professionals in a cost and time effective way330.    
More conclusive evidence to support the efficacy of III in improving medication 
adherence is provided by a UK based RCT to enhance adherence to epilepsy 
medication331.  In this study, written implementation intentions were made as part of a 
worksheet based intervention and adherence assessed via electronic monitoring.  
Statistically significant improvements in adherence were reported for intervention group 
patients compared to the control group, highlighting notable improvements from a 
straightforward and easily implemented intervention.  Following these encouraging 
findings, the III worksheet utilised in this study has recently been utilised in a pilot RCT 
to increase medication adherence in 62 stroke survivors332, 333.  This brief intervention, 
delivered over two sessions aimed to utilise III to assist patients in establishing better 
medication taking routines.  Additional techniques were also utilised to address 
erroneous illness perceptions and medication beliefs, identified via a brief 
questionnaire332.  O’Carroll et al. report a 10% increase in the percentage of doses 
taken on time for recipients of the brief intervention, a difference that was statistically 
significant in comparison to control group patients333. 
These studies highlight the potential of III, in conjunction with other ‘cognitive-based’ 
techniques as brief interventions to improve medication adherence and highlight the 
relevance of grounding interventions in theory and evidence.  In their protocol for the III 
RCT in stroke survivors, O’Carroll et al. make good reference to the frameworks used 
in developing the intervention and the need to identify processes which target both 
intentional and unintentional non-adherence332.  Whilst III are an exciting opportunity for 
medication adherence research, their efficacy in patients who are unmotivated to 
adhere is likely to be poor, as an intention to adhere may be non-existent. For 
intentionally non-adherent patients, with low motivation to adhere, it would seem logical 
to combine techniques; using motivational interviewing or its derivatives such as BCC 
to increase to patient’s motivation and confidence to adhere and then other cognitive 
based techniques such as III to equip patients with the tools to implement their 
intended behaviour changes. 
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3.5  Chapter summary 
3.5.1  Incorporating theory into a novel adherence intervention 
A plethora of theories to explain and predict health behaviours exist and interventions 
gain benefit from being grounded in such theory.  Recent work to synthesise these 
complex theories into a cohesive framework and develop a taxonomy of BCTs 
represents an exciting opportunity to advance the incorporation of theory into 
intervention design.  Similar to the approach used in other healthcare domains, there is 
ultimately potential to deliver evidence based BCTs to address specific adherence 
barriers, with selection of the BCT determined by the behavioural domain to which an 
identified barrier has been mapped to.  The first stage of this process is to develop a 
questionnaire, grounded in the TDF that will enable identification of individual barriers 
to medication adherence.  The development of such a questionnaire is described in 
chapter five.  
3.5.2 Using MI and other ‘cognitive-based’ techniques as interventions 
to improve adherence 
Literature has demonstrated that appropriate deployment of MI techniques can 
facilitate behaviour change in a wide range of health settings.  These techniques are 
likely to be useful in facilitating medication related behaviour change to improve 
adherence.  However, unlike the application of MI to many health behaviours, evidence 
to support the use of MI in improving medication adherence is relatively sparse and to 
date, meta-analytic synthesis of this research has not been undertaken.  In 2005, 
Broers et al. reported a PubMed search of MI based interventions to improve 
medication adherence.  Ten studies, all describing medication adherence in either HIV 
or psychiatry and with MI delivered by specially trained counsellors were sourced, with 
three studies describing positive adhere effects321.  Although useful as a preliminary 
indicator for the evidence of MI in facilitating improved medication adherence, the 
limitation of searching just one database must be considered and highlights the need 
for more comprehensive and robust literature searching and reviews for the role of MI 
in medication adherence.  
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4.1 Chapter introduction 
In chapter three, the psychological theories underpinning health related behaviours 
were explored, highlighting the complexity and plethora of factors which may influence 
a patient’s behaviour.  Chapter three also considered some of the ‘cognitive-based’ 
behaviour change techniques that utilise psychological processes to change a patient’s 
health behaviour by altering their thoughts, feelings, confidence or motivation to follow 
specific health behaviours.  
Whilst cognitive-based behaviour change techniques such as motivational interviewing 
may be efficacious in improving a wide range of health related behaviours, evidence for 
their application to medication adherence is not cohesive.  Such studies are diverse in 
terms of interventions evaluated and patients included and have shown promising but 
often heterogeneous results.  Any form of robust or conclusive evidence for this 
application of these techniques to medication adherence remains elusive. 
A systematic review and meta-analysis of MI and other cognitive-based behaviour 
change techniques as interventions to improve medication adherence was therefore 
necessary to estimate the overall efficacy of these approaches.  This chapter describes 
the methods, results and conclusions of the systematic review and meta-analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Four             ‘Cognitive-Based’ Interventions to Improve Medication Adherence 
 
 
154 
4.2 Systematic review and meta-analysis methods 
Standard systematic review methods334 were employed for this review and used to 
inform the development of the registered study protocol (PROSPERO register 
reference CRD42011001721).  The protocol development was led by Claire Easthall 
(CE) with supervisory guidance from Debi Bhattacharya (DB), David Wright (DW) and 
Fujian Song (FS). 
4.2.1  Aims and objectives 
4.2.1.1  Aims 
To describe and evaluate the use of motivational interviewing and other cognitive-
based behaviour change techniques as interventions to improve medication 
adherence.   
4.2.1.2  Objectives 
1) To estimate the effect size of these interventions on medication adherence 
2) To describe: 
• from where such interventions have been delivered and by whom 
• the training received by practitioners delivering the interventions 
• the nature of the interventions 
• the delivery of the interventions in terms of duration and number of sessions 
• which patient groups have been targeted with these interventions 
 
4.2.2  Literature search strategy 
Preliminary literature searching identified that classification of interventions as 
motivational interviewing or otherwise, is a contentious issue.  Similar interventions are 
often termed differently and conversely, different interventions can sometimes be given 
similar names.  Searches beyond specific terminology such as motivational 
interviewing or behaviour change counselling were therefore conducted, to include a 
broader search of cognitive-based behaviour change techniques.  
Studies were identified through comprehensive electronic and manual searches with 
use of appropriate subject headings and text words.  Scoping searches were 
conducted prior to finalising the search strategy. 
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The following databases were searched without language or date restrictions: 
1. MEDLINE 
2. EMBASE 
3. PsychINFO 
4. CINAHL 
5.  The National Electronic Library for Medicines (NELM) 
 
The references of included studies and the motivational interviewing website were also 
searched to identify additional studies. 
4.2.3  Search terms used in literature retrieval 
Search terms were devised using MESH (Medical Subject Headings) terms for 
‘medication adherence’ and other key variables such as ‘motivational interviewing’.  
Papers identified though preliminary literature searches were used to identify keywords 
for searches, as were previously identified systematic reviews and meta-analyses. 
Truncations (*), wild cards ($), hyphens and other relevant Boolean operators were 
used where appropriate and permitted.  The search terms applied to the Embase, 
Medline and PsychINFO databases using the OVID interface on the 4th of August 2011, 
and the CINAHL database on the 5th of August 2011 are provided in appendix 4.1.  The 
NeLM database did not permit combinations with Boolean operators, so an alternative 
search strategy was applied to account for the differing syntax rules (appendix 4.1).  
Language and date restrictions were not applied to the search strategies.  
4.2.4  Inclusion criteria 
As guided in the Cochrane Handbook for systematic reviews334, the study inclusion 
criteria were based around four parameters: 
1) Study populations and sites 
Population Any patient receiving an intervention to improve adherence to a 
prescribed medication 
Site No restrictions were applied as this study aimed to describe from where 
these interventions have been delivered 
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2) Types of interventions  
Any interventions that described motivational interviewing or other cognitive-based 
behaviour change techniques as an intervention to improve or facilitate medication 
adherence including (but not restricted to) motivational interviewing, motivational 
enhancement therapy, behaviour change counselling and implementation intentions/if-
then planning. 
In the case of interventions that did not explicitly use a defined technique, studies were 
included if the intervention pertained to using some form of cognitive or psychological 
technique.  Such techniques included (but were not exclusively restricted to): 
• Altering a patient’s beliefs, attitudes or feelings towards their medication and 
adherence 
• Increasing a patient’s motivation to adhere 
• Increasing the patient’s confidence and sense of self-efficacy to adhere 
• Using problem solving strategies to identify and resolve adherence barriers 
 
3) Study design 
Inclusion was not restricted to randomised controlled trials (RCTs) as this was 
considered likely to exclude too many studies and thus prohibit statistical synthesis 
through a meta-analysis.   Any evaluative study designs were therefore eligible.  For 
studies with a comparison or control group, comparators such as usual care or an 
alternative intervention were included. 
4) Outcomes 
The outcome measure of interest was intervention efficacy, defined as medication 
adherence.  Studies measuring adherence by self-report, observation, pill counts, 
prescription refill rates, electronic devices such as MEMS™ or surrogate markers such 
as drug plasma levels were included.  
4.2.5  Exclusion criteria 
In order to facilitate inclusion of a diverse range of studies, exclusion criteria were 
restricted to two domains: 
• Interventions where adherence was not assessed or reported 
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• Interventions targeted specifically towards adherence to medication for mental 
illnesses or for the treatment of addiction; these studies were excluded as the 
techniques used tend to be specific to mental health and addiction problems. 
4.2.6  Screening and selection 
Titles and abstracts were screened independently by two reviewers, who then 
compared their findings.  Disagreements were resolved through discussion and, if 
necessary, referred to a third reviewer.  CE led the review process and DB acted as the 
third reviewer. The second reviewer was Estelle Payerne, a research assistant working 
at UEA.  Agreement in abstract screening between the two reviewers (prior to 
discussion) was assessed by calculation of Cohen’s Kappa.  Study selection was 
conducted in two stages: 
1) For the abstracts identified via the electronic database searches, an abstract 
screening tool was used to screen the abstracts against the inclusion criteria. 
 
For the abstracts identified from the reference sections of included or other relevant 
papers, preliminary screenings of titles was undertaken to enable elimination of 
obviously irrelevant titles.  Abstracts were then obtained for the titles of interest, 
and subjected to the same screening tool as detailed above. 
At this stage, potential papers were grouped into four classifications: 
1. Papers for full text retrieval 
2. Papers where the abstract was insufficient to determine inclusion 
3. Papers that were not suitable for inclusion but which could be used as a 
reference source to identify additional papers 
4. Papers that were excluded 
 
2) Full texts were obtained for all papers falling into the first three classifications.  The 
number of papers excluded at each stage was recorded, with details of the reason 
for exclusion.  
 
4.2.7   Data extraction 
A bespoke data extraction tool was used to extract the following data from each study:  
• Author name, publication date, journal and country of origin 
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• Study design, disease area, intervention type and whether or not the intervention 
was delivered alone or in conjunction with non-MI/cognitive-based components 
such as education 
• Whether the study was a pilot, if the intervention was targeted towards non-
adherent patients and if participants were paid or reimbursed for participation 
• Who the intervention was delivered by, where it was delivered from and what 
training was received by the personnel delivering the intervention 
• The initial and final sample size  
• The number of participants in the intervention group and where applicable control 
group and the control group type 
• The average number of sessions over which the intervention was delivered, the 
average length of each session and time period over which it was delivered 
• Whether the intervention was delivered entirely in person, over the telephone or by 
a combination of these methods and whether the intervention was delivered by one 
facilitator alone or multiple facilitators 
• The intervention follow up period 
• The definition of adherence and tool used to assess this 
• Adherence rates with standard deviations and confidence intervals where 
applicable and relevant statistics such as p-values. 
 
Independent, duplicate data extraction of each included study was undertaken.  The 
data extraction forms were piloted using a representative sample of studies.  Inter-rater 
reliability was checked for the recording of outcome data and quality assessment. 
Where differences occurred, these were resolved through discussion and referral to a 
third independent reviewer if necessary.  Where necessary, additional information was 
obtained by contacting the study authors.  
4.2.8  Quality assessment 
Independent, duplicate quality assessment of each study was undertaken as part of the 
data extraction process.  Because different study types were included, it was not 
possible to use a standardised tool to assess the quality of all the study types.  Instead, 
validated tools such as those developed by the Critical Appraisal Skills Programme335, 
were used to determine the criteria for critiquing the studies, which enabled key 
variables or indicators of methodological quality to be considered in a structured 
manner.  The Cochrane Reviewer’s Handbook334 was also used as a guide to assess 
the quality of studies in terms of bias.  The criteria selected for assessing the 
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methodological quality of included studies are summarised in table 4.1, which 
highlights that the studies were critiqued on 12 different criteria.  
Studies were not excluded based on methodological quality.  Following comparison of 
the quality assessment data extracted by the two reviewers, an overall methodological 
quality assessment was agreed upon.  Studies were classified into five groups: 
1. Methodologically sound papers without concerns and of good overall quality 
2. Generally good papers with only minor problems that are of no real concern 
3. Papers with moderate problems and concerns 
4. Papers with notable problems and serious concerns 
5. Seriously questionable papers with extensive methodological flaws 
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Table 4.1 Quality assessment criteria for studies included 
Indicator of 
methodological 
quality 
Questions to assess methodological quality 
Undertaking 
fidelity checks 
• Were fidelity checks undertaken to ensure the intervention 
delivered actually matched the intended intervention? 
Research 
question and 
aims/objectives 
• Was a clearly focused question asked? 
• Was the research question clearly focussed in terms of the 
population studied, the intervention delivered and the outcomes 
considered? 
• Were the aims of the study clear and transparent? 
Study design • Was an appropriate study design used? 
• Was it the correct approach for the research question to be 
answered? 
Recruitment • Was the recruitment process appropriate and well executed? 
• Were participants recruited in a logical and fair way which is 
likely to minimise bias? 
• Was the recruitment process well described and transparent? 
Randomisation • Were subjects randomised into intervention and control groups 
in an appropriate way? 
• Did the process used minimise the risk of bias and is the 
process well described? 
• Were the intervention and control group comparable at baseline 
in terms of demographics and treatments related factors, or any 
other factors that may have influenced the results? 
Blinding • Were participants and/or researchers blinded? 
Loss to follow-
up/attrition 
• Were all of the patients entering the study accounted for at 
conclusion? 
• Does the study report reasons for and numbers of any 
participants that dropped out/did not finish the study? 
Sample sizes • Were power calculations or sample size calculations 
undertaken? 
Reporting • Are the results reported in a systematic and comprehendible 
way, do they make sense and are they clearly reported? 
• Has the data been analysed in a sensible and fair way? 
Outcome 
reporting 
• Were all of the important outcomes considered and reported? 
• Are all of the outcome measures described in the methods 
section reported?   
• Have the authors considered all variables that are pertinent to 
the results? 
Outcome 
measures 
• Were the outcome measures chosen appropriate and well 
measured? 
• Did they use the most appropriate tool to assess adherence 
and was a sensible adherence definition used? 
Follow up • Was the follow up study appropriate and likely to be long 
enough to fully assess the intervention effect? 
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4.2.9   Data analysis 
Descriptive statistics were used to convey the identification, retention and exclusion of 
studies.  Details of the included studies in terms of publication particulars, study design 
and disease area were also reported via descriptive statistics as were all other data 
variables extracted from the included papers.  
Study types were reported and the interventions grouped with reference to the 
following criteria: 
• Primary intervention component and number of components 
• For MI based interventions, whether pure MI was delivered or an intervention 
based on MI techniques  
• The disease area for which the prescribed medication studied was taken 
• The person delivering the intervention 
• The training of the person delivering the intervention 
• The setting from which the intervention was delivered 
• The communication methods (face-to-face or telephone) used in the intervention 
• The number of sessions received 
• The total length of sessions received 
• The total duration over which interventions were delivered  
• The follow up period for data collection post intervention 
• The targeting of interventions towards non-adherent patients 
• The payment or reimbursement of participants 
• The type of comparison group used 
• The overall methodological quality of the study 
4.2.10  Meta-analysis 
The decision to statistically pool data from studies in a meta-analysis was based upon 
the likely comparableness of interventions and their data, as pooling of results from a 
diverse range of non-randomised studies is not recommended334.  
Although many different adherence definitions and measures were used, in 
interventions delivered from a wide range of settings, by differing personnel to differing 
populations, ultimately all interventions shared one common theme; their use of some 
form of psychological based intervention to improve medication adherence.  As this 
common theme formed the fundamental premise of each study, the decision to 
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undertake a meta-analysis was made.  This decision was supported by the large 
number of methodologically robust RCTs included in the study. 
The adherence outcome data from individual studies were statistically pooled in a 
meta-analysis which assumed a random effects model.  A computerised programme 
was used to calculate effect sizes and produce forest plots336.  A random effects model 
was chosen as the studies were pooled from a heterogeneous sample.  A random 
effects model assumes that the treatment effect really does vary across studies, and 
that the results from individual studies were randomly distributed337.  The weighting 
assigned to each study under a random effects model is therefore based upon both 
within study and between study variance.  
The outcome measures from each study were frequently measured on different scales, 
so an effect size based on the standard difference in means (d) was calculated.  The 
standard difference in means (d) is calculated by dividing the mean difference in each 
study by the standard deviation for that study, transforming the effect size into a 
common metric338.  Quantitative results of each meta-analysis undertaken were 
reported as a point estimate with associated 95% confidence intervals and p-values, in 
line with recommended guidelines339. 
An important aspect of the meta-analysis was heterogeneity; the difference in results 
between individual studies beyond those attributable to chance340 and hence whether 
they were sufficiently similar to enable a meaningful combination.  As studies were 
pooled from a diverse sample, an assessment of the heterogeneity was undertaken.  
Given the small sample sizes in this meta-analysis, especially in the instance of sub-
group analyses, the I2 statistic was used to assess heterogeneity.   The I2 statistic 
describes the percentage of variation across studies that is attributable to 
heterogeneity rather than chance341, providing a far simpler and inherently more 
intuitive assessment of heterogeneity than comparator such as Cochrane’s Q.  
Moreover, low power due to small samples sizes will not influence this statistic in the 
same way that it would Q.  The I2 statistic allows heterogeneity to be calculated 
independently of scale, as a ratio of excess to total dispersion and is calculated as: 
     		  
A very small I2 value, close to zero infers that any observed between-study variance is 
spurious, with tentative benchmarks of 25%, 50% and 75% reflecting low, moderate 
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and high heterogeneity respectively338, 341.  These suggested benchmarks were 
referred to throughout the meta-analysis.   
A forest plot was used to display variation in effect size across studies and the estimate 
of mean effect size342.   The effect size from each individual study is represented by a 
solid square, with squares located to the right indicating a positive effect and squares 
to left indicating a negative effect.  The relative size of the square is proportional to the 
precision of the study and horizontal lines extend either side of the square to represent 
the 95% confidence interval (CI) around the effect size337.  The combined mean effect 
size across all included studies is represented by a diamond at the bottom of the plot, 
with the centre of the diamond representing the pooled point estimate and its width 
reflecting the confidence interval around this point estimate342.   
Assessment of publication bias was necessary to account for potential small study 
effects.  In a random effects model, small studies still receive a notable weighting of 
contribution to the overall effect size, therefore if missing, an exaggeration of effect size 
can be seen.  Funnel plots were therefore created to visually explore potential 
publication bias343.  In each funnel plot, the effect size for each study was plotted 
against the inverse of the standard error for that study.  The standard error was an 
intuitive measure of precision, reported on the same scale as the effect size and 
calculated as the square root of the variance.  The inverse of the standard error was 
used so that the larger (more precise) studies are clustered close to the mean effect 
size and are therefore found towards the top of the funnel.   
The funnel plot provides a visual means of checking for publication bias as a deficit in 
small studies with a small or negative effect size will be clearly visible.  An unbiased 
sample will be represented by a ‘cloud’ of effect size estimates symmetrical around the 
mean population effect size.  This ‘cloud’ assumes a funnel shape344, given by widely 
scattered smaller studies at the bottom of the funnel, which narrows as the studies 
become larger and more precise to form the top of the funnel.  Whilst funnel plots are a 
useful tool, careful interpretation is imperative as asymmetry can be attributable to 
other factors beyond reporting bias, including heterogeneity, methodological quality 
and chance340, 345.  Concrete conclusions were therefore not made from the funnel 
plots, which were instead used as a tentative guide to visually inspect the spread of 
studies and a generic tool to examine small study effects345. 
Despite recommendations that funnel plots should only be used when there are a 
minimum of ten studies in the meta-analysis334, funnel plots are still useful to assess 
publication bias in each subgroup where the covariates are discrete346.  Moreover, 
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funnel plot asymmetry can arise from heterogeneity caused by distinct sub-groups of 
studies, each with a different intervention effect340, 346.  A funnel plot was therefore 
created for each sub-group analysed to ensure a consistent analytical approach.  
The funnel plot produced for the main meta-analysis (all included studies) was 
indicative of publication bias which was further investigated using advanced meta-
analytical techniques via the STATA software programme.  Egger’s test for funnel plot 
asymmetry343 was deployed to determine whether the association between estimated 
effect size and study size was greater than would be expected by chance.  Egger’s test 
was selected as it is suitable for use on outcome measures assessed on a continuous 
scale and recommended for data based on means differences340.  The test is based on 
weighted linear regression of the effect estimates on their standard errors.  A p-value of 
<0.1 indicates significant funnel plot asymmetry343.  
Duval and Tweedie’s trim-and-fill method was used to calculate a population effect 
size, which was adjusted for publication bias347, 348.  The widely used technique is an 
iterative procedure to remove the most extreme small studies from the positive side of 
an asymmetrical funnel plot.  The effect size is re-computed at each iteration, until the 
funnel plot becomes symmetrical around the ‘new’ effect size.  This ‘trimming’ process 
corrects the point estimate in light of publication bias, but reduces the variance of the 
effects to a point where the confident intervals around the point estimate become too 
narrow.  To combat this, an algorithm is used to add the original studies back into the 
analysis and a mirror image for each reinserted study is imputed to ensure symmetry.  
Whilst this ‘filling’ stage does not affect the adjusted point estimate, it does correct the 
narrowed variance338, 347, 348.  Duvall and Tweedie’s technique has been praised as it 
enables a best estimate of an unbiased effect size to be calculated338. 
4.2.11  Sub-group analyses and meta-regression 
Sub-group analysis enabled variation in effect size across different sub-groups of 
studies to be explored and facilitated further exploration of potential sources of 
heterogeneity.  In line with methodological recommendations possible sub-groups were 
defined before under-taking the meta-analysis to enable a robust and transparent 
approach which avoided the temptation for ‘data dredging’ in the analysis phase334, 349.   
The study grouping variables listed in section 4.2.9 provided the premise for the sub-
groups created, with planned analyses detailed in table 4.2.  For variables, such as the 
person delivering the intervention, sub-groups were pre-defined as they could easily be 
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predicted.  For other variables such as the intervention types, the sub-groups could not 
be fully defined until the data were gathered.   
Sub-group analyses were restricted to variables deemed pertinent to exploring likely 
influences of intervention efficacy.  Restricting the number of sub-groups analysed 
improved the methodological robustness, as multiplicity testing increases the likelihood 
of generating spurious results through chance339.  Differences in results between 
subgroups were checked for statistical significance by means of the Z-statistic.  
Meta-regression was used to explore the magnitude, direction and significance of any 
linear association between treatment effect and intervention exposure.  Analyses 
based on the number of sessions, total intervention time (in hours) and total duration 
over which the intervention was delivered (in weeks) were undertaken using a random 
effects meta-regression.  Scatter plots for each co-variant were created to visually 
explore any linear correlations.  The meta-regression was undertaken using SPSS 
software with additional syntaxes350 as described by Lipsey and Wilson351. 
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Table 4.2 Summary of planned sub-group analyses 
  
Variable of interest Planned sub-groups 
Primary intervention 
component 
Unable to define fully pre-data collection; likely to include MI 
and III 
MI ‘purity’ Pure MI (delivered in full original form) 
Adaptations of MI 
Disease area Unable to define fully pre-data collection; likely to include HIV 
compared to other disease areas 
Person delivering the 
intervention 
Routine healthcare professionals (e.g. nurses, GPs and 
pharmacists) 
Specialists (e.g. psychologists and researchers) 
Training of person 
delivering intervention 
Unable to define fully pre-data collection; likely 
comprehensive and superficial 
Setting from which the 
intervention delivered  
Unable to define fully pre-data collection; likely community 
and hospital, clinical and non-clinical 
Communication method Unable to define fully pre-data collection; likely in person and 
via telephone 
Follow up period Unable to define fully pre-data collection; likely prolonged 
beyond intervention and follow up at end of intervention 
Targeting of 
interventions towards 
non-adherent patients  
Targeted towards patients with known non-adherence 
Delivered to all patients (no targeting) 
Payment or 
reimbursement of 
participants 
Interventions offering payment/reimbursement for participation 
Interventions that did not offer any payment/reimbursement 
for participation 
Comparison group type Standard care (treatment as usual) 
Alternative form of intervention (e.g. no cognitive-based 
component) 
Methodological quality Good methodological quality 
Poor methodological quality 
Fidelity checks undertaken 
No fidelity checks undertaken 
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4.3     Results 
In total 34 papers were included in the systematic review giving an overall sample size 
of 3554 participants.  Five papers could not be included in the meta-analysis leaving a 
sample size of 3247 for this stage of the review. 
4.3.1  Flow of articles identified 
Figure 4.1 shows the flow articles excluded and retained at the different screening 
stages, this figure conforms to the requirements of the PRISMA statement for reporting 
systematic reviews352.  Of the 242 citations excluded at the abstract screening stage, 
58 (24.0%) were not an intervention to improve medication adherence, 51 (21.1%) did 
not use MI or other cognitive-based techniques, 27 (11.2%) did not report medication 
adherence as an outcome measure and 65 (26.9%) related to the treatment of 
addiction or mental health.  Thirty-four of the full-text articles retrieved were included in 
the qualitative review330, 331, 353-384 and 29 contributed to the quantitative phase of the 
meta-analysis331, 353, 354, 357, 359-378, 380-384. 
Five studies 330, 355, 356, 358, 379 could not be included in the meta-analysis due to 
insufficient data for calculating the standard difference in means (effect size), most 
commonly because a sample size or assessment of dispersion (confidence intervals or 
standard deviation) were missing.  These five papers were however included in the 
systematic review as an indication of intervention effect was offered. 
Abstracts were screened with 76% agreement between the two reviewers and all cases 
of disagreement were resolved by discussion without need for referral to a third 
independent reviewer.  Disagreement between reviewers was most frequently 
attributed to conflict in classifying an intervention as a cognitive-based technique, which 
accounted for 55.1% of all discrepancies.  A Kappa statistic of 0.473 indicated 
moderate agreement232.   
Of the 16 studies identified through manual rather than electronic searches, ten 
(62.5%) related to ‘anti-retroviral therapy adherence’ or abbreviations of this and were 
therefore not detected by the more generic terms used for medication adherence.  
Three (18.8%) studies were referred to ‘treatment adherence’; a variant that was not 
included in the search terms and three studies did not mention ‘adherence’ at all 
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Figure 4.1
4.3.2  
Of the 34 studies included in the review, 16 (47.1%) were sourced from the references 
of other papers and 18 (52.9%) came from the electronic database searches.  
In
cl
u
de
d 
Id
en
tif
ic
at
io
n
Sc
re
en
in
g 
El
ig
ib
ili
ty
 
 Flow of articles identified and studies included in review
Source and range of studies 
Records identified 
through database 
searching 
(n = 339
Records after duplicates removed 
* Includes 35 records where 
decision could not be 
‘Cognitive-
 
6
(n =302)
Records screened 
(n = 302)
Full-text articles 
assessed for eligibility 
(n = 60)
from abstract alone
Studies included in 
qualitative synthesis 
(n = 34)
Studies included in 
quantitative synthesis 
(meta-analysis)
(n = 29 )
Based’ Interventions to Improve Medication Adherence
168
Additional records 
identified through 
other sources 
(n = 96)
 
 
 
 
made 
 
 
 
 
 
included
 
 
 
 
 
 
Records excluded 
Includes 42 records used as 
source to identify further records
Full-text articles excluded 
Not MI or ‘cognitive
technique n=
Not medication adherence n=
Adherence 
 
(n = 242) 
l
i i
(n=26) 
‘ i i -based’ 
i 9
i i
data unusable n=
 
 
 
 
 
6 
10 
Chapter Four             ‘Cognitive-Based’ Interventions to Improve Medication Adherence 
 
 
169 
The earliest publication date was 1990 and most recent 2011. Only three (8.8%) 
studies were published prior to the year 2000.  Fifteen (44.1%) studies were published 
between 2000 and 2005 and 16 (47.1%) between 2006 and 2011.  Studies came from 
nine different countries, with 21 (61.8%) from the USA and 4 (11.8%) from the UK. 
4.3.3  Types of studies included 
RCTs accounted for 24 (70.6%) of the included studies, before and after studies eight 
(23.5%) and non-randomised trials two (5.9%).  Thirteen (38.2%) studies were reported 
as pilot or feasibility studies.  
4.3.4  Intervention characteristics 
4.3.4.1  Intervention type 
Table 4.3 shows the number of studies falling into the groups created according to the 
primary intervention type, number of intervention components and in the case of MI 
based interventions, the purity with which the MI element was delivered. 
In total, 18 studies (52.9%) used MI in some form.  The studies classified as a ‘multi-
component intervention’ that did not contain any definable techniques such as MI, BCC 
or III, combined various elements such as increasing motivation and perceived self-
efficacy, problem-solving and identification of strategies to overcome adherence 
barriers.  A total of 12 (35.3%) studies used only one or two components whereas 22 
(64.7%) had multiple components. Interventions with multiple components frequently 
combined the MI or cognitive-based component with strategies such as education, pill 
reminders and monitoring. 
Intervention type Number (%) of studies 
Multi-component intervention using non-specific 
motivational and/or cognitive-based techniques 
13 (38.2%) 
Multi-component intervention using MI 7 (20.6%) 
Multi-component intervention MI-based techniques 2 (5.9%) 
Intervention with only one or two components based on 
application of MI techniques 
2 (5.9%) 
MI + CBT (SCRIPTASSIST) 4 (11.8%) 
MI alone (pure MI) 2 (5.9%) 
MI as feedback with  III 1 (2.9%) 
Implementation Intention Intervention (III) 3 (8.8%) 
Table 4.3 Intervention type in included studies 
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4.3.4.2  Disease area 
Interventions targeted medication non-adherence across 12 different disease areas; 17 
(50%) focused on HIV.  Five (14.7%) studies concerned asthma medication and three 
(8.8%) targeted medication adherence in patients with hypertension.  
4.3.4.3  Person delivering the intervention 
Interventions were primarily delivered by routine healthcare providers, with 18 (52.9%) 
studies delivered by nurses, clinicians or pharmacists.  Nurses and nurse practitioners 
constituted the majority of this group accounting for 13 (72.2%) of the 18 interventions 
delivered by a healthcare professional and 38.2% of interventions overall.  Community 
pharmacists were responsible for delivering 2 (5.9%) interventions.  A specialist, such 
as a psychologist or psychotherapist delivered the intervention in 8 (23.5%) studies and 
research personnel were used in 5 (14.7%) studies.  In 2 (5.9%) studies, the 
intervention was delivered via a computer based programme or questionnaire. 
The number of individuals involved in the intervention delivery could not be determined 
for the majority of studies due to a paucity of information.  However, 4 (11.8%) 
interventions were delivered by one person alone, whereas 23 (67.6%) were delivered 
by a team of people. 
4.3.4.4  Training of personnel involved in intervention delivery 
A summary of the training provided to intervention delivery personnel in the included 
studies is provided in table 4.4.  Training for intervention delivery was described in 17 
(50%) studies, although for 9 (26.5%) studies details of the training were insufficient to 
determine appropriateness.  Two studies (5.9%) did not require any personnel training 
as they were delivered via computer programmes and no specific training was given in 
4 (11.8%) studies since the intervention was delivered by somebody with ‘experience in 
the field’.  Details about training of any type were absent for 7 (20.6%) studies.  
Training deemed to be comprehensive and appropriate included full training on the 
research background and interventional components, role plays and case scenarios to 
practice the techniques, training by certified practitioners and recording of sessions 
with provision of coaching and performance feedback.  Studies without comprehensive 
and appropriate training were mostly commonly classified in this way due to a paucity 
of information, although brief sessions, delivered by inexperienced or unqualified 
personnel also fell into this category.   
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Type of training Number (%)  
of studies 
No reference to any type of training  7 (20.6%) 
No training needed as intervention not delivered in person 2 (5.9%) 
No training needed as intervention delivered by specialists e.g. 
psychotherapist 
3 (8.8%) 
Intervention delivered by ‘trained’ personnel but no details provided   4 (11.8%) 
Training mentioned but no detail provided 5 (14.7%) 
Well described training which appears comprehensive and appropriate 11 (32.4%) 
Table 4.4.  Summary of training provided to intervention delivery personnel 
Information regarding the amount of training received was available for nine studies; all 
involved a minimum of a full days training.  A single day of training was offered for two 
studies, and five studies offered training over three full days.  The maximum amount of 
training provided was a ‘five day intensive course’ and this was the case for one study.  
Six studies described training delivered by certified MI trainers and the training for one 
study was delivered by a specialist psychologist. 
4.3.4.5          Setting from which the intervention was delivered 
Table 4.5 shows the number of studies delivered from different settings.  A majority of 
22 (64.7%) interventions were delivered from community or hospital based clinics.  
Nine interventions (26.5%) involved contact with patients in their own home. 
Setting from which intervention was delivered  Number (%) of studies 
Community based clinic 9 (26.5%) 
Hospital based clinic 13 (38.2%) 
Specialist psychotherapy clinic 1 (2.9%) 
Community based non-clinical setting e.g. research office 2 (5.9%) 
Phone calls to patients home 7 (20.6%) 
Visits to patients own home 2 (5.9%) 
Table 4.5       Intervention delivery setting for included studies 
4.3.4.6  Intervention delivery style 
Interventions were delivered in person in 23 (67.6%) studies and only 2 (5.9%) studies 
involved group sessions.  Five (14.7%) studies were delivered over the telephone and 
4 (11.8%) involved sessions both in person and over the telephone.  One study (2.9%) 
was delivered by completion of a questionnaire.  
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4.3.4.7  Number and length of sessions received 
The mean length of sessions for each intervention could not be calculated from the 
data available.  However, the mean total length of the intervention could be estimated 
for 18 (52.9%) studies.  The intervention total length ranged from less than 30 minutes 
for two (11.1%) studies through to one (5.6%) study being 6.5 hours in duration.  Ten 
(55.6%) studies described an intervention lasting less than 3 hours in total.  
The mean number of sessions over which each intervention was delivered ranged from 
one off interventions, which was the case for 5 (15.2%) studies, through to 2 (5.9%) 
studies delivered over a mean of 12 sessions. 
Figure 4.2 shows the distribution of the mean number of sessions over which 
interventions were delivered.  A majority of 21 (63.6%) studies described an 
intervention delivered in between two and five sessions. 
 
Figure 4.2 Number of sessions over which interventions were delivered  
4.3.4.8  Intervention delivery and follow up period 
The maximum intervention delivery period was 12 months and this was the case for 4 
(11.8%) studies.  An intervention delivered over a time period of six months or less was 
recorded for 27 (79.4%) studies. 
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The follow up period was extended beyond the intervention period in 16 (47.1%) 
studies. 
4.3.4.9  Targeting of interventions towards non-adherent patients 
Interventions were targeted towards non-adherent patients in 23 (67.6%) studies.  Of 
these, 16 (47.1%), concerned patients with documented or reported non-adherence, 
and 7 (21.9%) concerned patients deemed to be ‘at risk’ of non-adherence such as 
those with recent changes to complex drug regimens and populations where 
adherence tends to be low. 
4.3.4.10 Payment for study participation 
Patients did not receive payment or reimbursement for participation in 25 (73.5%) 
studies.  Four (11.8%) studies reported payment for completion of each session or 
questionnaire and one (2.9%) study paid participants upon study completion and 
reimbursed their costs.  Three (8.8%) studies described reimbursing participants for 
costs incurred such as travelling costs and loss of time and one (2.9%) study reported 
‘incentivisation’ for study completion.  
4.3.4.11 Comparison group types 
Six (17.6%) studies assumed a before and after study design and did therefore not 
have a control group.  Treatment as usual or standard care was the control group type 
for 9 (26.5%) studies and 3 (8.8%) studies compared their data other studies with 
comparable demographics.  The remaining 6 (17.6%) studies had control groups who 
received the intervention in an alternate form, for example education alone, compared 
to education plus MI in the intervention group. 
4.3.5  Measures of adherence  
A summary of the adherence measures used in the included studies is provided in 
table 4.6.  In total, electronic monitoring was used to assess adherence in 10 (29.4%) 
studies and self-report questionnaires were used in 12 (35.3%) studies.  Five studies 
(14.7%) used patient interviews and three (8.8%) assessed adherence via prescription 
refill data.  A Composite Adherence Assessment Score (CAS) and pill count were used 
in 2 (5.9%) and 1 (2.9%) studies respectively. 
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Adherence assessment measure  Number (%) of studies 
Electronic monitoring   8 (23.5%) 
Patient self-report   7 (20.6%) 
Patient self-report plus an additional method (e.g. pill 
counts of plasma monitoring) 
 5 (14.7%) 
Patient interviews   5 (14.7%) 
Prescription refill data  3 (8.8%) 
Electronic monitoring plus patient self-report/interview  2 (5.9%) 
Composite Adherence Assessment Score (CAS)  2 (5.9%) 
Pill counts  1 (2.9%) 
Table 4.6 Summary of adherence assessment methods used in included 
studies 
4.3.6  Quality assessment of included studies 
Eighteen (52.9%) studies were considered to be of generally good methodological 
quality with only minor deficits that were not of any real concern and 14 (41.2%) studies 
were deemed to have moderate methodological concerns.  Two studies had notable 
problems which imparted serious concerns due to unreported data, anomalies in the 
flow of patients in the study, missing baseline adherence data and self -selection bias 
in patient recruitment. 
Missing or ambiguous study details were the primary cause of study classification as 
‘minor deficits of no real concern’, although studies with a less robust design such as 
non-randomised trials also fell into this group.  Studies deemed to have moderate 
methodological concerns included those with complex or ambiguous data analysis, 
missing data or poor choice of adherence assessment tool.  Fidelity checks were 
reported in 10 (34.5%) studies.  
4.3.7  Data extraction agreement between independent reviewers  
Agreement in data extraction between the two independent reviewers was matched for 
42 different points, with an average agreement rate of 89.5%.  Differences between the 
two reviewers were largely due to differing interpretations of the data extraction form, 
for example the ‘total length’ column was intended to record the total length of the 
sessions in hours but one reviewer used this column to record the total time period 
over which the intervention was delivered. 
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4.4  Meta-analysis 
Data from 29 studies were statistically pooled in the meta-analysis; the main 
characteristics of these studies are summarised in appendix 4.2.  The results data from 
each included study is summarised in table 4.7.   
The studies included within the meta-analysis were predominantly RCTs and sample 
sizes ranged from 6 to 367, with 12 (41.4%) studies including at least 100 participants.  
Adherence outcome measures were variable but included the percentage of doses 
taken in a given time period in nine (31.3%) studies and the percentage of patients 
reaching a specified adherence level in six (20.7%) studies.  Three (10.3%) studies 
showed a non-significant negative effect on medication adherence.  Conversely 26 
(89.7%) studies showed a positive adherence effect and this was found to be 
significant in 21 (72.4%) studies. 
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Multi-component intervention using non-specific techniques 
 
Study Study 
type 
Total 
Sample 
Size (n) 
Intervention 
group (n) 
Control 
group (n) 
Adherence definition Adherence measure Outcome summary 
Bailey et al 
1990353 
RCT 225  124 101 % of patients scored as adherent 
on all 6 items of a self-report scale  
Self-report 
questionnaire 
Significantly better adherence in 
intervention group  
Hovell et al 
2003364 
RCT 188  92 96 Cumulative number of doses taken 
over 9 months 
Patient interview Significantly better adherence in 
intervention group 
Molassiotis et 
al 2003369 
Cohort 6  6 0 % of doses taken in last 4 days  Self-report 
questionnaire 
Significantly better adherence 
post intervention  
Murphy et al 
2002370 
RCT 
pilot 
33  17 16 % of doses taken during 
intervention period  
Self-report 
questionnaire 
Better adherence in intervention 
group – non-significant 
Pradier et al 
2003372 
RCT 202 100 102 % of patients deemed to be 
adherent (taking 100% of doses)  
Self-report 
questionnaire 
Significantly more adherent 
patients in intervention group 
Put et al 
2003373 
RCT 23  12 11 Frequency of non-adherent 
behaviour over the last 3 months  
Self-report 
questionnaire 
Significantly less frequent non-
adherence  in intervention group 
Remien et al 
2005374 
RCT 215 106 109 % of doses taken during previous 2 
weeks  
Electronic monitoring Significantly higher proportion of 
doses taken in intervention group 
Smith et al 
2003378 
RCT 17  8 9 % of participants taking ≥ 80% of 
their weekly doses  
Electronic monitoring Significantly more adherent 
participants in intervention 
Tuldra et al 
2000381 
RCT 77  36 41 % of patients with monthly 
adherence ≥ 95%  
Self-reported no. of 
pills taken 
Significantly more adherent 
participants in intervention  
Van Es et al 
2001382 
RCT 67 33 34 Adherence score on self-report 
scale  
Self-report 
questionnaire 
Significantly better adherence in 
intervention group 
Wagner et al 
2006383 
RCT 135 97 48 % of doses taken during 
intervention period  
Electronic monitoring Better adherence in control group 
– non-significant.  
Weber et al 
2004384 
RCT 
pilot  
53 29 24 % of patients with monthly 
adherence ≥ 95%  
Electronic monitoring Significantly more adherent 
participants in intervention group  
Table 4.7 Data extracted from individual studies for pooling in meta-analysis 
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Interventions using MI alone as one component 
 
Study Study 
type 
Total 
Sample 
Size (n) 
Intervention 
group (n) 
Control 
group (n) 
Adherence definition Adherence measure Study outcome summary 
DiIorio et al 
2008361 
RCT 213  107 106 % of doses taken during intervention 
period  
Electronic monitoring Better adherence in intervention group 
– non-significant 
Lavoie et al 
2011367 
RCT 25  10 15 % increase in prescription refill rate 
during intervention period 
Prescription refill data Significantly better increase in 
prescription refill rate for intervention 
group 
Multi-component intervention using MI 
 
Study Study 
type 
Total 
Sample 
Size (n) 
Intervention 
group (n) 
Control 
group (n) 
Adherence definition Adherence measure Study outcome summary 
Cook et al 
2007357 
Non-
RCT 
255  225 0 % of patients still adherent (taking 
medication) at end point  
Pharmacy prescription 
refill data 
Significantly better adherence in 
intervention group  
George et al 
2010362 
RCT 343  170 173 % of participants classed as adherent  Morisky self-report scale 
questionnaire 
Better adherence in intervention 
group – non-significant 
Golin et al 
2006363 
RCT 117  59 58 % of prescribed doses taken take in 
month prior to study endpoint  
Composite Adherence 
Assessment Score (CAS) 
Better adherence in intervention 
group – non-significant 
Ireland et al 
2010365 
Before 
& after 
20  20 0 % of patients who did not miss one or 
more medicines in an average week 
Self-report Significant increase in 
adherence post intervention 
Lawrence et al 
2008368 
Non-
RCT 
199  123 76 % of prescription drugs re-initiated 
following a period of non-adherence  
Pharmacy prescription 
refill data 
Significantly better medication 
re-initiation in intervention group 
Riekert et al 
2011375 
Before 
& after 
37  37 0 % of patients taking their medication 
every day  
Self-report in patient 
interviews 
Adherence decreases post 
intervention, non-significant  
Safren et al 
2000 376 
RCT 
pilot 
53  28 25 % of prescribed doses taken over the 
last 2 weeks  
Self-report questionnaire Better adherence in control 
group – non-significant 
Thrasher et al 
2006380 
Before 
& after 
30 30 0 % of prescribed doses taken CAS Significantly better adherence 
post intervention  
Table 4.7 (continued) Data extracted from individual studies for pooling in meta-analysis 
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Interventions using techniques based on MI 
 
Study Study 
type 
Total 
Sample 
Size (n) 
Intervention 
group (n) 
Control 
group (n) 
Adherence definition Adherence 
measure 
Study outcome summary 
Berger et al 
2005354 
RCT 367  172 195 % of patients discontinuing 
treatment by study endpoint  
Patient interview Significantly better adherence in 
intervention group 
De Bruin et 
al 2005359 
Before 
& after 
19  19 0 % of patients with adherence ≥ 
95%  
Electronic 
monitoring 
Significantly more participants 
adherent post intervention  
DiIorio et al 
2003360 
RCT 
pilot 
17  8 9 Mean number of missed 
medicines in the last 30 days  
Self-report 
questionnaire 
Better adherence in intervention 
group – non-significant 
Kalichman 
et al 
2005366 
Before 
& after 
23  23 0 Mean number of doses missed in 
the last three days  
Patient interview Significantly fewer doses missed 
post intervention  
Ogedegbe 
et al 
2008371 
RCT 160  79 81 % of days during two month 
period in which medication was 
taken correctly  
Electronic 
monitoring 
Significantly better adherence in 
intervention group 
Interventions using III 
 
Study Study 
type 
Total Sample 
Size (n) 
Intervention 
group (n) 
Control 
group (n) 
Adherence definition Adherence 
measure 
Study outcome summary 
Brown et 
al 2009331 
RCT  69  36 33 % of prescribed doses taken over  
a month  
Electronic 
monitoring 
Significantly better adherence in 
intervention group 
Sheeran 
et al 
1999377 
RCT 78  38 40 Number of once daily doses 
missed over a 3 week period  
Self-report 
questionnaire 
Significantly fewer doses missed 
in intervention group 
Table 4.7 (continued) Data extracted from individual studies for pooling in meta-analysis 
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4.4.1  Estimates of overall effect size 
Figure 4.3 shows the forest plot for all 29 studies, separated by study design type.  
Whilst the figure exemplifies the strong overall trend towards positive adherence effects 
with intervention, it also highlights that before and after studies elicited the strongest 
summary effect size.  The pooled estimate of standardised difference in mean (95% CI) 
for all 29 studies was 0.38 (0.28, 0.48) with moderate heterogeneity (I2 = 48.5%).   
 
 
Figure 4.3 Calculated intervention effect sizes and summary effect size for all 
studies, separated by study design type 
NOTE: Weights are from random effects analysis
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A funnel plot for the 29 included studies is shown in figure 4.4, suggesting publication 
bias, as noted by the deficit in small studies of a small or negative effect size.  Egger’s 
test confirmed statistically significant funnel plot asymmetry (p= 0.005) and the trim and 
fill technique elicited a re-computed effect size (95% CI) of 0.30 (0.19, 0.41).  
Figure 4.5 shows the funnel plot for studies assuming an RCT design and also 
suggests publication bias; significant funnel plot asymmetry was found (p= 0.05) and 
the re-computed effect size (95% CI) was 0.31 (0.20, 0.41).   
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Figure 4.4 Funnel plot for meta-analysis of all included studies  
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Figure 4.5 Funnel plot for meta-analysis of all studies with an RCT design 
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4.4.2   Sub-groups analyses 
Table 4.8 summarises the main sub-group analyses.  In the majority of cases, 
differences in effect size between sub-groups were not statistically significant, as 
represented by a p-value of >0.05.  The exception to this was the sub-group analysis 
based around intervention delivery sites, which suggested that hospital based 
interventions achieved significantly greater effect than community based interventions.  
Whilst the majority of planned sub-group analyses were undertaken, the data extracted 
for facilitator training was too subjective to form meaningful sub-groups as 
differentiation between poor reporting and poor training could not be made.  Sub-
groups based on the duration of facilitator training and number of facilitators delivering 
the intervention were also subject to a paucity of information which prohibited 
meaningful analyses.  The data extracted on receipt of payment or reimbursements for 
participation were also deemed too unreliable for creation of sub-groups.   
4.4.2.1  Funnel plot asymmetries 
For the majority of sub-groups, the funnel plots created were not indicative of 
publication bias.  For these sub-groups, the effect sizes detailed in table 4.5 can 
therefore be accepted with reasonable confidence.  Publication bias was suggested by 
the funnel plots for both sub-groups relating to disease area, though this was more 
prominent for the group of interventions in disease areas other than HIV.  This 
publication bias infers that the true effect size for the group of interventions delivered in 
disease areas other than HIV may have been lower, as the small studies of negligible 
or negative effect that are missing (as indicated by the asymmetrical funnel plot) would 
have pulled the mean effect size closer to zero. The difference in effect size between 
these two groups may therefore have been greater in the absence of publication bias 
and thus HIV based interventions could yield greater adherence improvements.  Both 
funnel plots for the sub-groups based on clinical and non-clinical delivery settings were 
also suggestive of possible publication bias. Potential publication bias was also 
suggested by an asymmetrical funnel plot for the sub-groups of studies: 
• delivered from secondary care 
• that did not target the interventions towards non-adherent patients 
• where control group participants received standard care  
• without methodological concerns  
• without fidelity checks 
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Subgroup A Subgroup B  
Studies included No. of studies 
(sample size) 
Effect size 
(95%CI) 
I2 (%) Studies included No. of studies 
(sample size) 
Effect size 
(95%CI) 
I2 (%) p-value 
Multi-component interventions 
using non-specific techniques 
12 (1222) 0.47 
(0.27, 0.67) 
60.8 Interventions using some form of 
MI 
15 (1878) 0.29 
(0.21, 0.38) 
36.8 0.12 
Interventions using some form of 
MI 
15 (1878) 0.29 
(0.21, 0.38) 
36.8 Interventions using MI in its full, 
classically defined pure form 
10 (1292) 0.27 
(0.10, 0.43) 
49.9 0.76 
Interventions targeting 
adherence to HIV medication 
15 (1191) 0.43 
(0.24, 0.62) 
60.3 Interventions targeting 
adherence to other conditions 
14 (2056) 0.36 
(0.25, 0.47) 
31.8 0.52 
Interventions delivered by 
routine healthcare professionals 
17 (2067) 0.33 
(0.18, 0.47) 
55.4 Interventions delivered by 
specialists or the researchers 
9 (1008) 0.41 
(0.28, 0.53) 
11.7 0.40 
Interventions delivered in person 19 (1556) 0.38 
(0.21, 0.55) 
59.6 Interventions delivered by 
telephone calls/mixed methods 
7 (1467) 0.36 
(0.26, 0.47) 
0.0 0.87 
Interventions delivered from 
community-based settings 
17 (2113) 0.30 
(0.18, 0.43) 
50.8 Interventions delivered from 
hospital-based settings 
12 (1134) 0.51 
(0.35, 0.66) 
31.2 0.05 
Interventions delivered from 
clinical settings 
22 (2271) 0.40 
(0.28, 0.53) 
47.9 Interventions delivered from 
non-clinical settings 
7 (796) 0.33 
(0.13, 0.54) 
56.4 0.57 
Interventions where the follow-up 
period is identical to the 
intervention period 
15 (1269) 0.39 
(0.23, 0.55) 
46.4 Interventions where the follow-
up period is extended beyond 
the intervention period 
12 (1676) 0.36 
(0.21, 0.51) 
55.4 0.78 
Interventions targeted towards 
non-adherent patients 
20 (2262) 0.37 
(0.22, 0.51) 
60.8 Interventions not targeted 
towards non-adherent patients 
9 (925) 0.41 
(0.29, 0.53) 
0.0 0.66 
Controlled studies with a 
comparison group receiving 
treatment as usual/standard care 
17 (2658) 0.37 
(0.28, 0.45) 
0.0 Controlled studies with a 
comparison group receiving an 
intervention in an alternate form 
6 (589) 0.38 
(0.15, 0.62) 
48.3 0.94 
Studies deemed to have 
methodological concerns 
13 (1348) 0.45 
(0.25, 0.65) 
63.8 Studies without any notable 
methodological concerns 
16 (1899) 0.36 
(0.25, 0.47) 
28.8 0.43 
Studies which undertook fidelity 
checks 
10 (1140) 0.25 
(0.07, 0.42) 
55.3 Studies which did not undertake 
fidelity checks 
19 (2107) 0.45 
(0.33, 0.58) 
38.4 0.06 
Studies assuming an RCT 
design 
21 (2658) 0.36 
(0.26, 0.46) 
34.3 Studies assuming a before & 
after design 
6 (135) 0.68 
(0.12, 1.24) 
78.0 0.27 
Table 4.8 Summary of sub-group analyses undertaken   
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4.4.2.2  Variation in effect size with differing intervention types 
Whilst the sub-group analyses based on intervention type revealed no statistically 
significant differences, the types of intervention used were of particular interest and 
therefore further explored.  Table A4.3 (appendix 4.3) provides further detail about the main 
intervention components and demonstrates how these relate to the intervention type 
classifications made.  The majority of interventions utilised numerous different techniques 
and the most frequently occurring components were patient education, identification and 
resolution of adherence barriers, developing problem solving skills, increasing a sense of 
self-efficacy and encouraging effective social support. 
Table 4.9 provides a comparison of the most commonly occurring intervention components 
in the ‘non-specific multi-component’ group of interventions and the ‘MI based multi-
component interventions’.  Interventions that occurred more commonly in the ‘non-specific 
multi-component’ group aimed to: 
• increase social support 
• deliver education 
• challenge negative thoughts and beliefs  
• develop coping strategies 
• increase a sense of self-efficacy 
• improve communication with healthcare professionals 
Conversely, intervention components including diary keeping and self-monitoring, pill 
reminders, dosing aids or memory cues and medication reviews were all used more 
frequently in the group of interventions based on MI.  
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Table 4.9 Comparison of intervention components between ‘non-specific’ group and ‘MI’ group 
 
 
Intervention component No. (%) studies using 
component in ‘non-
specific’ group 
No. (%) studies using 
component in ‘MI’ 
group 
% difference between 
‘non-specific’ group 
and ‘MI’ group 
 
Interventions components more commonly used in the non-specific group of interventions 
Improving social support 8 (66.7%) 1 (11.1%) 55.6 
Challenging negative thoughts/changing attitude 4 (33.3%) 0 (0%) 33.3 
Education 10 (83.3%) 5 (55.6%) 27.7 
Increasing sense of self-efficacy 6 (50%) 3 (33.3%) 16.7 
Developing coping strategies 2 (16.7%) 0 (0%) 16.7 
Improving communication with healthcare providers  3 (25.0%) 1 (11.1%) 13.9 
Encouraging self-care/self-management/adherence skills 4 (33.3%) 2 (22.2%) 11.1 
Intervention components where there is no notable difference in use between the two groups 
Increasing confidence 1 (8.3%) 0 (0%) 8.3 
Identifying and resolving adherence barriers 6 (50.0%) 4 (44.4%) 5.6 
Identifying and addressing concerns 2 (16.7%) 1 (11.1%) 5.6 
Problem solving skills 4 (33.3%) 3 (33.3%) 0 
Increasing knowledge 1 (8.3%) 1 (11.1%) -2.8 
Behaviour rehearsal  1 (8.3%) 1 (11.1%) -2.8 
Regimen simplification/tailoring 2 (16.7%) 2 (22.2%) -5.5 
Goal setting/action planning 3 (25.0%) 3 (33.3%) -8.3 
Interventions components more commonly used in the ‘MI’ group 
Diary keeping/self-monitoring 1 (8.3%) 4 (44.4%) -36.1 
Pill reminders/dosing aids/adherence cues 1 (8.3%) 3 (33.3%) -25.0 
Medication review 1 (8.3%) 2 (22.2%) -13.9 
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4.4.3  Meta-regression 
Inverse variance weighted regression of the number of sessions over which the 
interventions were delivered was based on 25 studies.  Figure 4.6 shows a scatter plot 
of the number of sessions against the effect size, suggesting that a notable correlation 
between the two variables is unlikely.  The meta-regression confirmed this with a beta 
weight value (95% CI) of 0.021 (-0.019, 0.061) indicating that for each additional 
session, the effect size may increase by just 0.021.  With a wide confidence interval 
which crosses zero, any consistent increase in effect size with an increasing number of 
sessions is unlikely.  This result is supported by a non-significant p-value of 0.299. 
Inverse variance weighted regression was also used to explore a linear association 
between the number of weeks over which the intervention was delivered and the 
intervention effect size.  This analysis was based on 23 studies and the scatter plot 
obtained is shown in figure 4.7, indicating that any association is unlikely.  The meta-
regression revealed no indication of any significant association with a beta weight value 
(95% CI) of -0.004 (-0.012, 0.005) and a p-value of 0.412. 
 
Figure 4.6 Scatter plot for number of intervention sessions and effect size 
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Figure 4.7 Scatter plot for intervention duration (no. weeks) and effect size 
The total intervention length was also explored as a covariate which may have 
influenced the effect size, although no associations were found based on the data from 
the 15 studies with available data.  The scatter plot shown in figure 4.8 indicates no 
association between increasing intervention length and effect size, as confirmed by a 
beta weight value (95% CI) of 0.001 (-0.001, 0.020) and p-value of 0.476. 
 
Figure 4.8 Scatter plot for total intervention length and effect size 
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 4.5 Discussion  
Thirty-four studies have been described in narrative, with 29 of these combined in a 
random effects meta-analysis.  Given the diverse range of studies included, moderate 
heterogeneity was anticipated.  Whilst implying the effect sizes across the different 
studies are likely different, the moderate heterogeneity does not impart notable 
concerns regarding the trust with which we can accept the overall effect size.  Whilst 
the techniques used, patients studied and persons delivering the interventions varied, 
their ultimate aim and study premise remained consistent.  Statistical combination of 
these studies in a meta-analysis was therefore both intuitive and meaningful. 
Techniques to provide an unbiased, best estimate of effect which accounts for 
heterogeneity and publication bias increased the confidence placed in the effect size 
estimated.  This value of 0.31 (0.20, 0.41) infers that these interventions achieved a 
significant positive effect of the small to medium range385.  This study represents the 
first meta-analysis of MI and cognitive-based behaviour change techniques as 
interventions to improve medication adherence.  The effect size calculated in this 
study, is however higher than effects achieved for comparable adherence interventions 
delivered over similar time periods and in similar settings.  A meta-analysis reported by 
Peterson et al.164, comprised of educational and behavioural interventions to increase 
medication adherence in a range of illnesses, reported a correlation coefficient (r) 
equivalent to a Cohen’s d effect size of 0.16 (0.08, 0.24).  The interventions evaluated 
in Peterson’s meta-analysis are representative of the mainstay of current practice, thus, 
the novel motivational and cognitive-based techniques explored in this study seemingly 
improve medication adherence beyond traditional approaches.   
For MI, the effect size calculated in this review, closely matches the effect size 
calculated in the most recent and comprehensive meta-analysis of MI as an 
intervention in substance abuse, health-related behaviours, gambling and treatment 
engagement318.  Novel evidence for the wider use of MI, beyond these domains has 
therefore been provided.  Whilst any inferences are tentative, the similarity in effect 
sizes established in this study and that of Lundal et al. increases the confidence with 
which this study’s findings can be trusted.  Moreover, it may tentatively add further 
support to the hypothesis that it is the cognitive-based intervention elements, or the 
synergy between cognitive and motivational elements that enhance the effect sizes 
further.  
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4.5.1  Number, range and source of included studies 
The number of included studies was greater than anticipated from preliminary searches 
and is likely influenced by the fact that over a third of the included studies did not use 
specific techniques but instead combined multiple non-specific components.  The large 
number of studies relating to mental health or addiction represented a notable 
reduction in studies that were otherwise potentially suitable for inclusion.  However, the 
original justification for excluding these studies remains and has allowed a clearer 
picture of intervention impact to be obtained. 
Full text articles were most commonly excluded due to unusable adherence data and 
further studies, included in the systematic review but not in the meta-analysis, were 
subject to similar inappropriate reporting of data.  Whilst disappointing, it is not 
surprising that poor study reporting is problematic in this field, as many reviews of MI 
have previously identified this weakness, specifically stipulating that poor reporting and 
detail made intervention definition problematic301, 314-316. 
Whilst the exclusion of one study386 due to an inability to access the full text is not ideal, 
inclusion was dubious as it was unclear whether adherence data were reported and 
whether the intervention used MI or a cognitive-based technique.  The study was also 
published in 1980, long before the intervention types of interest became main stream, 
further decreasing the likelihood of suitability for inclusion.  The inability to access this 
study in full text was therefore not considered a notable limitation of the review. 
Whilst ‘moderate’ agreement for abstract screening may seem disappointing, perfect 
agreement was obtained following discussion.  This ‘moderate’ level of agreement can 
largely be explained by considering the differing levels of experience, knowledge and 
expertise between the two reviewers.  The main reviewer had extensive background 
knowledge of MI, cognitive-based techniques and medication adherence and had been 
responsible for the study protocol development since its inception.  In comparison, the 
second reviewer came into the review much later, with minimal background knowledge.  
This point is exemplified by the perfect agreement achieved by discussion, as many 
cases of disagreement had arisen from misunderstandings of the material.  Given this 
disparity in experience and knowledge, achieving moderate agreement is a reasonable 
accomplishment.  A paucity of information in screened abstracts also heavily influenced 
the agreement rate between reviewers. 
Discrepancies in data extraction for the meta-analysis were largely attributable to 
ambiguities on the data extraction form, though there were some sample size 
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discrepancies in the instances of intention-to-treat analyses.  The strong level of 
agreement between the reviewers, especially after discussion increases the confidence 
placed in the data extracted and therefore strengthens this study. 
Almost half of the studies included were not found via the electronic database screen, 
suggesting a possible deficit in the electronic database search terms.  Including the 
search term ‘treatment adherence’ and incorporating a search term to accommodate 
HIV adherence studies may therefore have increased the number of studies identified 
via the electronic database searches.  However, extensive manual searching of 
appropriate reference sources provided good coverage of the published material; study 
limitations in this domain are therefore unlikely. 
The vast majority of studies were published after the year 2000; this finding was 
anticipated as the use of MI and cognitive-based behaviour change techniques for 
medication adherence has only generated interest in more recent years.  Whilst studies 
were undertaken in a total of nine different countries, the majority of studies (61.8%) 
came from the USA, suggesting that international, widespread use of these novel 
concepts and techniques is not yet apparent.  Interestingly, whilst the UK was the 
second most prominent country of study origin, only 4 (11.8%) studies originated in the 
UK, indicating these techniques are scarcely used in UK based research. 
4.5.2  Types of studies included 
Due to the novel research concepts used in the studies, it was anticipated that the 
majority of studies would be small in size and of a before and after study design.  
However, the majority of studies assumed an RCT design; the most methodologically 
robust, gold-standard study design.  With a predominance of RCTs, increased 
confidence can be placed upon the data from which conclusions are drawn.  
4.5.3  Intervention components 
Defining the intervention type proved to be complex and numerous studies could not be 
grouped into a specific category, with 13 (38.2%) studies grouped as ‘multi-component 
non-specific interventions’.  The difficulties in defining whether an intervention used 
‘true’ MI as previously detailed in other reviews301, 314-316 was also evident. Despite the 
difficulties in classification of MI based interventions, just over half of the included 
studies described an intervention which used MI in some form.  A prominence of MI 
type studies was anticipated as MI is the most widely studied cognitive-type 
intervention in other health-related behaviours.  The marginal majority observed may 
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therefore be slightly lower than expected, but this is largely accounted for by the large 
group of ‘non-specific’ interventions, constituting over a third of the included studies.  A 
minority of studies used III as their intervention or described CBT as a definable 
component, indicating that these newer, lesser developed strategies are as yet, not 
widely utilised in the medication adherence domain.  MI purity was not associated with 
intervention efficacy, an observation consistent with the findings of Hetemma et al. for 
MI across a range of target problems317. 
Interventions also tended to refer to MI rather than BCC, indicating that this brief 
adaptation of MI is yet to be widely used.  The concept of BCC dates back to 1999387 
with further developmental work over the next five years 320, 321 and has therefore 
existed in a comprehensive form for almost ten years.  Given the promising potential of 
BCC, it is perhaps surprising that more interventions have not utilised this technique.  
However, it is possible that some of the interventions that pertained to use MI may 
actually have used a format that better reflected the premise of BCC, once again 
highlighting the problematic nature of defining interventions appropriately. 
The majority of included studies involved multiple components and this observation is 
not surprising as previous evidence suggests that complex, multi-faceted interventions 
are the most effective16 and that a combination of cognitive, behavioural and affective 
components is more effective than single focus interventions388.   
A larger difference in effect size was noted when interventions with multiple non-
specific components were compared to those which used MI in some definable way, 
though this difference was not statistically significant.  However, interventions occurring 
more commonly in the ‘non-specific’ group may be more strongly associated with 
efficacy compared to interventions occurring more commonly in the MI group.  
It is unsurprising that increasing social support appears to be an important intervention 
component as comprehensive meta-analytical evidence has identified a significant 
positive relationship between social support and adherence120, findings that mirrored 
earlier reports in a seminal systematic review42 and it’s later update163.  Di Matteo’s 
work identified that practical support in adherence elicited the greatest positive 
influence, with patients receiving practical support being 3.6 times more likely to be 
adherent than patients who did not120.  It is therefore not surprising that practical 
elements such as developing coping strategies also prevailed as ‘strong’ intervention 
components.  
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With extensive literature describing the detrimental effects of negative beliefs about 
medications on adherence38, 90, it is also unsurprising that ‘challenging negative 
thoughts’ appeared to be effective intervention component.  Likewise, it is intuitive that 
‘increasing a sense of self-efficacy’ was an intervention component more common in 
the ‘non-specific’ group of interventions associated with greater efficacy, as self-
efficacy is a core component of many of the theoretical models described in chapter 
three.  It is also interesting to see that interventions which addressed patient and 
prescriber relations and communications appear to be associated with efficacy.  Whilst 
consideration of research evidence83, 88 means this observation may have been 
expected, it is interesting to see adherence interventions have taken a specific focus on 
improving patient and prescriber communication, as this was not identified in the 
prominent review by Haynes et al. in 2008163. 
Whilst Haynes’ review suggested self-monitoring and pill reminders were common 
themes in adherence interventions163, evidence has suggested these are not always 
particularly effective interventions and more importantly not always appropriate173-176.  It 
is therefore interesting to see that this review has also hallmarked these components 
as potentially being associated with lower efficacy.  The evidence for the benefit of 
medication review has also been variable and fraught with controversy in recent years, 
as previously described in chapter one.  This meta-analysis tentatively suggests that 
adherence interventions based upon a medication review may be less effective than 
interventions based on other components such as increasing patient support and 
sense of self-efficacy.  Given the evidence relating to the value of medication review, 
this observation may not seem at all surprising.  However, this does impart notable 
questions around the value of current adherence interventions such as the nationally 
commissioned Medicines Use Review (MUR) service, also described in chapter one.  
Whilst the evidence suggests that interventions based on medication review may be 
less effective than those with more cognitive-based components, it is pertinent to 
consider the importance of reviewing medication appropriateness before intervening to 
improve adherence.  Improving adherence to a medication regimen that is clinically 
inappropriate has the potential for detrimental rather than positive health effects. 
The evidence provided in literature and more specifically in this review suggests that 
reviewing a patient’s medicines use, providing education and suggesting resolutions to 
non-adherence are unlikely to yield positive effects of a notable magnitude, especially 
in complex cases and in the instance of intentional non-adherence.  In such instances, 
the novel motivational and cognitive-based techniques explored in this review are 
seemingly more likely to elicit the desired outcome of improved medication adherence.   
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These techniques are however, far from widespread in their use even in an 
experimental domain, and represent an unknown concept to the majority of healthcare 
professionals.  This observation is disappointing given that sixteen years have now 
passed since Haynes and colleagues first identified the need for innovative approaches 
to improving medication adherence389.  The current format of routinely delivered 
adherence interventions may therefore represent a ‘missed opportunity’ in eliciting 
maximal outcome effectiveness.  Further research is therefore warranted. 
Whilst this review provides some tentative inferences as to which intervention 
components may be associated with greatest efficacy, further work is needed to fully 
identify the most effective intervention components with confidence.  However, the 
aforementioned paucity of well described studies prohibits the undertaking of this work.  
Without being able to describe the intervention components in a consistent and 
methodologically robust manner, teasing out the most effective intervention 
components is difficult.  At the time of completing this review, the BCT taxonomy V1293, 
as described in chapter 3, had not been published.  However, with the publication now 
available and online sessions to train researchers as ‘coders’ soon to be available, this 
work will be possible in the near future.  
4.5.4  Intervention delivery characteristics 
4.5.4.1  Intervention delivery personnel  
It is encouraging to see that over half of the interventions were delivered by routine 
healthcare professionals such as nurses, pharmacists and clinicians, as routine 
healthcare delivery is an important facet for wider application of these techniques.  
Whilst the effect sizes calculated suggest that interventions delivered by specialists 
may achieve greater effects than those delivered by routine HCPs, overlapping 
confidence intervals around the effect size estimates and a p-value of 0.40 infer that 
true differences between the two groups are unlikely. 
In their seminal review of MI research, Lundhal et al. reported that the practitioner 
training level did not influence intervention efficacy318.  These findings are echoed by 
the present systematic review of MI and other cognitive-based behaviour change 
techniques to enhance medication adherence.  Although the number of studies with 
interventions delivered by a community pharmacist was too small to determine an 
effect size via meta-analysis, it is still encouraging to see that the skills and expertise of 
community pharmacists can be utilised in this way.   
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Interventions were more commonly delivered by ‘multiple personnel’ but sufficient data 
to enable sub-group analyses were not available, further exemplifying the 
aforementioned reporting problems.  It is not surprising that delivery by multiple 
personnel rather than one facilitator working alone was more common as this is a more 
realistic model for service delivery in the wider healthcare domain.   
4.5.4.2        Intervention exposure 
Data relating to the intervention length proved difficult to elicit and were obtained for 
just over half of studies.  Linear associations between the intervention effect size and 
three co-variates of intervention exposure were found to be highly unlikely; intervention 
exposure does therefore not appear to influence intervention efficacy in any way.  It is 
intuitive to anticipate improved efficacy with prolonged intervention exposure as this 
relationship has been reported for MI interventions in other health domains316, 318.  
However, whilst Ruback et al.316 and Lundhal et al.318 both focused on one technique 
alone (MI), this study included numerous different techniques which likely contributed 
to the heterogeneity observed.  It is therefore plausible that any intervention exposure 
effects may have been over-shadowed by the differing intervention components.  It is 
also worth considering whether the poor study reporting regarding intervention duration 
may have accounted for the surprising observation of no increase in efficacy with 
greater intervention exposure.   
Further investigation of the observation that efficacy was not increased by intervention 
exposure is warranted as, if found to be true, questions over causality may be inferred.  
In 1965, Sir Austin Bradford Hill provided a classic essay on causal evidence where the 
minimal conditions necessary to provide adequate evidence of a causal relationship 
were defined390.  One of these minimal conditions for causality is, as termed by 
Bradford Hill, ‘biological gradient’ or in other words a dose-response effect.  Whilst 
these minimum criteria for causality are heavily focused on a medical model of factors 
which are causative in disease, there may be some useful application to explore a 
causal relationship between receipt of cognitive-based interventions such as MI and an 
increase in adherence.  
In consideration to the wider application of these techniques as routine healthcare 
interventions, it is encouraging to see that brief interventions, delivered in only one or 
two sessions can elicit small to medium sized, significant effects.  Routine healthcare 
professionals are unlikely to have sufficient resources to deliver an intervention over 
many sessions, lasting several hours, so the findings reported here may be supportive 
of practical and feasible delivery in the wider domain.  
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Extension of the follow up period beyond the intervention delivery period was not 
associated with any statistically significant changes in effect size.  It could therefore be 
argued that durability of effect may be evident as the effect size had not dropped when 
adherence was assessed beyond the end of the intervention.  This is however a 
tentative conclusion as robust inferences about the durability of the treatment effects 
could not be made from the data gathered.  Further work to determine the durability of 
these techniques is therefore warranted. 
4.5.4.3      Intervention targeting and comparison group type 
The majority of studies targeted the intervention towards non-adherent patients, which 
is unsurprising given the intervention aims.  Although the summary effect size for the 
‘non-targeted group’ was slightly higher than that for the ‘targeted group’, the closely 
matched effect sizes and overlapping confidence intervals suggest that the effect size 
in these two groups is unlikely to truly differ.  This hypothesis is supported by the 
publication bias in the ‘not-targeted’ group which may in part account for the slightly 
larger effect size observed, given the use of a random effects model.  Furthermore, a 
p-value of 0.66, confirms that any differences between the effects sizes calculated for 
the two sub-groups were not statistically significant.  It would however, seem logical to 
expect a greater effect in patients who were non-adherent and this may well still be the 
case.  The observations seen here could therefore be an artefact of the way ‘non-
adherent’ patients were identified, after all a wide range of tools were used to do this 
and some studies simply targeted the intervention towards patients at risk of non-
adherence.  
For controlled studies, the comparison group was most frequently standard care or 
treatment as normal which is to be expected as comparison to usual care is generally 
considered to be the gold standard.  However in terms of comparing effect sizes, 
standard care may be considered as a ‘weak’ comparator whereas delivering an 
alternate intervention may be considered as a ‘strong’ comparator, as the latter option 
enables determination of the most effective intervention type.  In this study, 
interventions using standard care or treatment as usual as the comparator elicited a 
near identical effect size to interventions where the comparison group received the 
intervention in an alternate form.  A p-value of 0.94 offered robust evidence to confirm 
that any differences in effect size between these two sub-groups were not statistically 
significant.  Other meta-analyses in similar domains have identified the comparison 
group type as an effect size moderator, with strong comparators such as other 
interventions eliciting greater effect sizes318.  Given the possible publication bias in the 
Chapter Four             ‘Cognitive-Based’ Interventions to Improve Medication Adherence 
 
 197 
group of studies using treatment as usual, it is possible that these finding could be 
mirrored in this study.  Advanced meta-analytical techniques to explore the impact of 
publication bias may therefore be warranted, however, resource limitation did not 
permit this. 
4.5.5  Study settings 
Half of the included studies were for HIV medication adherence which is not surprising 
given the documented adherence challenges in this group391-393  and need to maintain 
high adherence levels to ensure therapeutic benefit14.  Other disease areas with 
multiple studies included asthma and hypertension which are also known to attract 
adherence problems37, 43, 63, 105, 394.   Despite the predominance of HIV based studies, 
the meta-analysis included medication adherence across 12 different diseases, 
implying the techniques used are widely applicable across different domains.  Whilst 
studies relating to the treatment of addiction or mental health were excluded, the 
rationale for this decision is sound given the known differences in adherence 
behaviours for these conditions.  A limitation, in as much as this study is not applicable 
to these conditions has however been introduced.  Further work to consider the 
application of these techniques to these specific domains is therefore advised.  
The closely matched summary effect sizes, overlapping confidence intervals and non-
significant p-values for interventions targeting HIV adherence compared to those for 
other disease areas, also supports the wider application of these techniques.  
However, the inferred publication bias for studies in ‘other diseases’ may have 
artificially elevated the effect size for this sub-group, in which case a true difference 
between the two groups may have been observed.  Interventions targeting non-
adherence to HIV therapy may be expected to be more efficacious as the perceived 
necessity of these drugs and consequences of non-adherence may be greater than in 
other disease areas.  
The majority of interventions were delivered from hospitals, which is unsurprising given 
the prominence of interventions targeting adherence to HIV medication.  Interventions 
delivered from secondary care appeared to be more efficacious than those delivered 
from primary care and the confidence intervals around these two notably different effect 
sizes overlapped only minimally.  These inferences of true differences were supported 
by a p-value of 0.05, indicating a statistically significant difference in effect size 
between these two groups.  Publication bias in the sub-group of interventions delivered 
in secondary care, may however have caused an exaggeration of this effect which 
should ideally be further investigated, though resource limitations did not permit this. 
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Based on the evidence available, our best estimates suggest that whilst interventions 
delivered from hospitals may be more effective, community based interventions are still 
capable of eliciting small, statistically significant effects.  This is encouraging in terms of 
the widespread use of the techniques in community based settings.  However, if 
hospital based interventions really are more effective than those delivered in 
community, further investigation to establish the reasoning for this would be warranted.  
It may be feasible that the conditions treated in secondary care (such as HIV for 
example) are more amenable to benefit from such interventions or perhaps the 
practitioners working in secondary care are better able to implement the interventions.  
More likely however, is the possibility that there is no true difference; the potential for 
spurious findings as a result of multiplicity testing must therefore be considered.  
The majority of interventions were delivered in person, which is unsurprising given the 
counselling styles and techniques used in these interventions which intuitively benefit 
from face-to-face contact395.  Interventions delivered entirely in person were slightly 
more effective than interventions delivered by mixed methods (including telephone 
calls), however the p-value of 0.87 provides no evidence of a statistically significant 
difference in effect size between these two groups.  The differences observed may 
therefore have been due to chance, though with relatively small numbers of studies, 
there may also have been a lack of power to detect statistically significant differences.  
Intuitively, it may be expected that interventions delivered in person would elicit a 
greater effect as the facilitator may find it easier to build a rapport with the patient.  
Evidence of this has not been provided by this study. 
A systematic review of telephone based medical consultations identified that public 
satisfaction with telephone consultations is high and the effectiveness of health 
promotion interventions delivered over the telephone, are comparable to those 
achieved via face-to-face communication396.  Similar findings were also reported in a 
Cochrane review of telemedicine versus face-to-face care, however the need for further 
work to elucidate the full effect of telecommunications on health outcomes was also 
identified397.  Whilst further work in this domain is required, delivery of interventions via 
the telephone or other telecommunications such as web-based interventions may well 
be a useful tool in dissemination of these techniques, offering effectiveness 
comparable to that of face-to-face communications.  
The practical delivery of these interventions is an important factor that should not be 
overlooked as accessible delivery, that can easily be fitted into a busy healthcare 
provider’s hectic daily schedule, is likely pertinent to the widespread use of such 
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interventions.  Delivery methods such as the telephone may be an important factor in 
determining how accessible and deliverable an intervention is and is therefore an 
interesting concept worthy of further, more robust investigation.  
4.5.6  Methodological quality of studies 
Reporting of studies was variable but information was frequently absent, indicating 
poor reporting for many studies.  Subsequently, only half of the studies were 
considered to be of good quality with only minor deficits of no real concern.  Studies 
with methodological concerns elicited a slightly greater effect size than those without 
concerns, though a p-value of 0.43 confirmed that the methodological quality of each 
study does not significantly influence the effect size.  This observation is encouraging; 
a greater effect from poorer quality studies would infer bias from the methodological 
quality of the studies, but evidence of this has not been presented.  However, this could 
also suggest that the critical appraisal techniques were not effective.  Based on the 
evidence available it is impossible to say which of these explanations is most probable.  
However, a comprehensive checklist, based on recommended tools was used to 
assess methodological quality by two independent reviewers, therefore, we can be 
confident that all reasonable steps to ensure a robust methodology assessment were 
taken.   
The sub-group of studies that undertook fidelity checks produced an effect size notably 
lower than that for the sub-group of studies that did not undertake fidelity checks, with 
95% confidence intervals that overlapped marginally.  A p-value of 0.06 is close to 
statistical significance suggesting that true differences in effect size between the two 
sub-groups may exist.  However, the ‘no fidelity checks’ group’s effect size could be 
exaggerated by publication bias; advanced meta-analytical techniques such as Egger’s 
test for funnel plot asymmetry343 and Duval and Tweedie’s trim-and-fill methods347, 348 
could be used to investigate this further if resources permitted.   Reduced efficacy with 
fidelity checks may appear counterintuitive.  However, when fidelity checks are 
undertaken, facilitators will commonly follow an intervention manual or protocol; 
practice that may introduce a meticulous and rigid delivery style.  In comparison, 
studies without fidelity checks may be more fluid and amenable to adaptation and 
targeting to meet an individual’s needs, without concern for the rigidity of following a 
manual.  If this is so, these results would in part mirror the earlier work of Hettema72 
and Lundhal106  who independently provided meta-analytical evidence to suggest 
manual guided interventions were less effective than interventions which did not use 
manuals. 
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4.5.7  Study strengths and limitations  
A meticulously designed and executed study with a registered study protocol has been 
undertaken, with data largely drawn from RCTs covering a total of 3554 participants.  
Cumulatively, these factors act as study strengths.  However, the study has limitations, 
which largely centre on a paucity of information and a potential lack of statistical power 
due to small numbers of studies in the sub-group analyses.  The risk of obtaining 
spurious significant results due to the relatively large number of sub-group analyses 
undertaken (multiplicity testing) should also be acknowledged as a potential limitation. 
Such limitations have however been carefully considered throughout the data analysis 
and interpretation.   
Whilst an ‘adherence effect’ has been estimated, data to estimate a treatment and 
clinical effect are absent, adding further limitation to this work.  It is therefore unknown 
whether the adherence improvements yielded through use of these techniques 
translate into therapeutic and clinical benefits.  Scope for future work has therefore 
been identified, though given the documented paucity of information in many studies, 
eliciting these details may prove challenging.  
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4.6 Conclusion 
The evidence provided suggests that motivational and cognitive counselling techniques 
can effectively be delivered by routine healthcare professionals, in both primary and 
secondary care settings, and that positive effect is not restricted to diseases such as 
HIV.  Evidence also suggests that efficacy is not related to treatment exposure and that 
brief interventions, delivered over few sessions demonstrate comparable efficacy to 
interventions of far greater duration.  Interestingly, the results also suggest that these 
interventions can be delivered via telephone contact with comparable efficacy to similar 
interventions delivered via face-to-face contact.  Such factors are likely pertinent to the 
scope of these techniques as widespread, routinely utilised adherence interventions, 
and suggests that the techniques are adaptable to a wide range of settings and 
amenable to tailoring to meet individual need.  However, numerous sub-group analyses 
were undertaken which often related to relatively small numbers of studies; the 
potential for multiplicity testing and a lack of power to detect statistically significant 
differences must therefore be acknowledged.  
Despite the promising evidence provided for these techniques, their widespread use 
remains uncommon, especially in the UK where only four studies were undertaken.  
Publication of research in this domain has however seen steady growth in the last ten 
years, and looks set to continue expanding in the near future.  In comparison to 
common place interventions such as medicine use reviews, adherence checks and 
patient education, provided through the extensively funded MUR and NMS services, or 
provision of compliance aids which are also a costly intervention, the techniques 
evaluated in this study may represent a more effective intervention.  However, as 
details of cost effectiveness have not been established in this study, conclusions about 
likely cost-effectiveness cannot be made.  
Further research into the use of these techniques as medication adherence 
interventions is warranted in order to elucidate which techniques are most strongly 
associated with improved medication adherence.  Feasibility studies to determine both 
patient and healthcare practitioner satisfaction and acceptance of these techniques is 
also necessary as tentative work in establishing the role of these techniques in the 
widespread delivery of evidence-based, effective adherence interventions.   
This review has also highlighted that the quality of study reporting in this field is 
frequently problematic and thus represents a further marker for improvement in future 
research.  Future research in this field therefore needs to provide methodologically 
robust, well conducted and appropriately reported studies, with clearly articulated and 
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well defined interventions.  Such developments are likely pivotal in furthering the use of 
these techniques to the wider healthcare domain.  
The contribution of this chapter to the overall thesis is to provide substantial evidence 
that these novel cognitive-based behaviour change techniques are worthy of further 
pursuit in the quest to develop a gold-standard adherence intervention.  Whilst we can 
now be confident that these techniques are useful tools to improve adherence, the 
challenge, as referenced in chapter three, is to establish how these techniques can be 
incorporated into an intervention.   
With a plethora of techniques available, evidence based methods to establish which 
techniques are best used when, is pertinent to further development.  Chapter five 
considers the development of an adherence barriers identification questionnaire, which 
would in turn be used to determine which cognitive-based behaviour change technique 
would be most appropriate to address an individual patient’s adherence barriers.   
  
Chapter Four             ‘Cognitive-Based’ Interventions to Improve Medication Adherence 
 
 203 
4.7 Addendum  
In April 2013, the literature search for this meta-analysis was updated for publication.  
The original search, identified 21 RCTs suitable for inclusion in the meta-analysis; a 
figure that had increased to 26 RCTs 16 months later, highlighting the continued 
interest in these techniques and increase in quality publications within the field. 
For these 26 RCTs an effect size (95% CI) of 0.34 (0.23 to 0.46) was achieved with 
high heterogeneity (I2 = 68%).  Adjustment for publication bias was necessary due to 
statistically significant funnel plot asymmetry yielding a more conservative estimate of 
summary effect size as 0.21 (0.08 to 0.33).  As with the original meta-analysis, sub-
group analyses suggested that the interventions were amenable to use across different 
populations and in differing manners, without loss of efficacy. 
This update was published in August 2013 in BMJ Open and is available at: 
http://bmjopen.bmj.com/content/3/8/e002749.full 
Included within the update, was a UK based RCT involving 211 patients with type two 
diabetes who received an Implementation Intention Intervention (III) to improve 
adherence as a nurse delivered, one-off session398.  A further UK based study of 62 
stroke survivors prescribed medication for the prevention of further cardiac events, also 
based on III333 narrowly missed inclusion within the update due to publication in May 
2013.  Both studies were of high quality and achieved promising improvements in 
medication adherence.  This highlights that UK based research is, albeit gradually, 
starting to shift its research focus toward a more psychological basis for adherence 
improvements.  
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5.1 Chapter introduction 
5.1.1  The need for a tool to identify patient barriers to adherence 
Chapter one detailed the nature, magnitude and implications of non-adherence to 
prescribed medication.  Whilst a gold standard, evidence-based adherence intervention 
is elusive, a wealth of literature describing the predictors of adherence exists.  
Synthesis of this material, with a specific focus on adherence barriers, is an intuitive 
first step towards designing a questionnaire to enable identification of an individual’s 
adherence barriers, as proposed in chapter three.  A questionnaire, grounded in the 
TDF, will enable theory-based identification of medication adherence barriers and the 
interventions delivered to resolve these identified barriers can be targeted accordingly.  
Development of this questionnaire therefore represents an important step towards 
theory based adherence interventions that are targeted to meet individual needs.  The 
proposed questionnaire would form a pivotal part of an intervention whereby adherence 
barriers identified in the questionnaire would then be discussed with the patient.  
The best approach to resolving non-adherence, especially that of an intentional nature, 
is still unknown and a clear strategy for approaching this problem has not been defined.  
Through an understanding of the complexities of medication taking, it is clear to see 
that behaviour change is challenging, especially when the non-adherent behaviour is 
influenced by factors such as attitudes, confidence, motivation and health beliefs.  
Chapter four provided a systematic review and meta-analysis of cognitive-based 
behaviour change techniques to resolve these issues and improve adherence.  
Techniques such as MI and III were shown to improve medication adherence beyond 
the educational and behavioural strategies routinely used in practice.   
The evidence for cognitive-based behaviour change techniques is encouraging, 
however, much work is still needed to develop a robust, theory and evidence-based 
means of utilising these techniques appropriately to improve adherence.  Chapter three 
focused on theories to understand the psychology of intentional non-adherence.  It also 
summarised recent developments led by Michie et al. which propose a mechanism for 
mapping behaviour change techniques to the theoretical domains of behaviour to which 
they relate.  This novel approach would allow targeting of the interventions delivered to 
meet an individual’s needs by selecting the most appropriate evidence-based 
behaviour change technique(s) for the adherence difficulties identified. 
To be able to deliver an intervention to address a patient’s adherence barriers, we must 
first have a robust, theory based tool to identify these barriers.  Questionnaires 
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grounded in the Theoretical Domains Framework (TDF) to identify barriers to behaviour 
change have been described in chapter three.  This chapter will focus on the 
application of this approach to develop the ‘Identification of Medication Adherence 
Barriers Questionnaire’ (IMAB-Q).  
5.1.2  Questionnaire design; consideration of theory and methods  
5.1.2.1  General principles and questionnaire content 
Questionnaire development is a multi-stage process involving meticulous design to 
assure confidence in its rigour150.  The process can be loosely categorised into content 
development, presentation, refinement, pilot work and psychometric analysis.  Pilot 
work is an essential component to enable evolution of an appropriate questionnaire 
and the time needed to adapt and refine the questionnaire should not be overlooked150. 
Qualitative work such as interviews and focus groups are often undertaken in order to 
inform content development399.  Such work is particularly necessary when there is little 
existing evidence to support determination of questionnaire content.  Interviews offer 
an in depth exploration of ideas and are particularly useful for sensitive subject matters, 
where group discussions are less appropriate400.  On the other hand, focus groups can 
encourage group discussion and debate about the topics raised and highlight a wider 
range of experiences and understanding401, 402.  Individual views can also be collated to 
explore group perspectives and seek consensus, plus prioritisation of content can also 
be facilitated through group discussion401.  Focus groups are therefore a widely used 
component in the development of valid and reliable survey instruments, representing a 
cost effective and flexible tool to explore participants’ attitudes and responses399.  
Content development can be further expedited if a large evidence base is already in 
existence150; the evidence can be synthesised and supplemented with qualitative work 
to enable tailoring to meet the specific needs of the questionnaire being developed.  In 
2011, McEachan et al. reported identification of additional barriers plus a greater depth 
of understanding, when focus groups were used to supplement a list of literature 
identified barriers to worksite physical activity403.  Similar findings were reported by 
Lacey et al. who undertook patient focus groups and semi-structured interviews to 
identify obstacles to and motivations for adherence to glaucoma therapies404.   
Qualitative work with members of the public during the development of a questionnaire 
provides an opportunity to explore their understanding of the material developed.  The 
face and content validity of the questionnaire can therefore be checked in this way.  
Sofaer et al. note that consultation with members of the public provides an opportunity 
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to elicit the ‘commonplace’ and ‘lay’ language used to describe the questionnaire’s 
material.  The questionnaire content can subsequently be refined to reflect patient 
terminology and expression399.   Involving patients or members of the public in the 
design of a questionnaire (which will subsequently be used in a behaviour change 
intervention) also enables incorporation of NICE guidelines, which advise a partnership 
with individuals from the target population to take account of lay wisdom405.  
To determine the content of a questionnaire to identify barriers to medication 
adherence, due consideration must be given to relevant literature.  As described in 
chapter one, the existing body of quantitative and qualitative literature regarding 
medication non-adherence is vast.  There is however, no recent synthesis of this 
information in order to elucidate the barriers to medication adherence.   
In chapter one, non-adherence to medication for both acute and chronic conditions 
were considered and differences explored; this identified that the implications of non-
adherence in acute conditions is likely to be less profound.  The management of long 
term conditions is a UK priority due to its rising prevalence, negative health and social 
implications plus its significant impact on NHS and social care resources406.  It is 
therefore most appropriate to focus an ‘adherence barriers identification’ questionnaire 
towards patients prescribed medicines for the management of chronic conditions.  
However, Gellad et al. report that the circumstances surrounding non-adherence to 
medication for the treatment of addiction and mental health problems is often condition 
specific407; exclusion of these two conditions is therefore warranted.  
When questionnaire development is supplemented with qualitative work involving 
patients or members of the public, it is advisable to ensure a good coverage of people 
from differing backgrounds, to gain a diversity of perspectives on the material 
covered408.  For medication adherence barriers, socio-demographic factors such as 
age may be influential, especially with regard to ‘costs of medicines’ as all patients in 
England over the age of 60 years are exempt from prescription fees.  Inclusion of 
participants with differing medication regimen complexities and differing levels of health 
literacy would also be advisable as these parameters could influence perceptions of 
medication adherence barriers and comprehension of the questionnaire’s content.  Age 
and regimen complexity can be identified with relative ease by means of a simple 
questionnaire, but identification of varying levels of health literacy requires more 
consideration.  Whilst a wealth of detailed health literacy screening tools are available, 
many of these tools such as the TOFHLA tool409 and even its shortened version S-
TOFHLA410 are relatively complex and lengthy.  The Single Item Literacy Screener 
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(SILS)411 tool is less complex and consists of a single statement, relating to how 
frequently the participant needs assistance in reading health related materials, to which 
participants respond using a five-point Likert scale ranging from always to never.   
5.1.2.2  Assessing patient attitudes  
There are several approaches to measuring a respondent’s attitude, each with 
advantages and disadvantages.   
Dichotomous responses 
Attitudinal statements should be designed so that participants can express their 
agreement or disagreement.  The simplest attitudinal measure is therefore to offer a 
dichotomous response option of these choices.  This approach offers simplicity and 
brevity, both for the respondent completing the questionnaire and researcher scoring it.  
However, such brief data provides limited detail.  Oppenheim comments that attitudes 
have both intensity as well as content and that intensity is an important moderator of 
attitude function150.  A dichotomous response option does therefore not elicit a patient’s 
strength or intensity of agreement or disagreement with a statement.  
Continuous and ordinal type responses 
In order to establish the intensity with which a patient agrees or disagrees with a 
questionnaire statement, ordinal or continuous measurements are necessary.  Ordinal 
attitudinal scales such as Likert scales serve to roughly divide people into a number of 
broad groups with respect to a particular attitude.  They must be uni-dimensional, 
reliable, valid, linear and reproducible150.   
a) Visual analogue scales (VAS) 
Visual analogue scales provide a continuous measure of attitudinal agreement, from 
which parametric statistical analysis can be undertaken.  A VAS is a straight line, 
usually 10cm in length, with anchor points at each end labelling extreme boundaries of 
a sensation, feeling, attitude or response412.  For attitudinal statements, the anchor 
points will likely be ‘strongly disagree’ and ‘strongly agree’.  Participants are asked to 
express their level of agreement with a statement by placing a mark along a 10cm 
which best reflects how they feel413 This approach is of greatest value when assessing 
change within an individual, but less use in comparing a group of individuals at one 
time point414.  Whilst elicitation of continuous data offer benefits for statistical analyses, 
the process of measuring where each mark has been placed is time consuming and in 
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clinical practice, this approach is therefore rarely permissive415.  Problems with the 
validity and test-retest of this approach have also been reported412.   
b) Likert scales  
Likert scaling is a frequently adopted attitude measuring technique requiring 
participants to indicate their level of agreement on a symmetric agree-disagree scale 
for a series of statements150.  Of all the attitude measuring techniques, Likert scales are 
the most popular150 and have been shown to have the best correlations with actual 
behaviour of the various attitude measurement techniques416.  Likert scales use fixed 
choice response formats measuring attitude on an ordinal scale, for example, ranging 
from strongly agree to strongly disagree.  These scales may or may not include a mid-
point representing lack of an opinion, or ambivalence.  The mid-point may be 
interpreted as the ‘typical’ response and thus be used by respondents  as a reference 
for their own position417.  Absence of a mid-point may lead to participants selecting a 
choice which does not reflect their own attitude and thus produce erroneous data418 419.    
5.1.2.3  Questionnaire presentation and length 
Oppenheim’s seminal text highlights the importance of good questionnaire design and 
layout150, though McColl notes that there is little empirical evidence to guide the 
presentation of a questionnaire141.  There is however evidence to highlight that small 
errors in design can have notable implications, for example, boxes that were out of line 
with their responses were found to be confusing for respondents and subsequently 
ignored, as were statements that were cramped together420.  
Key considerations for the presentation of the questionnaire therefore include: 
• Inclusion of white space, to ensure the questionnaire appears less confusing, 
intimidating and difficult419 as a cluttered questionnaire is known to elicit reduced 
response rates421 
• Avoidance of separating a statement over two pages as this is more likely to 
increase the cognitive burden for completion422, 423  
• Using a minimum of a 10-point font141 in the general population, or 12-point for 
respondents of an older age424 
• Use of an easily read typeface with a distinct separation between characters141  
• Ensuring consistency in presentation425 and an eye catching design to arouse 
interest419  
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Widespread literature offering guidelines for wording of questionnaires are available.  
Key considerations for the formation of questionnaire statements include: 
• The avoidance of jargon, leading questions and ambiguity/multiple meanings141, 150, 
413, 422, 423, 426
 
• The avoidance of double negatives and double-barrelled statements427 
• The use of a conversational tone to facilitate rapport building with respondents424 
• Minimising the cognitive burden associated with questionnaire completion425  
• Using a mixture of both positively and negatively phrased statements to minimise 
the risk of acquiescent response bias in the questionnaire, whereby respondents 
have a tendency towards responding to each statement in a similar way428  
• Giving due consideration to social desirability bias and therefore phrasing 
statements in an open and non-judgemental manner150  
Further to considering the phrasing of the questionnaire statements, it is also pertinent 
to consider readability of the overall questionnaire.  Williams reports that the average 
reading age in the UK is 12 years75, therefore the questionnaire statements and 
instructions for completion must be comprehendible at this reading level to ensure 
respondent acceptability and accuracy of responses.  It is also recommended that 
questionnaires should be comprehendible to respondents at the lowest end of 
educational backgrounds in the target population, not the average422.  For all 
questionnaire components, a reading age of 12 must therefore be an absolute 
maximum.  The Flesch formula, a commonly used metric to assess readability, can be 
applied to the questionnaire to determine the reading age necessary to permit 
comprehension, as recommended in literature424. 
With regard to questionnaire length, brevity is pertinent as excessively lengthy 
questionnaires are likely to yield lower completion rates.  However questionnaires must 
not be so brief as to not elicit sufficient information.  A balance between sufficient 
brevity to facilitate response and sufficient detail to enable data analysis and 
psychometric testing is therefore advised150. 
5.1.2.4  Psychometric properties 
The psychometric properties of a questionnaire are those which describe how well the 
questionnaire performs, in terms of consistency, reliability and validity.  Establishing 
such parameters is essential to documenting the suitability and scientific worth of a 
questionnaire.  The process entails administering the questionnaire to a cohort of 
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patients that reflects the population for which it is intended and then analysing the 
questionnaire response data according to different parameters. 
For the IMAB-Q, this chapter concerns the development of the tool and not its 
validation.  Questionnaire validation is a time consuming and complex process which 
will therefore be undertaken as a separate study.  Whilst this thesis chapter does 
therefore not concern questionnaire validation directly, it is pertinent to design the 
questionnaire in a way that will facilitate later psychometric testing. 
Internal consistency 
Internal consistency estimates the extent to which items within a scale assess a single 
construct and is assessed using Cronbach’s alpha which gives a score of between 0 
and 1.  A score of 0 indicates no consistency whereas a score of 1 can be considered 
to mean the items are practically identical150.  For a theory based questionnaire, 
internal consistency is important to check that similar statements assess the same 
construct.  In designing a questionnaire it is therefore pertinent to ensure there are 
sufficient statements for each construct and that there is overlap between statements.  
Test-retest reliability 
This parameter concerns the likelihood of a questionnaire yielding the same result 
when repeated, for example two weeks after the first completion150.  Whilst this 
important metric must be considered in validation stages, at the developmental stage, 
there are no factors to consider from this regard. 
Validity 
Validity, concerns the process of ensuring the questionnaire actually measures what it 
claims to.  Oppenheim describes three main types of validity150: 
1) Content validity 
Concerns: 
a. Face validity, achieved through discussion of questionnaire content and 
phrasing with representatives from the target population 
b. Content validity, achieved by consultation with experts in the field to 
ensure the questionnaire items are comprehensive and representative 
of the construct under consideration 
2) Criterion validity concerns the comparison of the questionnaire to one or more 
external variables believed to measure the attribute under question  
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3) Construct validity concerns how well the statements measure the theoretical 
constructs that they are assumed to measure and involves looking at patterns 
of divergence and convergence using factor analysis 
As described earlier, face and content validity can be determined through consultation 
with patients and/or members of the public.  Criterion validity can be established via 
comparison to a gold-standard measure of the same construct measured in the new 
questionnaire.  However, where such a measure is non-existent , criterion validity can 
be judged on the basis of relationships between the questionnaire and other relevant 
constructs150.  A good example of the process of establishing criterion validity in such 
cases is the work of Horne et al. in the development of the Satisfaction with Information 
about Medicines Scale (SIMS)127.  As there were no comparative validated tools to 
assess adherence, Horne and colleagues hypothesised that greater satisfaction would 
impart lower concerns and better adherence.  The Beliefs about Medicines 
Questionnaire (BMQ)38 and Medication Adherence rating Scale (MARS)147 tools were 
therefore added to provide data on medication concerns and adherence respectively.  
The hypothesis about the relationship between these three constructs was then 
assessed with a Pearson correlation co-efficient.   For construct validity, confirmatory 
factor analysis is a commonly used approach to determine how well the questionnaire 
statements fit a theoretical model.  At the developmental stage the key consideration is 
to ensure sufficient data for later testing; due consideration should therefore be given to 
the questionnaire length and number of statements.  
To ensure that psychometric testing of a questionnaire can be undertaken with optimal 
effect, minimising likely confounding factors is imperative.  Due attention to potential 
moderators of medication adherence barriers must therefore be given.  Beyond the 
differentiation between acute and chronic conditions, consideration of the differences 
between symptomatic and asymptomatic conditions is advisable (as detailed in chapter 
one).  Non-adherence to asymptomatic conditions such as hypertension and 
hyperlipidaemia is known to be particularly problematic and is frequently intentional in 
nature429.  Cardiovascular preventative medicines are amongst those most commonly 
prescribed in the UK430 and non-adherence in often poor.  A recent meta-analysis of 
over 376,000 patients taking cardiovascular preventative medications, reported a 
summary adherence estimate (95% CI) of 57% (50-64%) after  a median of 24 
months431 post diagnosis.  Restriction to patients taking medicines for the prevention of 
cardiovascular disease may therefore be appropriate to minimise confounding factors 
in the psychometric analysis of the questionnaire.  This affords the additional benefits 
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of the potential for using clinical outcome measures (blood pressure and blood 
cholesterol levels) in subsequent studies.  
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5.2  Methods 
Figure 5.1 summarises the multi-stage method for developing the ‘Identification of 
Medication Adherence Barriers Questionnaire’ (IMAB-Q).   
                            Process                              People involved
                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Summary of method for developing IMAB-Q 
Literature search of medication adherence barriers 
to generate initial ‘barriers list’ Primary researcher 
‘Consultation exercise’ with members of the public 
who are prescribed medication for the prevention of 
cardiovascular disease to expand initial ‘barriers 
statements list’ and establish face and content 
validity of adherence barriers statements 
Primary researcher and 
members of the public 
Refinement of ‘barriers statements list’ and 
selection of ‘top 3’ barrier statements for each 
behavioural domain according to recommendations 
from public consultation exercise to generate a 
prototype questionnaire 
Panel of researchers with an 
interest in behaviour change 
theory and interventions 
Generation of adherence barriers statements to 
assess barriers identified from literature search and 
mapping of statements to behavioural domains of 
theoretical frameworks 
HCPs with experience of 
supporting adherence and 
academics with an interest 
in medication adherence  
Final refinements of ‘prototype questionnaire’ to 
incorporate suggested modifications 
Panel of researchers with an 
interest in behaviour change 
theory and interventions 
Panel of researchers with an 
interest in behaviour change 
theory and interventions  
Dissemination of ‘prototype questionnaire’ to 
healthcare professionals (HCPs) and academics for 
feedback and suggested refinements 
Refinements incorporated to produce second 
prototype questionnaire 
Panel of researchers with an 
interest in behaviour change 
theory and interventions 
Second prototype questionnaire disseminated back 
consultation exercise participants to re-check face 
and content validity and gain feedback/comments 
Primary researcher and 
members of the public 
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5.2.1  Literature search of barriers to medication adherence 
Table 5.1 shows the literature search strategy applied to The Embase, Medline and 
PsycINFO databases via the Ovid interface on the 18th of September 2012.  Abstracts 
relating to barriers to medication adherence in chronic conditions were selected for 
retrieval to elicit barriers.  
Terms relating to ‘medication’ and ‘non-adherence’ were searched in both the titles and 
abstracts fields to ensure a good coverage of potential material.  Terms relating to 
‘barriers’ were restricted to the title search field only, as scoping searches identified 
that inclusion of these synonyms in the abstract field generated an excess of irrelevant 
papers.  Scoping searches also revealed a number of key terms which yielded 
irrelevant papers and were subsequently stipulated in the search terms using the NOT 
operator, as detailed in table 5.1.  The search was also restricted to abstracts written in 
the English language and a date restriction of 2005 to present was applied to ensure 
the most relevant material was selected.  Prior to 2005, medication adherence 
research had focussed more heavily on compliance and thus the reasons for 
intentional non-adherence were little explored. 
Table 5.1 Search terms applied to electronic databases to identify barriers to 
medication adherence  
Despite the search term restrictions, a large number of irrelevant abstracts were 
sourced.  Abstract titles were therefore screened to remove duplicates and those that 
were obviously irrelevant.  The remaining abstracts were screened in depth against the 
inclusion and exclusion criteria, using a bespoke abstract screening tool.  Abstracts 
were eligible for inclusion if they: 
• Reported barriers to medication adherence 
• Concerned adherence to medication used to treat chronic conditions 
 
 Search terms 
1 Medication*.ti,ab OR Drug*.ti,ab OR Medicine*.ti,ab 
2 Adheren*.ti,ab OR Complian*.ti,ab OR Concordan*.ti,ab OR Non-adheren*.ti,ab OR 
Non-complian*.ti,ab 
3 Barrier*.ti OR Difficult*.ti OR Problem*.ti OR Reason*.ti (NOT Tissue.ti, NOT 
epithelial.ti, NOT cream*.ti, NOT skin.ti, NOT platelet.ti, NOT guideline*.ti) 
4 1 AND 2 AND 3 
5 4 NOT letter, NOT editorial, NOT comment 
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Abstracts were excluded if they: 
• Did not specifically focus on identification of barriers to medication adherence 
• Did not consider medication for the treatment of long-term chronic conditions 
• Concerned medication for the treatment of addiction or psychiatric problems 
• Included participants known to be abusing non-prescription drugs, suffering with 
addiction or suffering with mental health problems 
• Described a study which focused on the prevalence or further exploration of a 
specific barrier to medication adherence, for example cost or stigma 
• Described a research protocol with no data yet available or a conference abstract 
without full data 
As with the systematic review and meta-analysis reported in chapter four, studies 
reporting treatments for addiction or mental health problems were excluded as the 
nature of non-adherence is known to be condition specific. 
Studies concerning a specific barrier were excluded as in depth data regarding a 
specific barrier and its prevalence in a specified population was not necessary for this 
study.  Abstracts remaining after full screening were used to elicit barriers to 
medication adherence.  Full texts were accessed where possible, but in instances 
where full texts were not available, barriers to adherence listed in the abstract were still 
extracted.  Whilst it is not common practice to extract data from abstracts alone, for the 
purpose of this literature review, such practice was not deemed to be a notable 
limitation.  The aim of the literature review was simply to identify studies which report 
barriers to medication adherence, and extract the main barriers identified in these 
studies; details provided in the abstract were sufficient to meet this objective.  
The following data were extracted: 
• Authors 
• Date of publication 
• Journal of publication  
• Publication type – conference abstract or journal article 
• Disease state studied (medication type taken) 
• Population studied 
• Method of establishing barriers to adherence 
• Barriers to adherence 
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Adherence barriers were initially extracted using the exact terminology described in the 
article.  Once all barriers had been extracted, similar barriers were grouped into themes 
to generate a single cohesive list. 
5.2.2  Generation of adherence barrier statements and mapping to TDF 
For each adherence barrier identified, potential adherence barrier statements were 
generated and mapped to the one of the twelve domains of the original TDF275.  Whilst 
the updated TDF276 was acknowledged, a notable amount of work for this project had 
already been undertaken by the time the TDF update was published.  A collaborative 
decision to retain the original TDF was therefore made, however, following mapping 
with the original TDF, the updated TDF was considered to observe whether the 
updated version would have altered any decisions. 
The principle investigator (CE) was responsible for the initial mapping of each 
adherence barrier to a theoretical domain and the generation of potential adherence 
barrier statements.  The mapping and barrier statement generation process were 
undertaken in parallel as the phrasing of the adherence barrier statement was 
sometimes pertinent to the behavioural domain to which it was mapped.  Adherence 
barrier statements were phrased to reflect the context of the original extracted barriers 
and in a non-confrontational, unambiguous way.  The original literature was frequently 
referred to and research questions borne in mind throughout to ensure the adherence 
barriers statements remained relevant, as recommended in literature150, 427.   
The adherence barrier statements generated and behavioural domains to which these 
were initially mapped, were discussed over two telephone conferences between CE, 
NT and DB.  Interpretation of the meanings of the theoretical domains was discussed 
extensively to achieve group consensus as to which theoretical domain each 
adherence barrier statement would be mapped.  Discussion also enabled consensus 
as to the phrasing of each adherence barrier statement.  
5.2.3  Consultation exercises with members of the public 
Focus group style consultation exercises were undertaken   
5.2.3.1  Aims 
1) To assess the face and content validity of the generated adherence statements  
2) To identify any additional barriers to medication adherence that were not elicited in 
the literature search 
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3) To assess members of the public’s perspectives on which adherence barriers are 
most pertinent in each behavioural domain  
5.2.3.2  Inclusion criteria 
Eligible for inclusion were members of the public who were: 
• Aged 18 years or over and able to provide informed consent 
• Taking medication for the prevention of cardiovascular disease, which included, 
seven drug classes as recently defined in the literature431: 
o aspirin 
o angiotensin-converting enzyme inhibitors 
o angiotensin receptor blockers 
o beta-blockers 
o calcium-channel blockers 
o thiazides 
o statins 
5.2.3.3  Exclusion criteria 
Excluded from participation in the consultation exercises were members of the public 
who were: 
• Receiving medication for the treatment of addiction or mental illness 
• Unable to read or speak English 
The previously documented rationale for exclusion of patients suffering with mental 
health or addiction problems was also applied here.  
5.2.3.4  Participant recruitment 
Ethical approval from the University’s Faculty of Health (FoH) ethics committee was 
secured before recruitment commenced.  Correspondence confirming ethical approval 
for the study can be found in appendix 5.1.  Purposive sampling was undertaken to 
ensure a wide range of demographic characteristics were covered by the consultation 
exercise participants.  Participants were recruited from the large pool of employees and 
students at the University of East Anglia (UEA).   
Figure 5.2 summarises the participant recruitment process for the consultation 
exercises.  Posters ‘advertising’ the study and asking for volunteers were placed 
across the university campus, in prominent places such as coffee shops and social 
areas.  Electronic ‘advertisement’ of the study also occurred via a weekly bulletin which 
Chapter Five                                                       The IMAB-Q; developmental processes 
 
 
219 
is e-mailed to all staff and students.  The study was advertised in the e-bulletin on two 
separate occasions separated by a four week interval to optimise recruitment.  The 
study was also advertised on the university’s social media sites such as ‘Facebook’ 
and ‘Twitter’. 
 
 
 
                   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Consultation exercise recruitment process 
The study ‘advertisements’ offered a brief synopsis of the study and described the 
types of participants needed.  An example poster is shown in appendix 5.2.  The 
‘advertisements’ were carefully phrased to state ‘would you or anybody you know like 
to participate in a study’.  This wording extended the potential recruitment beyond UEA 
students and staff to include their friends and family and vastly extended the 
recruitment pool to an even wider, more diverse population.  The advertisement asked 
Study ‘advertised’ across university campus via posters, e-mail and digital media 
Member of public contacts PI at UEA either by telephone, e-mail or in writing and registers 
interest in study.  PI takes contact details and offers to send information pack either via 
internal mail (if UEA based) or first class post 
No further action taken 
Member of public reads information leaflet and decides whether to participate in the study 
Member of the public contacted 
to thank them for interest and 
reason for not including explained 
PI at UEA logs receipt of consent form 
and results from brief survey including 
participation preferences for focus group 
attendance dates 
* for example if a patient aged over 60 returns a 
consent form and brief questionnaire and the 
majority of patients already recruited also fall into 
this demographic, the patient will not be recruited 
Member of public decides not to 
participate and does not return 
brief survey and consent form 
Member of public decides to 
participate and returns brief survey 
and consent form to PI at UEA 
Participant suitable 
for focus group 
Participant NOT suitable 
for focus group* 
PI at UEA contacts member of public to 
thank them for their interest in the study 
and to arrange a date for the focus group 
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members of the public to contact the lead researcher (CE) if they would like more 
information about participation. 
Members of the public making contact with the lead researcher were sent an 
information pack containing: 
• A participant information leaflet – to explain the study 
• A consent form – to complete and return to UEA if they wished to participate 
• A brief survey to elicit demographic information and focus group preference 
information - to be completed and returned to UEA if they wished to participate 
• A pre-paid envelope – for returning the consent form and brief survey. 
The information leaflet, consent form and ‘brief survey’ are shown in appendices 5.3, 
5.4 and 5.5 respectively.  Members of the public wishing to participate were advised to 
complete the consent form and brief survey and then return these to the lead 
researcher at the UEA using the pre-paid envelope provided, or UEA internal mail.  
Upon receipt of a consent form and brief survey CE recorded this information and used 
this to assign participants to one of two potential focus groups (on differing dates and 
times).  The recruitment process continued until each focus group had between six and 
eight participants meeting the required inclusion criteria.  Each focus group aimed to 
include: 
• Participants of varying ages 
• Both males and females 
• Participants with low, average and high literacy levels 
• Participants who were exempt from prescription charges and those who paid 
• Participants with varying numbers of regularly prescribed medicines 
5.2.3.5  Participant information packs 
The information packs contained documents as shown in appendices 5.3, 5.4 and 5.5.   
The brief survey (as shown in appendix 5.5) was used to elicit: 
• basic demographic information from participants (age and gender) 
• the number of regularly prescribed medicines taken 
• whether or not the participant paid for their prescription 
• basic literacy levels 
• focus group attendance preferences  
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The inclusion of each section of the survey was explained to participants in the 
information leaflet so that the rationale behind the questions was understood.   It was 
hoped that this transparency would encourage honest answers and an increased 
response rate, plus allay any concerns that the participants may have about completing 
the survey or any confusion experienced as to why the questions are being asked.  
5.2.3.6  Consultation exercises 
Each consultation exercise was moderated by CE with co-facilitation from either DB or 
an additional research colleague, with experience of focus group moderation.  The co-
facilitator was responsible for ensuring the focus groups ran to time and that all audio 
equipment was working correctly.  They also made field notes during the sessions to 
record information (such as gestures and group interactions) that were not recorded by 
the audio equipment.  Two focus groups were planned, to take place at the UEA as this 
is the base from which participants were recruited and was thus likely to be a 
convenient venue.  Times and days were varied to give participants the option of 
attending at a time that was preferable to them. 
Each consultation exercise lasted approximately two hours, with time allocated for a 
break midway.  The sessions followed a structured format, whereby the adherence 
barriers statements for each behavioural domain were presented to the participants in 
turn.  The first behavioural domain and barriers mapped to this was explained by the 
moderator and then each statement associated with this behavioural domain was 
visually presented to the participants one-by-one.  For each statement the moderator 
asked the following of participants: 
• Whether they understood the statement and what it meant to them 
• Whether they thought the statement represented a legitimate barrier to medication 
adherence and how important they thought this barrier was 
• Whether they would have changed the statement in any way to make it clearer, 
easier to understand, or more representative of the adherence barrier 
After presentation of all of the barrier statements in one domain, participants were 
asked if they thought there were any additional barriers in the domain which were not 
represented.  Participants were also asked to give an indication of which three 
adherence barrier statements in the list were the most important.  Restriction to the 
three most pertinent barriers in each behavioural domain was made to generate a pool 
of statements sufficient in length to enable later psychometric testing and a 
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questionnaire that was comprehensive yet not excessively long. The next behavioural 
domain was then introduced and the above process repeated.  
Due to the volume of material, it was not feasible to cover all of the behavioural 
domains in a two hour session and extension of the session beyond two hours was 
neither feasible nor advisable401, 432.  The two sessions undertaken therefore 
considered barriers from differing behavioural domains.  One behavioural domain was 
covered by both groups to enable an assessment of how comparable the findings of 
each group were. 
5.2.3.7  Data analysis 
Primary analysis of the data was undertaken by CE and validated by DB as 
recommended in literature433.  Transcription of the focus groups audio data was 
undertaken by CE.  Data were analysed purely for the purpose of refining the 
adherence barriers statements in light of participants’ perceptions and understandings, 
using a framework analysis approach434.   
5.2.4 Refinement of adherence barrier statements and generation of 
prototype questionnaire 
Each of the behavioural domains were considered in turn using a mind map approach 
to summarise the material necessary to inform decision making, into one cohesive 
document.  These mind maps were informed by the transcripts from the participant 
consultation exercises and summarised: 
• The definition of the domain from the updated TDF 
• The definition developed by the research team for relation to medication adherence 
• The barriers originally mapped to the behavioural domain 
• The new barriers discussed during the consultation exercise 
• Barriers moved to (or retained in) a different behavioural domain 
• Barriers selected as most important 
• Behaviour Change Techniques (BCTs) that would be used to address barriers from 
this domain295 
Consideration to which BCT would be utilised (as described in chapter four) assisted 
the process by adding another dimension to the decision making strategy.  
Data from the participant consultation exercises were used to refine the adherence 
barrier statements according to the participant’s understanding of their meaning and 
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relevance.  Any additional barriers generated during the consultation exercises were 
also considered.  The same panel of researchers as used in the earlier stages of the 
questionnaires development (CE, NT and DB) were also used for this phase of the 
questionnaire development. 
Participants’ comments were used to influence selection of three statements from each 
behavioural domain for the questionnaire.  The selected statements were combined to 
generate a prototype questionnaire.  Instructions for completion of the questionnaire 
were written in clear and non-judgemental way to encourage honest responses.  
5.2.5  Dissemination of prototype questionnaire for feedback  
The prototype questionnaire was presented to a pre-selected panel of academic 
researchers with an interest in medication adherence research, for feedback and 
suggested amendments.  Research colleagues, naïve to the TDF and adherence 
barrier mapping processes, were emailed the questionnaire prior to a research group 
presentation.  Comments were collated by CE prior to delivery of a thirty minute 
presentation about the questionnaire’s construction and its theoretical components.   
A panel of healthcare providers including a GP, pharmacist and domiciliary medicine 
support technician also received the prototype questionnaire and were asked to 
provide suggestions for amendments based on their experience of consulting with 
patients with adherence difficulties.  A second prototype questionnaire was generated 
from this feedback process. 
5.2.6  Second consultation exercise with members of the public 
The second prototype questionnaire was sent to the consultation exercise participants 
used earlier in the questionnaire’s development.  The face and content validity of the 
prototype questionnaire was established by asking participants whether they 
understood each statement and whether it accurately reflected a barrier to medication 
adherence.  All participant comments were collated, reviewed and incorporated as 
necessary to generate a final IMAB-Q.  
5.2.7  Readability testing of IMAB-Q 
The Flesch-Kincaid readability test was applied to all sections of the completed IMAB-
Q to indicate comprehension difficulty.  The Flesch-Kincaid Grade Level was calculated 
using the following formula: 
0.39 (total words/total sentences) + 11.8 (total syllables/total words) – 15.59 
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The resulting number corresponds with a US educational grade, for example a score of 
7.1 would indicate that the material was suitable for comprehension by an average 
student in the 7th grade of the US education system.  The US and UK educational 
system are equivalent in so much as 7th grade is equivalent to year 7 in UK high 
school.  A Flesch-Kincaid score of 7.1 therefore means the material should be 
comprehendible to an average 11-12 year old in year 7 of UK high schools.  
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5.3  Results 
5.3.1  Literature search to identify barriers to medication adherence 
Figure 5.3 details the flow of studies from screening to inclusion.  The literature search 
identified 515 abstracts; 323 of these (62.7%) were excluded after two rounds of brief 
screening to remove clearly irrelevant titles and duplicates.  Of the remaining 192 
articles, the main reasons for exclusion were articles not relating to identifying barriers 
to adherence or focussing on specific adherence barriers.  These specific barriers 
included social stigmas, spiritual beliefs and medication costs.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Flow diagram for selection of studies from database search  
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A summary of the 47 studies included in the review is provided in appendix 5.6.  Full 
texts articles were available for 32 studies (68.1%); for the remaining 15 studies 
(31.9%), adherence barriers were extracted from the abstract alone.  Medication 
adherence was considered in 11 diseases; HIV was the most frequently considered 
disease, accounting for 14 (29.8%) studies.  Seven (14.9%) studies considered 
adherence to medicines for ‘chronic conditions’ and there were six studies (12.8%) 
each for hypertension and immunosuppressive therapy.   Diabetes and cardiovascular 
disease, each accounted for three (6.3%) studies and inflammatory bowel disease, 
cystic fibrosis and glaucoma were each considered in two (4.3%) studies.  Individual 
studies considered adherence to medication in dermatology and asthma.  
Studies tended to consider adherence barriers in adult populations and this was the 
case for 32 (68.1%) studies; seven studies (14.9%) focussed on adolescents, five 
studies (10.6%) concerned paediatrics and three (6.2%) studies considered adherence 
in older patients.  Participants were primarily from the USA (44.7%); four studies (8.5%) 
used patients based in India and two studies (4.3%) used UK based patients.  The 
remaining studies involved patients from across the globe including Europe, Australia, 
Africa and Arabic nations.  
Adherence barriers were most commonly elicited via questionnaires or surveys, 15 
(31.9%) studies used patient questionnaires, two (4.3%) used patients and caregivers 
questionnaires and three (6.3%) studies used telephone surveys.  Adherence barriers 
were also elicited via patient interviews in five (10.6%) studies, focus groups in four 
(8.5%) studies, systematic reviews in four (8.5%) studies and semi-structured 
interviews in three (6.4%) studies.  
Table 5.2 summarises the adherence barriers extracted from the literature review, with 
grouping of similar barriers.  The most frequently reported barrier was ‘forgetting to 
take medicines or collect prescriptions’ which was reported in 29 (61.7%) studies.  
Other frequently reported barriers included ‘poor understanding of the disease regimen 
or instructions’ and ‘the cost of medication’ which were each reported in 18 (38.3%) 
studies.  ‘Difficulties incorporating medicine taking into daily routines’ and ‘feeling 
negative emotions’ were each reported in 13 (27.7%) studies and 11 (23.4%) studies 
each reported ‘complex or confusing regimens’, ‘experience of side effects’, ‘difficulties 
getting to the pharmacy’ and ‘being too busy to take medicines’. 
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Adherence barrier 
grouping (total 
number of citations) 
Themes included in barrier grouping 
Denial of conditions 
existence or need for 
treatment (7) 
Denying illness existence or denying having illness/inability to 
accept diagnosis11, 27, 33 
Not thinking there is a need for the medication12, 18, 26, 48 
Communication 
barriers (4) 
Speaking different language to HCP11 
Poor health literacy19 
Poor or complex medication instructions45 
Communication problems with pharmacy9 
Drug and alcohol use 
(3) 
Alcohol use11 
Concomitant substance abuse17, 33 
Changes to usual 
routine (19) 
Being away from home/travelling 6, 11, 21, 24, 29, 33, 36, 39, 41, 47 
Disruptions to daily routine/chaotic lifestyle6, 10, 15, 17, 25, 32, 33, 36, 42 
Treatment related 
factors (6) 
Feeling better without treatment11, 33 
Decreased QOL/feeling worse with treatment33 
Stopping medicines when feeling better6, 22 
Stopping medicines as thought ineffective22 
Healthcare provider 
related factors (5) 
Poor relationship with healthcare provider2, 19, 25, 46 
Lack of trust in healthcare provider33 
Regimen related 
factors (10) 
Regimen too complex/ confusing17, 33 
Polypharmacy15, 19, 23 
Frequency of dosing10, 33 
Heavy pill burden/ too many treatments4, 10, 13 
Changes to regimen or dose8, 17, 21 
Side effects of 
medicines (14) 
Side effects (real or anticipated)6, 10, 17, 22, 33, 35, 38, 40, 43, 47, 48 
Perceived side effects of treatment11 
ADRs19, 45 
Social factors (22) Fear of stigma or discrimination4, 11, 17, 20, 25, 37, 35 
Fear of disclosure of illness17, 33 
Lack of social support/ support from friends & family/ living 
alone2, 7, 17, 30, 33, 44 
Negative publicity associated with medicines taking33 
Unwilling to take medicines in public5 
Social norms e.g. family rituals or social obligations25 
Concerns about image/perceptions of others/ bullying20  
Feeling embarrassed by taking medicines13, 39 
Medicine 
administration 
problems (11) 
Problems taking meds at specific times41 
Problems taking more than one medicine at the same time41 
Taste and/or size of medicines6, 33, 42 
Difficult characteristics of medicines27  
Difficulty administering medicines – practical problems31, 43 
Problems swallowing medicines or keeping them down6, 24 
Problems accessing medicines12 
Patient preference 
for alternatives (2) 
Choosing traditional or herbal remedies instead of prescribed 
medication 2, 11 
Patient confidence 
(5) 
Doubting ability to adhere/ low self-worth33 
Not emotionally ready for taking meds17 
Self-blame of condition17 
Table 5.2 Preliminary grouping of adherence barriers extracted from 
literature 
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Table 5.2 (continued) Preliminary grouping of adherence barriers extracted 
from literature 
 
 
Adherence barrier 
grouping (total 
number of citations) 
Themes included in barrier grouping 
Practical barriers (56) Long waiting times at the clinic or pharmacy11, 28  
Running out of medicines17, 29, 32, 41, 45-46 
No time to obtain repeat prescription33 
Problems getting the medicines form the pharmacy e.g. 
medicine not available, problem getting a repeat, opening times 
6, 8, 9, 12, 22, 33, 37 
Transport difficulties for getting to clinics and appointments or 
pharmacy or being unable to get there4, 9, 22, 33, 25, 28, 36, 40, 46 
Logistical problems in accessing medicines18, 19 
Financial constraints/ cost of medicines4, 10, 12, 14, 18, 25-26, 28, 30, 33, 
36-38 43, 45-46 48,  
No medical insurance/ insurance does not cover medicine22, 26, 
46, 48 
Homelessness/concurrent illness33 
Poor nutrition/ lack of access to food4, 16, 35, 40  
No healthcare provider48 
Being away from medicine at time dose3, 40 
Reading the labels on medicines37 
Losing medication13 
Knowledge related 
problems (19) 
Poor disease related knowledge7, 19 
Lack of knowledge or understanding/ being misinformed33, 35, 41, 
44, 46,  
Not understanding the implications of the disease17, 35 
Poor understanding of chronic nature of condition14 
Lack of understanding of medication benefit/ why prescribed4, 28 
Lack of information about disease and its treatment2 
Poor education31 
Poor counselling25 
Not understanding how to reconcile newly prescribed drugs or 
how to get repeats28 
Not understanding new directions/ how to take medicine7, 28  
Beliefs about 
medicines (12) 
Mistrust or beliefs2, 25, 41 
Suspicions about treatment33 
Not convinced of medicines efficacy33 
Uncertainty regarding long term effects33 
Medicines thought to be too harmful or toxic33 
Lack of belief in medicines12 
Concerns about safety of medicines/side effects14,18 
Influence of parents concerns about taking medicines44 
Fear of medicines adverse effects26 
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Table 5.2 (continued) Preliminary grouping of adherence barriers extracted 
from literature 
5.3.2 Mapping the adherence barriers to the behavioural domains of 
theTDF275 and generating the adherence barrier statements 
During the mapping process it was pertinent to fully establish how each of the 
behavioural domains in the TDF relates to medication adherence.  This process was 
undertaken collaboratively by the research team (CE, DB and NT) as part of the 
process of assigning barriers to the behavioural domains.  For many adherence 
Adherence 
barrier grouping 
(total number of 
citations) 
Themes included in barrier grouping 
Cognitive/memory 
related factors 
(32) 
Poor cognitive function, poor memory19, 45 
Problems recalling regimen12 
Not remembering to refill prescription21, 42 
Forgetfulness/failure to remember5, 6, 8, 10, 13, 15, 16, 18, 23, 24, 28, 29, 31-33, 36-
38 40-44, 47, 48 
Not emotionally ready for taking meds17 
Self-blame of condition17 
Patient related 
factors (22) 
Feeling low, depressed, angry, stressed, hopeless or overwhelmed 
6, 17, 27, 35, 33, 39, 44, 47  
Wanting to be free of taking medicines33 
Wanting to be ‘normal’13, 42 
Wanting to maintain control33 
Not wanting to listen to authority figures17 
Being tired of taking pills42 
Treatment being a reminder of illness33 
Unwanted changes to body image/ effects on appearance20, 33 
Feeling ready to die35 
Wanting to be with friends rather than take medicines5 
Lack of motivation31 
Low priority assigned to medicines taking44 
Refusal to take32 
Incompatibility of 
medicines taking 
with daily 
routine/lifestyle  
Inconvenient or difficult to incorporate medicines taking/dosing time 
inconvenient33, 43 
Lifestyle restriction from taking so many doses34 
Work, family or caregiving responsibilities33 
Too busy/distracted, lack of time5, 6, 8, 13, 17, 21, 22, 29, 33, 36, 39, 42 
Falling asleep and missing medicines dose time/sleeping through 
dose6, 29, 33 
Fasting for Ramadan15 
Perceived burden of extra planning27 
Too tired or unwell to take medicines6, 17, 42 
Interference with other activities24, 42 
Skipping meals39 
Scheduling medicines administration into daily routine7 
Forgetting to bring medicines away with them/ being away from 
medicines at dose time21, 42 
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barriers, such as experience of side effects, there were multiple behavioural domains to 
which the barrier could have been mapped.  Decisions were discussed extensively, 
with reference to guiding literature where possible290.  Using this collaborative 
approach, each of the behavioural domains of the TDF was considered as described in 
table 5.3.    
During the process of assigning barriers to the behavioural domains, it was noted that a 
number of barriers related to competing goals, such as being too busy, being unable to 
fit medicines taking into a daily routine and forgetting to take medicines when there is a 
change in routine.  An additional ‘goal conflicts’ behavioural domain was therefore 
created, as guided by relevant literature290.  In addition, the ‘social/professional role and 
identity’ domain plus the ‘nature of the behaviour’ domain were excluded as none of the 
adherence barriers identified in the literature search pertained to these behavioural 
domains.  As the entire study relates to the barriers to medication adherence, the 
behavioural regulation domain was also excluded. 
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Behavioural domain Definition with relation to medication adherence 
Knowledge All aspects of knowing how to take medicines correctly and how to 
obtain prescriptions, plus a knowledge and understanding of why 
the medicines have been prescribed and how they will work 
Skills The patient’s ability to take their medicines, including physical 
problems with administering medicines correctly and cognitive 
problems in understanding directions 
Memory, attention 
and decision 
processes 
All cognitive aspects of medication adherence e.g. remembering 
to take medicines and order prescriptions.  The ‘attention’ aspect 
includes becoming easily distracted 
Beliefs about 
capabilities 
The patient’s confidence in adhering to their regimen and 
perceived ability to take their medicines correctly.  Also relates to 
how easy or difficult the patient finds adherence and their 
confidence and ability to overcome problems and difficulties.   
Beliefs about 
consequences 
Patient’s beliefs about taking their medicines, specifically the 
consequences of taking (or not taking) their medicines, including 
denial of the existence of illness or need for medicines  
Motivation and 
goals 
The motivation expressed by a patient towards taking their 
medicines and how much of a priority this is to them 
Environmental 
context and 
resources 
Resource and material limitations which impede medication 
adherence; includes factors such as the cost of medications and 
access issues. 
Social influences Social factors or ‘other people’ that may influence the patient’s 
adherence behaviours; includes discrimination/being treated 
differently and availability of social support 
Emotion The emotional elements of taking medicines such as stress, 
anxiety and other negative emotions  
Social/professional 
role and identity 
The extent to which a patient sees their medication taking as part 
of their identity 
Behavioural 
regulation 
Facilitators and barriers to medication adherence 
Nature of the 
behaviours 
Past behaviours and whether the behaviour occurs as an 
automatic process 
Table 5.3 Behavioural domains of the TDF and their relation to medication 
adherence 
Table 5.4 summarises the preliminary mapping of the adherence barriers to the 
behavioural domains.  The number of barriers mapped to each behavioural domain 
ranged from two for the ‘knowledge’ domain to six for the ‘belief about consequences’ 
domain.  The spread of studies amongst each behavioural domain was relatively even, 
with the exemption of the ‘motivation and goals’ domain which only contained barriers 
from eight studies.  In comparison, the ‘environmental constraints’ domain contained 
barriers from 48 studies. 
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Behavioural domain Medication adherence barriers mapped to domain 
Knowledge Poor understanding of regimen/instructions or disease 
Not understanding how to obtain prescriptions 
Skills Practical difficulties in administering medicines (e.g. difficulties 
with dexterity or swallowing) 
Difficulty in understanding directions (language barriers, low 
health literacy, unable to read directions) 
Memory, attention &  
decision making  
processes 
Forgetting to take medicines or refill prescription 
Running out of medicines or losing medicines 
Being distracted  
Beliefs about  
capabilities  
 
Regimen too complex, confusing or frequent / too many medicines 
Experience of side effects 
Frequent changes to doses and/or regimen 
Doubting own ability to adhere 
Wanting to maintain control 
Beliefs about  
consequences  
 
Mistrust in medicines or lack of belief in their efficacy 
Fear that medicines will be harmful 
Not thinking there is a need for treatment/medication 
Denial of existence of illness or non-acceptance of diagnosis 
Stopping medicines when feeling better 
Thinking medication is not working 
Environmental  
context and  
resources 
 
Cost of medication 
Transport difficulties with getting to pharmacy or clinic  
Being away from home/travelling 
Problems with pharmacy e.g. not stocking medicines or closing 
too early, long waiting times 
Wanting to be ‘normal’ 
Family rituals or social obligations 
Emotions Feeling ‘negative emotions’ (low/depressed/angry/helpless/ 
tired/overwhelmed or stressed) 
Embarrassment of taking medicines  
Wanting to be free of taking medicines  
Treatment being a reminder of illness 
Goal conflicts Being too busy or distracted to take doses/ too busy to pick up 
repeat medication 
Difficulties incorporating medicines taking into daily routine (e.g. 
disruption of other activities or being away from meds at dose 
times, need to undertake other duties) 
Disruptions to daily routine/having a chaotic lifestyle 
Motivation and goals  
 
 
Lack of motivation/ low priority assigned to medication taking 
Too tired to take medicines 
Preference of traditional or herbal remedies 
Refusal to take medicines 
Burden of adhering to regimen 
Social influences  Lack of social support 
Fear of discrimination or social stigma, bullying, perceptions of 
other or disclosure of illness 
Embarrassment of taking medicines 
Poor relationship with or lack of trust in prescriber 
Table 5.4 Preliminary mapping of medication adherence barriers to TDF 
Difficulties with both side effects and complex regimens are ‘externalities’ that are not 
necessarily within the patient’s control.  However, as the focus of this work is on 
overcoming barriers, these factors were considered to be difficulties that patient’s 
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should (ideally) have the ability to address and overcome, for example through seeking 
help from their GP.  The adherence barriers ‘experience of side effects’ and ‘complex 
regimens’ were therefore included in the beliefs about capabilities behavioural domain. 
Some of the barriers extracted from the literature review, (for example self-blame for 
condition) were excluded as these were specific to the individual study and disease 
area (in this case HIV).  Other barriers such as no healthcare provider or no medical 
insurance were not included as they were not relevant in the UK.  Some adherence 
barriers such as feeling better without treatment, were considered to be better 
represented by more general barriers such as those contained within the beliefs about 
consequences domain. Extracted barriers that were not mapped onto the behavioural 
domains included: 
• Illicit substance or alcohol abuse  
• Feeling better without treatment/worse with treatment/ decreased QOL 
• Skipping meals 
• Self-blame for condition 
• Feeling ready to die 
• Influence of parents concerns about taking medicines 
• Not emotionally ready to take medicines  
• Poor nutrition or lack of access to food 
• Homelessness/ concurrent illness 
• Falling asleep and missing dose time 
• No healthcare provider 
• No medical insurance/ insurance does not cover medicine needed 
• Unwanted changes to body imagine/ effect of medication on appearance 
• Not wanting to listen to authority figures 
• Wanting to be out with friends rather than taking medicines  
Proposed adherence statements for each included adherence barrier are provided in 
appendix 5.7 and are re-visited in sections 5.3.5 and 5.3.6.    
5.3.3 Revisions to mapping of adherence barrier statements with 
consideration to the updated TDF276 
Having adapted the original TDF275 for relevance to medication adherence and mapped 
the adherence barrier statements to this, the mapping process was later reviewed in 
light of the recommended changes in the 2012 TDF update276.  The detailed definitions 
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provided by the updated TDF are compared to the definitions created for the 
application of the original TDF to medication adherence in appendix 5.8. 
The behavioural domain definitions using the original TDF closely mirrored the 
definitions provided by the updated version.  For the ‘knowledge’, ‘skills’, 
‘environmental context and resources’, ‘social influences’ and ‘emotions’ behavioural 
domains, a good match between the definitions from the updated TDF and the adopted 
definitions generated with the original TDF was observed.  Consequently, no changes 
were made to the mapping of adherence barriers for these behavioural domains 
The definition provided by the updated TDF for the ‘social/professional roles and 
identity’ behavioural domain added clarity to the meaning of the domain, but did not 
alter the group’s decision to exclude the domain.  In the updated TDF, the ‘beliefs 
about capabilities’ behavioural domain was divided into ‘beliefs about capabilities’ and 
‘optimism’, with ‘optimism’ added to reflect a general disposition rather than specific 
capabilities276.  Though the rationale for this distinction was acknowledged, the original 
TDF was maintained for this work, as it does not cover ‘general dispositions’ but 
instead concerns specific medication adherence barriers. The ‘beliefs about 
capabilities’ behavioural domain was also divided in the updated TDF to create ‘beliefs 
about capabilities’ and ‘reinforcement’. The newly created ‘reinforcement’ domain 
reflects constructs of associative learning; however, none of the identified adherence 
barriers were relevant to this domain.  The original TDF was therefore retained.  
The updated TDF also split the ‘motivation and goals’ behavioural domain into 
‘intentions’ and ‘goals’ to reflect a differentiation between an active decision to behave 
in a particular way (intention) and an end state viewed as a preferred option (goal).  As 
the majority of the adherence barrier statements mapped to the ‘motivation and goals’ 
behavioural domain specifically focussed on motivation, the original TDF was retained.   
For the ‘memory, attention and decision making processes’ domain, the definition 
provided by the updated TDF was comparable to the definition adopted by the research 
group, with the exception of the ‘decision making processes’ element which was not 
included as none of the identified adherence barriers concerning decision making 
processes fitted with this domain.  The updated TDF therefore provides a useful 
definition of this aspect, though no changes were necessary.  Interestingly, the 
‘behavioural regulation’ domain which was excluded by the research group when using 
the original TDF was also excluded from the updated TDF.  This infers further 
congruence between the two versions.  The research group still felt that an additional 
Chapter Five                                                       The IMAB-Q; developmental processes 
 
 
235 
domain of ‘goal conflicts’ was necessary as the updated TDF did still not cover this 
aspect. 
5.3.4  Participant recruitment for consultation exercises 
Recruitment of participants commenced in January 2013 and lasted four weeks.  In 
total, 32 members of the public expressed an interest in the study.  The majority of 
interest was generated through ‘word of mouth’ with 20 (62.5%) members of the public 
hearing of the study through a third party.  The original e-bulletin prompted contact 
from 6 (18.8%) members of the public and similar numbers were achieved when the 
study was re-advertised in the e-bulletin three weeks later, with 5 (15.6%) members of 
the public responding to this.  One member of the public specifically mentioned seeing 
the study advertised on Twitter. 
One respondent asked if they could be included despite a diagnosis of a mental health 
condition; with reference to the exclusion criteria detailed on the study advertisement, 
this respondent was excluded and therefore not sent an information pack.  A total of 31 
information packs to send to interested members of the public; 17 (54.8%) of which 
were returned with signed consent forms and completed brief surveys.  There was a 
reasonable gender split between respondents with 9 (52.9%) males and 8 (47.1%) 
females.  The ages of respondents ranged from 24 to 82 with a median (IQR) of 71.0 
(54.0 to 74.5) years.  The number of prescribed medicines per patient was also 
variable, ranging from one to ‘at least ten’ with a median (IQR) of 4 (2 to 8).  Given the 
median age of the respondents it was unsurprising that 12 (70.6%) respondents did not 
pay for their prescriptions, with only one of these aged less than 60 years.  Only one 
respondent reported ‘rarely’ needing assistance with reading written medical letters, the 
remaining respondents all stated that they ‘never’ needed assistance.  
The participant consultation exercises were attended by 14 (82.4%) of the 
respondents.  Two respondents could not attend either of the dates proposed and one 
could not be contacted.   
5.3.5  Consultation exercise one 
The first participant consultation exercise was held at UEA in March 2013 with three 
males and two females.  One participant was unable to attend due to ill health but 
agreed to attend the second session instead.  All five participants reported ‘never’ 
needing assistance in reading written material.  The participants’ ages ranged from 41 
to 82, with a median (IQR) age of 70.0 (45.5 to 76.5) years.  Two participants were 
aged less than 60 years and both paid for their prescriptions.  The number of 
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medicines taken by participants was variable and ranged from two participants who 
only took one medicine, to one participant who took “in excess of ten”.  
The following behavioural domains were discussed in this session: 
1) Knowledge 
2) Skills 
3) Memory, attention and decision making processes 
4) Social influences 
5) Environmental constraints 
6) Emotions 
Full details of all topics discussed and comments made with regard to the 
questionnaire statements are provided in appendix 5.8 and summarised in the sub-
sections below.  For the first domain (knowledge), ranking the barriers in order of 
importance proved to be difficult as participants reported that many of the barriers were 
very similar.  Ranking was therefore not requested in the subsequent sections; instead 
the facilitator guided conversation to highlight the important barriers.  
The following sub-sections cover the behavioural domains discussed within the first 
consultation exercise.  Each sub-section starts with a figure which replicates the 
adherence barriers presented to the participants; the topics of participant discussion 
regarding these adherence barriers are then summarised below this figure.  The 
questionnaire statements that had been developed to represent the adherence barriers 
are then shown in a figure, with a summary of the participant comments relating to 
these provided below.  
5.3.5.1  The ‘knowledge’ behavioural domain 
As the first behavioural domain to be discussed, several topics were raised by the 
participants and not all were necessarily related to the ‘knowledge’ behavioural domain. 
In total, 20 minutes were spent on this section of the consultation exercise; the time 
was split evenly between discussion of the adherence barriers and potential 
questionnaire statements. The adherence barriers presented to participants for the 
‘knowledge’ behavioural domain are shown in figure 5.4.   
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Figure 5.4 Adherence barriers discussed in ‘knowledge’ group 
Topics raised by the participants within this section included: 
• Frequent changes to medicines packaging and associated difficulties with medicine 
identification and differentiation 
• Difficulties accessing medicines from their packaging  
• Knowing what to do (i.e. going back to GP) in instances of not understanding 
medicines instructions 
• The importance of knowing why medicines are prescribed and ‘what to expect’ from 
them, especially if there are concerns about side effects  
• The importance of knowledge (for example from patient information leaflets (PILs)) 
in making informed decisions about the risks and benefits of taking medicines 
• The complexity of the repeat medicines ordering process, specifically getting to a 
pharmacy or doctors surgery to order and collect prescriptions and the difficulties of 
balancing medicines ordering and collecting with other priorities  
• The importance of knowing the ‘systems’ available to make the ordering and 
collecting process easier 
Following the discussion of the adherence barriers, six questionnaire statements were 
displayed to the participants, as summarised in figure 5.5. 
 
 
 
Knowledge 
barriers 
Not knowing HOW to 
take medicines 
Not knowing WHEN to 
take medicines 
Not knowing WHY 
medicines were 
prescribed 
Not knowing HOW 
medicines will work/ be 
beneficial 
Not knowing HOW to 
obtain a repeat 
prescription 
Not knowing WHY medicines 
should be taken 
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Figure 5.5 Questionnaire statements discussed in ‘knowledge’ group 
Participants understood the concept of completing the questionnaire and the need to 
only tick one box for each statement.  Comments relating to the questionnaire 
statements concerned: 
• The similarity between statements four and five 
• The disparity of statement six, which did not appear to ‘fit’ with the others 
5.3.5.2  The  ‘skills’ behavioural domain 
The ‘skills’ behavioural domain was discussed for approximately 13 minutes, with an 
even split of discussion time between the adherence barriers and questionnaire 
statements.  The adherence barriers presented to participants for the ‘skills’ 
behavioural domain are shown in figure 5.6.  
 
 
 
 
 
 
Figure 5.6 Adherence barriers discussed in ‘skills’ group 
‘Skills’ 
barriers  
Patient’s ABILITY to take medicines as prescribed  
Difficulties 
ADMINISTERING 
medicines 
Difficulties READING 
directions/ instructions 
Difficulties UNDERSTANDING directions/ instructions 
 
 
Knowledge 
questionnaire 
statements 
1) I know when to take 
my medicines 
2) I know how to 
take my medicines 
3) I know why I have been 
prescribed my medicines 
4) I know why I should 
take my medicines 
5) I know how my 
medicines will help me 
6) I know how to get further 
supplies of my medicines 
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Topics raised by the participants within this section included:  
• Difficulties with accessing medicines from the packaging and identifying tablets that 
have been dropped onto the floor 
• The importance of ‘having a system’ and ‘forward planning’ as a skills for managing 
medicines, especially ordering to ensure sufficient supplies 
• The ‘skill’ of knowing how to cope when there is a problem or difficulty and the 
importance of the PIL for resolving medicines difficulties 
• The difficulty of reading the small print on PILs 
• The difficulties of receiving medicines at the correct time when staying in hospital  
• The problem of confusion associated with changes in medicines  
Figure 5.7 summarises the questionnaire statements presented to participants to 
represent the adherence barriers in the ‘skills’ domain.  
 
 
 
 
 
 
 
 
Figure 5.7 Questionnaire statements discussed in ‘skills’ group 
For the questionnaire statements, participants commented that: 
• There was overlap between statements four and five as one could not really be 
done without the other 
• For statement one, the word ‘administer’ may be confusing for some patients  
o The words ‘take’ and ‘use’ were suggested as alternatives 
 
 
‘Skills’ 
questionnaire 
statements  
1) I am able to administer my 
medicines  2) I am 
physically able 
to take all of my 
medicines 
5) I am able to 
understand the directions 
given to me about my 
medicines  
3) I am able to take 
the prescribed dose 
of my medicines 
4) I am able to take 
my medicines at the 
prescribed times 
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5.3.5.3 The ‘memory, attention and decision making processes’ 
behavioural domain 
The ‘memory, attention and decision making processes’ behavioural domain attracted 
comparatively more discussion than the other domains, with a total of 26 minutes spent 
on this section of the consultation exercise. The adherence barriers and questionnaire 
statements were discussed for 19 and 7 minutes respectively.  The adherence barriers 
presented to participants for discussion in this section are displayed in figure 5.8. 
 
 
 
 
 
 
 
Figure 5.8 Adherence barriers discussed in ‘memory, attention and decision 
making processes’ group 
Topics raised by the participants included: 
• The decision making dilemma that can occur between a preference for managing 
health through health foods and yoga and a doctor’s prescription for a medicine 
• The difficulty of always remembering medicines doses, especially lunchtime doses 
which can particularly problematic as there is less routine at this time of day, unlike 
breakfast time and bedtime 
• A hectic lifestyle and distractions such as ‘getting the children ready for school’, 
which can also impede adherence, especially in the mornings 
• The barrier of forgetting to order and collect prescriptions 
• The differing needs of patients  for support with ordering their prescriptions 
• The importance of having strategies for remembering and managing medicines 
• The relevance of different ‘life stages’ as to whether or not medicines taking is seen 
as a priority 
‘Memory, 
attention & 
decision making 
processes’ 
barriers 
FORGETTING to take 
medicines  
FORGETTING to 
order or collect 
prescription 
RUNNING OUT of 
medicines  
Being easily 
DISTRACTED 
LOSING medicines or 
prescription 
Other justifiable reasons reflecting a 
DECISION process 
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o Older patients tended to accept taking medicines as ‘the norm’ and 
important priority whereas younger patients tended assign less priority to it 
as they had other factors such as raising a family to consider. 
Following discussion of these barriers, the potential questionnaire statements for this 
section were displayed to the participants, as summarised in figure 5.9 
 
 
 
 
 
 
 
 
Figure 5.9 Questionnaire statements discussed in ‘memory, attention & 
decision making processes’ group 
Comments made with regard to the questionnaire statements were that: 
• Statement one could be improved by using the phrase ‘I usually remember…’ 
• Statement four could be re-phrased to ‘I can be easily distracted’ to better reflect 
something that doesn’t happen every day 
• Statement three may be superfluous as it relates directly to statement two 
• Statement five may need to be refined as personal reasons are not always ‘good’ 
reasons 
o A suggestion of ‘I have my reasons for not taking my medicines as 
prescribed’ was agreed to be the best option. 
5.3.5.4  The ‘social influences’ behavioural domain 
In this section of the consultation exercise, the adherence barriers and questionnaire 
statements were discussed for approximately 12 and 2 minutes respectively.  The 
adherence barriers discussed for this behavioural domain are shown in figure 5.10. 
 
‘Memory, attention 
& decision making 
processes’ 
questionnaire 
statements 
1) I remember to take 
my medicines  
2) I remember 
to order/ my 
medicines 
3) I never run out of my 
medicines  4) I’m easily distracted when taking my medicines 
5) I have good reasons for not taking my 
medicines correctly  
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Figure 5.10 Adherence barriers discussed in ‘social influences’ group 
The topics raised by the participants included: 
• Discrimination had not been experienced and bullying was thought to be something 
only relevant to school children 
o Medicines taking was better accepted and seen as ‘normal’ for older people 
• Lack of trust in prescribers was a barrier that participants could identify with 
• Poor relationships with GPs receptionists and their ‘hostility’ can also be a barrier to 
adherence as they can be a barrier to seeing the GP and thus getting medicines 
• Family obligations were a barrier to adherence in younger participants with families 
• Social support was considered important and the relevance of various sources of 
support, including support groups acknowledged. 
The potential questionnaire statements for this section were then displayed to the 
participants, as summarised in figure 5.11.  
 
 
 
 
 
 
 
 
Figure 5.11 Questionnaire statements discussed in ‘social influences’ group 
‘Social 
influences’ 
barriers 
Fear of DISCRIMINATION, STIGMA 
or BULLYING 
Fear of DISCLOSURE 
of illness or 
PERCEPTIONS of 
others 
Poor RELATIONSHIP with healthcare 
provider/ lack of TRUST in healthcare provider  
Wanting to be 
‘NORMAL’ 
Lack of SOCIAL SUPPORT 
FAMILY rituals or SOCIAL obligations 
‘Social 
influences’ 
questionnaire 
statements 
1) People would treat me differently 
if they knew I was taking medicines  
2) I trust my doctor(s) 
with decisions about 
my healthcare 
4) My friends and family 
encourage me to take my 
medicines 
5) I don’t like taking 
medicines, I just 
want to be ‘normal’ 
3) If I needed help with taking my 
medicines, my friends and family 
would help me 
6) In my culture, it’s acceptable 
to take medicines  
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For the questionnaire statements, participants commented that: 
• Statement six could be changed to ‘my faith and religion’ or ‘my beliefs’ 
5.3.5.5  The ‘environmental constraints’ behavioural domain 
The adherence barriers discussed in this section are shown in figure 5.12.  With only 
four adherence barriers to discuss for this behavioural domain, the adherence barriers 
and questionnaire statements were discussed in just five and two minutes respectively.  
 
 
 
 
 
 
 
 
Figure 5.12 Adherence barriers discussed in ‘environmental constraints’ group 
The key points of participant discussion for this section included: 
• The expression of genuine shock by participants exempt from prescription charges 
at the current prescription charges; this was recognised as an important barrier  
• ‘Problems with pharmacy’ could include difficulties getting to the pharmacy, 
frequent changes to packaging and inconvenient opening times 
• Forward planning for travelling and being away from home were considered 
important skills for overcoming this potential barrier 
The questionnaire statements displayed to the participants for this section are 
summarised in figure 5.13. 
 
 
 
‘Environmental 
constraints’ 
barriers 
PROBLEMS with pharmacy (e.g. not stocking medicines, closing too early, 
long waiting times) 
Being away from 
home/ TRAVELLING 
COST of 
medication 
TRANSPORT difficulties getting to pharmacy/clinic 
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Figure 5.13 Questionnaire statements discussed in the ‘environmental 
constraints’ group 
All of the statements were considered acceptable, though statement four was thought 
to only relate to stock issues and not wider problems as anticipated. 
5.3.5.6  The ‘emotions’ behavioural domain  
As the final behavioural domain to be discussed in the first consultation exercise, time 
was limited.  Discussion of the adherence barriers and questionnaire statements for 
this behavioural domain therefore lasted just five and two minutes respectively.  The 
adherence barriers discussed in this section are shown in figure 5.14. 
 
 
 
 
 
 
 
 
Figure 5.14 Adherence barriers discussed in ‘emotions’ group 
 
‘Emotions’ 
barriers 
EMBARRASSMENT of taking 
medicines 
Wanting to be FREE of 
taking medicines  
Thinking of treatment as a 
BURDEN 
Treatment being a REMINDER of 
illness 
Feeling LOW or 
DEPRESSED 
Feeling ANGRY 
or STRESSED 
Feeling HOPELESS, TIRED or 
OVERWHELMED 
‘Environmental 
constraints’ 
questionnaire 
statements 
3) I am able to take my medicines when I’m away from home or travelling  
4) I often have 
problems getting 
medicines from my 
pharmacy 
2) I can easily get to 
my local pharmacy 
or surgery to collect 
my medicines  
1) Taking my medicines as prescribed is too expensive for me 
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The main points of participant discussion in this section were: 
• Whether or not taking tablets is a reminder of illness is likely to be dependent upon 
the condition treated and individual concerned 
• The ‘negative emotions’ listed could be caused by side effects of medicines 
• Experiences of negative feelings could also act as a promoter of adherence if the 
negative feelings are a reminder of a need for treatment 
The questionnaire statements discussed in this section are summarised in figure 5.15. 
 
 
 
 
 
 
 
 
Figure 5.15 Questionnaire statements discussed in the ‘emotions’ group 
Participants commented that: 
• Statements three and seven were very similar 
• Several of the statements could be combined to create a more general statement 
relating to experience of negative emotions 
5.3.6 Consultation exercise two  
The second participant consultation exercise was also held at the UEA, ten days after 
the first meeting.  The meeting was moderated by CE, with DB assuming the assistant 
moderator role.  Nine participants joined the meeting; five males and four females.  The 
majority of participants reported ‘never’ needing assistance in reading written material, 
with only one participant stating that they ‘rarely’ needed assistance.  Participant ages 
ranged from 24 to 81 with a median age (IQR) of 62.0 (54.0 to 75.5) years.  Four 
participants were aged less than 60 years and all except one paid for their 
Emotions 
questionnaire 
statements 
1) I feel embarrassed by having to 
take my medicines 
4) I don’t want to be 
reminded that I’m ill by 
taking medicines 
5) I feel overwhelmed by 
having to take my medicines 
6) Taking my medicines 
makes me feel low 
9) Knowing I’m 
taking my 
medicines correctly 
makes me feel 
good about myself 
7) I feel frustrated by 
having to take medicines 
10) I feel a sense of success 
when I take all of my 
medicines correctly  
2) I want to be free of taking medicines 
3) Having to take my 
medicines is a burden to me 
8) Taking my medicines 
is stressful for me 
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prescriptions.  The number of medicines taken by participants ranged from one to 
seven, with a median (IQR) of 2 (2 to 6). 
The following behavioural domains were discussed in this session: 
1) Motivation and goals 
2) Goal conflicts 
3) Beliefs about consequences 
4) Beliefs about capabilities 
5) Emotions 
Full details of the topics discussed and comments made are provided in appendix 5.9 
and summarised in the following sub sections. 
5.3.6.1  The ‘motivation and goals’ behavioural domain 
Similar to the first consultation exercise, as the first behavioural domain to be 
discussed, participants raised several topics that related to other domains.  In total, 30 
minutes were spent discussing the ‘motivation and goals’ behavioural domain; the 
adherence barriers and questionnaire statements were discussed in 20 and 10 minutes 
respectively. The adherence barriers discussed in this section are shown in figure 5.16.  
 
 
 
 
 
 
 
Figure 5.16 Adherence barriers discussed in ‘motivation and goals’ group 
Key points of participant discussion included: 
• ‘Tiredness’ seemed unintuitive as a direct barrier to adherence but may increase 
the likelihood of forgetfulness  
• Motivation is often the single most important factor in taking medication 
‘Motivation 
and goals’ 
barriers 
Lack of 
MOTIVATION 
Low PRIORITY 
assigned to 
medication taking 
BURDEN of adhering 
to regimen 
Being too TIRED 
to take medicines 
REFUSAL to take 
medicines 
PREFERENCE for traditional, 
herbal or alternative remedy 
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• Experience of side effects is an important barrier to medication adherence; 
previous experience  may reduce motivation to adhere to a new regimen 
• Even when motivation is strong, incapacity might inhibit  adherence 
• Questioning whether a prescribed medicines represents ‘good value for money’ can 
impinge upon motivation to adhere  
• Negative feelings towards medicines could be evoked by a sense of getting a ‘raw 
deal’ with regard to medicines supply 
• PILs could affect motivation to adhere by ‘terrifying’ patients and ‘putting them off’ 
The questionnaire statements discussed in this section are summarised in figure 5.17. 
 
 
 
 
 
 
 
 
Figure 5.17 Questionnaire statements discussed in ‘motivation & goals’ group 
Comments with regard to the questionnaire statements included: 
• The term ‘bothered’ in statement one was considered to be ambiguous as it could 
mean worried as well as unmotivated  
• For statement six, it was suggested that the term ‘sometimes’ could be added to 
reflect a problem that does not occur every day 
5.3.6.2  The ‘goal conflicts’ behavioural domain 
The adherence barriers and questionnaire statements for the ‘goal conflicts’ section 
were discussed in 8 and 1 minutes respectively.  The adherence barriers presented to 
participants in this section are summarised in figure 5.18.   
 
‘Motivation 
and goals’ 
questionnaire 
statements 
1) I’m not bothered about taking my 
medicines as prescribed 
2) Taking my medicines 
as prescribed is high on 
my list of priorities 
3) I have more important 
things to think about than 
taking my medicines 
6) I’m too tired to 
take medicines 
5) I refuse to take my 
medicines 
7) I take herbal or other alternative remedies 
instead of my prescribed medicines  
4) Having to take my 
medicines is a burden to me 
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Figure 5.18 Adherence barriers discussed in ‘goal conflicts’ domain 
Topics discussed by the participants within this section included: 
• Ordering and collecting prescriptions can be problematic, posing a barrier to 
adherence for some people; being ‘disciplined’ and ‘having a system in place’ are 
therefore imperative to ensure adherence 
• Changes in routine such as forgetting medicines when going away was perceived 
as a common barrier that many people would experience 
Only three questionnaire statements were presented to participants for this section, as 
summarised in figure 5.19. 
 
 
 
 
 
 
 
Figure 5.19 Questionnaire statements discussed in ‘goal conflicts’ group 
With regard to the questionnaire statements, participants commented that: 
• Statement two was ‘too wordy’ 
o ‘changes’ were thought to be easier than ‘disruptions’ 
‘Goal 
Conflicts’ 
barriers 
Being too BUSY to take doses 
Being too BUSY to collect 
or order prescription 
Difficulties incorporating 
medicines taking into daily 
ROUTINE 
Disruption to daily ROUTINE Having a CHAOTIC lifestyle 
‘Goal 
Conflicts’ 
questionnaire 
statements 
1) I’m too busy to take my 
medicines as prescribed 
3) Life gets in the way of 
me taking my medicines 
as prescribed 
2) I struggle to take 
my medicines when 
there are disruptions 
to my daily routine 
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5.3.6.3  The ‘beliefs about consequences’ behavioural domain 
In total, discussions for this section of the consultation exercise lasted approximately 
25 minutes.  The adherence barriers and questionnaire statements were discussed 
over 12 and 13 minutes respectively.  The adherence barriers presented to the 
participants in this section are shown in figure 5.20. 
Whilst there is clear overlap between the barriers ‘mistrust in medicines’ and ‘fear that 
medicines will be harmful’ both were included as the former represents a more general 
belief whilst the latter represents a specific concern (belief).  
 
 
 
 
 
 
 
 
Figure 5.20  Adherence barriers discussed in ‘beliefs about consequences’  
Topics discussed by participants within this section included: 
• ‘Mistrust in medicines’ and ‘fear that medicines will be harmful’ were strongly 
identified with by a participant who had previously experienced a severe adverse 
drug reaction that had led to hospitalisation 
• Knowing what a medicine was for and why it had been prescribed were considered 
as important aspects of knowledge which in turn influence beliefs; this knowledge 
was subsequently described as “what drives confidence and motivation” 
• Non-acceptance of a diagnosis was questioned, as a mistrust in the prescribers 
proficiency may be more pertinent 
• Dose and brand changes were considered as factors which could evoke mistrust in 
medicines and prescribers 
• Asymptomatic conditions were thought to be more likely to lead to questioning of 
whether a medicine was needed and doubting of a diagnosis 
‘Beliefs about 
consequences’ 
barriers 
MISTRUST in medicines 
Lack of belief 
in 
EFFICACY 
of medicines 
Thinking that medication is not 
WORKING 
DENIAL of 
existence of illness  
Fear that medicines will 
be HARMFUL 
NON-ACCEPTANCE 
of diagnosis 
Thinking that there is 
NO NEED for 
medication/treatment 
STOPPING medicines 
when feeling better  
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• Fear about the unknown, long term effects of medicines was also considered a 
barrier to medication adherence 
• Prescribing of multiple medicines was deemed to be a factor that could augment 
fear of side effects as information regarding interactions is difficult to obtain 
• Non-acceptance, denial and thinking there is no need for treatment were 
considered as phases that people might go through when they are first diagnosed 
with a condition. 
The questionnaire statements presented to participants in this section are summarised 
in figure 5.21.  
 
 
 
 
 
 
 
 
Figured 5.21 Questionnaire statements discussed in ‘beliefs about 
consequences’ group 
Participant comments regarding these questionnaire statements included: 
• Statement one was considered too emotive 
• The wording of ‘work for me’ in statement four was considered to be ambiguous 
o ‘beneficial’ was suggested as a popular alternative 
• The word ‘disease’ in statement six was considered unhelpful; ‘medical condition’ 
was considered more appropriate 
• The term ‘feel better’ in statement seven was considered to be potentially 
confusing, especially in the context of preventative medicine such as 
cardiovascular disease. 
 
‘Beliefs about 
consequences’ 
questionnaire 
statements 
1) Medicines should 
not be trusted 
2) Medicines are not 
effective in treating and 
preventing illnesses 
4) I don’t think my medicines work for me 
3) Medicines are safe to take 
6) I have a disease that 
needs to be treated with 
medicines 
5) Taking my 
medicines is 
important for my 
health and well 
being  
7) I keep taking my medicines as 
prescribed even if I feel better 
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5.3.6.4  The ‘beliefs about capabilities’ behavioural domain 
The adherence barriers and questionnaire statements for this behavioural domain were 
discussed over 10 and 9 minutes respectively.  The adherence barriers discussed in 
this section are summarised in figure 5.22. 
 
 
 
 
 
 
 
 
Figure 5.22 Adherence barriers discussed in ‘beliefs about capabilities’ 
behavioural domain  
Topics discussed by the participants within this section included: 
• Participants struggled with this domain and found the barriers difficult to relate to 
• ‘Wanting to maintain control’ was identified as a potential cause of refusing to take 
medicines, but could also promote of adherence 
• Lack of confidence was viewed as a potential barrier that could be overcome with 
appropriate support, such as pill organisers 
Following discussion of the adherence barriers, eight questionnaire statements were 
presented as summarised in figure 5.23. 
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Doubting own ABILITY 
to adhere 
Thinking regimen is 
too COMPLEX or 
CONFUSING 
Experiencing SIDE 
EFFECTS 
Wanting to maintain 
CONTROL 
Struggling to cope with 
frequent CHANGES to 
regimen 
Lack of CONFIDENCE 
to overcome adherence 
barriers 
Lack of CONFIDENCE in 
adhering  
INABILITY to cope with 
difficulties or problems 
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Figure 5.23 Questionnaire statements discussed in ‘beliefs about capabilities’ 
group 
Participant comments regarding these questionnaire statements included: 
• Statements four and six were thought to be verbose and in need of refinement 
o Participants were also confused by the ‘I’ element of these statements as 
overcoming problems was considered to be something done in collaboration 
with the prescriber 
• Reluctance to take medicines as prescribed due to side effects was considered to 
be the key barrier for inclusion 
• Statement eight was described as “adventurous” and inaccurate as resolution of 
problems would not be undertaken alone 
• Statement three caused some confusion as for one patient it was his dose that 
regularly changed not his medicine. 
5.3.6.5  The ‘emotions’ behavioural domain 
Discussion of the ‘emotions’ group represented replication of material covered in the 
first session and enabled an opportunity to compare the data collected across the two 
sessions.  The adherence barriers and questionnaire statements discussed were 
therefore identical to those displayed previously in figures 5.14 and 5.15 respectively.  
The adherence barriers and questionnaire statements for this section were discussed 
over 10 and 3 minutes respectively.  
>? $
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1) I don’t think I can take my 
medicines as prescribed 
2) I take too many 
medicines to be able 
to take them all as 
prescribed 
4) I am confident  I could 
resolve any difficulties 
caused by side effects of 
my medicines 
5) I feel in control of my 
health by taking my 
medicines 
3) I struggle to take my 
medicines as prescribed 
because they’re always 
changing 
6) If I had any difficulties in 
taking my medicines, I feel 
confident that I would find 
a way to overcome this 
7) I feel confident about taking 
my medicines as prescribed 
8) I can cope if there is 
a problem with my 
medicines 
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Topics discussed by the participants included: 
• Participants could identify with the barrier of ‘embarrassment’  
• Seeing treatment as a burden could involve burden to carers and family members 
as well as to the patient 
• Negative emotions were thought to be potential barriers to adherence 
• Negative emotions associated with medicines taking may be more common in 
younger people who become ‘depressed’ at the prospect of having to take 
medicines for life 
• Being reminded of an illness by taking medicines can be a motivating factor for 
some patients, reminding them of the importance of their medicines  
• Annoyance from having to take medicines was suggested as another ‘emotional’ 
barrier to adherence with specific reference to declarations to the DVLA and 
holiday insurance forms creating a sense of frustration and grievance 
With regard to the questionnaire statements, participants commented that for statement 
six, rephrasing was necessary as being reliant on taking a medicine is more likely to 
induce a low mood than the physical act of taking the medicine. 
5.3.7 Selection and refinement of adherence barrier statements following 
the participant consultation exercises 
Following the analysis of the consultation exercises, several adherence barriers were 
re-mapped to an alternative domain to better reflect the participants’ comments and 
understanding.  As this section represents an intermediary stage rather than end point, 
a summary of the key changes and decisions made are provided rather than full 
details.  As previously detailed in the methods section, for each behavioural domain, 
three adherence barriers (and their corresponding questionnaire statements), were 
selected for progression to the next stage of the IMAB-Q’s development.  Three 
statements per domain were selected to provide a questionnaire appropriate for future 
psychometric evaluation.  
The mind maps produced to summarise all ten behavioural domains are included in 
appendix 5.10.  The changes made and adherence barriers selected following the 
consultation exercises are summarised in the following sub-sections.  Each behavioural 
domain is considered in a separate sub-section.  Each sub-section starts with a table to 
summarise the changes made to the barriers mapped to the behavioural domain.  The 
three adherence barriers selected for the behavioural domain are then provided in 
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bullet points, followed by a table to summarise the questionnaire statements selected 
to represent the chosen adherence barriers.   
5.3.7.1 Selection and refinement of adherence barrier statements for the 
‘knowledge’ behavioural domain 
Table 5.5 summarises the key refinements made to the mapping of adherence barriers 
to the ‘knowledge’ domain and provides a rationale for the changes made.  Three 
barriers originally mapped to this domain were moved to alternate domains considered 
to be more appropriate. 
Nature of change Rationale 
‘Knowing how to identify medicines’ 
barrier moved to skills behavioural 
domain 
Behaviour represents an ability that can be 
acquired through practice more than direct 
knowledge 
‘Knowing how to access medicines from 
packaging’ barrier moved to skills 
behavioural domain 
As above 
‘Knowing how to overcome problems or 
difficulties’ barrier moved to beliefs about 
capabilities behavioural domain 
Barrier reflects a sense of perceived ability 
to undertake something that may or may not 
have happened and therefore better fits 
‘beliefs about capabilities domain’ 
Table 5.5 Summary of changes to ‘knowledge’ behavioural domain following 
participant consultation exercise 
Review of the transcripts and the team’s expertise allowed the following knowledge 
barriers to be preferentially selected for inclusion in the questionnaire: 
• Not knowing how and when to take medicines 
• Not knowing why medicines were prescribed and how they will be beneficial  
• Not knowing the system of how to order repeat prescriptions 
Details of the questionnaire statements selected to represent these barriers and the 
rationale for their selection is provided in table 5.6. 
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Questionnaire 
statement 
Barrier 
represented 
Rationale for statement & factors considered 
I know how to 
take/use my 
medicines as 
prescribed 
Not knowing how 
and when to take 
medicines 
 
• ‘How’ considered sufficiently generalised to 
also cover ‘when’ 
• Although not ideal for readability, the 
phrasing ‘take/use’ was selected as both 
aspects considered important 
I know enough 
about my 
medicines to 
decide whether to 
take them 
Not knowing why 
medicines were 
prescribed and 
how they will be 
beneficial  
 
• Aim is to capture provision of information to 
meet the individual’s need, as this is known 
to vary between patients127.  The phrasing of 
‘know enough’ covers patients who do and 
do not wish to have extra information about 
their medicines 
I know about the 
different ways to 
order and collect 
my repeat 
prescriptions 
Not knowing the 
system of how to 
order repeat 
prescriptions 
 
• Barrier received notable discussion in both 
consultation exercises, with patients 
expressing the importance of knowing about 
the systems such as delivery, repeat 
collection and online ordering services which 
make the process far easier 
Table 5.6 Questionnaire barrier statements selected for ‘knowledge’ 
behavioural domain 
5.3.7.2 Selection and refinement of adherence barrier statements for the 
‘skills’ behavioural domain 
Table 5.7 summarises the key barrier mapping changes made at this stage; three 
barriers, previously mapped to the ‘skills’ domain were moved to alternate domains. 
Nature of change Rationale 
‘Inability to overcome or resolve 
problems’ barrier moved to ‘beliefs 
about consequences’ domain 
Barrier most closely related to a perceived 
ability or confidence to undertake a task rather 
than direct ability (skill) 
‘Inability to cope with changes’ barrier 
moved to ‘beliefs about consequences’  
As above 
‘Not being able to understand 
directions’ barrier moved to 
‘knowledge’ domain 
Knowing how to take/use medicines statement 
in knowledge domain also covered this barrier, 
replication therefore unnecessary 
Table 5.7 Summary of changes to ‘skills’ behavioural domain following 
participant consultation exercise 
Three barriers were preferentially selected for inclusion in the questionnaire: 
• Not being able to administer medicines  
• Not having an ordering and management system in place 
• Not being able to identify medicines 
Table 5.8 summarises the questionnaire statements selected to represent these 
barriers and the rationale for their selection.  Two new barriers that had not been 
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included prior to the consultation exercise are included, highlighting the enhanced 
information and insight provided through the consultation exercises. 
Questionnaire 
statement 
Barrier 
represented 
Rationale for statement & factors considered 
I am able to 
take/use all of 
my medicines 
as prescribed 
Inability to take 
or administer 
medicines as 
prescribed 
• Importance of barrier conveyed in consultation 
exercises 
• Minor re-phrasing to represent all medicines 
formulations including creams and inhalers  
I am able to put 
a system in 
place to help 
me order, 
collect AND/OR 
take my 
medicines 
Disorganisation 
(lack of system) 
with regard to 
medicines 
management 
• Noted as important adherence barrier in both 
consultation exercises 
• Process components of ordering, collecting and 
taking should ideally be separated but this is not 
possible; and/or conjunction considered most 
reasonable compromise 
I am able to 
identify each of 
my medicines 
from others 
Inability to 
identify 
medicines and 
differentiate 
between them 
• Barrier raised as a notable issue in both 
consultation exercises 
• Medicines identification considered to be an 
ability that could be acquired through practice 
and therefore met definition of ‘skill’ 
Table 5.8 Questionnaire barrier statements selected for ‘skills’ behavioural 
domain 
5.3.7.3 Selection and refinement of adherence barrier statements for 
‘memory, attention and decision making processes' domain 
Table 5.9 summarises the barrier mapping changes made to this domain following the 
participant consultation exercises.  Only two changes were made, with removal of one 
barrier and moving of another.  
 
Nature of change Rationale 
'Not having a routine and strategy for 
managing medicines' barrier removed 
Barrier already covered by amendments to 
‘skills’ behavioural domain 
‘Medicines taking not being a priority’ 
barrier moved to ‘motivation and goals’ 
behavioural domain 
Priorities aspect clearly related to motivation 
and goals domain 
Table 5.9 Summary of changes to ‘memory, attention and decision making 
processes’ behavioural domain following participant consultation 
exercise 
The three barriers selected as the most important were: 
• Being distracted  
• Forgetting to order, collect or take medicines 
• Preference for an alternative/ making an alternative decision 
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Table 5.10 summarises the questionnaire statements selected to represent these 
barriers and the rationale for their inclusion and phrasing.  
Questionnaire 
statement 
Barrier 
represented 
Rationale for statement & factors considered 
I struggle to 
remember to 
order, collect 
AND/OR take 
my medicines 
Forgetting to 
order, collect 
or take 
medicines 
• Statement is amenable to grouping as, for the 
purposes of the questionnaire, it does not matter 
at which process stage the forgetting occurs, 
simply that forgetting is an adherence barrier 
I can easily be 
distracted from 
taking my 
medicines 
Lack of 
attention to 
medicines 
taking 
• Identified as potential adherence barrier in 
consultation exercises 
• ‘Easily’ added following consultation exercise to 
represent something that does not happen every 
day 
I have my own 
reasons for not 
taking my 
medicines as 
prescribed 
Decision 
making which 
impedes 
adherence 
• ‘Good reasons’ removed following advice in 
consultation exercises to avoid perceived 
condolence of inappropriate behaviours 
• ‘My own reasons’ added to reflect personal 
decisions  
Table 5.10 Questionnaire barrier statements selected for ‘memory, attention 
and decision making’ behavioural domain 
5.3.7.4 Selection and refinement of adherence barrier statements for the 
‘social influences’ behavioural domain 
Changes to the adherence barriers mapped to this behavioural domain, following the 
participant consultation exercise are summarised in table 5.11.  Only one change was 
necessary, and this was heavily influenced by the wealth of data elicited via the 
consultation exercises.  
Nature of change Rationale 
‘Family obligations’ barrier 
moved to goal conflicts 
behavioural domain 
Insights from consultation exercise clearly 
demonstrated ‘conflict’ with regard to wanting to adhere 
but family commitments sometimes impeding this 
Table 5.11 Summary of changes to ‘social influences’ behavioural domain 
following participant consultation exercise 
The three preferentially selected adherence barriers for the ‘social influences’ 
behavioural domain were: 
• Poor relationships with (or lack of trust in) healthcare providers  
• A lack of social support 
• Religious or cultural obligations (concerns about others perceptions) 
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Table 5.12 summarises the three adherence barriers statements selected to represent 
these barriers and the rationale for their inclusion. 
Questionnaire 
statement 
Barrier 
represented 
Rationale for statement & factors considered 
I trust my doctor(s) 
with decisions 
about my 
healthcare 
Lack of trust in 
prescriber 
• Strong evidence for lack of trust in HCPs as a 
barrier to adherence plus notable discussion 
on topic in both consultation exercises 
I have the support 
that I need from 
others to help me 
take my medicines 
as prescribed 
Lack of support 
to adhere 
• Lack of social support recently identified as a 
powerful predictor of non-adherence120 
• Statement modified to refer to support in a 
more general sense rather than specifically 
from friends and family and to capture 
element social support that was needed as 
patients having differing needs 
I worry that other 
people will think 
badly of me if I 
take my medicines 
Concerns of 
others 
perceptions 
• More generic statement created to capture all 
concerns about other people’s perceptions, 
including social pressures such as faith, 
religion and social stereotypes. 
Table 5.12 Questionnaire barrier statements selected for ‘social influences’ 
behavioural domain 
5.3.7.5 Selection and refinement of adherence barrier statements for the 
‘environmental constraints’ behavioural domain 
Table 5.13 summarises the key changes made to the barriers mapped to this domain; 
only one change was necessary; moving a barrier to a different behavioural domain.  
Nature of change Rationale 
‘Not having a system in place to cope with 
being away from home or changes’ barrier 
moved to skills behavioural domain 
Barrier best captured by ‘not having a 
system in place’ which had already been 
mapped to the skills behavioural domain 
Table 5.13 Summary of changes to ‘environmental constraints’ behavioural 
domain following participant consultation exercise 
Three adherence barriers were preferentially selected for inclusion in the questionnaire: 
• Cost of medicines 
• Problems with getting to the pharmacy (including inconvenient opening hours) 
• Travelling and changes to routines  
Table 5.14 summarises the adherence barrier statements selected to represent these 
barriers and the rationale for their inclusion in the questionnaire. 
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Questionnaire 
statement 
Barrier 
represented 
Rationale for statement & factors considered 
Taking all of my 
medicines as 
prescribed is not 
good value for 
money 
Cost of 
medicines 
• Worded to reflect consultation exercise 
comments regarding perceived value for money 
• Generic statement represents any barrier 
associated with monetary value of medicines 
I can easily get to 
my local 
pharmacy or 
surgery to collect 
my medicines 
Difficulties 
getting to 
pharmacy 
• Remains unchanged  
• Could also cover inconvenient opening hours 
I struggle to take 
my medicines as 
prescribed when 
there are 
changes to my 
daily routine 
Changes to 
daily routine 
• Previously mapped to ‘goal conflicts’ domain 
• Updated TDF made clear that this domain 
included ‘any circumstance, situation or 
environment’ that could impede adherence 
Table 5.14 Questionnaire barrier statements selected for ‘environmental 
constraints’ behavioural domain 
5.3.7.6 Selection and refinement of adherence barrier statements for the 
‘emotions’ behavioural domain 
None of the barriers that were originally mapped to this domain were moved.  The 
three barriers considered to be most important for this domain were: 
• Experiencing negative emotions including frustration 
• Feeling embarrassed 
• Being reminded of illness by taking medicines  
Table 5.15 summarises the adherence barrier statements selected to represent these 
barriers and describes the rationale for their inclusion in the questionnaire. 
Questionnaire statement Barrier 
represented 
Rationale for statement & 
factors considered 
Having to take my medicines 
makes me feel negative 
emotions (e.g. frustration, 
anger, embarrassment) 
Experience of 
negative emotions 
• Generic statement to capture a 
range of negative emotions, 
with example provided for clarity 
Taking my medicines as 
prescribed is an unwelcome 
reminder of my illness 
Medicines taking 
being a reminder of 
illness 
• Re-phrased to provide greater 
clarity as recommended in 
consultation exercises 
I feel positive about taking 
my medicines as prescribed 
No sense of positive 
gain or reward from 
adherence 
• Produced via merging of two 
similar statements presented in 
consultation exercise 
Table 5.15 Questionnaire barrier statements selected for ‘emotions’ 
behavioural domain 
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5.3.7.7 Selection and refinement of adherence barrier statements for the 
‘motivation and goals’ behavioural domain 
Table 5.16 summarises the changes made to the mapping of adherence barriers 
following the participant consultation exercise, highlighting the utility of the participants’ 
comments in fully elucidating the nature of the adherence barriers. 
Nature of change Rationale 
‘Feeling burdened’ barrier moved 
to ‘emotions’ behavioural domain 
Sense of burden regarded as a genuine emotion 
associated with medicines taking more than a lack 
of motivation manifested in an ‘excuse’ 
‘Feeling negative’ barrier moved 
to ‘emotions’ behavioural domain 
Experience of negative emotions regarded as a 
genuine emotion associated with medicines taking 
more than a lack of motivation manifested in an 
‘excuse’ 
Table 5.16 Summary of changes to ‘motivation and goals’ behavioural domain 
following participant consultation exercise 
The three barriers preferentially selected for inclusion in the questionnaire were: 
• Lack of motivation to adhere 
• Low priority assigned to medicines taking 
• Lack of intention to take medicines as prescribed 
Table 5.17 summarises the questionnaire statements chosen to represent these 
adherence barriers and the rationale for their inclusion and phrasing.  Whilst the first 
and third statements (regarding motivation and intention respectively), may seem 
similar, the two terms are not synonymous.  Whilst motivation relates to ‘a stimulus for 
action towards a goal directed response’, intention concerns the ‘mental application of 
effort’6.  Put simply, the two terms are closely related but motivation focuses on the 
patient’s desires whereas as intention concerns the planning of behaviour.  With regard 
to medication adherence, a patient could, for example, be motivated to take their 
medicines as prescribed (they wish to do so and can see the benefits), however, they 
may not intend to take their medicines as prescribed as they know this is not possible, 
for example due to dexterity problems.  The inclusion of items that are closely related 
to one another is also necessary to enable testing of construct validity at a later date.  
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Questionnaire 
statement 
Barrier 
represented 
Rationale for statement & factors 
considered 
I am motivated to 
take my medicines as 
prescribed  
Lack of 
motivation to 
adhere 
• Newly written statement to reduce 
ambiguity of ‘motivation’ statement 
Taking my medicines 
as prescribed is high 
on my list of priorities 
Lack of priority 
assigned to 
medicines taking 
• Addition of ‘as prescribed’ to ensure 
consistency between statements 
I intend to take my 
medicines as 
prescribed  
Lack of intention 
to adhere 
• Recent evidence has highlighted the 
importance of intention in behaviour and 
therefore needed to be included 
Table 5.17 Questionnaire barrier statements selected for ‘motivation and 
goals’ behavioural domain 
5.3.7.8 Selection and refinement of adherence barrier statements for the 
‘goal conflicts’ behavioural domain 
Table 5.18 summarises the key barrier mapping changes made; two barriers, 
previously mapped to the ‘goal conflicts’ domain were excluded as they had already 
been re-mapped to more appropriate domains.  
Table 5.18 Summary of changes to ‘goal conflicts’ behavioural domain 
following participant consultation exercise 
The three adherence barriers selected for further development were: 
• Being too busy 
• Regimens not fitting in with daily routines 
• Family commitments  
Table 5.19 summarises the questionnaire statements selected to represent these 
barriers and provides a rationale for the wording of the selected statements. 
 
 
 
 
Nature of change Rationale 
‘Changes to daily routine’ barrier excluded 
from this domain 
Barrier already covered by ‘environmental 
constraints’ behavioural domain 
‘Not having a system in for managing 
medicines’ barrier removed from this domain 
Barrier already covered by ‘skills’ 
behavioural domain 
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Questionnaire 
statement 
Barrier 
represented 
Rationale for statement & factors 
considered 
I’m too busy to order, 
collect AND/OR take my 
medicines 
Being too busy – 
competing 
priorities 
• Combines adherence process stages 
of ordering, collecting and taking to be 
consistent with rest of questionnaire 
Taking my medicines as 
prescribed does not fit 
with my daily routine 
Difficulty 
incorporating 
medicines regimen 
into daily routine 
• Newly added statement to reflect 
comments regarding this barrier 
especially lunchtime doses 
Life gets in the way of 
me taking my medicines 
as prescribed 
Competing 
priorities 
• Provides generic statement to 
encompass barriers such as family 
commitments  
Table 5.19 Questionnaire barrier statements selected for ‘goal conflicts’ 
behavioural domain 
5.3.7.9 Selection and refinement of adherence barrier statements for the 
‘beliefs about consequences’ behavioural domain 
Barriers such as ‘misunderstanding’ and ‘insufficient information’ were raised in this 
section but remained mapped to the ‘knowledge’ behavioural domain.  No barriers 
originally mapped to the ‘beliefs about consequences’ behavioural domain were 
changed or remapped to an alternate domain following the consultation exercises. 
The adherence barriers selected for development as questionnaire statements were: 
• Fear that medicines will be harmful 
• Not thinking there is a need for treatment 
• Mistrust/lack of belief in medicines 
Table 5.20 summarises the adherence barrier statements selected.  All three 
statements were refined following the consultation exercise to improve clarity. 
Questionnaire 
statement 
Barrier 
represented 
Rationale for statement & factors 
considered 
Taking my medicines 
as prescribed is 
harmful to me 
Belief that 
medicines are 
harmful 
• Minor amendment from ‘could be 
harmful’ to ‘is harmful’ to better 
represent belief about consequences/ 
be clearer 
If I don’t take my 
medicines as 
prescribed my 
condition will get worse 
Not thinking that 
medicines are 
necessary 
• Re-phrased to provide stronger link 
between worsening health and non-
adherence; original statement too 
vague 
I don’t think my 
medicines will help me 
with my condition  
Lack of belief in 
medicines efficacy 
• Re-phrased to convey clearer link 
between medicines taking and 
condition treated 
Table 5.20 Questionnaire barrier statements selected for ‘beliefs about 
consequences’ behavioural domain 
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5.3.7.10 Selection and refinement of adherence barrier statements for the 
‘beliefs about capabilities’ behavioural domain 
All of the adherence barriers included within this domain were retained and unchanged 
following the consultation exercise.  The three adherence barriers selected for further 
development into questionnaire statements were: 
• Lack of confidence to adhere 
• Lack of confidence in ability to overcome problems 
• Inability to cope with problems/changes 
Table 5.21 summarises the adherence barrier statements to represent these 
adherence barriers and provides a rationale for their phrasing and inclusion. 
Questionnaire statement Barrier 
represented 
Rationale for statement & factors 
considered 
I am confident about 
ordering, collecting 
AND/OR taking my 
medicines as prescribed 
Lack of 
confidence in 
ability to adhere 
• Newly introduced statement to reflect 
importance of confidence.  All three 
stages of adherence combined to 
ensure comprehensiveness and 
questionnaire consistency 
If I experienced difficulties 
with my medicines I would 
know what to do to 
overcome these 
Inability to 
overcome 
difficulties 
• Minor amendments to reflect 
confidence to undertake an active 
resolution strategy 
I could easily overcome 
any difficulties that arise 
from side effects of my 
medicines 
Inability to cope 
with side effects 
• Side effects consistently identified as 
prominent adherence barriers; 
statement concerns confidence in 
ability to overcome this problem 
Table 5.21 Questionnaire barrier statements selected for ‘beliefs about 
capabilities’ behavioural domain 
5.3.7.11 Development of the first prototype questionnaire 
The first prototype questionnaire is shown in appendix 5.11.  The research team 
agreed that four sides of A4, printed on an A3 sheet to produce a booklet format would 
be an optimal design layout given the questionnaires length. 
The front page was developed to create a professional appearance with background 
information added to provide clear expectations, collated into four brief bullet points to 
improve readability.  In highlighting that there are no right or wrong answers, honest 
opinions were encouraged and any concerns about conforming to ‘expected answers’ 
minimised.  Succinct and clear instructions for completion were provided and the non-
judgemental nature of the questionnaire was further reinforced to encourage patients to 
see that non-adherence is common place and occurs for many different reasons.  
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Arial font size 12 was used throughout the questionnaire to provide a font size that was 
clear to read and (hopefully) large enough for any respondents with visual impairments.  
The text was non-justified as this is known to be problematic for certain populations 
such as people with dyslexia141.  The adherence barrier statements were alternated in 
sequence between the behavioural domain that they related to, starting with the first 
‘knowledge’ statement and ending with the third ‘beliefs about consequences’ 
statement.  
5.3.8 Feedback from research colleagues and subsequent refinements 
In total, ten research colleagues offered feedback, with eight also receiving the 
presentation about the theoretical construction of the questionnaire.  In general the 
questionnaire was well received and colleagues recognised its importance in identifying 
barriers to adherence.  Specific recommendations were covered by considering each 
behavioural domain in turn.  
5.3.8.1 Recommendations for the overall layout and introductory section 
Overall, the design and layout were pleasing, with experts in questionnaire design 
noting that it’s clear layout and good readability should facilitate completion.  The front 
cover was described as eye-catching and professional looking and the background 
statements were generally acceptable, with the exception of the statement providing an 
estimate of completion time, where changes were recommended.  Whilst the time 
frame of 5-10 minutes was deemed appropriate, re-phrasing of the statement ‘the 
questionnaire should not take any longer....’ was recommended, as this could impose 
an expectation that would alarm patients if they needed longer.  After considering these 
recommendations, the research team agreed to re-phrase this fourth bullet point as: 
‘The questionnaire will take about 5-10 minutes to complete’ 
Minor amendments to the instructions for completion were also recommended as this 
section was slightly verbose and at times repetitive.   
5.3.8.2  Recommendations for the adherence barrier statements 
A summary of the recommended changes to the adherence barrier statements and the 
research team’s subsequent decisions is provided in table 5.22.  In general, the 
recommendations largely related to rephrasing of statements to improve readability and 
reduce ambiguity.  Recommendations that affected more than one statement included: 
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• For the statements ‘I know how to take/use all of my medicines as prescribed’ and ‘I 
am able to take/use all of my medicines as prescribed’, changing the ‘take/use’ 
term to either ‘take’ or ‘use’, with ‘take’ generally considered most appropriate as 
most patients will have oral preparations and the term ‘take’ should not be unduly 
confusing for any non-oral preparations such as creams or inhalers 
• For the statements containing ‘AND/OR’ (e.g. remember to order, collect and/or 
take my medicines) replacing this with three distinct statements to represent each 
adherence process stage (ordering, collecting and taking) separately 
Whilst the first of these recommendations was easily implemented, the second proved 
more complex as creating three unique statements was not possible, due to the 
restraint of having three statements per behavioural domain.  When the purpose of the 
questionnaire in terms of identifying which behavioural domains adherence barriers 
were primarily within, the group of colleagues became less anxious about the need to 
differentiate between each adherence process stage.  For some statements, all three 
process stages were therefore retained and combined with the ‘and’ conjunction to 
reduce confusion.  For other statements, the most pertinent process stage was 
selected, as described in table 5.22.  
Beyond minor rephrasing of statements, more notable changes were also necessary 
for the ‘memory, attention and decision making processes’ behavioural domain.  The 
third statement in this domain was: 
‘I have my own reasons for not taking my medicines as prescribed’.  
Reflection identified that this barrier had been mis-mapped, and did not accurately 
reflect a decision making process as originally intended.  Whilst choosing an alternative 
to prescribed medicines involves decision making processes, the factor which may 
impede adherence is the preference for alternatives, not the decision making process.  
A barrier relating to decision making processes would, for example, be an inability to 
choose between two or more options.  For medication adherence, this is therefore 
irrelevant as there are not multiple options to choose between plus no barriers 
pertaining to this were identified in either the literature search or consultation exercises.   
No barriers relating to decision making processes were therefore included, leaving 
opportunity for a new, third statement in this domain.  The research team agreed that 
splitting the first statement (‘I struggle to remember to order, collect AND/OR take my 
medicines as prescribed’) to distinguish between ‘remembering to take medicines as 
prescribed’ and ‘remembering to order and collect medicines on time’ was the most 
intuitive approach.  The adherence barrier relating to decision making, specifically 
Chapter Five                                                       The IMAB-Q; developmental processes 
 
 
266 
having ‘own reasons for not adhering’, was retained and moved to the ‘beliefs about 
consequences domain’ as this represented an important barrier.  The beliefs about 
consequences domain was chosen as the ‘justifiable reason’ for non-adherence would 
likely be informed by consideration of the consequences of this choice.  
The ‘environmental constraints’ domain was also subject to more notable refinements, 
with the first statement, (‘taking all of my medicines as prescribed is not good value for 
money’), attracting notable debate.  Discussion revealed that, in an attempt to 
incorporate aspects from the consultation exercise, the core of the adherence barrier 
had been lost.  The group of research colleagues suggested that the concept of ‘value 
for money’ as proposed in the consultation exercises, was ambiguous and also unlikely 
to relate to ‘environmental constraints’, unlike the original barrier of not being able to 
afford a prescription.  Upon closer inspection, the adherence barrier ‘cost of medicines’ 
proved to be complex and multifaceted as summarised in appendix 5.12.  For the 
literature identified adherence barrier, ‘cost of medicines’ related to a genuine inability 
to pay for prescriptions; this data was primarily based on HIV studies based in the 
USA.  The UK based healthcare system however, means that a genuine inability to pay 
for prescriptions may be less likely.  More likely however, is an enforced choice 
between paying for a prescription and paying for something else deemed to be 
important, due to limited financial resources.  This choice between two alternatives, 
imposed due to limited funds is better represented by the ‘goal conflicts’ behavioural 
domain.  The ‘cost of medicines’ barrier was therefore switched from the 
‘environmental constraints’ domain to the ‘goal conflicts’ domain where the following 
statement was included: 
 ‘I have to choose between paying for my prescription and paying for other things that 
are important to me’. 
With the removal of the cost related barrier from the ‘environmental constraints’ 
section, only two barriers remained, the literature review and consultation exercise 
transcripts were therefore reviewed again to identify important adherence barriers in 
this domain.  Barriers such as ‘unfriendly’ or ‘unhelpful’ staff, losing prescriptions, failed 
orders and so forth were captured in a new statement: 
 ‘My pharmacy or surgery provides an efficient service for ordering and collecting my 
medicines’. 
For the ‘emotions’ behavioural domain, the third statement (‘I feel positive about taking 
my medicines as prescribed’) did not appear to relate to a specific barrier.  This barrier 
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was therefore replaced by a statement to reflect ‘seeing treatment as a burden’ as the 
literature review and consultation exercises identified this as an important adherence 
barrier.   Changes were necessary for the ‘goal conflicts’ domain, to accommodate the 
‘cost of medicines’ barrier which had been newly mapped to this domain.  The first 
statement (‘I’m too busy to order, collect AND/OR take my medicines’) was removed as 
this was represented well by other statements and therefore replaced with the ‘cost of 
medicines’ statement.  
The third statement in the ‘beliefs about capabilities’ domain (‘I could easily overcome 
any difficulties that arise from side effects of my medicines’), was also removed, as this 
was considered to be unnecessarily specific and duplicated the second statement in 
this domain (‘If I experienced difficulties with my medicines I would know what to do to 
overcome these’).  The removed statement was replaced by a new statement to reflect 
the important barrier of ‘inability to cope with changes’.   
The research team also agreed that the second and third statements in the ‘beliefs 
about consequences’ domain, (‘If I don’t take my medicines as prescribed my condition 
will get worse’ and ‘I don’t think my medicines will help me with my condition’ 
respectively), were sufficiently similar to warrant removal of the third statement.   The 
removal of this statement enabled addition of the ‘own reasons for not taking 
medicines’ barrier to this domain.  
5.3.8.3 Summary of questionnaire refinements following feedback from 
research colleagues 
Aside from refinements in the phrasing of many statements, the feedback process also 
permitted a reflective process, whereby the team critically assessed the value of each 
statement and its accuracy in representing the intended barrier.  Appendix 5.13 
summarises this reflective process, adding transparency to the research team’s 
rationale for the decisions made. 
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Behavioural 
domain 
Adherence barrier 
statement  
Recommended refinement Outcome/changes 
Knowledge I know how to take/use all 
of my medicines as 
prescribed 
‘Take/use’ term unanimously agreed to 
be unnecessarily confusing  
‘Take’ selected as majority of patients will have oral 
formulations.  Term should not be unduly confusing for 
those using non-oral formulations  
‘All of my medicines’ considered as 
unnecessary 
Statement amended to ‘I know how to take my 
medicines as prescribed’ 
Skills I am able to put a system in 
place to help me order, 
collect AND/OR take my 
medicines as prescribed 
‘And/or’ term unacceptable and far too 
complex to process.  Inappropriate to 
combine three distinct processes in one 
statement; use three separate statements 
Changed to ‘and' 
‘I have a system in place’ would better 
represent a skill, current phrasing 
pertains more to a belief about capability 
Changed to ‘I have a system in place…’ after referring 
to TDF definitions and agreeing with recommendations 
I am able to take/use all of 
my medicines as prescribed 
‘Take/use’ term unacceptable, either term 
but not both should be used 
Changed to ‘take’ 
I am able to identify each of 
my medicines from others 
Not clear what this means and what 
barrier it relates to plus ‘identify’ is 
ambiguous; needs rephrasing 
Changed to ‘I am able to tell each of my medicines 
apart from each other’ to improve clarity 
Memory, attention 
and decision 
making processes 
I struggle to remember to 
order, collect AND/OR take 
my medicines as prescribed 
‘AND/OR’ conjunction unacceptable; 
three separate statements recommended 
Re-phrased to ‘I remember to order, collect and take 
my medicines as prescribed’ as ‘and’ conjunction 
appears acceptable for positively phrased statements 
I can be easily be distracted 
from taking my medicines 
Change to ‘distractions can stop me from 
taking my medicines as prescribed’ as 
currently unclear 
Changed to ‘I am easily distracted from taking my 
medicines’ to optimise reflection of original barrier and 
participant comments in consultation exercise 
I have my own reasons for 
not taking my medicines as 
prescribed 
No changes necessary Re-evaluation led the team to agree this barrier was 
misplaced and better fitted with the ‘beliefs about 
consequences’ domain 
Table 5.22 Summary of recommended changes to barrier statements following feedback from research colleagues 
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Behavioural domain Adherence barrier 
statement  
Recommended refinement Outcome/changes 
Social influences I worry that other people will 
think badly of me if I take 
my medicines 
Indistinguishable ambiguity around 
statement, various amendments 
suggested 
Statement changed to ‘I worry about what other people 
will think of me if they knew I took medicines’ 
Environmental 
constraints 
Taking all of my medicines 
as prescribed is not good 
value for money 
Value for money concept is confusing 
and does not relate to original barrier of 
inability to pay for prescriptions, needs to 
be refined extensively 
Barrier moved to ‘goal conflicts’ domain and rephrased 
as ‘I have to choose between paying for my 
prescriptions and paying for other things that are 
important to me’ 
I can easily get to my local 
pharmacy or surgery to 
collect my medicines 
None suggested Refined upon reflection to ‘I can easily get hold of my 
medicines from my pharmacy or surgery’ to better 
represent adherence barrier to and covered multiple 
aspects including inconvenient opening hours 
Emotions Having to take my 
medicines makes me feel 
negative emotions (e.g. 
frustration, anger, 
embarrassment) 
Anticipated guilt/regret is an important 
emotion that may have been overlooked, 
refinements to include this may be 
necessary 
Importance of anticipated regret acknowledged though 
this may not directly represent an adherence barrier 
per se.  Moreover, no literature identified barriers, nor 
consultation exercise comments related to this 
therefore statement remained unchanged.  
I feel positive about taking 
my medicines as prescribed 
No changes recommended Statement did not represent a specific barrier and was 
therefore removed.  New statement of ‘taking my 
medicines as prescribed is a burden to me’ added to 
reflect importance of ‘burden’ barrier as expressed in 
literature and consultation exercises.  
Goal conflicts I’m too busy to order, 
collect AND/OR take my 
medicines. 
‘AND/OR’ phrasing unacceptable and 
needs to be rephrased 
Barrier represented adequately by other statements 
elsewhere therefore this statement was removed to 
make way for the ‘cost of medicines’ barrier which had 
been newly mapped to this domain.  
Table 5.22 (continued) Summary of recommended changes to barrier statements following feedback from research colleagues 
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Table 5.22 (continued) Summary of recommended changes to barrier statements following feedback from research colleagues 
  
Behavioural 
domain 
Adherence barrier 
statement  
Recommended refinement Outcome/changes 
Beliefs about 
capabilities 
I am confident about ordering, 
collecting AND/OR taking my 
medicines as prescribed 
‘AND/OR’ phrasing unacceptable 
and needs to be rephrased 
‘OR’ removed plus ‘I am’ replaced by ‘I feel’ to better reflect a 
belief about capabilities 
If I experienced difficulties with 
my medicines I would know 
what to do to overcome these 
Slightly muddled, rephrase to 
improve readability 
Statement changed to ‘ if I experienced difficulties with my 
medicines I would know how to overcome these’ 
I could easily overcome any 
difficulties that arise from side 
effects of my medicines 
No recommended changes Duplication of second statement (see above) therefore replaced 
with ‘I don’t think I could cope if my medicines or doses kept 
changing’ to reflect barrier of inability to cope with changes, as 
described in literature and the consultation exercises 
Beliefs about 
consequences 
Taking my medicines as 
prescribed is harmful to me 
‘is harmful’ implies medicines have 
already been taken and caused 
adverse effect and does therefore 
not reflect a ‘belief about 
consequences’ 
Changed to  ‘I worry about the harmful effects of taking my 
medicines or their side effects’ to better reflect a belief and 
emphasise the relevance of side effects to this barrier 
 
I don’t think my medicines will 
help me with my condition 
No recommended changes Removed to accommodate ‘own reasons’ barrier as deemed 
sufficiently similar to ‘condition getting worse’ statement.  
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5.3.9  Feedback from healthcare providers and subsequent refinements 
Feedback was provided by three hospital pharmacists two community pharmacists and 
one pharmacist employed by a Clinical Commissioning Group.  Feedback was also 
received from two GPs, one pharmacy technician specialising in domiciliary medicines 
support and one nurse with a specialist interest in medicines for the elderly.  
Feedback was largely positive, with only minor points of criticism and improvement.  
Positive comments related to the clear instructions and explanations, professional 
design, good layout and good use of font size.  The HCPs reported that the majority of 
patients should be able to complete the questionnaire without undue difficulty, given 
the clear instructions and ‘user-friendly’ format.  Both GPs also commented that they 
felt the right questions were being asked and that they would be interested to see the 
results. Other respondents also commented that they did not feel there were any 
surplus questions and that it had been well written, with a clear value to healthcare 
providers exploring the nature of non-adherence. 
General recommendations included re-phrasing the terms ‘doctor(s)’, used at several 
points in the questionnaire to encompass the fuller range of potential prescribers such 
as nurses.  Alternative terms such as ‘prescribers’ and ‘healthcare providers’ were 
considered, but neither option were thought to be suitably clear or unambiguous.  A 
specific question to inform the resolution of this matter was therefore posed to the 
consultation exercise participants in the next round of feedback.  
Further general recommendations included: 
• Numbering the statements to give respondents a sense of progress and facilitate 
data entry/analysis 
• Removing the first bullet point on the front page which thanks the respondent for 
completing the questionnaire; this assumption may be offensive 
• Including barriers that consider problems with physical dexterity and difficulties with 
swallowing tablets or opening packages 
Whilst the first two recommendations were implemented with ease, the third 
recommendation posed a problem, as the statement ‘I am able to take my medicines 
as prescribed’ had been included to represent these barriers.  The research team had 
anticipated that if a patient were unable to swallow their medicines, access their 
medicines from their packets or collect their medicines due to mobility problems, then 
they would ‘disagree’ or ‘strongly disagree’ with this statement as they are not able to 
take their medicines as prescribed.  However, the HCPs comments suggested that this 
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statement may not represent these barriers adequately and may not be interpreted as 
intended.  The research team agreed to probe the consultation exercise participants for 
further information about their interpretation of this statement and it’s appropriateness 
in detecting the intended barriers, in the next round of questionnaire feedback.  
Table 5.23 provides a summary of the HCPs recommendations for specific statements 
and any changes that were subsequently made.  In the ‘goal conflicts’ behavioural 
domain, the ‘cost of medicines’ barrier statement evoked feedback, with suggestions to 
remove this statement as it would be irrelevant to the large majority of respondents 
who do not pay for their prescription.  Whilst this suggestion was acknowledged the 
research team felt outright removal of the statement was inappropriate as this 
statement represented an important barrier, albeit one which may only affect a minority 
of patients.  Two resolution strategies were therefore considered: 
1) Inclusion of a ‘not applicable’ response option 
2) Use of two questionnaires, one for patients who pay for their prescription and one 
for patients who are exempt from payment, where the cost related statement would 
be replaced by an alternative ‘goal conflicts’ statement.   
As ‘not applicable’ response options are controversial141, 150 this option was rejected.  
The option of creating two different questionnaires according to patient prescription 
payment status was also rejected, as this would create unacceptable and unnecessary 
complications.  Moreover, this strategy would also not directly resolve the underlying 
issue of a poorly phrased adherence barrier statement.  In designing the statement, the 
research team had hoped that if a patient did not pay for their prescription they would 
respond ‘disagree’ or ‘strongly disagree’ as they do not have to make the choice 
between their prescription or something else because they do not pay.  The HCPs 
feedback suggested that this aspiration was conceived in error and thus a problem with 
face validity may exist.  The next round of feedback from the consultation exercise 
participants was used as opportunity to further explore this matter, by directly asking 
whether the statement posed a problem and had been answered as intended.  
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Table 5.25 Summary of recommended changes following feedback from healthcare professionals 
 
  
Behavioural domain Adherence barrier statement  Recommended refinement Outcome/changes 
Memory attention & 
decision making 
processes 
‘I am easily be distracted from taking 
my medicines’ 
Typographic error identified with 
word ‘be’ 
‘Be’ removed so that statement reads ‘I am easily 
distracted..’ 
Goal conflicts I have to choose between paying for 
my prescription and paying for other 
things that are important to me 
May be redundant as so many 
patients do not pay for their 
prescriptions 
Agreed statement will not be relevant for many 
respondents but that this was not adequate justification 
for its removal as this may be a notable barrier for 
some patients.  
Beliefs about 
consequences 
If I don’t take my medicines as 
prescribed my condition will get 
worse 
Statement appears to be a 
knowledge based factual 
statement rather than one 
grounded in patient beliefs  
Agreed that this statement needed refinement and was 
changed to  ‘If I don’t take my medicines as prescribed, 
I think my condition will get worse’ to more accurately 
reflect a belief about consequences 
Knowledge I know how to take my medicines as 
prescribed 
Many patients will ‘think’ they 
know what to do and not realise 
they are doing it wrong 
Whilst this is a valid point, it was considered to be 
beyond the remit of the questionnaire’s objectives. The 
statement was therefore unchanged.  
Beliefs about 
capabilities 
I don’t think I could cope if my 
medicines or doses kept changing 
Patients may not understand 
what doses are 
Considered as unlikely to be problematic as the term 
had been used without problem in the consultation 
exercise.  Agreed seek further advice on this statement 
in next round of feedback.  
Skills I have a system in place to help me 
order, collect and take my medicines 
as prescribed 
Patients may think that ‘having a 
system’ only refers to using an 
MDS 
Phrase was derived directly from consultation exercise 
and is therefore unlikely to be problematic.  No 
changes were therefore made 
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5.3.10 Feedback from consultation exercise participants and subsequent 
refinements 
Of the fourteen consultation exercise participants involved in the earlier stages of the 
questionnaires development, 13 (92.9%) agreed to being sent the feedback 
documents.  One participant did not respond to the contact e-mail and was therefore 
excluded from receipt of the documents.  The prototype questionnaire, ‘feedback 
booklet’ and covering letter posted to participants are shown in appendices 5.16, 5.17 
and 5.18 respectively.  
Completed feedback booklets were returned by 12 (92.3%) participants.  
5.3.10.1 General feedback 
Overall, the questionnaire was well received and without notable concerns with regard 
to design, layout and instructions for completion.  Several comments concerned the 
pleasing and professional layout, good use of font size and clear instructions, adding 
confidence to the suitability of the questionnaire.  The feedback provided made clear 
that both the questionnaire and consultation exercise process were well received and 
highly regarded. 
Suggestions for delivering the instructions for completion via bullet points and re-
phrasing the questionnaire title to something less ‘intimidating’ were both actioned.  
The research team agreed to re-phrase the questionnaire title to ‘You and your 
medicines’, to provide a non-threatening title and generic sense of the content.   
Further recommendations included reconsidering the repetitiveness of the 
questionnaire and including an additional ‘comments box’. Neither of these 
recommendations were actioned; a comments box was deemed unnecessary as the 
questionnaire will be used as part of a discussion, where fuller details will be elicited 
and patients will have ample opportunity to verbally confer additional comments.  The 
repetitive nature of the questionnaire was considered necessary at this stage of the 
development, to enable psychometric testing and subsequent refinement in later 
developmental stages.  
5.3.10.2 General questionnaire statements 
Of the 30 questionnaire statements, 26 were included in a section for provision of 
general comments and feedback, a summary of the comments attracted for these 
statements is provided in appendix 5.19, which also describes the rationale for any 
changes made following this feedback. 
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Of the 26 statements included in this section, 18 (69.2%) attracted recommended 
changes, leaving eight without need for further development.  Many of the 
recommendations related to minor rephrasing of the statements that were deemed 
superfluous.  Consequently, for nine statements which such recommendations, the 
research team agreed that no changes were necessary.  For the remaining nine 
statements, careful considerations were made to optimise the phrasing of statements 
and ensure the intended adherence barriers were adequately reflected.  
5.3.10.3 Specific questionnaire statements 
Questionnaire statements 2, 4, 8 and 29 were considered in greater depth in the 
consultation exercise participant’s feedback form, as the HCPs feedback had 
highlighted these statements as in need of further refinement.  Table 5.22 provides a 
summary of the changes that were made to these statements.  No changes were 
necessary for statement four and the concerns with statements two and 29 were 
resolved through minor re-phrasing of the statements.  
Statement eight, relating to choosing between paying for a prescription and other 
important things, required more extensive changes as only one participant (3.8%) 
completed this statement as intended and reported no need for refinements.  Two 
participants (18.2%) responded ‘neither agree nor disagree’ providing a comment that it 
was hard to respond as they did not pay for their prescriptions and three participants 
(27.3%) left this statement blank, commenting that is was not applicable as they did not 
pay.  Re-phrasing of this statement to ‘I do not have to choose between paying for my 
prescriptions and paying for other things that are important to me’ was selected as a 
resolution strategy.  It was anticipated that this switched phrasing would make a 
response of ‘strongly agree’ or ‘agree’ more intuitive for participants who do not have to 
choose because they do not pay.  
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Questionnaire 
statement 
Rationale for seeking 
specific feedback 
Summary of feedback from consultation 
exercise participants 
Agreed changes and rationale 
2) I am able to take my 
medicines as prescribed 
Statement did not appear to 
reflect intended barriers of 
dexterity and swallowing 
difficulties 
Majority of participants did not consider 
physical difficulties for this statement and 
had assumed it related to knowledge and 
memory 
Statement was changed to ‘I am physically 
able to take my medicines as prescribed’.  
Additional of word ‘physically’ should better 
represent intended barrier 
4) I trust my doctor(s) 
with decisions about my 
healthcare 
 
Term doctor(s) may be 
problematic as some 
patients may have their 
medicines prescribed by a 
nurse 
Two (16.6%) participants thought 
statement was fine, four (33.3%) conveyed 
a preference for the original term. ‘Doctor 
or healthcare provider’ suggested as 
resolution strategy 
Phrasing of ‘doctor or healthcare provider’ 
made statement overly cumbersome and 
therefore unacceptable. Original wording 
therefore retained 
8) I have to choose 
between paying for my 
prescriptions and paying 
for other things that are 
important to me 
Majority of patients do not 
pay for their prescription 
and will therefore find this 
statement to be irrelevant 
Majority of participants struggled with 
statement confirming the need for 
changes. All participants (bar one) felt that 
a ‘not applicable’ response option was 
needed 
‘Not applicable option’ is best avoided for 
Likert scales150 and therefore not adopted. 
Statement re-phrased to ‘I do not have to 
choose between paying for my prescriptions 
and paying for other things that are 
important to me’. 
29) I don’t think I could 
cope if my medicines or 
doses kept changing 
 
Term ‘doses’ thought likely 
to confuse respondents 
Some suggestions for improved clarity 
provided but on the whole, participants did 
not struggle with this term 
Statement re-phrased to ‘I don’t think I could 
cope if my medication regime kept changing’ 
to overcome any potential ambiguity 
regarding the terms ‘medicines’ and ‘doses’  
Table 5.22 Summary of changes to specific questionnaire statements following consultation exercise participants’ feedback  
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5.3.11  The IMAB-Q 
Figure 5.24 shows the final version of the IMAB-Q, as agreed by the research team 
following the final round of consultation with members of the public.  The layout has 
been amended slightly to accommodate incorporation within the margin restraints of 
this thesis; font size 11 has been used for the questions whereas font size 12 is used in 
the full version.  The full version also fits neatly onto four sides of A4 so that a booklet 
layout can be used.  These changes have only been used to allow inclusion within the 
thesis and do not reflect the final IMAB-Q.   
  
••
•
You and Your Medicines 
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Many people often struggle to take their medicines as prescribed, for many 
different reasons.   We understand that different things can ‘get in the way’ of 
following your doctors recommendations about taking your medicines.
This questionnaire lists 30 different statements about taking your medicines.   
For each statement:
• Please tick (
statement
• Please only tick ONE box per statement
Some of the statements may appe
to respond to each statement. 
 Statement
1 I know how to 
take my 
medicines as 
prescribed 
2 I am physically 
able to take my 
medicines as 
prescribed
3 I remember to 
take my 
medicines as 
prescribed
4 I trust my 
doctor(s) with 
decisions about 
my healthcare
5 I can easily get 
hold of my 
prescribed 
medicines from 
the pharmacy or 
surgery
 
 
 
) 
 
 
 
 
 
 
 
You and Your
 
the box that best reflects your level of agreement with the 
Strongly 
agree
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 Statement Strongly 
agree 
Agree Neither 
agree 
nor 
disagree 
Disagree Strongly 
disagree 
6 I have negative 
emotions (e.g. 
frustration, 
embarrassment 
anger) about 
taking my 
medicines as 
prescribed 
     
7 I am motivated to 
take my 
medicines as 
prescribed 
     
8 I do not have to 
choose between 
paying for my 
prescriptions and 
paying for other 
things that are 
important to me 
     
9 I feel confident 
about all aspects 
of managing 
(ordering, 
collecting and 
taking) my 
medicines  
     
10 I worry about the 
unwanted effects 
(e.g. harmful 
effects or side 
effects) of taking 
my medicines  
     
11 I know enough 
about my 
medicines to 
decide whether 
to take them 
     
12 I have a system 
in place to help 
me order, collect 
and take my 
medicines as 
prescribed 
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 Statement Strongly 
agree 
Agree Neither 
agree 
nor 
disagree 
Disagree Strongly 
disagree 
13 I am easily 
distracted from 
taking my 
medicines 
     
14 If I needed 
support from 
others to take my 
medicines as 
prescribed, I 
could get it 
     
15 Changes to my 
daily routine 
would not 
interfere with 
taking my 
medicines as 
prescribed 
     
16 Taking my 
medicines as 
prescribed is an 
unwelcome 
reminder of my 
condition 
     
17 Taking my 
medicines as 
prescribed is 
high on my list of 
priorities 
     
18 Taking my 
medicines as 
prescribed does 
not fit with my 
daily routine 
     
19 I am confident 
that I could find 
ways to solve 
any difficulties 
that I have with 
taking my 
medicines as 
prescribed 
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 Statement Strongly 
agree 
Agree Neither 
agree 
nor 
disagree 
Disagree Strongly 
disagree 
20 If I don’t take my 
medicines as 
prescribed I think 
my condition will 
get worse 
     
21 I have the 
information that I 
need to be able 
to easily order 
and collect my 
prescriptions 
     
22 Telling my 
medicines apart 
from each other 
would not be a 
problem for me 
     
23 I remember to 
order and collect 
my medicines on 
time 
     
24 I worry about 
what other 
people would 
think of me if 
they knew I took 
medicines  
     
25 My pharmacy or 
surgery provides 
an efficient 
service for 
ordering and 
collecting my 
medicines 
     
26 Taking my 
medicines as 
prescribed is a 
burden to me 
     
27 I intend to take 
my medicines as 
prescribed  
     
28 Life gets in the 
way of me taking 
my medicines as 
prescribed 
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 Statement Strongly 
agree 
Agree Neither 
agree 
nor 
disagree 
Disagree Strongly 
disagree 
29 I don’t think I 
could cope if my 
medication 
regime kept 
changing 
     
30 I have my 
reasons for not 
taking my 
medicines as 
prescribed 
     
 
Thank you for your time 
Figure 5.24  The identification of Medication Adherence Barriers 
Questionnaire (IMAB-Q) V1 
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5.3.12  Calculations for the readability of IMAB-Q 
Table 5.23 summarises the Flesch-Kincaid scores for each section of the questionnaire 
and the overall document.  For the entire documents, the Flesch-Kincaid score is 7.5, 
indicating that it is comprehendible to an average UK student in year 7 or 8 of high 
school.  This therefore covers a reading age of between 11 and 13 years, though an 
age of 12 years is most likely for the midpoint of year seven at high school.  
Whilst the Flesch-Kincaid scores for the front page and instructions for completion are 
well represented by the score for the entire questionnaire, the individual questionnaire 
statements were more variable.  Flesh-Kincaid scores for the questionnaire statements 
ranged from 2.3 to 13.5; at the lowest the questionnaire statements therefore require a 
reading age of 6 to 7 years, though for two statements, the reading age would be in 
excess of eighteen years. 
Assuming the average UK reading age is 12 years75, 19 questionnaire statements 
(63.3%) have a Flesch-Kincaid score equivalent to 12 years or less and can therefore 
be considered as suitable.  For three statements (10.0%), whilst the reading age range 
encompasses the age of 12, it may also exceed it and for eight statements (26.7%) a 
reading age of 12 years is exceeded. 
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IMAB-Q section Total 
words 
Total 
sentences 
Total 
Syllables 
Flesch-
Kincaid 
score 
Equivalent UK 
reading age 
(years) 
Front page 49 4 78 8.0 12-13 
Instructions 93 8 146 7.5 11-13 
Statement 1 9 1 12 3.7 7-9 
Statement 2 10 1 16 7.2 11-12 
Statement 3 8 1 13 6.7 10-12 
Statement 4 9 1 14 6.3 10-11 
Statement 5 14 1 21 7.6 11-13 
Statement 6 14 1 28 13.5 18+ 
Statement 7 9 1 14 6.3 10-11 
Statement 8 21 1 29 8.9 12-14 
Statement 9 14 1 27 12.6 16-18 
Statement 10 16 1 28 11.3 15-16 
Statement 11 12 1 18 6.8 10-12 
Statement 12 17 1 23 7.0 11-12 
Statement 13 8 1 14 8.2 12-13 
Statement 14 16 1 22 6.9 10-12 
Statement 15 14 1 23 9.3 13-14 
Statement 16 12 1 22 10.7 14-16 
Statement 17 12 1 18 6.8 10-12 
Statement 18 12 1 18 6.8 10-12 
Statement 19 21 1 32 10.6 14-16 
Statement 20 15 1 20 6.0 10-11 
Statement 21 17 1 26 9.1 13-14 
Statement 22 14 1 20 6.7 10-12 
Statement 23 10 1 16 7.2 11-12 
Statement 24 16 1 22 6.9 10-12 
Statement 25 14 1 28 13.5 18+ 
Statement 26 10 1 15 6.0 10-11 
Statement 27 8 1 10 2.3 6-7 
Statement 28 12 1 16 4.8 8-10 
Statement 29 12 1 17 5.8 9-11 
Statement 30 11 1 16 5.9 9-11 
Thank you 5 1 5 -1.8  

"	
#$% %$ &'( ()# *$
Table 5.23  Flesch-Kincaid scores for IMAB-Q 
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5.4 Discussion 
Best practices in questionnaire design have been utilised in a multi-stage process to 
develop a novel questionnaire to identify barriers to medication adherence using the 
theoretical domains framework.  A multi-disciplinary approach and consultation with 
members of the public has added further robustness to this new tool.  To be the best of 
our knowledge, the TDF has not previously been utilised to develop a theory based 
questionnaire to identify medication adherence barriers; a novel contribution to this field 
has therefore been made.   
5.4.1  Literature review 
The majority of adherence barriers extracted from literature were predictable, given the 
known moderators of adherence as described in chapter one.  Given the breadth of 
literature reporting barriers to medication adherence, the choice to synthesise existing 
literature was intuitive and a good range of adherence barriers were extracted.  
However, a full systematic review rather than literature review may have added greater 
rigour to the study proceedings. 
5.4.2  Mapping of adherence barriers and use of the TDF 
The framework provided by the TDF offered a useful structure for grouping medication 
adherence barriers and has enabled incorporation of a theoretical approach in better 
understanding this domain.  The TDF was designed to facilitate utility and allow non-
psychologists easier access to health psychology theory.  In this study, the TDF has 
been successfully utilised by two pharmacists (CE and DB) with collaborative guidance 
from a health psychologist (NT).  Whilst the work was led by CE, it is unlikely that the 
mapping process would have been undertaken with such success, were it not for the 
guidance of the experienced psychologist on the team.  Michie’s ambition to create a 
tool that is accessible and useful to non-psychologists has therefore, in part, been met 
and the clarified definitions offered by the updated TDF may facilitate this further. 
Despite both the experience and guidance offered within the research team, the 
mapping process was complex, with numerous iterations necessary to reach the final 
product.  Mapping dilemmas were frequent with many barriers falling into more than 
one behavioural domain.  However, as exemplified by the ‘cost of medicines’ barrier, 
such dilemmas were often created by overly generalist or ambiguous barriers.  As 
such, it is not necessarily a deficit in the TDF that created these difficulties; precise and 
specific barriers are therefore key to effective mapping.  
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5.4.3  Participant, practitioner and researcher consultation 
The participant consultation exercises were an invaluable aspect of the questionnaire’s 
development, offering a first-hand account of adherence barrier perceptions and 
detailed advice for the phrasing of questionnaire statements.  Barriers such as 
‘difficulties with ordering and collecting medicines’ were of particular interest and an 
enhanced understanding was elicited through discussions.  Participants expressed 
genuine discontent at the disparity in services offered by different GP surgeries and 
pharmacies, especially with regard to the quantity of medicines supplied.  The concept 
of feeling “ripped off” with regard to medicines supply has received little attention in 
literature yet, from discussion, it became clear that such grievances can yield negative 
emotions that detrimental to good adherence.  Many other adherence barriers were 
also clarified through discussion and provision of anecdotes.  Consultation with 
members of the public is therefore a highly recommend strategy for similar work. 
Despite the benefits of the consultation work with members of the public, there are 
limitations to the methods deployed.  Most notably, the recruitment strategy provided a 
self-selecting sample of participants who may therefore not be representative of the 
wider population.  There was however a good variety of people, from many different 
backgrounds and of differing ages, with varying medication regimen complexities, 
therefore the sampling procedure appeared to provide the variety of people intended.  
Having mixed groups within the consultation exercise was an important decision to 
ensure representation of different adherence barriers such as cost of medicines which 
would only be relevant to some participants.  
There was however, poor diversity with regard to health literacy level as only one 
participant reported ‘sometimes’ needing assistance with reading health related 
material.  Based on the depth and detail of feedback provided by the participants, it is 
likely that the reading comprehension abilities of the sample population were beyond 
the UK average.  Therefore, whilst the questionnaire statements were largely 
acceptable to this group, this may not be so in the wider population.  The lack of 
variation in health literacy could in part be attributed to the recruitment strategy from a 
university campus, where there is a predominance of well-educated people.  However, 
UEA covers a wide range of non-academic employments and recruitment was also 
open to friends and family of university staff and students.  Only three consultation 
exercise participants were directly associated with the university; one as a student, one 
as a professor and one as an administrative assistant.  The remaining 11 consultation 
exercise participants heard of the study through friends or family members, or via the 
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social media advertisements.  Any biases introduced by having a seemingly well-
educated sample with good health literacy may therefore be more likely to be 
attributable to self-selection bias rather than flawed recruitment strategies, though the 
potential for this must be considered.  
A further limitation of the study may be that the patients’ clinical conditions are 
unknown.  Whilst all patients were receiving treatments for the prevention of 
cardiovascular disease, it is likely that participants were also taking medicines for other 
clinical conditions.  Such information may have been useful to characterise the 
participants and determine how representative the sample was.  It is also worth 
considering whether discussion of the adherence barriers in just two consultation 
exercises may have also imposed a limitation.  Duplication of the material across 
different groups or with greater numbers of participants may have added further 
robustness to the topics of discussion and yielded a greater depth of information.  
However, the information discussed was a synthesis of extensive qualitative work that 
had already been undertaken, replication of this was therefore not necessary and 
notable limitations are unlikely.  As the emphasis was on facilitation of group 
discussion, the chosen methods of a focus group style consultation were appropriate.  
Individual interviews would have lacked the interactive component achieved through 
the methods deployed and the group discussions and shared idea generation aspects 
of this work were particularly useful.  Finally, given the large volume of material 
discussed within each consultation exercise, it is reasonable to question whether each 
behavioural domain was discussed in sufficient depth to yield informative data.  Whilst 
it is likely that a greater depth of information could be yielded through a slower pace of 
discussion, the time allocated was sufficient for the purpose of these consultation 
exercises, given the synthesis of an already extensive literature base.  
Consultation with research colleagues and HCPs also proved useful and added a 
further dimension of robustness to the study procedures.  However, the convenience 
sampling strategies deployed may be a limitation.  Whilst a good range of HCPs 
provided feedback, it may have been beneficial to have included more GPs and also 
hospital prescribers.  With regard to the research colleagues, feedback from a panel of 
medication adherence experts would have been preferable, though all colleagues had 
some experience in this field.  
5.4.4  IMAB-Q (V1) 
The IMAB-Q developed in this study represents a starting point, from which further 
refinements should yield a tool suitable for feasibility testing in routine community 
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pharmacy consultations.  Once the mapping and adherence barrier selection phases 
had been completed, further refinement to the phrasing of the questionnaire statements 
was undertaken, representing a notable developmental phase of the questionnaire.  
Calculation of the Flesch-Kincaid scores for the entire questionnaire and each 
statement highlighted the need for further developmental work.  Refinement of almost a 
third of the questionnaire statements is advisable, as the calculated Flesch-Kincaid 
scores suggest that these statements are too complex for comprehension by average 
UK citizens.  Two statements attracted particularly high scores, equivalent to a reading 
age of in excess of 18 years: 
Statement 6:  “I have negative emotions (e.g. frustration, embarrassment 
anger) about taking my medicines as prescribed” 
Statement 25: “My pharmacy or surgery provides an efficient service for 
ordering and collecting my medicines” 
For statement six, removal of one of the example emotions (embarrassment) would 
reduce the Flesch-Kincaid score from 13.5 to 11.3, which, whilst an improvement, is 
still not sufficient to ensure adequate readability.  If all of the example emotions are 
removed the Flesch-Kincaid score reduces further to 8.4, which is equivalent to a 
reading age of 12-13 years and therefore at the upper end of acceptability.  User 
testing would therefore be necessary to establish whether this was comprehendible, 
and whether the term ‘negative emotions’ is unambiguous without example emotions. 
For statement 25, public consultation could be used to determine whether the term 
‘pharmacy’ or ‘surgery’ is preferable so that both need not be used.  However, such an 
amendment may not be sufficient, therefore re-phrasing to, for example, ‘I receive an 
efficient service...’ could be considered.  It is however important to remember that the 
Flesch-Kincaid scores are just a guide for readability and should not be used instead of 
comprehensive user testing in the intended population.  
The questionnaire statements for the ‘beliefs about capabilities’ domain were 
particularly troublesome as best efforts were made to avoid hypothetical or ‘if-then’ type 
statements.  Oppenheim advises that hypothetical questions should be avoided as 
patients often make poor predictions about their future behaviour, especially if the 
behaviour has not been experienced previously150.  However, as the ‘beliefs about 
capabilities’ domain concerns perceived self-confidence and ability, hypothetical 
statements can be difficult to avoid.  With regard to avoidance of hypothetical 
statements, ‘the belief about consequences’ domain was also difficult as there was 
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frequent need to refer to future events.  User testing will be necessary to establish 
whether any residual hypothetical statements are problematic with regard to accurate 
participant completion.  
5.4.5  Future work 
Whilst the first full version of the IMAB-Q opens exciting opportunities for future 
research, further work and refinements are still needed.  With numerous amendments 
at the final stages, re-consultation with members of the public is advisable to check 
face and content validity.   
Once the content of the questionnaire and its readability have been re-checked, the 
questionnaire must be validated in terms of criterion and construct validity.  A grant 
proposal, to fund completion of the IMAB-Q in routine MURs in sufficient quantities to 
allow psychometric testing is currently under review. 
Following validation, feasibility work will be necessary to establish whether the IMAB-Q 
can be used to identify adherence barriers in routine practice.  Routine community 
pharmacy consultations such as MURs represent an ideal opportunity for deployment 
of the IMAB-Q.  Moreover, given the paucity of evidence to support the benefits of an 
MUR and the lack of theoretical background (as described in chapter one) utilisation of 
the IMAB-Q in an MUR offers further potential benefits.   
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6.1 Conclusion 
The 2008 systematic review of adherence interventions reported by Haynes et al. 
remains a seminal text and offers a bleak perspective on adherence interventions.  
Haynes et al. report that adherence interventions tend to elicit modest 
improvements at best and highlight the need for innovative approaches to provide 
complex, multi-faceted interventions that are tailored to meet individual needs163.  
Whilst MURs and the NMS promote routine, community pharmacy-based 
adherence interventions, neither are grounded in theory nor is there rigorous 
evidence to support efficacy and tailoring to meet individual need is minimal.  
Moreover, these interventions are ill equipped to resolve complex adherence 
difficulties, especially those of an intentional nature which requires a notably 
different approach.  At present, we therefore find ourselves far removed from the 
gold-standard adherence intervention that is much needed. 
In recent years strategies to improve medication adherence have become 
increasingly prominent in government agendas182.  In May 2013, the Royal 
Pharmaceutical Society (RPS) issued the ‘Medicines Optimisation’ document as 
good practice guidelines for healthcare professionals in England435.  Endorsed by 
cross-disciplinary professional bodies, this document sets out key recommendations 
to help patients gain maximal benefit from their medicines.  Improving medication 
non-adherence is a core facet of this document, which calls for patient-centred 
approaches, multidisciplinary team working and an understanding of patients’ 
beliefs and preferences about medicines.  The document also highlights an 
important role for pharmacists in facilitating ‘medicines optimisation’.  Medication 
adherence is firmly set on government and research agendas providing an ideal 
backdrop to the work undertaken in this thesis. 
Chapter one also highlighted that at present, pharmacy interventions to improve 
adherence are centred upon practical resolution strategies such as reducing 
regimen complexities and providing adherence aids.  The service evaluation 
undertaken in chapter two supported this claim.  The domiciliary service appeared 
to support medication adherence and reduce patients’ risk of harm to good effect.  
However, this service may not be representative of other domiciliary support 
services as national provision is variable.  Standardisation of these domiciliary 
support services and sharing of best practices is therefore advisable and within the 
last year, an active forum to facilitate this has emerged via the RPS website.    
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From chapter two it is reasonable to conclude that as a profession, pharmacists are 
reasonably well equipped to remedy simple adherence difficulties of a 
predominantly practical nature in older, vulnerable patients.  Whilst patients over the 
age of 65 represent the greatest proportion of medicines users in the UK, there are 
many patients who do not fall into this demographic and many who will be 
intentionally non-adherent.  For these patients, pharmacists are less well prepared 
and there is a notable deficit in strategies to resolve non-adherence that is 
influenced by illness perceptions, motivation and health beliefs. 
Health psychology theory can be applied to medication adherence to better 
understand intentional behaviours and inform intervention development.  Recent 
developments in this field have provided a taxonomy of behaviour change 
techniques and a theoretical framework, to enable greater access to this wealth of 
theory.  These developments will undoubtedly facilitate incorporation of the MRC 
guidelines to ground complex behaviour change interventions in theory.  Moreover, 
through application of this work there is potential to develop a theory based 
intervention to address medication adherence barriers using BCTs specific to the 
type of identified barrier. 
Further potential benefits of the novel work described in chapter three include the 
increased ease with which health psychology theory can now be accessed by non-
psychologists as the need to choose between multiple overlapping theories has 
been negated. Research from the realms of pharmacy practice (especially 
medication adherence research) and behavioural medicine are intrinsically linked 
and collaborations across psychology and pharmacy are therefore intuitive.  Recent 
research has increasingly highlighted the relevance of psychology to medication 
adherence research including reports of the association between personality traits 
such as neuroticism with non-adherence436 and conscientiousness with better 
adherence437.  As a profession, pharmacists should embrace the expertise of 
psychology in the field of medication adherence.  Facilitation of networking and 
collaborative opportunities across these two disciplines is therefore advised. 
An understanding of the role of psychology in medication adherence research, 
allowed for consideration of psychological or ‘cognitive-based’ techniques as 
interventions to improve medication adherence in chapter four.  A systematic review 
and meta-analysis of these techniques highlighted a potential to elicit improvements 
in adherence beyond the educational and behavioural strategies currently used in 
routine practice.  Techniques such as MI and III have great potential as components 
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of adherence interventions and further exploration of these techniques is warranted.  
Chapter four also highlighted that the efficacy of these techniques is stable across 
many sub-groups, including delivery from routine HCPs rather than specialists.  The 
potential role of pharmacists in delivering these techniques to improve adherence 
was therefore identified.   
Following completion of the meta-analysis detailed in this thesis, the first full version 
of the BCT taxonomy has been published293, which should enable accurate 
description of the intervention components using ‘approved’ terminology.  Mapping 
of the identified intervention components to the BCT taxonomy is therefore advised 
to enable the wider application of this work.  Following this, further statistical 
processes such as meta-regression should be deployed to establish which 
intervention components (BCTs) were associated with greatest efficacy.  
With a strategy for incorporating theory into intervention design and preliminary data 
to identify effective BCTs in medication adherence, a questionnaire to identify 
medication adherence barriers (the IMAB-Q) was developed through an iterative, 
interdisciplinary approach.  This questionnaire is the precursor to a novel adherence 
intervention to identify and resolve barriers to medication adherence.  This approach 
is in accordance with NICE guidelines which recommend that health behaviour 
change interventions should identify potential barriers to change.  These guidelines 
also recommend prioritisation of interventions that are tailored to tackle individual 
beliefs, attitudes, intentions, skills and knowledge associated with the target 
behaviour405.   
Validation of the IMAB-Q is essential before any feasibility work is started; a grant 
proposal to undertake this work is currently under review.  Once validated, the best 
approach for feasibility testing and implementation of the IMAB-Q must be carefully 
considered.  The MRC framework for complex interventions states that researchers 
often neglect the developmental and piloting phases of intervention development 
and do not give due consideration to the practical issues294.  These aspects must 
therefore not be overlooked.  At present the IMAB-Q is comprised of 30 statements 
and is therefore long, this may limit its routine use in healthcare consultations.  
However, it is pertinent to consider that the IMAB-Q currently has multiple 
statements to represent each behavioural domain so that subsequent validation and 
psychometric work can be undertaken.  Following these essential stages, the IMAB-
Q will be shortened to a more manageable length.  
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Utilisation of the IMAB-Q and the intervention that will follow is intended for routine 
community pharmacy consultations.  Whilst the NMS has shown promising results 
for enabling smooth initiation of a medicine, patient behaviour and perceived 
barriers change over time.  IMAB-Q will enable identification of barriers to 
medication adherence that may have emerged over time, capturing the variable and 
sometimes sporadic nature of non-adherent behaviours and supplementing the 
adherence support offered in community pharmacists.  Consultation with 
pharmacists prior to implementation of the intervention is paramount to explore the 
facilitators and barriers to its use.  In doing so, consideration of behaviour change at 
both the practitioner and patient level will be considered and guidance from novel 
theory sought438 
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Appendix 2.1 Ethics approval for service evaluation study  
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Dear Claire 
 
Domiciliary Medicines Management Service Evaluation – Reference: 2010/2011-29 
The submission of your above proposal has now been reviewed by the Chair of the Faculty 
Research Ethics Committee and we can confirm that it is considered to be a service evaluation. 
There are no issues of confidentiality or harm to participants. 
The Chair has requested that before your start your evaluation you add a final paragraph to the 
‘Patient questionnaire covering letter’ at Appendix 3, as follows: 
“When the results have been analysed we may try to publish them in an academic journal so 
people elsewhere can also learn from our evaluation. One of the researchers at UEA is studying 
for a PhD and may use the results for that.” 
Please could you ensure that any amendments to either the protocol or documents submitted 
are notified to us in advance and also that any adverse events which occur during your project 
are reported to the Chair. Please could you also arrange to send us a report once your project is 
completed. 
The Chair would like to wish you good luck with your project.  
Yours sincerely 
 
 
Maggie Rhodes 
Research Administrator 
 
Cc Dr Debi Bhattacharya
 
Miss Claire Easthall 
School of Pharmacy 
University of East Anglia 
Norwich 
Norfolk 
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Faculty of Medicine and Health Sciences 
Elizabeth Fry Building, Room 2.30 
University of East Anglia 
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submitted are notified to us in advance and also that any adverse events which occur during 
your project are reported to the committee. Please could you also arrange to send us a report 
once your project is completed. 
Yours sincerely 
 
 
Maggie Rhodes 
Research Administrator 
 
 
 
 
 
 
Miss Claire Easthall 
School of Pharmacy 
University of East Anglia 
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Elizabeth Fry Building, Room 2.30 
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Norwich NR4 7T 
Email: 	
 
Direct Dial: +44 (0) 1603 59 7190 
Research:  +44 (0) 1603 59 1720 
Fax: +44 (0) 1603 59 1132 
 
Web:   
14th March 2011 
  
 
 
 
 
 
 
 
 
 
Appendix 2.2 Initial visit data collection form 
Cambridgeshire Community Services Domiciliary Medicines Management Service Initial Visit Data Collection Form 
Patient Details 
 
ID no:                                 Age: 
 
Gender:  Male     Female  
 
Co-habitation status: Living alone   Living with partner   
 
Living with other family member     Other (please specify)  
 
Patient background and referral information 
 
Referral Date:  
 
Referral type: GP   Nurse   Family member   Self-referral    
 
Other (please specify)   
 
Reason for referral:  
 
Patient medication details 
Name, dose, strength and form  
 
 
Taking as 
prescribed? (Y/N) 
Difficulties reported and comments  
 
   
   
   
   
   
   
   
   
   
 
 
  
   
Patient’s mental state 
 
Formal diagnosis of dementia        Alert and orientated      Slightly forgetful              Notes:  
 
Slightly confused    Very confused    Very forgetful            
 
Patient’s vision (with respect to reading medication labels and directions) 
 
Can read with no aids                    Struggles to read print even with glasses or aid               Notes:  
 
Needs glasses or aids to read print       Unable to see       Registered blind     Illiterate  
 
Patient’s social circumstances 
 
Living with someone who can fully support medication needs                Living alone but has help from carers/friend/family  
 
Living with someone who usually or sometimes supports medication needs     Live alone with no help  
 
Patient’s physical condition 
 
Can access all medications independently with ease              Requires assistance with accessing or administering medicines  
 
Can manage to access all medication but struggles                Severely disabled and unable to manage  
 
Patient has difficulty swallowing all/some of their medicines    Comments: 
 
Patient’s attitude towards their medication 
 
Shows interest in medicines:  YES   NO         Believes medicines are important:  YES   NO        Willing to take medicines:  YES   NO     
             
Able to administer medicines safely:  YES   NO     Able to recall regimen and knowledgeable:  YES    NO      
 
Details of domiciliary visit 
 
Date of visit:                                                    Length of preparation time:                               Length of visit:  
 
Intervention suggested & comments:   
 
 
 
  
 
 
 
 
 
 
 
Appendix 2.3 Follow up visit data collection form
Cambridgeshire Community Services Domiciliary Medicines Management Service Follow-up Visit Data Collection Form 
Patient ID:  Date of referral:  Date of initial visit:  Date of follow up visit:  
 
Phone call:  Visit:  
Intervention costs: 
 
Time spent of follow visit and/or telephone call:  
Total amount of time spent implementing intervention (e.g. GP liaison time etc):   
 
Patient’s co-habitation status 
 
No changes since initial visit      Changes:  
 
Patient’s mental state 
 
No changes since initial visit      Changes:  
 
Patient’s vision  (with regard to reading medication labels and directions) 
 
No changes since initial visit      Changes: 
 
Patient’s social circumstances  
 
No changes since initial visit      Changes:  
 
Patient’s physical condition 
 
No changes since initial visit      Changes:  
 
Patient’s attitude towards their medication 
 
No change since initial visit       Changes:  
 
Patient medication details 
 
All recommendations on initial assessment form implemented  
 
Some recommendations on initial assessment form implemented  
 
No recommendations on initial assessment form implemented  
 
Intervention summary, outcomes and any other changes to patients medicines management: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Details of questionnaire dissemination: 
 
Patient questionnaire sent to patient?: YES  NO                  
 
Patient Caregiver questionnaire sent to caregiver?  YES   NO               Does the caregiver live with the patient? YES   NO   
 
Caregiver relationship to patient:  Husband/wife/partner      Son/daughter     Other family member       Friend        Other  
 



 
 
 
 
 
 
 
 
 
Appendix 2.4 Domiciliary project patient questionnaire 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cambridgeshire 
Community Services NHS 
Trust - Domiciliary 
Medicines Management 
Service Evaluation Study 
	   

Service Evaluation Questionnaire 
 
• This questionnaire has three sections 
• It should take about 10 to 15 minutes to complete 
• Please read the letter that came with this questionnaire 
before deciding whether to complete it as it contains useful 
information 
• Please put your completed questionnaire in the pre-paid 
envelope provided and return it in the post to the Service 
Evaluation Team at the UEA. 
• If you have any questions about this questionnaire, or you 
would like to arrange for somebody to help you complete it, 
please telephone Pippa Scrimshaw on 01353 652233 
 
Thank-you for completing this questionnaire 


Section One: Using your medicines 
• Many people have difficulty taking their medicines or find a way to use 
their medicines which best suits them. 
  
• The statements listed below are common situations that people 
experience. 
 
• For each statement, please tell us how often these lead to you taking 
your medicines differently to the instructions on the label or from your 
doctor. Please tick () the response that best reflects how you feel. 
 
 
 
 
I take my medicines 
differently to instructed 
because: 
 
Always 
 
Often Some-
times 
Rarely Never 
I have difficulties opening 
medicine packaging, or using 
items such as inhalers or eye 
drops  
     
I have difficulties swallowing 
my medicines 
 
     
I struggle to read the 
instruction labels 
 
     
I have difficulties in 
remembering what time to 
take each medicine 
     
I forget to take my medicine 
 
 
     
I forget when to order or 
collect my medicines from 
the doctor or pharmacy 
     
I choose to alter the dose of 
my medicines if I feel better 
or worse 
     
I choose to miss out doses of 
my medicines if I feel better 
or worse 
 
     
I choose to stop taking my 
medicines for a while 
 
     
Section Two: Your confidence with managing your medicines 
and health 
 
• We’d like you to think about how you feel about managing your medicines 
and general health and whether these feelings may have changed following 
your recent visit from the medicines support service. 
 
• For each of the statements below, please tick (√) the response that best 
reflects how you feel: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As a result of my recent home 
visit to help me with my 
medicines, I feel: 
 
Much 
better 
Better The 
same  
Worse 
My confidence in taking my 
medicines correctly is 
 
    
My ability to take my medicines 
correctly is 
 
    
My ability to cope with life is     
My ability to keep myself healthy is     
My ability to help myself is     
My confidence in managing my 
health is 
 
    
Section Three: Your satisfaction with the service  
 
We would like to know more about your thoughts on the service you received 
when you were visited to get help with your medicines. 
 
• We are interested in your honest opinions, whether they are positive or 
negative 
 
• For the following questions please tick (√) the response that best suits you. 
 
1. How would you rate the quality of the service you received? 
 
 
Excellent 
 
Good 
 
Fair 
 
Poor 
 
 
2. If a friend were in need of similar help, would you recommend to them 
the same service you received? 
 
 
Yes, definitely  
  
Yes, I think so 
  
No, I don’t think 
so 
  
No, definitely 
not 
 
 
 
3. How satisfied are you with the amount of help you received? 
 
 
Very satisfied  
  
Mostly satisfied 
  
Indifferent or 
mildly 
dissatisfied 
  
Quite 
dissatisfied 
 
 
4. Have the services you received helped you to deal more effectively with 
your medicines? 
 
 
Yes, they have 
helped a great 
deal 
  
Yes, they 
helped 
somewhat 
  
No, they really 
didn’t help 
  
No, they 
seemed to 
make things 
worse 
 
 
5. In an overall, general sense, how satisfied are you with the service you 
have received? 
 
 
Very satisfied 
  
Mostly satisfied 
  
Indifferent or 
mildly 
dissatisfied 
  
Quite 
dissatisfied 
 
• Finally, please could you tell us who filled in this questionnaire: 
 
 
Myself (the 
patient) 
  
A family 
member 
  
A friend/carer 
  
Somebody 
else 
 
 
If you have any other thoughts or comments about the medicines 
management support service you have received, please record 
these in the box below 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for taking the time to complete this 
questionnaire 
 
Please place the questionnaire in the envelope provided, and return 
it to the service evaluation research team at the university by putting 
it in the normal post using the pre-paid envelope provided. 
 
The questionnaires will go straight back to the service evaluation 
research team and will not been seen by any of the healthcare team 
involved in your care
  

 
 
 
 
 
 
 
 
 
Appendix 2.5 Patient questionnaire covering letter – first 
mailing 
  

 
 
                        Cambridgeshire Community Services (CCS) NHS Trust 
Domiciliary Medicines Management Service Office (ECF) 
Princess of Wales Hospital 
Lynn Road, Ely 
Cambs, CB6 1DN 
01353 652233 
 
<date> 
 
<Patient name> 
<Patient address> 
<Patient address> 
<Patient address> 
<Patient address> 
 
Dear <Patient name>, 
 
I recently visited you to offer you help with managing your medicines at home. 
When I spoke to you on the telephone to discuss how you were getting on, we also 
talked about whether you would be happy to fill in a questionnaire about the service 
that you received. Please read this letter before you decide whether to fill in the 
enclosed questionnaire. 
 
I explained on the telephone that Cambridgeshire Community Services NHS Trust, 
who  provide the service are working with the Medicines Management Research 
Group at the University of East Anglia (UEA) in Norwich to find out the views of the 
people who have received the service, and that this is why we’d like you to fill in the 
questionnaire. We’re working with the UEA so that all of the information you give is 
looked at independently. If you choose to fill in the questionnaire, it will go straight 
to the UEA and will not be seen by anybody involved with your care. Furthermore, 
the people at the UEA will not be able to identify you as the questionnaire you send 
back will just have a reference number on it, not your name. 

By filling in the questionnaire, your views will be counted and these may help to 
further improve the service that we offer. However, it is entirely your decision 
whether you choose to fill in this questionnaire and whatever decision you make, it 
will not affect the care you receive in any way. You can talk to your friends, family 
or carers about completing the questionnaire if you are not sure what to do or if you 
would like any help completing it.  
 
If you choose to complete the questionnaire, you will be asked to answer a series 
of questions by ticking boxes on the questionnaire. If you would like to answer the 
questions but have a difficulty which stops you from doing this, we can arrange for 
somebody to ask you the questions over the telephone and complete the 
questionnaire on your behalf. The person telephoning you would be a research 
assistant working for CCS NHS Trust. They would talk you through each question 
on the phone and then send your completed questionnaire straight off to the UEA, 
nobody involved in your care would see the responses you gave. 
 
If you’d like to arrange for somebody to telephone you to help you complete the 
questionnaire then you can call me, Pippa Scrimshaw on 01353 652233 and I’ll  
ask the research assistant to give you a call. If you have any other concerns or 
questions about this questionnaire and study, you can also speak to Pippa about 
these by calling the same number.   
 
When the results have been analysed we may try to publish them in an academic 
journal so people elsewhere can also learn from our evaluation. One of the 
researchers at the UEA is studying for a PhD and may use the results from this 
study for that. If you would like a copy of the report once it has been written, this 
can be arranged by telephoning me,  Pippa Scrimshaw on 01353 652233. 
 
Yours Sincerely, 
 
 
 
Pippa Scrimshaw 
Specialist Pharmacy Technician – Domiciliary Medicines Management  
 



 
 
 
 
 
 
 
 
 
Appendix 2.6 Patient questionnaire covering letter – second 
mailing   
  
              
 
 
Cambridgeshire Community Services (CCS) NHS Trust 
Domiciliary Medicines Management Service Office (ECF) 
Princess of Wales Hospital 
Lynn Road, Ely  
Cambs, CB6 1DN 
01353 652233 
 
Dear <patient> 
 
I recently visited you to offer you help with managing your medicines at home. 
When I spoke to you on the telephone to discuss how you were getting on, we also 
talked about whether you would be happy to fill in a questionnaire about the service 
that you received.  I sent the questionnaire to you two weeks ago; however, I’ve 
included another copy of it with this letter today as I know people often misplace 
paperwork or forget to fill it in and I wanted to make sure you had another chance 
to express your views.  If you’ve already returned the questionnaire then please 
ignore this letter and thank you very much for taking the time to give us your 
thoughts.   
 
Please read this letter before you decide whether to fill in the enclosed 
questionnaire.  I explained on the telephone that Cambridgeshire Community 
Services NHS Trust, who  provide the service are working with the Medicines 
Management Research Group at the University of East Anglia (UEA) in Norwich to 
find out the views of the people who have received the service, and that this is why 
we’d like you to fill in the questionnaire. We’re working with the UEA so that all of 
the information you give is looked at independently. If you choose to fill in the 
questionnaire, it will go straight to the UEA and will not be seen by anybody 
involved with your care. Furthermore, the people at the UEA will not be able to 
identify you as the questionnaire you send back will just have a reference number 
on it, not your name. 
 


By filling in the questionnaire, your views will be counted and these may help to 
further improve the service that we offer. However, it is entirely your decision 
whether you choose to fill in this questionnaire and whatever decision you make, it 
will not affect the care you receive in any way. You can talk to your friends, family 
or carers about completing the questionnaire if you are not sure what to do or if you 
would like any help completing it.  
 
If you choose to complete the questionnaire, you will be asked to answer a series 
of questions by ticking boxes on the questionnaire. If you would like to answer the 
questions but have a difficulty which stops you from doing this, we can arrange for 
somebody to ask you the questions over the telephone and complete the 
questionnaire on your behalf. The person telephoning you would be a research 
assistant working for CCS NHS Trust. They would talk you through each question 
on the phone and then send your completed questionnaire straight off to the UEA, 
nobody involved in your care would see the responses you gave. 
 
If you’d like to arrange for somebody to telephone you to help you complete the 
questionnaire then you can call me, Pippa Scrimshaw on 01353 652233 and I’ll  
ask the research assistant to give you a call. If you have any other concerns or 
questions about this questionnaire and study, you can also speak to Pippa about 
these by calling the same number.   
 
When the results have been analysed we may try to publish them in an academic 
journal so people elsewhere can also learn from our evaluation. One of the 
researchers at the UEA is studying for a PhD and may use the results from this 
study for that. If you would like a copy of the report once it has been written, this 
can be arranged by telephoning me,  Pippa Scrimshaw on 01353 652233. 
 
Yours Sincerely, 
 
 
 
 
Pippa Scrimshaw 
Specialist Pharmacy Technician – Domiciliary Medicines Management  



 
 
 
 
 
 
 
 
 
Appendix 2.7 Caregiver’s questionnaire 
  

 
 
 
 
 
  
	   
Cambridgeshire 
Community Services NHS 
Trust - Domiciliary 
Medicines Management 
Service Evaluation Study 
 

Patient caregiver’s questionnaire 
• This questionnaire has two sections 
• It should take about 10 minutes to complete 
• Please read the letter that came with this questionnaire 
before deciding whether to complete it as it contains useful 
information 
• Please put your completed questionnaire in the pre-paid 
envelope provided and return it in the post to the Service 
Evaluation Team at the UEA. 
• If you have any questions about this questionnaire, or you 
would like to arrange for somebody to help you complete it, 
please telephone Pippa Scrimshaw on 01353 652233 
 
Thank-you for completing this questionnaire 
 


 
 Section One: Your feelings as a caregiver 
 
• We’d like you to think about how you feel as a care giver and whether these 
feelings may have changed since the person that you care for was visited by 
the Medicines Management Service. 
 
• For each of the statements below, please tick (√) the response that best 
reflects how you feel: 
 
 
 
 
 
 
 
As a result of the recent Medicines 
Management visit received by the 
person that I care for, I feel: 
 
Much 
better 
Better The 
same 
Worse 
My confidence in their ability to take 
their medicines correctly is     
My confidence in their ability to manage 
their medicines more independently is 
 
    
My confidence in their ability to manage 
their health and well-being is 
 
    
 Much 
less 
Less The 
same 
More 
My level of anxiety about them taking 
their medicines wrongly is 
 
    
The difficulties that they had in taking 
their medicines are 
 
    
The amount of time I have to spend 
helping them with their medicines is 
 
    
The amount of time I spend worrying 
about them taking their medicines is 
 
    
The level of reliance that they have on 
me is 
 
    
Section Two: Your satisfaction with the service 
 
• We would like to know more about your thoughts on the service that the 
person you care for received when they were visited to get help with the 
medicines that they take. 
 
• We are interested in your honest opinions, whether they are positive or 
negative 
 
• For the following questions please tick (√) the response that best suits you. 
 
1. How would you rate the quality of the service received? 
 
 
Excellent 
 
Good 
 
Fair 
 
Poor 
 
2. If a friend were in need of similar help, would you recommend the same 
service to them? 
 
 
Yes, definitely 
  
Yes, I think so  
  
No, I don’t think 
so 
  
No, definitely 
not 
 
3. How satisfied are you with the amount of help received by the person 
that you care for? 
 
 
Very satisfied  
  
Mostly 
satisfied 
  
Indifferent or 
mildly 
dissatisfied 
 
 
  
Quite 
dissatisfied 
4. Have the services received by the person you care for helped them to 
deal more effectively with their medicines? 
 
 
Yes, they have 
helped a great 
deal 
  
Yes, they 
helped 
somewhat 
  
No, they really 
didn’t help 
  
No, they 
seemed to 
make 
things 
worse 
 
 
 
 
 
5. In an overall, general sense, how satisfied are you with the service 
received by the person you care for? 
 
 
Very satisfied 
  
Mostly satisfied 
  
Indifferent or 
mildly 
dissatisfied 
 
  
Quite 
dissatisfied 
 
 
If you have any other thoughts or comments about the medicines 
management support service the person that you care for received, 
please record these in the box below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for taking the time to complete this 
questionnaire 
 
Please place the questionnaire in the envelope provided, and return 
it to the service evaluation research team at the university by posting 
using the pre-paid envelope provided. 
The questionnaires will go straight back to the service evaluation 
research team and will not been seen by any of the healthcare team 
involved in the care of the person that you care for 

 
 
 
 
 
 
 
 
 
Appendix 2.8 Covering letter for caregiver’s questionnaire 
  
 
 
Cambridgeshire Community Services (CCS) NHS Trust 
Domiciliary Medicines Management Service Office (ECF) 
Princess of Wales Hospital 
Lynn Road, Ely 
Cambs, CB6 1DN 
01353 652233 
<date> 
 
<Patient carer’s name> 
<Patient carer’s address> 
<Patient carer’s address> 
<Patient carer’s address> 
<Patient carer’s address> 
 
Dear <Patient’s carer name>, 
 
I recently visited <insert patients name>, who I know you care for, to offer help with 
managing medicines at home. We are undertaking an evaluation of this service and 
so are interested in the views of the people who care for patients that have difficulty 
in managing their medicines, as well as the views of patients themselves. The 
questionnaire is with this letter, but please read this letter first, before you decide 
whether to fill in the questionnaire as it contains some important information. 
 
Cambridgeshire Community Services NHS Trust, who provided the service, is 
working closely with the Medicines Management Research Group at the University 
of East Anglia (UEA) in Norwich to review the service and the views of the people 
who have received it and their carers.  We’re working with the UEA so that all of the 
information you give is looked at independently and in a scientific way. If you 
choose to fill in the questionnaire, it will go straight to the UEA and will not be seen 
by anybody directly involved with the service. Furthermore, the people at the UEA 
will not be able to identify you as the questionnaire you send back will just have a 
reference number on it, not your name. 
 


By filling in the questionnaire, your views will be counted and these may help to 
further improve the service that we offer. However, it is entirely your decision 
whether you choose to fill in this questionnaire and whatever decision you make, it 
will not affect the care received by the person that you care for. 
 
If you choose to complete the questionnaire, you will be asked to answer some 
questions by ticking boxes. If you have decided you would like to answer the 
questions but have a difficulty which stops you from doing this, then we can 
arrange for somebody to ask you the questions over the telephone and complete 
the questionnaire on your behalf. The person telephoning you would be a research 
assistant working for CCS NHS Trust. They would talk you through each question 
on the phone and then send your completed questionnaire to the UEA, nobody 
directly involved in the service would see the responses you gave. 
 
If you’d like to arrange for somebody to telephone you to help you complete the 
questionnaire, please call me, Pippa Scrimshaw on 01353 652233 and I will then 
ask the research assistant to telephone you. Furthermore, if you have been sent 
this questionnaire, but think that there is someone else who would be better suited 
to complete it; please telephone me on the number above. If you have any other 
concerns or questions about this questionnaire or study, you can also speak to me 
about these by telephoning the same number.   
 
When the results have been analysed we may try to publish them in an academic 
journal so people elsewhere can also learn from our evaluation. One of the 
researchers at the UEA is studying for a PhD and may use the results from this 
study for that. If you would like a copy of the report once it has been written, this 
can be arranged by telephoning me,  Pippa Scrimshaw on 01353 652233. 
 
Yours Sincerely, 
 
 
 
Pippa Scrimshaw 
Specialist Pharmacy Technician - Domiciliary Medicines Management 
 
 
 
 
 
 
 
 
 
 
Appendix 2.9 Summary of patient mean risk scores pre and 
post intervention using NPSA risk matrix
 Pre-intervention 
risk scores 
Post-intervention 
risk scores 
  Pre-intervention risk 
scores 
Post-intervention 
risk scores 
  Pre-intervention 
risk scores 
Post-intervention 
risk scores 
Patient ID Mean Category Mean Category  Patient ID Mean Category Mean Category  Patient ID Mean Category Mean Category 
01-PRI-D 18 EXTREME 4 MEDIUM  29-PRI-C 6 MEDIUM 5 MEDIUM  52-CAT-B 14 EXTREME 6 MEDIUM 
03-PRI-F 13 HIGH 5 MEDIUM  30-RIV-H 14 EXTREME 6 MEDIUM  54-STM-P 14 EXTREME 6 MEDIUM 
04-NOR-D 11 HIGH 4 MEDIUM  31-MER-B 6 MEDIUM 5 MEDIUM  55-CAT-H 11 HIGH 6 MEDIUM 
05-NOR-M 13 HIGH 2 LOW  32-MER-D 7 MEDIUM 5 MEDIUM  56-STG-S 6 MEDIUM 4 MEDIUM 
06-COR-S 10 HIGH 4 MEDIUM  33-STM-H 8 HIGH 5 MEDIUM  57-STM-S 13 HIGH 4 MEDIUM 
07-MER-L 5 MEDIUM 3 LOW  36-STG-C 17 EXTREME 5 MEDIUM  58-STM-M 12 HIGH 11 HIGH 
08-STM-M 19 EXTREME 13 HIGH  38-STM-S 15 EXTREME 7 MEDIUM  59-BUR-S 15 EXTREME 6 MEDIUM 
09-STM-R 13 HIGH 5 MEDIUM  39-STM-S 13 HIGH 4 MEDIUM  60-BUR-H 12 HIGH 5 MEDIUM 
10-STG-F 6 MEDIUM 3 LOW  41-BUR-R 21 EXTREME 8 HIGH  61-PRI-S 9 HIGH 5 MEDIUM 
11-TRI-C 14 EXTREME 5 MEDIUM  43-STA-F 14 EXTREME 4 MEDIUM  62-BUR-B 6 MEDIUM 5 MEDIUM 
12-STM-S 12 HIGH 5 MEDIUM  44-STM-O 17 EXTREME 4 MEDIUM  63-STA-R 8 HIGH 3 LOW 
14-NOR-M 14 EXTREME 5 MEDIUM  47-STM-C 15 EXTREME 2 LOW  64-STA-H 6 MEDIUM 3 LOW 
16-TRI-S 14 EXTREME 7 MEDIUM  48-TRI-W 16 EXTREME 2 LOW  65-STM-T 7 MEDIUM 7 MEDIUM 
17-GEO-S 12 HIGH 6 MEDIUM  49-BUR-C 18 EXTREME 4 MEDIUM  66-MER-M 15 EXTREME 3 LOW 
18-CLA-D 8 HIGH 3 LOW  50-STA-L 21 EXTREME 4 MEDIUM  67-CAT-S 15 EXTREME 3 LOW 
19-STM-R 13 HIGH 6 MEDIUM  51-STA-H 19 EXTREME 3 LOW  68-GEO-T 11 HIGH 5 MEDIUM 
20-STM-T 12 HIGH 5 MEDIUM  70-STA-C 17 EXTREME 11 HIGH  69-HAD-T 16 EXTREME 3 LOW 
21-MER-P 14 EXTREME 6 MEDIUM  75-PRI-T 6 MEDIUM 4 MEDIUM  35-GEO-P 17 EXTREME 4 MEDIUM 
22-MER-H 12 HIGH 7 MEDIUM  77-GEO-T 7 MEDIUM 4 MEDIUM  37-STG-C 12 HIGH 5 MEDIUM 
23-RIV-F 10 HIGH 6 MEDIUM  85-RIV-P 14 EXTREME 5 MEDIUM  40-RIV-H 11 HIGH 4 MEDIUM 
24-COR-H 6 MEDIUM 4 MEDIUM  13-NOR-M 5 MEDIUM 5 MEDIUM  42-STM-S 11 HIGH 4 MEDIUM 
25-GEO-H 11 HIGH 5 MEDIUM  27-MER-W 16 EXTREME 6 MEDIUM  45-GEO-D 11 HIGH 6 MEDIUM 
26-TRI-K 12 HIGH 7 MEDIUM  28-MER-W 16 EXTREME 6 MEDIUM  86-HAD-E 20 EXTREME 7 MEDIUM 
46-CAT-A 12 HIGH 6 MEDIUM  34-GEO-S 12 HIGH 3 LOW  87-STG-E 17 EXTREME 5 MEDIUM 
 
Appendix 2.9  Summary of mean risk scores assigned using NPSA risk matrix at pre and post intervention stage 
 
Pre-intervention 
risk scores 
Post-intervention 
risk scores 
  
Pre-intervention risk 
scores 
Post-intervention 
risk scores 
  Pre-intervention 
risk scores 
Post-intervention 
risk scores 
Patient ID Mean Category Mean Category 
 
Patient ID Mean Category Mean Category  Patient ID Mean Category Mean Category 
88-TRI-S 10 HIGH 2 LOW  97-JEN-D 10 HIGH 3 LOW  100-CAT-W 9 HIGH 6 MEDIUM 
89-STM-B 13 HIGH 2 LOW  98-NOR-T 12 HIGH 2 LOW  101-STM-F 6 MEDIUM 5 MEDIUM 
90-TRI-B 15 EXTREME 3 LOW  99-NOR-C 8 HIGH 5 MEDIUM  102-COR-H 7 MEDIUM 3 LOW 
91-GEO-E 13 HIGH 2 LOW  73-HAD-G 8 HIGH 6 MEDIUM  103-STM-W 13 HIGH 3 LOW 
92-CLA-J 15 EXTREME 2 LOW  76-MER-S 13 HIGH 7 MEDIUM  94-RIV-R 15 EXTREME 3 LOW 
95-PRI-N 11 HIGH 4 MEDIUM  83-STM-S 14 EXTREME 12 HIGH  81-PRI-D 13 HIGH 4 MEDIUM 
96-STM-C 13 HIGH 2 LOW  71-STA-S 15 EXTREME 3 LOW  84-MER-R 10 HIGH 7 MEDIUM 
72-JEN-D 8 HIGH 12 HIGH  93-MER-G 2 LOW 2 LOW  74-NOR-T 6 MEDIUM 6 MEDIUM 
80-STM-B 8 HIGH 5 MEDIUM  79-RIV-C 11 HIGH 7 MEDIUM  78-RIV-W 16 EXTREME 16 EXTREME 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2.10 Supporting data for ‘patient’s comments’ 
section of questionnaire  
  
Comments provided in patient questionnaires 
Positive comments described the effectiveness of the service but also focussed on the 
patient’s satisfaction with the SPT delivering the service as highlighted in the example 
patient comments provided below: 
“An excellent service which gave me great help (money well spent) when I was not 
able to cope with my drugs well and in a complete muddle”. 
“I would like to say my medicine lady is a really super person.  She is so easy to take 
to; she makes me feel so comfortable because she explains things, not using a lot of 
medicines words I don’t understand.  She talks so that I understand what she is saying, 
I look forward to her visits she’s a lovely lady and she makes me feel better too”. 
“This is the best support service I have received, what a wonderful asset to the NHS is 
Pippa Scrimshaw, she instantly put me at ease, she talked everything through with me 
and made sure that I had understood everything. I have severe hand problems and she 
found ways for me to manage things.  I would thoroughly recommend Pippa to visit 
anyone who has problems with tablets”. 
  
 
 
 
 
 
 
 
 
 
Appendix 2.11 Supporting data for ‘caregiver’s comments’ 
section of questionnaire 
  
Comments provided in patient caregiver questionnaires 
Comments focussed on feelings of less worry and greater confidence about correct 
medicines taking and also on general satisfaction and the personable approach and 
care offered by the SPT.  The selected quotes highlight these points: 
“This service has been a huge relief to me and my family.  Pippa Scrimshaw was so 
nice to my parents on her visit; she made them feel so at ease and happy to try out her 
recommendations which are working very well for the both.  Many thanks, a great 
service I say” 
“I was so grateful for the help and advice given that I have given your number to a 
friend in a similar situation” 
“I am more than pleased with the new arrangement and I am feeling more settled in my 
own piece of mind” 
 
 
 
 
 
 
 
 
 
 
Appendix 3.1 Theoretical domains and component 
constructs of the original TDF1 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3.1  Theoretical domains and constructs of TDF1 
Behavioural domain 
(Corresponding 
domain on Fishbein 
Framework)
Constructs
Knowledge
• Knowledge 
• Knowledge about condition 
• Schemas, mindsets and illness representations 
• Procedural knowledge 
Skills (Skills) 
• Skills 
• Competence, ability and skill assessment 
• Practice/skills development 
• Interpersonal skills 
• Coping strategies 
Social/professional 
role & identity (Self-
standards) 
• Identity 
• Professional identity/boundaries/roles 
• Group/social identity 
• Social/group norms 
• Alienation/organisational commitment 
Beliefs about 
capabilities (Self-
efficacy) 
• Self-efficacy 
• Control of behaviour, material & social environment 
• Perceived competence 
• Self/professional confidence 
• Empowerment 
• Self-esteem 
• Perceived behavioural control 
• Optimism/pessimism 
Beliefs about 
consequences 
(Anticipated 
outcomes/attitudes) 
• Outcome expectancies 
• Anticipated regrets 
• Appraisal/evaluation/review 
• Consequents 
• Attitudes 
• Contingencies 
• Reinforcements/punishment/consequences  
• Incentives/rewards 
• Beliefs 
• Unrealistic optimism 
• Salient events/sensitisation/critical incidents 
• Characteristics of outcome expectancies: 
o Physical, social and emotional, 
sanctions/rewards, proximal/distal, valued/not 
valued, probable/improbable, salient/not salient 
• Perceived risk/threat 
 
  
Social influences 
(Norms) 
• Social support 
• Social/group norms 
• Organisational development 
• Leadership 
• Team working 
• Group conformity 
• Organisational climate/culture 
• Social pressure 
• Power/hierarchy 
• Professional boundaries/roles 
• Management commitment 
• Supervision 
• Inter-group conflict 
• Champions 
• Social comparisons 
• Group and social identity 
• Organisational commitment/alienation 
• Feedback 
• Conflict – competing demands or conflicting roles 
• Change management 
• Resource management 
• Negotiation 
Motivation and goals 
(Intentions) 
• Intention; stability of intention/certainty of intention 
• Goals (autonomous, controlled) 
• Goal target/setting 
• Goal priority 
• Intrinsic motivation 
• Commitment 
• Distal and proximal goals 
• Transtheoretical model and stages of change 
Memory, attention 
and decision 
processes 
• Memory 
• Attention 
• Attention control 
• Decision making 
Environmental 
context and 
resources 
(environmental 
constraints) 
• Resources/ material resources (availability and 
management) 
• Environmental stressors 
• Person x environment interaction 
• Knowledge of task environment 
Appendix 3.1 (continued)  Theoretical domains and constructs of TDF1
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Appendix 3.1 (continued)  Theoretical domains and constructs of TDF1 
 
Reference for appendix 3.1 
1. Michie, S., et al. (2005). "Making psychological theory useful for implementing evidence 
based practice: a consensus approach." Quality and Safety in health care 14(1): 26-33. 
  
Emotion (Emotion) 
• Affect 
• Stress 
• Anticipated regret 
• Fear 
• Burn-out 
• Cognitive overload/tiredness 
• Threat 
• Positive/negative affect 
• Anxiety/depression 
Behavioural 
regulation 
• Goal/target setting 
• Implementation intention 
• Action planning 
• Self-monitoring 
• Goal priority 
• Generating alternatives 
• Feedback 
• Moderators of intention-behaviour gap 
• Project management 
• Barriers and facilitators 
Nature of the 
behaviour
• Routine/automatic/habit 
• Breaking habit 
• Direct experience/past behaviour 
• Representation of tasks 
• Stages of change model 
 
 
 
 
 
 
 
 
 
 
Appendix 3.2 Theoretical domains and refined definitions of 
updated TDF1 
Domain Definition 
Knowledge An awareness of the existence of something 
Skills An ability of proficiency acquired through practice 
Social/professional role & 
identity 
A coherent set of behaviours and displayed personal 
qualities of an individual in a social or work setting 
Beliefs about capabilities 
 
Acceptance of the truth, reality, or validity about an 
ability, talent or facility that a person can put to 
constructive use 
Optimism 
 
The confidence that things will happen for the best or 
that desired goals will be obtained 
Beliefs about consequences 
 
Acceptance of the truth, reality or validity about 
outcomes of a behaviour in a given situation 
Reinforcement 
 
Increasing the probability of a response by arranging a 
dependent relationship, or contingency between the 
response and a given stimulus 
Intentions 
 
A conscious decision to perform a behaviour or a 
resolve to act in a certain way 
Goals 
 
Mental representations of outcomes or end states that 
an individual wants to achieve 
Memory, attention and 
decision processes 
 
The ability to retain information, focus selectively on 
aspects of the environment and choose between two or 
more alternatives 
Environmental context and 
resources 
 
Any circumstances of a person’s situation or 
environment that discourages or encourages the 
development of skills and abilities, independence, 
social competence and adaptive behaviour 
Social influences 
 
Those interpersonal processes that can cause 
individuals to change their thoughts, feelings and 
behaviours 
Emotion 
 
A complex reaction pattern involving experiential, 
behavioural and physiological elements, by which the 
individual attempts to deal with a personally significant 
matter or event 
Behavioural regulation 
 
Anything aimed at managing or checking objectively 
observed or measured actions 
Table A3.2 Domains and definitions of the refined TDF
Reference for appendix 3.2 
1. Cane, J., et al. (2012). "Validation of the theoretical domains framework for use in 
behaviour change and implementation research." Implementation Science 7(1): 37. 
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Appendix 3.3 Summary of Abraham and Michie’s 26 
Behaviour Change Techniques (BCTs)1 
Behaviour change technique Description/definition 
Provide information about the 
behaviour-health link 
General information about behavioural risk, for example susceptibility to poor health outcomes or mortality risk 
in relation to behaviour 
Provide information on 
consequences 
Information about the benefits and costs of action or inaction, focussing on what will happen if the person does 
or does not perform the behaviour 
Provide information about others 
approval 
Information about what others think about the person’s behaviour and whether others will approve or disapprove 
of any proposed behaviour change 
Prompt intention formation Encouraging the person to decide to act or set a general goal, for example, to make a behavioural resolution 
such as “I will take more exercise next week” 
Prompt barrier identification Identify barriers to performing the behaviour and plan ways to overcome them 
Provide general encouragement Praising or rewarding the patient for effort or performance without this being contingent on specified behaviours 
or standards of performance 
Set graded tasks Set easy tasks and increase difficulty until target behaviour is performed 
Provide instruction Telling the person how to perform the behaviour and/or preparatory behaviours 
Model or demonstrate the behaviour An expert shows the person how to correctly perform the behaviour, for example in a class or on video 
Prompt specific goal setting Involves detailed planning of what the person will do, including a definition of the behaviour specifying 
frequency, intensity or duration and specification of at least one context, that is, where, when, how or with whom 
Prompt review of behavioural goals Review and/or reconsideration of previously set goals or intentions 
Prompt self-monitoring of behaviour The person is asked to keep a record of the specified behaviour(s) (e.g. in a diary) 
Provide feedback on performance Providing data about the recorded behaviour or evaluating performance in relation to a set standard or others’ 
performance, i.e. the person received feedback on their behaviour 
Provide contingent rewards Praise, encouragement or material rewards that are explicitly linked to the achievement of specified behaviours 
Teach to use prompt or cues Teach person to identify environmental cues that can be used to remind them to perform a behaviour including 
times of day or elements of contexts 
Agree on behavioural contract Agreement (e.g. signing) of a contract specifying behaviour to be performed so that there is a written record of 
the person’s resolution witnessed by another 
Prompt practice Prompt the person to rehearse and repeat the behaviour or preparatory behaviours  
Use follow-up prompts Contacting the person again after the main part of the intervention is complete 
Table A3.3 Summary of Abraham and Michie’s taxonomy of behaviour change techniques used in interventions1 
Behaviour change technique Description/definition 
Provide opportunities for social 
comparison 
Facilitate observation of non-expert others’ performance for example, in a group class or using video or case 
study 
Plan social support or social change Prompting consideration of how others could change their behaviour to offer the person help or (instrumental) 
social support, including ‘buddy’ systems and/or providing social support 
Prompt identification as a role model Indicating how the person may be an example to others and influence their behaviour or provide an opportunity 
for the person to set a good example 
Prompt self-talk Encourage the use of self-instruction and self-encouragement (aloud or silently) to support action 
Relapse prevention Following initial change, help identify situations likely to result in readopting risk behaviours or failure to maintain 
new behaviours and help person to plan to avoid or manage these situations 
Stress management May involve a variety of techniques (e.g. progressive relaxation) that do not target the behaviour but seek to 
reduce anxiety and stress 
Motivational interviewing Prompting the person to provide self-motivating statements and evaluations of their own behaviour to minimise 
resistance to change 
Time management Helping the person to make time for the behaviour (e.g. to fit into a daily schedule) 
Table A3.3 Summary of Abraham and Michie’s taxonomy of behaviour change techniques used in interventions1 
Reference for table A3.3 
1. Abraham, C. and S. Michie (2008). "A taxonomy of behavior change techniques used in interventions." Health Psychology 27(3): 379. 
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Appendix 3.4 Summary of the BCTs deemed to be effect for 
changing the behavioural domains of the TDF1 
 
  
Theoretical domain 
of TDF 
BCTs agreed to be effective1  
Social/ professional 
roles & identity 
• Social processes of encouragement, pressure and support 
Knowledge • Information regarding behaviour, outcome 
Skills • Goal target specified: behaviour or outcome 
• Monitoring 
• Self-monitoring 
• Rewards; incentives (inc. self-evaluation) 
• Graded task, starting with easy task 
• Increasing skills: problem-solving, decision-making, goal-
setting 
• Rehearsal of relevant skills 
• Modelling/demonstration of behaviour by others 
• Homework 
• Perform behaviour in different settings  
Beliefs about 
capabilities 
• Self-monitoring 
• Graded task, starting with easy task 
• Increasing skills: problem-solving, decision-making, goal-
setting 
• Coping skills 
• Rehearsal of relevant skills 
• Social processes of encouragement, pressure and support 
• Feedback 
• Self-talk 
• Motivational Interviewing 
Beliefs about 
consequences 
• Self-monitoring 
• Persuasive communication 
• Information regarding behaviour, outcome 
• Feedback 
Motivation and 
goals 
• Goal target specified: behaviour or outcome 
• Contract 
• Rewards; incentives (inc. self-evaluation) 
• Graded task, starting with easy task 
• Increasing skills: problem-solving, decision-making, goal-
setting 
• Social processes of encouragement, pressure and support 
• Persuasive communication 
• Information regarding behaviour, outcome 
• Motivational Interviewing 
Memory, attention, 
decision and 
processes 
• Self-monitoring 
• Planning, implementation 
• Prompts, triggers, cues 
Environmental 
context & resources 
• Environmental changes e.g. objects to facilitate behaviour 
Social influences • Social processes of encouragement, pressure and support 
Table A3.4 Summary of effective BCTs for changing behaviours 
Theoretical domain 
of TDF 
BCTs agreed to be effective1 
Emotion • Stress management 
• Coping skills 
Action planning • Goal target specified: behaviour or outcome 
• Contract 
• Planning, implementation 
• Prompts, triggers, cues 
• Use of imagery 
Table A3.4 (continued) Summary of effective BCTs for changing behaviours 
Reference for table A3.4 
1. Michie, S., et al. (2008). "From Theory to Intervention: Mapping Theoretically Derived 
Behavioural Determinants to Behaviour Change Techniques." Applied Psychology 
57(4): 660-680. 
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Appendix 4.1 Literature search strategy for systematic review 
  
Table A4.1: Search terms applied to OVID interface and CINAHL database 
The following terms were individually applied to the NeLM database: 
Medication adherence cognitive techniques, medication adherence motivational 
interviewing, drug adherence motivational interviewing, cognitive intervention 
medication adherence, implementation intentions medicine, if then planning adherence, 
behaviour change counselling adherence, motivational behaviour change adherence, 
medication compliance motivational interviewing, motivational enhancement therapy 
adherence, motivational enhancement therapy. 
  
No. Search term 
1 medication* .ti,ab OR  drug* .ti,ab OR  medicine.ti,ab  OR  patient.ti,ab 
2 adheren*.ti,ab OR complian*.ti,ab OR concordan*.ti,ab OR  non-adheren*.ti,ab 
OR  non adheren*.ti,ab. OR  non-complian*.ti,ab OR  non complian*.ti,ab. OR 
persist*.ti,ab. 
3 1 AND 2 
4 motivation* interview*.ti,ab OR  motivation* enhancement therap*.ti,ab. OR  
behavio?r change counsel?ing.ti,ab OR implementation* intention*.ti,ab. OR  if-
then plan*.ti,ab OR  if then plan*.ti,ab. OR motivation* counsel?ing.ti,ab. OR  
motivation* behavio?r.ti,ab OR  motivation* change.ti,ab. OR  motivation* 
intervention*.ti,ab. OR  health behavio?r change*.ti,ab. OR  brief 
intervention*.ti,ab. OR  cognitive intervention*.ti,ab. OR  cognitive technique*.ti,ab 
OR  health behavio?r counsel?ing.ti,ab. OR  problem solving treatment*.ti,ab. OR  
problem solving therap*.ti,ab 
5  3 AND 4 
6 Remove duplicates from 5 
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Appendix 4.2 Summary of studies included in meta-analysis 
Multi-component intervention using non-specific techniques 
 
Study Study 
type 
Study setting Disease 
area 
Intervention 
personnel 
Delivery personnel 
training 
Intervention 
delivery style 
Intervention length 
(average) 
Follow 
up 
period 
Bailey et al. 
19901 
RCT Hospital clinic, 
USA 
Asthma Specialist No details given Telephone calls 
and in person 
240 hours (4 x 60min 
sessions) over unknown 
period 
12 
months 
Hovell et al. 
20032 
RCT Hospital clinic, 
USA 
TB Researcher Trained research 
assistants used but no 
details provided 
Telephone calls 
and in person 
12 sessions of 15-30 
minutes over 6 months 
9 
months 
Molassiotis 
et al. 20033 
RCT Hospital clinic, 
Hong Kong 
HIV Routine HCP No details given In person 12 sessions of unknown 
duration over 3months 
6 
months 
Murphy et al. 
20024 
RCT 
pilot 
Community 
clinic, USA 
HIV Specialist No details given as 
delivered by specialist  
In person Unknown number of 
sessions of unknown 
duration over 7 weeks  
3 
months 
Pradier et al. 
20035 
RCT Hospital clinic, 
France 
HIV Routine HCP Five day intense training 
course delivered by 
psychologists and 
monthly supervision 
In person 3 sessions of 45-60 
minutes over 3 months 
6 
months 
Put et al. 
20036 
RCT Hospital clinic,  
Belgium 
Asthma Researcher No details given In person 360 hours (6 x 60 minutes 
sessions) over 3 months 
6 
months 
Remien et al. 
20057 
RCT Community 
clinic, USA 
HIV Routine HCP HCPs trained and 
supervised; no further 
details given 
In person 4 sessions of 45-60 
minutes over 5 weeks 
8 weeks 
Smith et al. 
20038 
RCT Community 
research 
office, USA 
HIV Routine HCP No details given In person Unknown number of 
sessions of unknown 
duration over 12 weeks 
12 
weeks 
Tuldra et al. 
20009 
RCT Hospital clinic, 
Spain 
HIV Routine HCP Training delivered by a 
trained psychologist; no 
further details given 
Unknown No details provided  48 
weeks 
Table A4.2 Summary of interventions included in meta-analysis 
Multi-component intervention using non-specific techniques 
 
Study Study 
type 
Study setting Disease 
area 
Intervention 
personnel 
Delivery personnel training Intervention 
delivery style 
Intervention length 
(average) 
Follow 
up 
period 
Van Es et 
al. 200110 
RCT Hospital clinic, 
Netherlands 
Asthma Routine HCP Interventions delivered by 
‘specially trained asthma 
nurses’; no further details given 
In person 7 sessions of 30-90 
minutes over 12 months 
2 years 
Wagner 
et al. 
200611 
RCT Community 
clinic, USA 
HIV Routine HCP Training delivered by trained 
research nurse and feedback 
offered; no further details given. 
In person Unknown number of 
sessions of 30-45 minutes 
over 48 weeks 
48 
weeks 
Weber et 
al. 200412 
RCT 
pilot  
Psychotherapy 
clinic, 
Netherlands 
HIV Specialist  Intervention delivered by trained 
psychotherapist; no further 
training described 
In person 11 sessions of 45 minutes 
over 12 months  
12 
months 
Interventions using MI alone as one component 
 
Study Study 
type 
Study setting Disease 
area 
Intervention 
personnel 
Delivery personnel training Intervention 
delivery style 
Intervention length 
(average) 
Follow 
up 
period 
DiIorio et 
al. 2008 
13
 
RCT Hospital clinic, 
USA 
HIV Routine HCP 24 hours worth of training by 
certified MI trainers, skills 
assessment, on-going training & 
booster sessions as needed 
Mostly in person 
with some 
telephone calls  
5 sessions of 35 minutes 
over 12 months 
12 
months 
Lavoie et 
al. 2011 
14
 
RCT Hospital clinic , 
Canada 
Asthma Unknown No details given In person 3 sessions of 30 minutes 
over 6 weeks 
6 months 
Table A4.2 (continued) Summary of interventions included in meta-analysis 
 
 
Multi-component intervention using MI 
 
Study Study 
type 
Study setting Disease 
area 
Intervention 
personnel 
Delivery personnel 
training 
Intervention 
delivery style 
Intervention length 
(average) 
Follow 
up period 
Cook et 
al. 200715 
Non-
RCT 
Telephone calls 
to patients at 
home, USA 
Osteoporosis Routine HCP No details given, 
registered nurses used 
to deliver intervention  
 
Telephone 
calls 
1 hour (4 x 15 minute 
sessions) over 4 
months 
6 months 
George et 
al. 201016 
RCT Community 
pharmacies, 
Australia and 
Tasmania 
Hypertension Routine HCP Face-to-face and online 
training, largely about 
study design and 
rationale, no other 
details given 
In person 3 sessions of unknown 
duration over 6 months 
6 months 
Golin et 
al.  200617 
RCT Community 
clinic, USA 
HIV Specialist 3 full days training by 
accredited MI trainers 
In person 2 sessions of unknown 
duration over 2 months 
3 months 
Ireland et 
al. 201018 
Before 
& after 
Hospital clinic , 
Canada 
Hypertension Routine HCP Group training provided, 
no details given 
In person and 
telephone calls 
4.8 hours delivered 
over 7 sessions in 6 
months 
6 months 
 
Lawrence 
et al. 
200819 
Non-
RCT 
Telephone calls 
to patient’s at 
home, USA 
CVD Routine HCP Training on health 
behaviour change 
techniques, no other 
details provided 
Telephone 
calls 
One-off intervention of 
unknown duration 
3 months 
Riekert et 
al. 201120 
Before 
& after 
Visits to patients 
own homes, 
USA 
Asthma Routine HCP Two days MI training 
delivered by a specialist, 
role play training & bi-
weekly supervision 
In person 5 sessions of 30-40 
minutes delivered over 
8 weeks  
10 weeks 
Safren et 
al. 200121 
RCT 
pilot 
Community 
clinic, USA 
HIV Routine HCP No details given In person One-off intervention of 
unknown duration  
12 weeks 
Thrasher 
et al. 
200622 
Before 
& after 
Community 
clinic, USA 
HIV Specialist 3 full days training by MI 
experts, bi-weekly 
feedback and group 
meetings  
In person 1 hour ( 2 x 30 minute 
sessions) delivered 
over 12 weeks 
12 weeks 
Table A4.2 (continued) Summary of interventions included in meta-analysis 
Interventions using techniques based on MI 
 
Study Study 
type 
Study 
setting 
Disease 
area 
Intervention 
personnel 
Delivery personnel 
training 
Intervention 
delivery style 
Intervention length 
(average) 
Follow up 
period 
Berger et al.  
200523 
RCT Telephone 
calls to 
patients at 
home, USA 
Multiple 
Sclerosis 
Researcher 8 hour training sessions on 
study background, role 
playing and case scenarios 
Telephone calls 9 sessions of 
unknown duration 
delivered over 3 
months 
3 months 
De Bruin et 
al. 200524 
Before 
& after 
Hospital 
clinic, 
Netherlands  
HIV Routine HCP Interventions delivered by 
trained HIV nurse; no 
further details provided 
In person 2 sessions lasting 
10-45 minutes 
delivered over 3 
months 
3 months 
DiIorio et al. 
200325 
RCT 
pilot 
Community 
clinic, USA 
HIV Routine HCP 25 hours of training and 
practice sessions by MI 
trainer and evaluation of 
counselling skills 
In person 5 x 35 minutes 
sessions delivered 
over 12 months 
8 weeks 
Kalichman et 
al. 200526 
Before 
& after 
Community 
based non-
clinical 
setting, USA 
HIV Routine HCP Intervention delivered by 
‘staff with experience in the 
field’; no further details 
provided 
In person 3 sessions lasting 
2.5 hours in total 
delivered over 3 
weeks 
3 months 
Ogedegbe et 
al. 200827 
RCT Community 
clinic, USA 
Hypertension Researcher 2 full day training sessions 
delivered by experienced MI 
trainers plus one day 
booster session 
In person 4 sessions lasting 
30-40 minutes 
delivered over 12 
months 
12 months 
Interventions using III 
 
Study Study 
type 
Study setting Disease area Intervention 
personnel 
Delivery personnel 
training 
Intervention 
delivery style 
Intervention length 
(average) 
Follow up 
period 
Brown et 
al. 200928 
RCT  Hospital clinic, 
UK 
Epilepsy Not in person Not delivered in person Questionnaire 
completion 
One-off intervention 
of unknown duration 
1 month 
Sheeran 
et al. 
199929 
RCT Visits to 
patient’s at 
home, UK 
Vitamin 
Supplements 
Not in person Not delivered in person  Questionnaire 
completion 
One-off intervention 
of unknown duration 
3 weeks 
Table A4.2 (continued) Summary of interventions included in meta-analysis 
References for table A4.2 
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Appendix 4.3 Identified intervention components for studies 
included in meta-analysis 
 
Multi-component intervention using non-specific techniques 
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Interventions using MI as sole component 
Study Identified intervention components 
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Table A4.3 (continued) Identified intervention components for studies included in meta-analysis 
 
Multi-component interventions using MI 
Study Identified intervention components 
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Invention using MI-based techniques 
Study Identified intervention components 
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Table A4.3 (continued) Identified intervention components for studies included in meta-analysis 
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Table A4.3 (continued) Identified intervention components for studies included in meta-analysis 
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Appendix 5.1 Ethics committee communications for consultation 
exercises 
 
  

 
 
Dear Claire 
Project Title: Development of a screening tool to identify patient barriers to medication 
adherence. 
Reference: 2012/2013-04 
The amendments to you above proposal have been considered be the Chair of the Faculty 
Research Ethics Committee and we can confirm that your proposal has been approved. 
Please could you ensure that any further amendments to wither the protocol or documents 
submitted are notified to us in advanced and also that any adverse events which occur during 
your project are reported to the Committee. Please could you also arrange to send us a report 
once your project is completed. 
The Committee would like to wish you good luck with your project. 
Yours sincerely 
 
 
Yvonne Kirkham 
Project Officer 
  
 
 
Claire Easthall 
School of Pharmacy 
University of East Anglia 
Norwich Research Park 
Norwich 
NR4 7TJ 
  
Research & Enterprise Services 
REN West (SCI) 
University of East Anglia 
Norwich  
NR4 7TJ 
 
21 November 2012 
 
 
 
 
 
 
 
 
 
 
Appendix 5.2 Example of ‘recruitment poster’ used in participant 
consultation exercise 
 
  
 
 
 
Researchers from the School of Pharmacy at the University of East Anglia are looking 
for volunteers to help with an important part of their study. 
 
 
We need people who are: 
• Prescribed any medicines to prevent heart disease; this includes low dose aspirin, 
blood pressure medicines and ‘statins’ to reduce cholesterol 
• Aged over 18 years of age 
• Able to read and speak English 
• Not taking medicines for the treatment of addiction or mental health problems 
 
If you know anybody who matches these criteria and who you think may like to join 
the study, please let them know of the study and pass on the researchers contact 
details. 
 
 
If selected, you will be invited to attend an informal meeting between two researchers 
and 6-8 other members of the public.  The group will be asked for their thoughts on 
some written statements concerning why people may not take their medicines as 
prescribed.  
The meeting will last two hours and will most likely be held at the UEA.  Participants 
will be given a £10 high street shopping voucher as a thank you for their time.   
 
 
If you’re interested in participating in this study (or you know somebody else who is) 
please contact the lead researcher Claire Easthall on c.easthall@uea.ac.uk or 
01603 591973 with your contact details. An information pack containing a consent 
form and full details of the study will be sent to you, with instructions for what to do if 
you would like to participate. 
 Finding out the difficulties of taking 
medicines: An invitation to participate 
in a focus group study 
Who are we looking for? 
What would you have to do if you participate? 
Who should I contact if I’m interested in participating? 

 
 
 
 
 
 
 
 
 
Appendix 5.3 Participant information leaflet for consultation 
exercise
  

 
 
 
 
 
 
 
 
 
 
 
Appendix 5.4 Consent form for participant consultation 
exercise 
  
 
   
Thank you for taking an interest in this study. If you would like to take part in the focus 
groups, please complete this consent form by initialling the boxes below and filling in 
the details at the bottom of the form.  Once completed, please return this form, together 
with the brief survey, to the University of East Anglia (UEA), by post, using the pre-paid 
envelope provided. Alternatively if you are based at UEA, the forms can be returned to 
Claire Easthall in the School of Pharmacy via the internal mail system. 
 
 
 
 
 
 
1. I confirm that I have read and understand the information sheet 
dated Oct. 2012 (version 2) for the above study.   
 
2. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
  
3.  I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my 
medical care or legal rights being affected. 
 
4. I am willing to allow the discussion within the focus group to be 
audio-taped for the purposes of analysing the conversations that 
take place. 
 
5.  I understand that the research team will use the information that I 
give on the brief survey to decide whether I am suitable for the 
focus group and that they will contact me accordingly with further 
details. 
 
6.  I understand that the research team will contact me again after the 
focus group to ask my thoughts on the questionnaire that they have 
developed. 
 
7. I agree to take part in the above study.    
 
Family name:  _________________  First name:  ________________________ 
 
Signature:       _________________  Date:          _______________________ 
Focus group consent form  
Finding out the difficulties of taking medicines: 
focus group consent form  

 
 
 
 
 
 
 
 
 
 
 
Appendix 5.5 Brief survey for consultation exercise 
recruitment 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5.6 Summary of study characteristics of studies included 
in literature review of medication adherence barriers 
Table A5.6 Summary of studies included in literature review of adherence barriers 
 
Author and date Full text used? Disease area Population Barrier identification 
method 
No. of 
participants/studies 
Alqasem et al. 
20102 
No – conference 
abstract 
Hypertension Patients from the United Arab 
Emirates receiving anti-
hypertensives 
Semi-structured interviews 20 hypertensive patients 
recruited from cardiology 
outpatient clinic 
Amico et al. 
20073 
Yes HIV HIV positive patients in the 
deep south of America 
Patient interviews 72 HIV+ patients 
confessing self-reported 
non-adherence 
Biadgilign et al. 
20094 
 
No- full text not 
available 
HIV Paediatric HIV+ patients in 
Ethiopia 
Qualitative study – no 
specific details 
12 caregivers and 14 key 
informants from 5 hospitals  
Bregnballe et al. 
20115 
Yes Cystic Fibrosis (CF) Danish adolescents and young 
adults with CF  
Questionnaire based survey 88 adolescents and 161 
parents 
Buchanan et al. 
20126 
Yes HIV USA based HIV infected 
children and youth 
Questionnaire regarding 
potential barriers 
120 patients 
Campbell et al. 
20127 
No – conference 
abstract 
Chronic conditions Cognitively impaired older 
adults  
Systematic review 10 observational studies  
Cedillo-Galindo & 
Gracida 20118 
Yes Immunosuppressive 
therapy – renal 
transplant  
Renal transplant recipients in 
Mexico 
Patient surveys 177 patients 
Compton et al. 
20109 
Yes Chronic conditions US based Latino patients who 
had failed to collect a repeat 
prescription from the pharmacy 
Patient survey over 
telephone 
38 patients 
Constantiner & 
Cukor 201110 
No – could not 
access 
Immunosuppressive 
therapy – renal 
transplant  
US based renal transplant 
patients 
Patient questionnaires 94 patients 
Dahab et al. 
200811 
Yes HIV South African HIV+ patients Qualitative interviews 6 Patients on ART therapy 
and 6 healthcare providers 
Table A5.6 (continued) Summary of studies included in literature review of adherence barriers 
Author and 
date 
Full text used? Disease area Population Barrier identification 
method 
No. of participants/studies 
 
Dennis et al. 
201112 
Yes Hypertension Indian based patients with 
hypertension 
Patient questionnaire 608 patients  
Dziuban et al. 
201013 
Yes Cystic fibrosis (CF) US based adolescents 
with CF 
Patient questionnaire 60 patients 
Ellis et al. 
201114 
Yes Dermatology Caregivers of US based 
children with skin problems 
e.g. eczema 
Caregiver survey 101 caregivers of children 
attending dermatology outpatient 
clinic 
Farsaei et al. 
201015 
No – conference 
abstract 
Type two diabetes Iranian patients taking oral 
anti-diabetic drugs 
Open ended questions 248 patients 
Fetzer et al. 
201116 
No – could not 
access 
HIV Paediatric patients in a 
sub-Saharan setting 
In depth qualitative 
interviews 
24 HIV positive children and their 
caregivers  
Fields et al. 
201217 
No – conference 
abstract 
HIV Adolescents with HIV 
(country unknown) 
Semi-structured interviews 30 patients 
Gadkari et al. 
201118 
No – conference 
abstract 
General chronic conditions General populations Systematic review 117 studies included 
Gellad et al. 
201119 
Yes Chronic conditions -elderly USA based elderly 
patients 
Systematic review 9 studies included (cost and 
regimen complexity excluded) 
Gidman et al. 
201120 
No – conference 
abstract 
Chronic diseases Adolescent school children 
in UK 
Semi-structured focus 
groups 
23 school children 
Gordon et al. 
200921 
Yes Immunosuppressive 
therapy 
US based renal transplant 
patients 
Semi-structured interviews 82 patients 
Greenley et al. 
201022 
Yes Inflammatory bowel 
disease 
Adolescents with IBD – US 
based 
Self-report questionnaires 64 adolescents and 86 parents 
Ibrahim et al. 
201123 
No- full text not 
available 
Chronic diseases – 
diabetes, hypertension or 
hyperlipidaemia 
Patients in the United Arab 
Emirates 
Patient questionnaire 240 patients 
Ingerski et al. 
201024 
Yes Inflammatory bowel 
disease (IBD) 
US based adolescents 
with IBD 
Questionnaires and semi-
structured interviews 
174 adolescents and their carers 
Table A5.6 (continued) Summary of studies included in literature review of adherence barriers 
Author and 
date 
Full text used? Disease area Population Barrier identification method No. of 
participants/studies 
 
Joglekar et al. 
201125 
Yes HIV Indian patients with HIV Patient interviews 32 patients 
Kennedy et al. 
200826 
Yes Chronic illnesses US based medicare patients Patient survey 664 patients 
Konkle-Parker 
et al. 200827 
Yes HIV Minority populations in southern 
US states 
3 focus groups 20 patients with HIV 
Kripalani et al. 
200828 
Yes Cardiovascular 
(acute coronary 
syndrome(ACS)) 
US based patients recently 
discharged from hospital 
following an admission for ACS 
Telephone interviews 84 patients  
Kulchaitanaroaj 
et al. 201029 
No – conference 
abstract 
HIV HIV+ patients living in rural 
states of USA 
Patient survey 202 patients 
Kumarasamy et 
al. 200530 
 
Yes HIV HIV+ Indian patients In-depth patient interviews 60 patients  
Lacey et al. 
200931 
Yes Glaucoma UK based patients with 
glaucoma 
Focus groups and semi-structured 
interviews 
24 patients 
Marhefka et al. 
200832 
Yes HIV US based paediatric HIV 
patients 
Caregiver interviews Caregivers of 127 HIV 
positive children 
Mills et al. 
200633 
Yes HIV Multi-national including both 
developed and developing 
nations 
Systematic review and meta-
analysis of patient reported barriers 
84 studies including both 
qualitative and 
quantitative work 
Morales et al. 
201234 
Yes Immunosuppressive 
therapy 
Spanish liver and renal 
transplant patients 
Patient questionnaire 1983 renal transplant 
and 1479 liver transplant  
patients 
Murray et al. 
200935 
Yes HIV Urban Zambian women with HIV Qualitative techniques – free listing 
and key informant interviews 
47 patients 
Table A5.6 (continued) Summary of studies included in literature review of adherence barriers
Author and 
date 
Full text used? Disease area Population Barrier identification method No. of participants/studies 
 
Nair et al. 
201136 
Yes Hypertension US based non-adherent 
hypertensive patients 
Telephone survey 2451 patients 
Odegard and 
Gray 200837 
No – could not 
access 
Type two diabetes US based patients with poorly 
controlled type 2 diabetes 
Questionnaire 77 patients 
Pallares et al. 
200938 
Yes Cardiovascular  US based patients taking 
clopidogrel post stent placement 
Telephone interviews 257 patients 
Peyrot et al. 
201239 
Yes Diabetes Insulin dependent diabetics from 
China, France,  Japan, Germany, 
USA and UK 
Internet survey of patients and 
healthcare providers 
1250 healthcare providers 
and 1530 patients  
Senkomago et 
al. 201140 
Yes HIV Rural HIV population in Uganda Self-reported questionnaire 140 patients 
Silva et al. 
200941 
No – conference 
abstract 
Hypertension Portuguese patients with 
hypertension 
Self-reported questionnaire 1005 patients 
Simons et al. 
200942 
Yes Immunosuppressive 
therapy 
US based adolescent transplant 
recipients 
Interviews with patients and 
their caregivers 
80 patients and their 
caregivers 
Sleath et al. 
200943 
Yes Glaucoma Indian patients with glaucoma Patient survey 243 patients 
Talati et al. 
201044 
No- conference 
abstract 
Asthma Inner city African American 
adolescents with asthma 
Focus groups 4 patients 
Toh et al. 
201045 
Yes Heart failure Australian patients with chronic 
heart failure 
Observational study  66 patients 
Turner et al. 
200946 
Yes Hypertension Racially diverse group of elderly 
patients in USA with hypertension 
Telephone survey 202 patients 
Van der Loock 
et al. 201147 
No – conference 
abstract 
Immunosuppressive 
therapy – transplant  
Renal, liver and heart transplant 
recipients – unknown country  
Novel questionnaire to identify 
barriers 
440 transplant recipients 
Vawter et al. 
200848 
Yes Hypertension (HT) US based – adults with 
hypertension 
Data from larger ‘health styles’ 
survey 
1432 survey respondents 
receiving medicines for HT 
References for table A5.6 
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Appendix 5.7 Preliminary adherence barriers statements 
 
Whilst positively and negatively phrased statements were created, only one option for 
each statement is shown. 
* In barrier column represents a barrier added in from background knowledge and 
NOT something identified through literature search 
* In adherence barrier statement column represents a negatively phrased statement 
that will be reverse scored in the questionnaire 
     Barrier                                     Adherence barrier statements 
 
 
 
 
 
 
 
 
 
Figure A5.7.1 Adherence barriers and proposed statements for the 
‘knowledge’ behavioural domain 
     Barrier                                 Adherence barrier statements 
 
 
 
 
        
 
 
 
Figure A5.7.2 Adherence barriers and proposed statements for the 
‘skills’ behavioural domain 
 
Practical difficulties 
administering medicines 
I have difficulties administering my medicines* 
I am physically able to take all of my medicines 
correctly 
I am able to take the correct dose of my medicines 
I am able to take my medicines at the correct times 
Difficulties reading or 
understanding directions 
I don’t understand the directions given to me about 
taking my medicines* 
Poor knowledge of 
instructions 
I don’t know how to take my medicines correctly* 
Poor knowledge of regimen I know when to take my medicines correctly 
Poor knowledge of disease 
  
I know why I have been prescribed my medicines 
I don’t know how my medicines will help me* 
Poor knowledge of how to 
obtain a repeat prescription 
I know how to get further supplies of my medicines 
I know why I should take my medicines 
       Barrier                                      Adherence barrier statement 
 
 
 
 
 
 
 
 
 
 
Figure A5.7.3  Adherence barriers and proposed statements for the 
‘memory, attention and decision making processes’ 
behavioural domain 
  Barrier                                     Adherence barrier statements 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A5.7.4 Adherence barriers and proposed statements for the 
‘beliefs about consequences’ behavioural domain 
 
Forgetting to take medicines I forget to take my medicines* 
Forgetting to order/ collect 
prescription 
I remember to order/ collect my medicines 
Running out of medicines or 
losing medicines 
Being easily distracted I’m easily distracted when taking my medicines* 
I never run out of my medicines 
Justifiable reasons for non-
adherence reflecting decision 
making processes* 
I have good reasons for not taking my medicines 
correctly* 
Mistrust in medicines Medicines should not be trusted* 
Fear that medicines will be 
harmful 
Taking my medicines is harmful to me* 
Lack of belief in efficacy of 
medicines 
I need to take my medicines to keep me in good 
health and prevent future illness 
I don’t think my medicines work for me* Thinking medication is not 
working 
Stopping medicines when 
feeling better 
I keep taking my medicines as prescribed, even if I 
feel better 
Not thinking there is a need 
for treatment/medication 
Taking my medicines correctly is important for my 
health and wellbeing 
 
Denial of existence of illness 
or non-acceptance of 
diagnosis 
I do not believe that I have a medical condition that 
needs to be treated* 
                  Barrier                                       Adherence barrier statements 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A5.7.5 Adherence barriers and proposed statements for the 
‘beliefs about capabilities’ behavioural domain 
                Barrier                                       Adherence barrier statement 








Figure A5.7.6 Adherence barriers and proposed statements for the 
‘environmental constraints’ behavioural domain 
Regimen too complex 
confusing/too many pills 
I take too many medicines to be able to be able to 
take them all correctly* 
Frequent changes to regimen 
I struggle to take my medicines correctly as they are 
always changing* 
Doubting own ability to adhere I don’t think I can take my medicines correctly* 
Lack of confidence in adhering* I feel confident about taking my medicines correctly 
Lack of confidence to 
overcome adherence barriers* 
If I had any difficulties in taking my medicines 
correctly, I feel confident that I could find a way to 
overcome this 
Inability to cope with difficulties 
or problems* 
I can’t cope if there’s a problem with my medicines* 
Finding the behaviour difficult* I find it really difficult to take my medicines correctly* 
Experience of side effects I am confident I could resolve any difficulties caused by side effects from my medicines. 
Wanting to maintain control I feel in control of my health by taking my medicines 
Cost of medication Taking my medicines correctly is too expensive for me* 
Transport difficulties with 
getting to pharmacy or clinic 
appointments 
I can easily get to my local pharmacy or surgery to 
collect my medicines 
Being away from home/ 
travelling
Travelling or being away from home stops me from 
taking my medicines correctly* 
Problems with pharmacy 
e.g. not stocking medicines 
or closing too early, long 
waiting times 
I often have problems getting my medicines from 
the pharmacy* 
                  Barrier                                       Adherence barrier statements 
 
 
 
 
 
 
 
 
 
Figure A5.7.7 Adherence barriers and proposed statements for the 
‘Motivation and goals’ behavioural domain 
        Barrier                                       Adherence barrier statement












Figure A5.7.8 Adherence barriers and proposed statements for the 
‘social influences’ behavioural domain 
 
 
Preference of traditional or 
herbal remedies 
I take herbal or other traditional remedies instead 
of my prescribed medicines* 
Refusal to take medicines I refuse to take my medicines* 
Lack of motivation I’m not bothered about taking my medicines 
Burden of adhering to regimen Having to take my medicines is a burden to me* 
Low priority assigned to 
medication taking 
Taking my medicines correctly is not high on my 
list of priorities* 
Too tired to take medicines I’m too tired to take my medicines* 
Fear of discrimination or 
stigma/bullying, perceptions of 
others or disclosure of illness
People would treat me differently if they knew I 
was taking medicines* 
I don’t have anybody who could help me to take 
my medicines correctly* 
Wanting to be ‘normal’ 
I don’t like taking medicines, I just want to be 
‘normal’* 
Family rituals or social obligations 
Lack of social support 
My friends and family encourage me to take my 
medicines 
In my culture, it’s acceptable to take medicines 
Poor relationship with healthcare 
provider/ lack of trust in healthcare 
provider 
I trust my doctor(s) with decisions about my 
healthcare 
                   Barrier                                  Adherence barrier statement 













     
 
 
Figure A5.7.9 Adherence barriers and proposed statements for the 
‘emotions’ behavioural domain 
 
Barrier                                       Adherence barrier statement 
 
 
 
 
 
  

Figure A5.7.10 Adherence barriers and proposed statements for the ‘goal 
conflicts’ behavioural domain 
Embarrassment of taking 
medicines 
I feel embarrassed by having to take medicines* 
Feeling 
low/depressed/angry/helpless
/ tired/overwhelmed or 
stressed
 
I feel overwhelmed by having to take my medicines* 
Wanting to be free of taking 
medicines I want to free of taking medicines* 
I feel a sense of success when I take all of my 
medicines correctly 
Thinking of treatment as a 
burden Having to take my medicines is a burden to me* 
Treatment being a reminder 
of illness 
I don’t want to be reminded that I’m ill by taking 
medicines* 
Taking my medicines makes me feel low* 
I feel frustrated by having to take medicines* 
Taking my medicines is stressful for me* 
 
Knowing I’m taking my medicines correctly makes 
me feel good about myself 
Being too busy to take doses/ too 
busy to pick up repeat medication 
I’m too busy to take my medicines correctly* 
Disruptions to daily routine/having a 
chaotic lifestyle 
I struggle to take my medicines when there 
are disruptions to my daily routine* 
Life gets in the way of taking my 
medicines correctly* 
Difficulties incorporating medicines 
taking into daily routine (e.g. 
disruption of other activities or being 
away from meds at dose times, need 
to undertake other duties) 
 
 
 
 
 
 
 
 
 
Appendix 5.8 Topics discussed in first participant consultation 
exercise 
  
Knowledge 
The first topic discussed related to medicines packaging and specifically how receipt 
of medicines in different packaging each month can be confusing.  One participant 
raised this issue, stating that the frequent changes in packaging made it difficult to 
know how to identify his tablets and suggested that this could be another barrier.  The 
participant expressed strong feelings on this topic and felt that standardisation of 
packaging was an important issue to support medicines taking, especially for older 
patients.  Other participants expressed agreement. 
In addition to changes in tablet packaging, one participant raised the issue of 
accessing her medicines out of the blister packs, commenting on the difficulties of 
getting her thumb behind the foil seal and then dropping the tablets on the floor.  This 
raised notable agreement from other participants, indicating that this may be a 
common barrier to adherence. 
When discussing the specific barriers displayed, one participant suggested that 
knowing ‘how’ and ‘when’ to take medicines were unlikely to pose barriers to 
adherence as these were printed on the box.  When probed further by the moderator 
and asked what would happen if these instructions were not clear, she agreed this 
was something that she’d not thought of and another participant added that in that 
situation he would go back to the doctors surgery.  This respondent elaborated to say 
that this had never happened to him personally, but that he would know to go back to 
the surgery if his medicines instructions were not clear. 
The moderator asked the participants for their thoughts on ‘knowing why medicines 
had been prescribed’ and whether this was important; one participant instantly 
commented that it was important to him.  Another participant commented that knowing 
why the medicine had been prescribed was important when experience of side effects 
can create reluctance to take the medicine. The participant described an occasion 
where he had felt notable conflict between his prescriber’s recommendation to 
continue taking a medicine because ‘it was good for him’ and his desire to stop the 
medicine because of side effects.  It was agreed amongst the group that in addition to 
knowing why the medicine had been prescribed, it was also important to know what to 
expect from a medicine and how likely side effects may be.  A different participant 
commented that he had experienced a similar problem regarding his statin: 
“I got the impression from the GP that unless the side effect is serious, you should 
continue taking the statin because it’s good for you, they kind of ignored anything else 
I said”. 
This anecdote sparked a discussion about weighing up the risks and benefits of taking 
medicines and the group agreed that ‘knowledge’ was important to enable informed 
decision making about medicines taking.  One participant commented that the 
information about likely side effects and medicine indication are contained within the 
Patient Information Leaflet (PIL) and that this is a very useful document.  The 
participant went on to state that when a new medicine is prescribed he always reads 
the PIL and for every box of medicine he always keeps the PIL until all of the tablets 
are used in case there is a side effect.  When asked by the moderator if he found the 
information in the PIL worrying or frightening he replied that he did not and another 
participant stated that she found it interesting not frightening.  In contrast, another 
participant confessed that she had never read the PIL and discarded the leaflet as 
soon as she opened the box of tablets. 
When the moderator asked the participants to rank the barriers in order of importance, 
this proved to be difficult.  However, useful comments about the barriers were yielded; 
participants felt ranking was difficult as many of the barriers were very similar.  Upon 
displaying the questionnaire statements for the ‘knowledge’ behavioural domain, 
participants agreed that on the whole, the statements were clear and made sense.  
Participants understood the concept of completing the questionnaire the need to only 
tick one box for each statement.   
In relation to specific statements, one participant commented that statements four and 
five looked to be very similar.  Another participant took interest in statement six and 
suggested that this was a separate topic from the others in this group.  With probing, 
the participant went on to describe that the process of ordering prescriptions is lengthy 
and complex, often taking a full day.  One participant expressed agreement and 
another commented that it can be difficult unless the prescription can be collected 
from the pharmacy at the same time as going to the doctor’s surgery.  This comment 
sparked debate regarding discrepancies in the services that participants had access 
to, with some participants collecting their prescriptions from pharmacies attached to 
their GP surgery and other having to make separate journeys.  It was agreed that 
difficulties in getting to the pharmacy can be a notable problem for many people, 
especially the elderly or those living in remote rural communities without access to 
transport.  
Input from the moderator regarding mechanisms for easing difficulties in the 
prescription ordering and collection process such as prescription collection and 
delivery services facilitated further discussion on the topic.  It was agreed that 
‘knowing’ that these services are available is an important aspect.  One participant 
added that he felt the process of how to get further prescriptions was not well 
explained and went on to describe that he only recently found out that his pharmacy 
will order and collect his prescription from the GP surgery for him.  This service had 
transformed the participant’s experience of ordering and collecting his prescription into 
a streamlined and far more straightforward process that had really helped him. 
The topic of ordering and collecting prescriptions was also described by a participant 
who used an online ordering system at her GP surgery.  Her prescription then went 
straight to her local pharmacy for collection and her surgery sent her e-mail reminders 
to say when her next prescription should be ordered.  Other participants commented 
on how impressive this service was and how much easier it must be.  The participant 
using the service commented that with two young children and working full time, 
without the service she would really struggle.  In discussion of different ways to order 
prescriptions, one participant commented that he always telephoned his order so that 
he could order exactly what was needed as he sometimes used up a backlog of 
tablets rather than ordering every month.  It was agreed that knowing different ways to 
order prescriptions and that it’s possible to order individual items rather than 
everything on the repeat list are important factors.  
Skills 
As the barriers were introduced, the participant who had previously commented on 
difficulties with accessing medicines from the packaging became active, suggesting 
that this point perhaps fitted better here.  On discussing difficulties with accessing 
medicines from their packaging, one participant added that their tablets often ‘jump 
out’ of the packet and fall on the floor, adding that it’s then even harder to identify a 
dropped tablet if the shape and packaging regularly change. 
One participant also commented on a current batch of medicines that appeared to 
break into pieces when being pushed through the packaging.  The participant 
commented that not only was this frustrating, it had also made him ‘run short’ on this 
particular medicine.  This prompted discussion on the importance of ‘having a system’ 
for ordering medicines to ensure ample supplies are always available.  ‘Forward 
planning’ was considered to be an important skill for managing medicines. 
In relation to difficulties reading and understanding directions, the participant who had 
previously spoken about the usefulness of PILs reiterated this again, detailing an 
occasion where he was unsure of how to take his medicine and had used the PIL to 
assist.  This raised some discussion on the ‘skill’ of knowing how to cope when there 
is a problem or difficulty.  Another participant commented that the print on PILs is very 
small so patients who have difficulties reading medicines labels, would unlikely be 
able to cope with the small print on PILs. 
Prioritisation of the barriers was not deemed necessary as the moderator felt the 
discussions had been sufficient.   
The potential questionnaire statements were displayed and read in turn.  One patient 
commented that there was overlap between statements four and five as one could not 
really be done without the other.  However, one participant disagreed and suggested 
they were better as separate statements as although he understood the directions on 
his medicines, he often forgot to take them at the correct time. 
The thought of taking medicines at the correct time of the day prompted one 
participant to mention the difficulties of receiving medicines at the correct time when 
staying in hospital: 
“You do your best for yourself at home but when you go into hospital you get them 
when they’re ready not when you want them” 
The participant added that for some patients, changes to medicines and routines 
whilst in hospital can be very confusing and make the transition back to home even 
harder.  Strong feelings regarding changes to medicines were evoked: 
“It’s when they muck about with them that’s the trouble, that’s when the fun really 
begins” 
In relation to statement two, one participant mused upon the future and whether he 
would continue to be able to take all of his medicines.  The participant said that it 
wasn’t a worry for him and it wouldn’t prevent him for being able to complete the 
questionnaire but that it was more just something that he was mindful of.  Two other 
participants agreed that this is something they’d considered too.  The moderator 
asked if the phrase ‘administer my medicines’ in statement one was appropriate and it 
was noted that this may confuse some patients.  One participant suggested changing 
the wording to, ‘take’ rather than ‘administer’ and participants agreed this might be 
better.  Another participant suggested ‘use’ as an alternative that would cover other 
dosage forms such as creams or inhalers and it was agreed that this was the best 
suggestion 
Memory, attention and decision making processes’ 
The introduction to the topic prompted one participant to share his experiences of 
practicing yoga to reduce his blood pressure and cholesterol levels.  The participant 
explained the yoga techniques and their benefit at length, describing the conflict that 
occurred in his mind when the doctor advised that he no longer needed his cholesterol 
tablets as his cholesterol levels had reduced.  The participant related his preference 
for yoga, cycling and eating certain foods as a decision making process that had 
affected his medicine taking, but noted that it had been a confusing and difficult 
decision to make.  The participant elaborated that he had intended undertake these 
preferences as an addition to his medicines, so then felt a sense of dilemma when the 
doctor advised stopping the medication.  The participant also linked this back to the 
knowledge section as he felt not knowing about alternatives to medicines could be a 
barrier. 
In relation to ‘forgetting to take medicines’, the group agreed that it can be hard to 
always remember every dose of medicine.  One participant commented that his 
lunchtime doses were the most difficult to remember as he was not always at home or 
doing the same thing at that time.  A variable routine therefore made remembering 
more difficult.  One participant added that she sometimes forgot to take her medicines 
in the morning due to the distraction of getting her two young children ready for 
school. 
The participant who had previously mentioned ordering their prescription online 
commented that without the e-mail reminder she would forget to order and collect her 
prescription, and so could identify with this particular barrier.  Other participants 
agreed that it can be easy to forget about collecting or ordering your prescriptions.  In 
discussion on this topic, one participant suggested that because the ordering and 
collecting of prescriptions is so difficult for her, she doesn’t forget because it’s at the 
forefront of her mind.  It was agreed that for some people, if the process was very 
easy it might be easier to forget about it.   For other participants, an easy ordering 
system was pertinent to be able to collect the medicines. 
As with the other sections, formal prioritisation of the barriers was not necessary as it 
was agreed that ‘being distracted’, ‘forgetting to take’ and ‘forgetting to order or 
collect’ were the most important barriers and that ‘losing medicines’ was less 
important. 
Participants agreed that they would be able to complete the questionnaire for the 
statements shown.  One participant suggested that statement one could perhaps be 
improved by using the phrase ‘I usually remember…’ and other participants agreed 
that this might be helpful.  
Strategies for remembering to take medicines were discussed, as well as the 
necessity of knowing how to manage medicines.  One participant commented that he 
had not taken his ‘water tablet’ before coming out as he did not wish to disturb the 
meeting by needing frequent toilet visits.  However, through having a strategy and 
knowing what to do, he had planned to take the tablet as soon as he got home so that 
he did not miss it.  Strategies for remembering and managing medicines included the 
use of daily pill boxes, which were used by two participants and described as ‘a god 
send’.  One of the participants using daily pill boxes commented that preparing his 
boxes in advance helped him to remember to order his prescriptions in plenty of time.  
In relation to this, it was discussed whether medicines taking is a ‘priority’ as the older 
participants stated that they didn’t forget their prescriptions as it’s such an important 
part of their lives.  Conversely, the younger patient with two young children confessed 
that taking her medicines was not a priority for her.  This prompted consideration of 
statement four and the participant suggested that re-phrasing to ‘I can be easily 
distracted’ might be useful, as this better reflects something that doesn’t happen every 
day. 
It was suggested that statement three may be superfluous as it related directly to 
statement two.   Statement five also attracted comments as it was suggested that the 
wording ‘good’ should be removed as personal reasons are not necessarily good 
reasons.  The moderator also identified that ‘correctly’ should be altered to ‘as 
prescribed’.  It was agreed that phrasing this statement as ‘I have my reasons for not 
taking my medicines as prescribed’ reflected the best option.  
Social influences 
Participants indicated that they had not personally felt any sense of discrimination or 
stigma relating to their medicines taking and suggested that these factors, especially 
the fear of being bullied were more likely relevant to school children and teenagers.  
One participant commented that he could see how it could be an issue for younger 
people, but that older people are far more accepting and just discuss it.  It was agreed 
that for older people, medicines taking was seen as ‘normal’.  
The adherence barrier ‘lack of trust in healthcare provider’ prompted comment from 
the participant who had previously discussed his dilemma of being told to stop his 
statin after his yoga proved to be successful: 
“In all honesty, in the beginning I didn’t trust my doctor” 
The participant described how he had felt when the doctor had doubted his blood 
pressure readings that had been taken through self-monitoring, commenting that trust 
has to operate in both directions.  A different patient commented that doctors can be 
very persistent and not ‘take no for an answer’ which can adversely affect 
relationships.  
On the topic of poor relationships with healthcare providers, one participant 
commented that relationships with surgery receptionists are known to be particularly 
fraught.  The participant went on to describe the difficulties that many people have in 
getting access to their GP as they are ‘protected from being bothered’ by the 
receptionists.  With further questioning the participant agreed that hostile reception 
staff at surgeries could lead to negative feeling about medicines: 
“Some people wouldn’t want to face what they consider to be hostility from the 
receptionists” 
Poor relationships with surgery staff were therefore considered to be a barrier to 
adherence.   In discussing ‘family rituals or social obligations’, the participant who had 
previously mentioned her young children, agreed that her family obligations were 
sometimes a barrier to adherence.  Another participant commented that religions and 
faiths could act as barriers, citing the Islamic faith as an example where medicines 
containing alcohol would need to be avoided.  
One participant commented that ‘lack of social support’ could be addressed by the 
many support groups that exist, expressing his sentiment that such groups were very 
important for sharing experiences and talking through the troubles of medicines 
taking, especially for carers who can have tremendous worries about medicines.  
For the questionnaire barrier statements, one participant suggested amending 
statement six to ‘my faith and religion’ and another participant suggested ‘my beliefs’. 
These suggests prompted further contributions from other participants regarding 
Chinese medicines, superstitions and other religions such as Jehovah Witnesses’ 
refusing blood transfusions. It was agreed that phrasing this statement as ‘my faith or 
culture’ was the best option for capturing these different potential barriers 
Environmental context and resources 
The adherence barrier ‘cost of medicines’ sparked notable discussion, with 
participants who were exempt from prescription charges expressing genuine shock at 
the current levy.  Participants were largely knowledgeable about the prescription pre-
payment card, but commented that it was still an expense that may be difficult for 
many people.  ‘Cost of medicines’ was therefore agreed to be an important barrier to 
adherence. 
Previously discussed topics such as difficulties with getting to the pharmacy and 
frequent changes to the boxes medicines are supplied in were revisited in relation to 
the barrier ‘problems with the pharmacy’.  Further consideration was also given to 
pharmacy opening hours and the participant with two young children commented on 
how reliant she was on her pharmacy opening on a Saturday morning.  
In relation to the barrier ‘being away from home/travelling’ the participant who had 
previously mentioned struggling to remember his lunchtime doses conveyed the 
importance of preparation and forward planning for travelling to ensure adequate 
medicine supplies are taken.  Again, the participant made reference to his medicines 
being ‘a way of life’ for him and high on his list of priorities. 
As the questionnaire statements were read, participants nodded in agreement, which 
suggests the statements were acceptable.  When asked about the interpretation of 
statement four, one participant said they would take this to mean the medicines were 
not in stock and wouldn’t consider this statement to cover wider issues or other 
problems with the pharmacy such as its opening hours.  Other participants expressed 
their agreement. 
Emotions 
The final group to be discussed in the first consultation exercise was ‘emotions’.  As 
time was running short this section was not discussed in as much depth as previous 
sections, but this was not considered to be problematic as this section was also be 
discussed in the second focus group. 
When asked if taking tablets was a reminder of illness, one participant commented 
that he did not feel this was so and that he just ‘lived with it’.  It was agreed that 
maybe this depended on the condition and medicines taken, for example taking 
medicines for cancer could be an unwelcome reminder of a terminal illness.  One 
participant said that if taking medicines was a reminder of illness, the negative 
thoughts evoked could make the condition worse and stop the tablets from working.  
The participant described a friend who has been ‘OK’ until he started taking medicines 
and who had then become very depressed as they kept focussing on their illness.   In 
agreement, another participant added that being reminded of an illness could trigger 
any of the negative emotions listed. This also prompted some discussion on 
acceptance of the condition and need for medication, one participant commented: 
“You accept it after a while; it might be a shock at first but then you just accept it” 
One participant commented that all of the ‘negative’ emotions listed as barriers such 
as feeling low, angry or stressed could actually be caused as a side effect of 
medicines.  Another participant added that she felt worse if she didn’t take her 
medicines and could notice a difference after a few days; experience of negative 
feelings was therefore an adherence promoter for this participant.  
For the questionnaire statements, one participant proposed that statements three and 
seven were very similar as thinking of medicines as a burden would likely evoke 
feelings of frustration.  The moderator asked if several of the similar statements could 
be combined into more general terms such as ‘taking my medicines makes me feel 
negative feelings’.  It was agreed that this may be possible, but that the statements 
would need to be carefully worded; ‘mood changes’ was suggested as wording by one 
participant. 
In concluding the session, participants agreed that it had been an enjoyable and 
informative meeting and that there were not any points that they had wished to raise 
but had not had an opportunity to.  One participant concluded: 
“It’s been fascinating”. 
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Motivation and goals 
In relation to being too tired to take medicines, one participant commented that it was 
not being too tired that caused a problem but more that in the evening forgetfulness 
can prevail.  Once all of the barriers had been displayed, one participant commented 
that motivation was very important and the single most important factor in taking 
medication: 
“For me, the motivation is very strong and that alone would be thing that makes me 
take it, some of the things like being too tired might impinge on it, but my motivation is 
very high” 
The issue of side effects was also raised during this section, generating marked 
discussion and demonstrating a clear topic of interest.  One participant commented 
that experience of side effects had affected his medicines taking in the past.   In 
agreement, one participant commented that he could relate to almost all of the 
barriers presented due to his previous experience of a severe side effect from one of 
his medicines which had effectively caused a stroke.  When asked if his previous 
experience of side effects had made him reluctant to take medicines, he replied that it 
had put him off taking the problem causing medicine and elaborated that he would be 
reluctant to take newly prescribed medicines until he had ‘researched’ them, as he is 
now very cautious with which medicines he will take.  
Incapacity to take medicines was also commented upon, with one respondent noting 
that even when motivation is very strong, forgetting or not being able to cope with 
taking medicines can be a problem.  Following on from this, the moderator explained 
that incapacity could relate to other factors such as difficulties with getting the 
medicines out of their packaging which sparked numerous comments, once again 
indicating that this was barrier of note.  One participant described tablets ‘flicking out’ 
of the packaging and being lost down the sink plughole and another reported having 
to pick their tablets up off of the floor after they had ‘popped out and gone 
everywhere’.   
Discussing the difficulties of accessing medicines from their packaging prompted one 
participant to reflect upon the fact that she now received one of her medicines in a pot 
rather than blister pack.  The participant commented that this was because she chose 
to buy it herself rather than getting a prescription as she knew it would save NHS 
money.  For this participant, the cost of medicines was not an adherence barrier.  The 
concept of the cost of medicines sparked an interesting discussion regarding the 
perceived value of medicines.  One participant explained that his daughter was 
studying pharmacy and had told him how much his medications cost to the NHS and 
that he realised this is less than the prescription charge that he paid.  The participant 
described how this had made him question whether he was getting value for money 
and the best possible treatment that could be afforded.  When asked whether this had 
affected his medicines taking, the participant described an intrinsic link between the 
known monetary value of a medicine and its perceived quality and that this had 
initially affected his perception of the medicine.  The participant added that he had 
later been able to rationalise this therefore not been affected in his medicines taking. 
Consideration of medication costs generated discussion regarding variations in the 
quantities of medications prescribed, as some participants received two or three 
months’ worth of medication at a time whereas others only received one months 
supply.  The inconvenience and unfairness of this was discussed and participants said 
that only receiving a month’s worth of medication rather than two made a difference to 
them, especially for those who pay for their medication.  Participants agreed that 
negative feelings towards medicines could be evoked by knowing other people were 
getting more medicines at a time, leading to a sense of being given a ‘raw deal’. 
The topic of Patient Information Leaflets (PILs) was raised by one participant and this 
also generated discussion.  In raising the topic, the participant described PILs as “one 
of the most terrifying things about taking medicines”.  When asked whether reading 
the PIL had made him reluctant to take the medicines he replied that it had not as he 
trusted his doctor but recognised that reading the PIL could unnerve some patients.  
One participant had brought their PILs to the meeting to ask what ‘he was missing’ 
and confessed that he always threw them straight in the bin.  Another participant 
added that he thought most people start reading the PILs and then wished they hadn’t 
as they are quite off putting. 
In reference to the specific barriers, one participant commented that ‘refusal to take 
medicines’ was very strong and that ‘reluctance’ may be more appropriate.  When 
asked if they could prioritise the barriers in order of their perceived importance, the 
group struggled and one participant commented that he felt it was quite a personal 
thing to do and that it would also depend on the circumstances.  When asked if the 
prioritisation would also depend on which specific medicine was considered, the 
participant agreed. 
When asked if they could prioritise the barriers in order of their perceived importance, 
the group struggled and one participant commented that he felt it was quite a personal 
thing to do and that it would also depend on the circumstances.  When asked if the 
prioritisation would also depend on which specific medicine was considered, the 
participant agreed. 
With regard to questionnaire statements, Participants agreed that they understood 
they layout of the questionnaire and how they would need to fill it in.  However, when 
asked if they would be able to complete it, whilst most nodded or agreed that they 
would, one participant commented that they wouldn’t be able to fill it in because it 
would be different for each medicine that he took. 
One participant expressed concern with the questionnaire design as they considered 
themselves to be somebody that would tend to tick at the polar ends rather than in the 
middle and that the alternating positive and negative statements could cause 
confusion and ‘ticking the wrong box’.  The ‘strong wording’ of the statements was 
also discussed and one respondent felt this would make it hard to know whether to 
say ‘agree’ or ‘strongly agree’.  Another respondent added that he found himself 
having to re-read the statements two or three times to check they he had understood 
them correctly.  In response to this, another participant posed that having to re-read 
the statements to check understanding wasn’t necessarily a bad thing. In further 
discussion and with explanation from the moderator, participants appeared to agree 
with the rationale for using a mixture of positive and negative statements. 
One participant suggested that his responses would be considered as ‘a spoilt paper’ 
because he would give conflicting responses.  Another participant thought that 
providing the option of ‘neither agree nor disagree’ was a bit ‘negative’ because this 
would not provide an indication of the respondent’s real views. 
In relation to the specific statements, one participant expressed dissatisfaction with 
the first statement, and suggested that the term ‘bothered’ was ambiguous as it could 
also mean worried, several respondents agreed that they would interpret it as 
‘worried’ rather than ‘not motivated’.  One respondent suggested phrasing the 
statement as ‘I don’t care’ instead of ‘I’m not bothered’.  Statement number six was 
discussed with the suggestion that the word ‘sometimes’ could be added to read ‘I’m 
sometimes too tired to take my medicines’.  The participant felt this would be useful as 
he could not imagine any patient would always miss their medicines because of being 
too tired.  Agreement on this was not achieved as another participant disagreed and 
noted that ‘sometimes’ could be added to every statement.  
Goal conflicts 
The first barrier selected for discussion was ‘being too busy to collect or order 
prescriptions’, generating several participant comments.  One participant related back 
to the previously discussed topic of having to order and collect your prescription every 
month compared to those who only have to collect every three months and reflected 
that it’s far harder for the patients who only get one month’s worth.  The same 
participant commented that he would be more than willing to pay somebody to deliver 
his prescription and post it through the letter box which sparked a discussion on 
prescription delivery services.   
Opening hours of pharmacies and getting there at a particular time was also raised as 
an issue as were the benefits of using automated or online ordering systems.  This 
prompted reflection upon the different experiences people may have depending upon 
which surgery and pharmacy they use.  One participant commented that the hardest 
thing about their medicines was the collection as they lived quite a distance from their 
GP surgery.  One participant also talked about the need to be ‘disciplined’ and ‘having 
a system’ in order to stay on top of managing your medicines. 
The issue of forgetting to pack medicines when being away from home or travelling 
was raised by one participant in response to the ‘change in routine’ barrier and a 
fellow participant agreed that he felt everyone had most likely forgotten to take their 
medicines away with them at some point.  Further comments were added that when 
travelling away, running out of medicines would be possible if insufficient supplies had 
been packed. Discussions also took place on the matter of twice daily dosing being 
convenient as it fitted into daily routines of being at home morning and evening. 
Beliefs about consequences 
In relation to ‘mistrust in medicines’ and ‘fear that medicines will harmful’ the 
participant who had previously described a serious side effect from one of his 
medicines commented that he could strongly identify with these barriers, but not with 
the others.  The moderator used an example of a prescription for antibiotics in 
discussing ‘stopping medicines when feeling better’ and one participant stated that it 
is the prescribers job to explain why the full course must be taken.  One participant 
noted that he could relate all of the displayed barriers to a character in a popular soap 
who had a brain tumour but was in denial of this. 
The concept of misunderstanding was raised by one participant, who questioned 
whether a misunderstanding of how medicines worked or why they were prescribed 
could be an adherence barrier, if the relevant information was not explained properly.  
When asked if he felt whether knowing what a medicine was for and why it had been 
prescribed were important, he agreed and commented ‘it’s what drives confidence 
and motivation’.  General agreement was expressed.  One participant commented 
that this information should be ‘every part of the explanation’ and one participant 
added that the patient should ask for it. 
‘Non-acceptance of the diagnosis’ prompted discussion, as one participant felt this 
wasn’t necessarily accurate and that mistrust in their prescriber’s proficiency may be 
more pertinent: 
“I accept the diagnosis, I just don’t accept that the guy necessarily knows what he’s 
doing” 
Dose changes were raised as an issue which could spark mistrust, as one participant 
described a friend who had recently been switched to a different medicine of different 
strength and that this prompted consideration of whether the previous dose was 
correct.  Adding to this, one participant reporting having their dose of one medication 
reduced to avoid side effects and that he was now uncertain as to whether the 
medicine would still be effective.  
The asymptomatic nature of conditions such as hypertension was considered by one 
participant, who posed that feeling well and not having any symptoms could prompt 
doubting of the diagnosis and need for medication.  In relation to ‘fear that medicines 
might be harmful’ one participant commented on the uncertainty of long term effects.  
The participant agreed that the long term effects were a worry to her, but that it did not 
impose a barrier to her adherence because her motivation was sufficient to overcome 
her worries; her motivation was driven by her father’s history of hypertension and 
subsequent stroke.   Following on from this, one participant suggested that the ‘fear 
that medicines will be harmful’ was likely the most important barrier as it was more 
quantifiable.  Another participant agreed with this and suggested that this fear is 
augmented when multiple medicines are prescribed as information regarding 
interactions is often difficult to obtain. 
Non-acceptance, denial and thinking there is no need for treatment were considered 
to be phases that people might go through when they are first diagnosed with a 
condition.  The participant raising this suggested that with time, these thoughts pass 
and acceptance prevails.  With consideration to this, the participant suggested that it 
was therefore the remaining barriers which were perhaps most important and 
agreement in this thought was expressed by other participants. 
In response to the questionnaire statements, statement one evoked a reaction from 
one participant who felt that it was very emotive and ‘too far’. The moderator 
suggested that emotive statements were useful for eliciting polar responses rather 
than those which fall into the middle and one participant agreed with this.  Statement 
two also elicited a negative response from the same participant and another 
participant commented that it was completely untrue.  This participant went on to 
suggest that it must be the diagnosis that was doubted not the medicine and felt that 
the statement was ‘nonsense’ posing that if somebody didn’t trust their medicine then 
there was no way they could trust the person giving it to them.  When asked by the 
moderator whether he would be able to respond to this question as patient, he 
commented that he would easily tick ‘strongly disagree’ and two other participants 
showed agreement 
The third statement also prompted discussion with one participant commenting that 
she would be uncertain in answering this statement and therefore unable to offer her 
usual polar responses.  Another participant added that medicines can be correctly 
prescribed, even if they’re not safe.  Statement four was considered to be more 
personal and the terminology ‘work for me’ was found to be ambiguous.  Alternative 
wording of ‘have an effect’ was suggested but another participant noted that this could 
include having a side effect.  Another participant suggested wording as ‘beneficial’ 
and this was more popular.  In further relation to this statement, one participant asked 
if we were considering whether the medicines were working or whether the correct 
medicines had been prescribed and it was agreed that these were two different 
matters.  Another participant mentioned ‘benefit balances’ of weighing up benefits and 
risks and several participants agreed that this was important. 
The moderator asked if the term ‘medical conditions’ in statement six was clear and 
one participant suggested that it perhaps meant something temporary rather than a 
disease.  With explanation form the moderator, participants agreed that ‘disease’ was 
not a useful term and one participant suggested leaving the word ‘medical’ out to 
simply say ‘I have a condition’.  Participants agreed that this was an improvement. 
Statement seven was also discussed, with one participant commenting that he 
continues to take his medicines as it reduces his risk of further problems, irrespective 
of how he ‘feels’.  Another participant added that he would be fearful of stopping his 
medicines as although he might feel well for a time, his symptoms might return.  It was 
also noted that the term ‘feel better’ might be confusing in the context of preventative 
medicines such as those for cardiovascular disease.  It was agreed that separate 
questionnaires, one for active treatments and one for preventative treatments may be 
necessary.  Altering the phrasing of this statement to ‘even if I feel well’ was also 
suggested and other participants agreed with this recommendation. 
Beliefs about capabilities 
This group proved to be quite challenging for participants to understand and the 
majority of participants stated that they could not relate to the barriers presented from 
their personal experiences.  One participant posed that perhaps the central concept of 
‘beliefs about capabilities’ was incorrectly phrased. 
Whilst participants struggled to relate to the barriers based on their own experiences, 
anecdotes of friends and family member’s experiences were shared in trying to further 
understand the barriers.  One participant described a friend, whose elderly parents 
were unable to cope with their medicines or any difficulties that arose.  The moderator 
suggested that this represented a genuine barrier rather than perceived inability or 
belief and participants agreed with this and suggested that this barrier may be better 
suited to a different group. 
One participant reflected on his own experiences when faced with caring for his father 
who was unable to manage his medicines following a stroke and the difficulties that 
arose from this.  The participant identified with the ‘wanting to maintain control’ barrier 
as his father refused his medication for this reason.  Another participant added that to 
her, wanting to maintain control was a promoter of adherence as she felt that by 
taking her medicines, she maintained control of her illness.  It was agreed that the 
phrasing of this barrier was in the questionnaire would be pertinent as it could be a 
barrier to some people and promoter to others depending upon interpretation.   A 
further comment was also made relating to wanting to maintain control, with a 
participant suggesting that this though would most likely be  a barrier to adherence in 
the early stages of being prescribed a medicine, before there had been time to adjust. 
One participant provided an example of lack of confidence in managing medicines by 
relating this to his brain damaged son, and explaining that his son took many 
medicines and lacked confidence in taking them correctly and sticking to the regime.  
The participant’s son had found the use of a weekly pill organiser very useful in 
overcoming the deficit in confidence. 
In relation to the questionnaire statements for this section, It was agreed that 
statements four and six were verbose and may need refinement.  With specific 
relation to statement four, one participant commented that the ‘I’ element of the 
statement was confusing as resolution of side effects is unlikely to be something that 
would be undertaken alone.  The participant suggested that ‘we’ may be better as this 
would reflect inclusion of the patient’s GP in the process.  It was agreed that the 
phrasing of this statement needed some refinements, and that reluctance to take 
medicines as prescribed due to side effects was the pertinent barrier for inclusion. 
Statement eight was described as ‘an adventurous statement’ by one participant who 
commented that this statement did not make sense.  Another participant added that 
the statements phrasing implied that a patient could cope on their own without 
seeking advice and it was agreed that this was not accurate.  One participant 
suggested altering the phrasing to ‘I know what to do if there is a problem with my 
medicines’ and it was agreed that this represented a good starting point for an 
improved statement, which would covered multiple barriers. 
One participant commented that he could identify with the third statement as his 
warfarin dose regularly changed, but commented that for him, it was the dose that 
changed not the medicine.  It was agreed that .the phrasing of this statement should 
perhaps be altered to better reflect this.  Another participant expressed agreement 
that changes to doses or medicines was confusing and made adherence more 
difficult. 
Emotions 
Contrary to the first session, one participant could identify with ‘embarrassment of 
taking medicines’, describing an occasion where she had collected three large carrier 
bags full of medicines from the pharmacy and had tried to hide them in her coat as 
she had felt embarrassed and concerned about what other people might think.  
Another participant described himself as ‘the black sheep’ of his family and felt 
embarrassed by having to take medicines when the rest of his family were ‘super’ 
healthy.  He added that the embarrassment would however, not be an adherence 
barrier for him.  
The barrier ‘thinking of treatment as a burden’ prompted one participant to ask if this 
meant a burden to the patient or a burden to other people such as caregivers and 
other helpers.  It was agreed that either would be possible and one participant added 
that feelings of being a burden to others would be the stronger of the two emotions.  
One participant summarised many of the barriers as ‘mental health’ and commented 
that if a patient’s mental health was fragile, their ability to follow their prescribed 
regimen might be impaired.  Another participant added that people may experience 
negative emotions by questioning why they have a condition and why they have to 
take medicines when other people around them do not.  It was agreed that this may 
relate to the idea of ‘stages of change’ that had previously been mentioned by another 
participant. 
One participant commented that the experience of negative emotions might be more 
likely in younger people, adding that he had only had to start taking medicines in his 
seventies and at this stage of life, he was grateful for medicines to prolong his health.  
The participant stated that if he had started taking medicines in his thirties, he 
suspected he would have been very depressed at the thought of having to take 
medicines for the rest of his life.  
For one participant, ‘treatments being a reminder of illness’ was seen as a motivating 
factor rather than barrier.  The participant explained that being reminded of her illness 
motivated her to keep taking her medicines due to a strong family history of heart 
disease.  Another participant agreed with this and commented that she felt the same 
way about her medicines.  However, this participant added that her daughter was 
embarrassed by her condition and hating taking her medicines at it reminded her of 
the illness she had.  It was agreed that the emotion evoked by being reminded of an 
illness may well depend upon the illness in question and vary from one individual to 
another.  
One participant suggested that ‘annoyance about taking medicines’ could be another 
emotion that could be evoked when insurance forms are completed and medicines 
have to be declared.  Several other participants agreed with this and declaration of 
medicines taking was also mentioned for the DVLA.  One participant added that for 
holiday insurance forms, taking multiple medicines can make a substantial difference 
to the cost of insurance.  The participant went on to describe an occasion where he 
had persuaded his doctor to reduce the number of prescribed medicines and 
prescribe a combination product to keep the number below the threshold for an 
increase in insurance cost.  Another participant commented that this must have been 
quite stressful, and also reflected on the stress of making sure you’re adequately 
covered for insurance.   
In response to the questionnaire statements, the second statement was the first to be 
commented upon, as one participant commented that surely everyone wants to be 
free of taking medicines.  In relation to embarrassment, one participant commented 
that the only other person who saw him taking tablets was his wife and that he 
therefore wondered how common medicines taking in public was.  Another participant 
replied that it might depend on what medicines were prescribed or how frequent the 
doses were.  The notion of embarrassment was also related to travelling on holiday 
and the hotel cleaners seeing tablets laid out ready to take, one participant 
commented that he was conscious of what the cleaner might think.  
In relation to the sixth statement, one participant stated that rephrasing may be 
necessary as it’s not the physical act of taking the tablet that might induce low mood, 
but more the reliance on having to take the tablet. 
In summary, participants were thanked for their time and the future proceedings were 
explained.  Participants commented that they had enjoyed the evening and that they 
had all had opportunity to raise all points that they had wished to and they did not 
think that there was anything that had been missed. 
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Appendix 5.10 Mind maps used in questionnaire refinement process
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Appendix 5.10 Mind map for ‘knowledge’ behavioural domain 
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Our definition: All aspects of knowing how to take 
medicines correctly and how to obtain prescriptions, 
together with knowledge and understanding of why the 
medicines have been prescribed and how they will work 
TDF definition1: 
An awareness of 
the existence of 
something Barriers originally mapped to 
this behavioural domain: 
• Not knowing WHY 
medicines should be taken
• Not knowing HOW 
medicines should be taken 
• Not Knowing WHEN to take 
medicines
• Not knowing WHY 
medicines were prescribed
• Not knowing HOW 
medicines will work/be 
beneficial 
• Not knowing HOW to obtain 
a repeat prescription 
New barriers identified during 
focus group: 
• Not knowing how to identify 
medicines 
• Not having sufficient 
knowledge to make an 
informed decision about 
medicines taking 
• Not knowing about repeat 
ordering systems available 
to make process easier
• Not knowing how to access 
medicines from packaging
• Not knowing how to 
overcome problems
• Not knowing what to expect 
from medicines 
Barriers selected as most 
important: 
• Knowing how and when to 
take medicines
• Knowing why medicines 
were prescribed and how 
they will be beneficial 
• Knowing the system of how 
to order repeat 
prescriptions
Barriers moved to (or kept 
in) other domains: 
• Knowing how to identify 
medicines (Skills)
• Knowing how to access 
medicines from packaging 
(Skills)
• Knowing how to overcome 
problems/difficulties 
(Beliefs about capabilities)
BCTs that would be used for 
this domain: 
• Provide information about 
the behaviour-health link
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Appendix 5.10 Mind map for ‘skills’ behavioural domain
Skills 
TDF definition: 
An ability or 
proficiency 
acquired through 
practice 
Our definition: The patient’s ability to take their 
medicines. Practical difficulties administering 
problems are included, which relates to both physical 
problems with administering medicines correctly and 
cognitive problems in understanding directions. 
Barriers originally mapped to 
this behavioural domain: 
• Not being able to take 
medicines as prescribed
• Not being able to administer 
medicines
• Not being able to 
understand 
directions/instructions
• Not being able to read 
directions/instructions
New barriers identified during focus 
group: 
• Not being able to identify medicines 
(especially when dropped on floor)
• Not having a system/plan for managing 
and ordering medicines
• Not being able to forward plan for 
holidays and changes in routine
• Not being able to cope with changes
• Not being able to resolve/overcome 
difficulties or problems with medicines 
Barriers selected as most 
important: 
• Not being able to 
administer medicines 
• Not having an ordering and 
management system in 
place
• Not being able to identify 
medicines
Barriers moved to (or kept in) other 
domains: 
• Inability to overcome/resolve problems 
(Beliefs about capabilities)
• Inability to cope with changes (Beliefs 
about capabilities)
• Not being able to understand 
directions (Knowledge i.e. not knowing 
how to take)
BCTs that would be used for this domain: 
• Prompt intention formation and goal 
setting
• Use follow-up prompts
• Prompt self-monitoring
• Provide feedback on performance
• Set graded tasks
• Prompt practice
• Model or demonstrate behaviour
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Appendix 5.10 Mind map for 'memory, attention and decision making processes' behavioural domain 
Memory, 
attention & 
decision making 
processes 
TDF definition: The ability to retain 
information, focus selectively on aspects 
of the environment and choose between 
two or more alternatives 
Our definition: All cognitive aspects of medication 
adherence such as remembering to take medicines and 
order prescriptions.  The ‘attention’ aspect of this 
behavioural domain includes becoming easily distracted 
Barriers originally mapped 
to this behavioural 
domain: 
• Forgetting to take 
medicines
• Forgetting to 
order/collect prescription
• Running out of 
medicines
• Losing medicines or 
prescription 
• Being distracted
• Other justifiable reason 
reflecting decision 
making process
New barriers identified during 
focus group: 
• Preference for alternative 
treatments/remedies
• Forgetting doses that don’t 
fit with routine e.g. 
lunchtime doses
• Not having a routine and 
strategy to help you 
remember
• Medicines taking not be a 
priority
• Distractions caused by 
competing interests e.g. 
children 
Barriers selected as most 
important: 
• Being distracted
• Forgetting to take
• Forgetting to order/collect 
prescription 
• Preference for 
alternatives/decision making
Barriers moved to (or kept in) other 
domains: 
• Medicines taking not being a priority 
(motivation & goals)
• Not having a routine & strategy (skills)
BCTs that would be used for 
this domain: 
• Use of prompts or cues
• Prompt intention formation
• Prompt self-monitoring of 
behaviour
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Appendix 5.10 Mind map for 'social influences’ behavioural domain 
Social 
influences 
TDF definition: 
Those interpersonal 
processes that can 
cause individuals to 
change their 
thoughts, feelings 
or behaviours 
Our definition: Social factors and ‘other people’ who may 
influence the patient’s adherence behaviours.  Social factors 
include issues such as discrimination or being treated 
differently and ‘other people’ include those who may be 
influential in decision making such as friends and family as 
well as healthcare providers. Availability of social support is 
also an important aspect of this behavioural domain. 
Barriers originally mapped 
to this behavioural 
domain: 
• Family rituals/social 
obligations
• Fear of discrimination, 
stigma or bullying
• Fear of disclosure of 
illness or perceptions of 
others
• Lack of social support
• Poor relationship with 
healthcare provider/ lack 
of trust in healthcare 
provider
• Wanting to be normal
New barriers identified during 
focus group: 
• Poor relationships with 
surgery staff
• Family obligations e.g. 
getting kids ready for school
• Religious obligations e.g. 
avoiding alcohol or gelatine 
containing products
• Lack of access to support 
groups
• HCPs not trusting patient
Barriers selected as most 
important: 
• Lack of support
• Poor relationship/lack of trust
• Religious or cultural 
obligations
BCTs that would be used for this domain: 
• Model or demonstrate the behaviour
• Provide information about others approval
• Provide general encouragement
• Provide opportunities for social 
comparison
• Plan social support or social change
Barriers moved to (or kept in) other 
domains: 
• Family obligations (goal conflicts)
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Appendix 5.10 Mind map for 'environmental constraints’ behavioural domain 
‘Environmental 
constraints’ 
TDF definition: Any circumstances of 
a person’s situation or environment 
that discourages or encourages the 
development of skills and abilities, 
independence, social competence and 
adaptive behaviour 
Our definition: Any resource 
and material limitations which 
impede medication adherence 
and includes factors such as 
the cost of medications and 
access issues. 
Barriers originally mapped 
to this behavioural 
domain: 
• Transport difficulties 
getting to 
pharmacy/clinic
• Cost of medication
• Problems with pharmacy 
(e.g. shutting too early, 
not stocking medicine)
• Being away from 
home/travelling
New barriers identified during 
focus group: 
• Not having a system in 
place to cope with being 
away from home/travelling 
Barriers selected as most 
important: 
• Problems getting to pharmacy
• Cost of medicines
• Pharmacy shutting too early
• Travelling/ change in routine?
BCTs that would be used 
for this domain: 
None listed for this domain.  
Would focus on problem 
solving skills and generating 
alternative plans.  
Barriers moved to (or 
kept in) other domains: 
• Not having a system in 
place to cope with 
being away from 
home/travelling (skills)
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Appendix 5.10  Mind map for ‘emotions’ behavioural domain 
Emotions 
TDF definition: A complex reaction 
pattern involving experiential, 
behavioural and physiological 
elements, by which the individual 
attempts to deal with a personally 
significant matter or event 
Our definition: The emotional 
element of taking medicines and 
how adhering to a medication 
regimen makes the patient feel. The 
focus is on emotions that may 
hinder adherence. 
Barriers originally mapped 
to this behavioural 
domain: 
• Embarrassment of taking 
medicines
• Wanting to be free of 
taking medicines
• Thinking of treatment as 
a burden
• Treatment being a 
reminder of illness
• Feeling angry or 
stressed
• Feeling low or 
depressed
• Feeling tired, hopeless 
or overwhelmed
New barriers identified during 
focus group: 
• Medication side effects 
causing negative emotions 
such as aggression or 
depression
• Annoyance at taking 
medicines when filling in 
health or insurance forms
• Negative emotions due to 
being reminded of illness
• Burden to family 
members/carers
Barriers selected as most important: 
• Embarrassment
• Altered mood
• Reminder of illness
• Annoyance
BCTs that would be used for 
this domain: 
• Stress management
• Prompt barrier identification
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Appendix 5.10  Mind map for ‘motivation and goals’ behavioural domain
Motivation 
and goals 
TDF definition: Intentions: A conscious decision to perform a behaviour 
or a resolve to act in a certain way. Goals: Mental representations of 
outcomes and end states that an individual wants to achieve. 
Our definition: The motivation that a patient expresses 
towards taking their medicines and how much of a 
priority this is to them. 
Barriers originally mapped to 
this behavioural domain: 
• Lack of motivation
• Low priority assigned to 
medication taking
• Burden of adhering to regimen
• Refusal to take
• Being too tired to take 
medicines
• Preference for 
alternative/herbal/ remedy
New barriers identified during focus group: 
• Being too tired to remember to take 
medicines
• Experience of side effects adversely affects 
motivation
• Inability to access medicines from 
packaging
• Feeling ‘short-changed’ or not getting value 
for money
• Worried about taking medicines after 
reading PIL. 
Barriers selected as most 
important: 
• Not motivated to take 
medicines as prescribed
• Low priority
• No intention to take 
medicines as prescribed 
BCTs that would be used for this domain: 
• Motivational interviewing
• Provide information about behaviour-
health link
• Provide information on consequences
• Provide information about others approval; 
provide general encouragement; provide 
opportunities for social comparison; plan 
social support or social change
• Set graded tasks
• Provide feedback on performance
• Agree on behavioural contract
• Prompt intention formation; prompt specific 
goal setting
Barriers moved to (or kept in) other 
domains: 
• Burden, worry, feeling short-changed and 
being too tired (Emotions)
• Inability to access medicines (Skills)
• Side effects (Beliefs about consequences) 
• Preference for alternatives (Decision 
making)
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Appendix 5.10 Mind map for ‘goal conflicts’ behavioural domain
Goal 
Conflicts 
TDF definition: No 
definition available as this 
is our own, added domain 
Our definition: Competing priorities or interests that may 
impede adherence including family commitments, being too 
busy and inability to fit medicines taking into daily routine 
Barriers originally mapped to 
this behavioural domain: 
• Being too busy to take 
medicines
• Being too busy to collect/ order 
prescription
• Disruption to daily routine
• Chaotic lifestyle
• Inability to incorporate 
medicines taking into daily 
routine
New barriers identified during focus 
group: 
• Not having a system in place to 
manage medicines
• Forgetting to take medicines with 
you when travelling/ taking 
insufficient supplies
• Having a medicines regimen that 
does not fit with daily routine
Barriers selected as 
most important: 
• Too busy
• Regimen not fitting 
with daily routine
• Family commitments
BCTs that would be used for 
this domain: 
None listed as bespoke domain 
for this behaviour 
Barriers moved to (or kept in) 
other domains: 
• Not having a system in 
place (Skills)
• Changes to daily routines 
(Environmental constraints)
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Appendix 5.10 Mind map for ‘beliefs about consequences’ behavioural domain
Beliefs about 
consequences 
TDF definition: 
Acceptance of the truth, 
reality or validity about 
outcomes of a behaviour in 
a given situation 
Our definition: All barriers relating to a patient’s beliefs about 
taking their medicines, specifically their beliefs about the 
consequences of taking (or not taking) their medicines. Denial 
of the existence of illness or need for medicines was strongly 
associated with this behavioural domain 
Barriers originally mapped 
to this behavioural 
domain: 
• Mistrust in medicines
• Lack of belief in efficacy 
of medicines
• Fear that medicines will 
be harmful
• Thinking that medication 
is not working
• Thinking that there is no 
need for 
medication/treatment
• Denial of existence of 
illness
• Non-acceptance of 
diagnosis
• Stopping medicines 
when feeling better
New barriers identified during focus 
group: 
• Misunderstanding of information about 
prescribed medicines
• Mistrust from frequent dose changes
• Asymptomatic conditions
• Fear of long-term side effects
• Fear that co-prescribing of medicines 
is harmful
• Mistrust in prescriber
• Weighing balance up balance of 
benefits
• Insufficient information from prescriber
• Lack of confidence in prescriber’s 
competence
Barriers selected as most important: 
• Fear that medicines will be harmful 
(combinations or long-term 
included)
• Not thinking there is a need for 
treatment (asymptomatic nature 
included)
• Mistrust of/lack of belief in 
medicines
BCTs that would be used for this 
domain: 
• Prompt self-monitoring of behaviour
• Provide information on consequence
• Provide information about behaviour-
health link
• Provide feedback on performance
Barriers moved to (or kept in) other 
domains: 
• Misunderstanding of information 
(Knowledge)
• Mistrust/lack of confidence in prescriber 
(Social influences)
• Weighing up balance of benefits 
(Knowledge/decision making)
• Insufficient information (Knowledge)
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Appendix 5.10 Mind map for ‘beliefs about capabilities’ behavioural domain 
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TDF definition: 
Acceptance of the truth, 
reality or validity about 
an ability, talent or 
facility that a person can 
put into constructive 
use.  
Our definition: The patient’s confidence in adhering to their 
regimen and their perceived ability to take their medicines 
correctly.  This behavioural domain also relates to how easy 
or difficult the patient finds it to adhere to their medicines and 
their confidence and ability to overcome problems and 
difficulties. Experience of side effects and finding the regimen 
too complex were considered to be difficulties that patient’s 
should (ideally) have the ability to address and overcome and 
have therefore been included in this behavioural domain 
Barriers originally mapped 
to this behavioural 
domain: 
• Doubting own ability to 
adhere
• Thinking regimen is too 
complex/confusing
• Struggling to cope with 
changes to regimen
• Experiencing side effects
• Wanting to maintain 
control
• Lack of confidence to 
overcome adherence 
barriers
• Lack of confidence in 
adhering
• Inability to cope with 
difficulties/problems
New barriers 
identified during 
focus group: 
• Inability to 
cope with 
managing 
medicines
• Frequent 
changes to 
doses and 
medicines
Barriers selected as most important: 
• Lack of confidence to adhere
• Lack of confidence to overcome 
difficulties/problems
• Inability to cope with problems/changes
BCTs that would be used 
for this domain: 
• Motivational interviewing
• Prompt self-talk
• Provide feedback on 
performance
• Provide information 
about others approval
• Provide general 
encouragement
• Provide opportunities for 
social comparison
• Plan social support or 
social change
• Prompt practice
• Prompt barrier 
identification
• Set graded tasks
Barriers moved to (or kept in) other 
domains: 
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• Thank you for taking the time to 
complete this questionnaire 
• The questionnaire will help us to 
understand more about any 
difficulties that you may have with 
taking your medicines 
• There are no right or wrong 
answers to the questions asked, 
we’re interested in your honest 
views 
• The questionnaire should not 
take any longer than15 minutes 
to complete  
The Identification of 
Medication Adherence 
Barriers (IMAB) Questionnaire 
 
The identification of medication adherence barriers questionnaire 
Many people who are prescribed medicines often struggle to take their medicines as 
prescribed.  There can be many different reasons for not taking medicines as 
prescribed and we understand that lots of different things can ‘get in the way’ of 
following your doctors recommendations about taking your medicines. 
This questionnaire lists 30 different statements about taking your medicines.   For each 
of the statements below, please tick ( ) the box that best reflects your level of 
agreement with the statement.  Please only tick ONE box per statement. Some of the 
statements may appear to be similar to others but please be sure to respond to each 
statement.  
Statement Strongly 
agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
disagree 
I know how to 
take/use all of my 
medicines as 
prescribed  
     
I am able to take/use 
all of my medicines 
as prescribed 
     
I struggle to 
remember to order, 
collect AND/OR take 
my medicines as 
prescribed 
     
I trust my doctor(s) 
with decisions about 
my healthcare 
     
Taking all of my 
medicines as 
prescribed is not 
good value for 
money 
     
Having to take my 
medicines makes me 
feel negative 
emotions (e.g. 
frustration, anger, 
embarrassment) 
     
I am motivated to 
take my medicines 
as prescribed 
     
I’m too busy to order, 
collect AND/OR take 
my medicines. 
     
Statement Strongly 
agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
disagree 
I am confident about 
ordering, collecting 
AND/OR taking my 
medicines as 
prescribed 
     
Taking my medicines 
as prescribed is 
harmful to me 
     
I know enough about 
my medicines to 
decide whether to 
take them 
     
I am able to put a 
system in place to 
help me order, collect 
AND/OR take my 
medicines as 
prescribed 
     
I can easily be 
distracted from taking 
my medicines 
     
I have the support 
that I need from 
others to help me 
take my medicines 
as prescribed 
     
I can easily get to my 
local pharmacy or 
surgery to collect my 
medicines 
     
Taking my medicines 
as prescribed is an 
unwelcome reminder 
of my illness 
     
Taking my medicines 
as prescribed is high 
on my list of priorities 
     
Taking my medicines 
as prescribed does 
not fit with my daily 
routine 
     
If I experienced 
difficulties with my 
medicines I would 
know what to do to 
overcome these 
     
Statement Strongly 
agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
disagree 
If I don’t take my 
medicines as 
prescribed my 
condition will get 
worse 
     
I know about the 
different ways to 
order and collect my 
repeat prescriptions 
     
I am able to identify 
each of my 
medicines from 
others 
     
I have my own 
reasons for not 
taking my medicines 
as prescribed 
     
I worry that other 
people will think 
badly of me if I take 
my medicines 
     
I struggle to take my 
medicines as 
prescribed when 
there are changes to 
my daily routine 
     
I feel positive about 
taking my medicines 
as prescribed 
     
I intend to take my 
medicines as 
prescribed  
     
Life gets in the way 
of me taking my 
medicines as 
prescribed 
     
I could easily 
overcome any 
difficulties that arise 
from side effects of 
my medicines 
     
I don’t think my 
medicines will help 
me with my condition  
     
Thank you for your time 
 
 
 
 
 
 
 
 
Appendix 5.12  Summary of ‘cost of medicines’ adherence 
barrier
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Appendix 5.12  Summary of the adherence barrier ‘cost of medicines’ 
Aspect of barrier Corresponding 
behavioural domain 
Rationale 
Not having sufficient funds to pay for prescription 
Having restricted funds so that a choice has to be made 
between prescription and something else e.g. food or 
clothing  
Goal conflicts 
Having sufficient funds but not wanting to pay for 
prescription due to preference for spending money on 
alternatives 
Motivation & 
goals 
Preference for spending money on alternatives 
demonstrates a lack of motivation to adhere 
Restricted funds may mean a patient wants to take 
their medicines as prescribed but has to choose to 
prioritise spending the money on something else 
Feeling aggrieved at having to pay a prescription charge  
Emotions 
(social 
influences) 
Feeling aggrieved is a negative emotion. Could stem 
from having to pay when others do not (social 
influence)  
Questioning whether medicine may be inferior to a more 
expensive treatment 
Questioning inferiority of medicine may cause doubts 
about its efficacy and benefit 
Questioning whether medicine represents best value for 
money or ‘cheated’ through knowing medicine costs less 
than prescription charge 
Emotions 
Feeling cheated or aggrieved relates to negative 
emotions 
A lack of funds to pay for a prescription demonstrates 
an environmental constraint  
Environmental 
constraints 
Beliefs about 
consequences 
Aspect of ‘cost of medicines’ 
barrier 
Strategy for incorporation into 
questionnaire 
Not having sufficient funds to pay for 
prescription 
 
Unlikely to represent genuine barrier for chronic 
condition such as cardiovascular disease in UK 
populations therefore not included 
Having restricted funds so that a 
choice has to be made between 
prescription and something else e.g. 
food or clothing  
New statement included in goal conflicts 
domain; ‘I have to choose between paying for 
my prescription and paying for other things that 
are important to me’ 
Having sufficient funds but not wanting 
to pay for prescription due to 
preference for spending money on 
alternatives 
Relates to ‘motivation and goals’ domain, as 
patient has resources to pay for medicines but 
would prefer not to (not motivated to). Covered 
by ‘I am motivated…’ and ‘I intend to…’ 
statements 
Feeling aggrieved at having to pay a 
prescription charge  
Covered by generic statement in ‘emotions’ 
domain relating to experience of negative 
emotions 
Questioning whether medicine 
represents best value for money or  
through knowing medicine costs less 
than prescription charge 
Covered by generic statement in ‘emotions’ 
domain relating to experience of negative 
emotions 
Questioning whether medicine may be 
inferior to a more expensive treatment 
Covered in ‘belief about consequences’ domain 
by statement relating to medicines being an 
effective treatment 
Table A5.12 Incorporation of barrier aspects into questionnaire 
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Appendix 5.13 Overall summary of refined questionnaire 
statements following research colleagues 
feedback 
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Behavioural domain Questionnaire statement 
I know how to take my medicines as 
prescribed 
Knowledge 
Knowledge 
Knowledge 
Skills 
Skills 
I know enough about my medicines to decide 
whether to take them 
I have the information that I need to be able to 
order and collect my prescriptions with ease 
I am able to take my medicines as prescribed 
I have a system in place to help me order, 
collect and take my medicines as prescribed 
Adherence barriers represented 
• Not knowing how (and when) to take medicines  
• Not knowing how medicines will work, why they were 
prescribed, how they will be beneficial, risks of side effects 
• Not knowing how to order and collect prescriptions 
• Not knowing about variety of ordering & collection services 
available to make system as ‘barrier free’ as possible 
• Not being physically or mentally able to take medicines  
• Not being able to access medicines from packaging 
• Not being able to swallow medicines  
• Lack of organisational and forward planning skills 
• Not having a system in place to manage medicines 
• Not having a ‘medicines taking routine’  
Skills I have difficulties telling my medicines apart 
from each other 
• Inability to identify and differentiate between different 
medicines  
Appendix 5.13 Summary of changes to barrier statements following feedback from research colleagues 
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Memory, attention & 
decision making processes 
Behavioural domain Questionnaire statement Adherence barriers represented 
I remember to take my medicines as 
prescribed 
• Memory deficits (forgetting to take medicines) 
I am easily distracted from taking my 
medicines 
• Being easily distracted and then taking medicines 
incorrectly or forgetting to take (lack of attention) 
I remember to order and collect my 
medicines on time 
• Memory deficits (forgetting to order & collect 
prescriptions) 
Social influences I trust my doctor(s) with decisions about my healthcare • Lack of trust in prescriber 
Social influences 
I have the support that I need from others to 
help me take my medicines as prescribed • Lack of social support 
Memory, attention & 
decision making processes 
Memory, attention & 
decision making processes 
Social influences 
I worry about what other people would think 
of me if they knew I took medicines 
• Fear of judgement, discrimination or social stigma 
• Fear of being treated differently from peers 
• Cultural and religious norms and expectations 
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Environmental 
constraints 
Environmental 
constraints 
Behavioural domain Questionnaire statement Adherence barriers represented 
I can easily get hold of my medicines 
from my pharmacy or surgery 
• Physical and/or transport difficulties getting to pharmacy/surgery to 
collect prescriptions 
• Inconvenient pharmacy/surgery opening hours 
• Pharmacy not stocking medicine 
I struggle to take my medicines as 
prescribed when there are changes 
to my daily routine 
• Environmental changes and changes to daily routine which impede 
medicines taking  
Environmental 
constraints 
My pharmacy or surgery provides an 
efficient service for ordering and 
collecting my medicines 
• Problems with the pharmacy not stocking a medicine 
• Problems with the pharmacy closing too early/ not opening at 
weekends/ closing at lunchtimes etc. 
• Problems with pharmacy incompetence e.g. losing the prescription, 
giving it out to the wrong person 
• Problems with the prescription not being ready when expected, e.g. 
when a managed repeat or order and collection system has failed 
Emotions 
Having to take my medicines makes 
me feel negative emotions (e.g. 
frustration, anger, embarrassment) 
• Experience of negative emotions associated with medicines taking  
Appendix 5.13 (continued)  Summary of changes to barrier statements following feedback from research colleagues 
• Medicines taking seen as negative reminder of illness Emotions Taking my medicines as prescribed is 
an unwelcome reminder of my illness 
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Behavioural domain Questionnaire statement Adherence barriers represented 
• Medicines taking seen as a burden Emotions Taking my medicines as prescribed is a burden to me 
• A lack of motivation to adhere Motivation & goals I am motivated to take my medicines as prescribed 
• Not seeing medicines taking as a priority Motivation & goals Taking my medicines as prescribed is high on my list of priorities 
• A lack of intention to adhere Motivation & goals I intend to take my medicines as prescribed 
• Cost of medicines (limited financial resources 
enforcing a choice between prescription and 
Goal conflicts 
I have to choose between paying for my 
prescription and paying for other things that are 
important to me 
• Having a busy lifestyle 
• Having other priorities which make medicines taking at 
specific times difficult  
Goal conflicts Taking my medicines as prescribed does not fit 
with my daily routine 
Appendix 5.13 (continued)  Summary of changes to barrier statements following feedback from research colleagues 
• Being too busy to order and collect prescription 
• Having other priorities which impede ordering and 
collecting prescriptions 
Goal conflicts Life gets in the way of ordering and collecting my 
medicines on time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adherence barriers represented Questionnaire statement Behavioural domain 
• A lack of confidence in ability to adhere and manage 
medicines 
Beliefs about 
capabilities 
I feel confident about ordering, collecting and 
taking my medicines as prescribed 
• Confidence to overcome difficulties with taking medicines 
Beliefs about 
capabilities 
If I experienced difficulties with my medicines 
I would know how to overcome these 
• Perceived inability to cope with medicine related changes  Beliefs about 
capabilities 
I don’t think I could cope if my medicines or 
doses kept changing 
• Fear that medicines will be (are) harmful Beliefs about 
consequences 
I worry about the harmful effects of taking my 
medicines or their side effects  
• Not believing that there is a need for treatment 
• Denial of illness  
• Failure to accurately perceive susceptibility to worsening 
health without treatment  
• Failure to recognise link between medicines taking and 
improved health (doubting efficacy of medicines) 
Beliefs about 
consequences 
If I don’t take my medicines as prescribed, my 
condition will get worse 
• Decision making process justified by belief about 
consequences (or lack of consideration of consequences) 
Beliefs about 
consequences 
I have my reasons for not taking my 
medicines as prescribed 
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Appendix 5.14 Prototype questionnaire sent to consultation 
exercise participants for feedback 
  


• This questionnaire will help us to 
understand more about any difficulties 
that you may have with taking your 
medicines 
• There are no right or wrong answers to 
the questions asked, we’re interested 
in your honest views 
• The questionnaire will take 
approximately  5-10 minutes to 
complete  
The Identification of Medication 
Adherence Barriers (IMAB) 
Questionnaire 
The Identification of Medication Adherence Barriers (IMAB) Questionnaire 
Many people often struggle to take their medicines as prescribed, for many 
different reasons.   We understand that different things can ‘get in the way’ of 
following your doctors recommendations about taking your medicines. 
This questionnaire lists 30 different statements about taking your medicines.   
For each of the statements below, please tick ( ) the box that best reflects your 
level of agreement with the statement.  Please only tick ONE box per statement. 
Some of the statements may appear to be similar to others but please be sure 
to respond to each statement.  
 Statement S. 
agree 
A Neither 
agree nor 
disagree 
Disagree S. 
disagree 
1 I know how to take my 
medicines as prescribed  
     
2 I am able to take my 
medicines as prescribed 
     
3 I remember to take my 
medicines as prescribed 
     
4 I trust my doctor(s) with 
decisions about my 
healthcare 
     
5 I can easily get hold of 
my medicines from my 
pharmacy or surgery 
     
6 Having to take my 
medicines makes me feel 
negative emotions (e.g. 
frustration, anger, 
embarrassment) 
     
7 I am motivated to take 
my medicines as 
prescribed 
     
8 I have to choose between 
paying for my 
prescriptions and paying 
for other things that are 
important to me 
     
9 I feel confident about 
ordering, collecting and 
taking my medicines as 
prescribed 
     
10 I worry about the harmful 
effects of taking my 
medicines or their side 
effects 
     
 Statement S. 
agree 
A Neither 
agree nor 
disagree 
Disagree S. 
disagree 
11 I know enough about my 
medicines to decide 
whether to take them 
     
12 I have a system in place 
to help me order, collect 
and take my medicines 
as prescribed 
     
13 I am easily distracted 
from taking my medicines 
     
14 I have the support that I 
need from others to help 
me take my medicines as 
prescribed 
     
15 I struggle to take my 
medicines as prescribed 
when there are changes 
to my daily routine 
     
16 Taking my medicines as 
prescribed is an 
unwelcome reminder of 
my illness 
     
17 Taking my medicines as 
prescribed is high on my 
list of priorities 
     
18 Taking my medicines as 
prescribed does not fit 
with my daily routine 
     
19 If I experienced 
difficulties with my 
medicines I would know 
how  to overcome these 
     
20 If I don’t take my 
medicines as prescribed I 
think my condition will get 
worse 
     
21 I have the information 
that I need to be able to 
order and collect my 
prescriptions with ease 
     
22 I have difficulties telling 
my medicines apart from 
each other 
     
23 I remember to order and 
collect my medicines on 
time 
     
 Statement S. 
agree 
A Neither 
agree nor 
disagree 
Disagree S. 
disagree 
24 I worry about what other 
people would think of me 
if they knew I took 
medicines  
     
25 My Pharmacy or surgery 
provides an efficient 
service for ordering and 
collecting my medicines 
     
26 Taking my medicines as 
prescribed is a burden to 
me 
     
27 I intend to take my 
medicines as prescribed  
     
28 Life gets in the way of me 
taking my medicines as 
prescribed 
     
29 I don’t think I could cope 
if my medicines or doses 
kept changing 
     
30 I have my reasons for not 
taking my medicines as 
prescribed 
     

Thank you for your time 
 
 
 
 
 
 
 
 
 
*Note abbreviations and smaller font have been used in this replication to 
enable production in thesis format 
 
 
 
 
 
 
 
 
 
 
Appendix 5.15 Consultation exercise participants ‘feedback 
booklet’
Identification of Medication Adherence Barriers (IMAB) Questionnaire – Focus Group Participant Feedback Document 
Section one – feedback on the questionnaire statements 
• The thirty statements below are taken directly from the prototype questionnaire that you have been sent.  They have been replicated on this form 
to provide you with the space to give any comments, concerns or feedback.  Please feel free to provide as much detail as you wish as every piece 
of information that we gather will be really helpful for improving the questionnaire. 
 
• As you read each statement, please think about how you would respond as a patient yourself, if you want to tick the boxes as if you were filling it 
for real, please feel free to do so.  Please use the comments/feedback box to tell us what you thought as you read the statement.  We’re 
particularly interested to know if the statement was clear; did it make sense to you, did you know how to answer it and how easy or difficult was 
this?  There’s extra space at the end of this form to write any further comments if you haven’t got enough room here.  
 
 Statement Strongly 
agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
disagree 
Comments/feedback 
1 I know how to take my 
medicines as prescribed  
 
      
2 I am able to take my medicines 
as prescribed 
 
      
3 I remember to take my 
medicines as prescribed 
 
      
4 I trust my doctor(s) with 
decisions about my healthcare 
 
      
 Statement Strongly 
agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
disagree 
Comments/feedback 
5 I can easily get hold of my 
medicines from my pharmacy 
or surgery 
      
6 Having to take my medicines 
makes me feel negative 
emotions (e.g. frustration, 
anger, embarrassment) 
      
7 I am motivated to take my 
medicines as prescribed 
 
      
8 I have to choose between 
paying for my prescriptions and 
paying for other things that are 
important to me 
      
9 I feel confident about ordering, 
collecting and taking my 
medicines as prescribed 
      
10 I worry about the harmful 
effects of taking my medicines 
or their side effects 
      
11 I know enough about my 
medicines to decide whether to 
take them 
      
 Statement Strongly 
agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
disagree 
Comments/feedback 
12 I have a system in place to help 
me order, collect and take my 
medicines as prescribed 
      
13 I am easily distracted from 
taking my medicines 
 
      
14 I have the support that I need 
from others to help me take my 
medicines as prescribed 
      
15 I struggle to take my medicines 
as prescribed when there are 
changes to my daily routine 
      
16 Taking my medicines as 
prescribed is an unwelcome 
reminder of my illness 
      
17 Taking my medicines as 
prescribed is high on my list of 
priorities 
      
18 Taking my medicines as 
prescribed does not fit with my 
daily routine 
      
19 If I experienced difficulties with 
my medicines I would know 
how  to overcome these 
      
 Statement Strongly 
agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
disagree 
Comments/feedback 
20 If I don’t take my medicines as 
prescribed I think my condition 
will get worse 
      
21 I have the information that I 
need to be able to order and 
collect my prescriptions with 
ease 
      
22 I have difficulties telling my 
medicines apart from each 
other 
      
23 I remember to order and collect 
my medicines on time 
 
      
24 I worry about what other people 
would think of me if they knew I 
took medicines  
      
25 My Pharmacy or surgery 
provides an efficient service for 
ordering and collecting my 
medicines 
      
26 Taking my medicines as 
prescribed is a burden to me 
 
      
 Statement Strongly 
agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
disagree 
Comments/feedback 
27 I intend to take my medicines 
as prescribed  
 
      
28 Life gets in the way of me 
taking my medicines as 
prescribed 
      
29 I don’t think I could cope if my 
medicines or doses kept 
changing 
      
30 I have my reasons for not 
taking my medicines as 
prescribed 
      
 
 
 
 
 
 
 
 
Section two – general feedback on the questionnaire 
• We’re keen to be sure that the questionnaire has a professional feel but that the instructions are clear and easy to understand and that overall the 
questionnaire is as ‘user-friendly’ as possible.  The questions below relate to these points, please provide as much detail as possible.  All points 
are important, it doesn’t matter if they may seem a small or silly point to you, we’re really want to hear any thoughts that you may have, no matter 
how big or small they are. 
 
1) Do you have any comments on the design or layout of the of the questionnaire?  Is the front cover OK? Is the font size acceptable? 
 
 
 
 
 
 
2) Do you have any comments on the instructions for completion? Is it clear what you are expected to do? Would a patient understand what the 
questionnaire is about? Do you think our estimate of 5-10 minutes for completion is accurate (if not what would be a more realistic time frame)? 
 
 
 
 
 
 


3) Do you have any other comments about the questionnaire?  Can you think of any ways to improve it? 
 
 
 
 
 
Section three – specific questions 
• Based on the feedback that we’ve already received from other researchers and some healthcare providers, there are a few specific points that 
we’d really value your feedback on. 
 
1) Statement number 29 is ‘I don’t think I could cope if my medicines or doses kept changing’.  Is the word ‘doses’ here OK? Is it clear and easily 
understood? 
 
 
 
 
 
 


2) Statement number 2 is ‘I am able to take my medicines as prescribed’.  We had hoped that this statement would cover factors such as problems 
with swallowing the tablets or getting them out of their packets (or dropping them!).  If you were a patient experiencing these kinds of problem, 
would you think to disagree with this statement?  What did you think this statement meant? 
 
 
 
 
 
 
3) Statement number 8 is ‘I have to choose between paying for my prescriptions and paying for other things that are important to me’.  How did you 
fill in this statement if you do not pay for your prescription?  Did you find that this statement was really difficult for you complete, would a ‘not 
applicable’ option have made it easier if you do not pay? 
 
 
 
 
 
 
 


 
4) Statement 4 mentions trust in your doctor(s) and similarly, we mention ‘following your doctor’s recommendations...’ in the introduction.  Do you 
find the term ‘doctors’ acceptable or is it too specific?  Imagine you had your medicines prescribed by a nurse rather than a doctor or your 
pharmacist had given you recommendations rather than the doctor, would this statement then be confusing to you?  We wondered whether the 
term ‘prescriber’ or ‘healthcare provider’ would work instead of ‘doctor’.  How do you find these terms, are they clear and understandable to you or 
do you think they would cause confusion? 
 
 
 
 
Section four – overall summary 
• Thank you for taking the time to provide this feedback, it will be invaluable in the questionnaire development.  The findings from the focus group 
were also incredibly useful.  In summary, we just wanted to ask if there were any other comments you wanted to provide, be it about the 
questionnaire, or the research project in general.  If you have any further comments, please use the space below to record these: 
 
 
 
 
 
Thank you so much for your time and feedback


 
 
 
 
 
 
 
 
 
 
Appendix 5.16 Covering letter sent with ‘feedback 
booklet’ to consultation exercise 
participants 
  
 
 
 
<Participant name> 
<Participant address 1> 
<Participant address 2> 
<Participant address 3> 
<Participant address 4> 
<Date> 
Dear participant, 
Thank you so much for agreeing to give your feedback on the prototype questionnaire 
that we’ve been working on.  I’m so pleased to have your continued support with this 
important piece of research. 
Since the focus groups that you participated in, we have been busy working through 
the recordings made and analysing the discussions that were held.  The focus groups 
were a real success and a pivotal part of this research thanks to your views, opinions 
and honesty.  Using the work from the focus groups we have been able to develop a 
prototype questionnaire, which we would now like to receive your feedback on. 
As discussed, you will find enclosed a full colour copy of the questionnaire and an 
additional document titled ‘focus group participant feedback form’.  Once you have read 
through the questionnaire, please work through the feedback form where you will be 
guided through specific points that we would value your thoughts on. 
I hope that the feedback form will be straightforward for you to complete but if there is 
anything that is not clear, or you feel it would be easier to discuss a matter with me 
directly rather than leave written feedback, then please do not hesitate to contact me.  
My contact details can be found at the end of this letter. 
Thank you once again for your valued support, 
With kindest regards and best wishes, 
 
 
 
 
 
Claire Easthall MPharm, MRPharmS 
Research Pharmacist & PhD Student 
School of Pharmacy 
University of East Anglia 
Norwich Research Park 
Norwich, Norfolk, NR4 7TJ 
c.easthall@uea.ac.uk 
01603 591973/07807 389493 
 
 
 
 
 
 
 
Appendix 5.17 Summary of recommended changes to 
questionnaire following consultation 
exercise participant’s feedback  
 
Table A5.16  Summary of changes made following feedback from consultation exercise participants 
Questionnaire statement Participant suggested changes Agreed changes Rationale 
1) I know how to take my 
medicines as prescribed 
‘I know how and when’ might be better, 
as prescribed could be confusing 
No changes necessary As prescribed deemed appropriate and ‘how and when’ 
should be avoided due to ‘double loading’  
3) I remember to take my 
medicines as prescribed 
Add ‘always’ No changes necessary 5 point Likert scale allows for strength of frequency to be 
conveyed e.g. always remember = strongly agree, 
mostly remember = agree etc. 
5) I can easily get hold of 
my medicines from my 
pharmacy or surgery 
‘Prescribed medicines’? ‘I can easily get hold of my 
prescribed medicines from 
the pharmacy or surgery’ 
Specification of ‘prescribed medicines’ useful to 
differentiate from purchased over-the-counter medicines. 
Specificity of ‘my’ pharmacy or surgery is unnecessary 
as patients can choose to go to any pharmacy  
6)  Having to take my 
medicines makes me feel 
negative emotions (e.g. 
frustration, anger, 
embarrassment) 
‘Have’ negative emotions not feel I have negative emotions 
(e.g. frustration, anger, 
embarrassment) about 
taking my medicines as 
prescribed.  
According to Scherer in 2005, a feeling is the subjective 
experience of emotional state once it has occurred1. 
Emotions are therefore something that are experienced 
(had) rather than felt. Wording chosen to ensure there is 
no inference of medicines causing negative emotions as 
side effects, as identified in consultation exercises 
9) I feel confident about 
ordering, collecting and 
taking my medicines as 
prescribed  
None I feel confident about all 
aspects of managing 
(ordering, collecting and 
taking) my medicines 
Research team agreed that ‘AND’ conjunction had the 
potential to be misleading and cause response 
difficulties.  Statement rephrased to focus on confidence 
in managing medicines as this reflects the barrier and 
participant used terminology well. 
10)  I worry about the 
harmful effects of taking 
my medicines or their side 
effects 
‘I worry about taking my medicines or 
having side effects’ 
 
I worry about unwanted 
effects (e.g. harmful 
effects or side effects) 
from taking my medicines 
‘Worry about taking’ could be quite ambiguous as this 
could include many components, plus worrying about 
harmful effects is important.  Re-phrased to improve 
clarity  
Table A5.16 (continued) Summary of changes made following feedback from consultation exercise participants 
Questionnaire statement Participant suggested changes Agreed changes Rationale 
11) I know enough about my 
medicines to decide whether 
to take them  
‘I know enough about my medicines to 
decide whether to take them or not’ 
 
No changes necessary The addition of ‘or not’ adds greater complexity to 
the sentence without any justifiable benefit and is 
therefore best avoided 
13)  I am easily distracted from 
taking my medicines 
I wonder if you mean ‘do you forget’. No changes necessary Forgetting and being easily distracted are similar 
but different constructs and should therefore 
remain distinct 
14)  I have the support that I 
need from others to help me 
take my medicines as 
prescribed 
• Add a not applicable options as 
patients may not need support 
• Two separate statements may be 
necessary, whether they need any 
help and whether its available 
‘If I needed support from 
others to take my 
medicines as prescribed, 
I could get it’ 
Worded amended to facilitate completion for 
patients who do not need support.  ‘To help me’ 
removed as considered unnecessary and removal 
facilitates easier readability.  
15) I struggle to take my 
medicines as prescribed when 
there are changes to my daily 
routine 
Difficult to answer if you haven’t 
experienced this therefore might need 
to be changed 
‘Changes to my daily 
routine would not 
interfere with taking my 
medicines as prescribed’ 
This barrier relates to environment constraints and 
therefore needs to establish whether changes to 
routine acts as a barrier to adherence.  Phrased to 
enable easier completion for patients who have not 
experienced changes to their routine 
16)  Taking my medicines as 
prescribed is an unwelcome 
reminder of my illness 
‘Taking my medicines as prescribed is 
an unwelcome reminder of my illness or 
condition’ 
‘Taking my medicines as 
prescribed is an 
unwelcome reminder of 
my condition’ 
‘Condition’ and ‘illness’ are synonymous terms, but 
condition may be more appropriate for preventative 
medication as patients may not perceive 
themselves as having an illness 
18)  Taking my medicines as 
prescribed does not fit with my 
daily routine 
‘Taking my medicines as prescribed 
does not fit in with my daily routine’ 
No changes necessary Recommended change relates to minor semantics 
which does not improve the statement but may 
reduce readability 
Table A5.16 (continued) Summary of changes made following feedback from consultation exercise participants 
References for table A5.19  1) Scherer, K. R. (2005). "What are emotions? And how can they be measured?" Social science information 44(4): 695-729. 
Questionnaire statement Participant suggested changes Agreed changes Rationale 
19)  If I experienced difficulties 
with my medicines I would know 
how  to overcome these 
‘I know how to overcome difficulties with 
my medicines’, as  if-then statements 
can be difficult 
‘I am confident that I could 
find ways to solve any 
difficulties that I have with 
taking my medicines as 
prescribed’ 
Suggested change and original statement relate 
to knowledge not beliefs about capabilities and 
are therefore not appropriate.  New statement 
worded to reflect belief about capability.  
20)  If I don’t take my medicines 
as prescribed I think my 
condition will get worse 
‘My condition will get worse if I don’t 
take my medicines as prescribed’; 
avoids if-then statements 
No changes necessary  Whilst recommended change lessens impact of 
‘if-then’ statement it does not resolve the issue.  
Moreover, recommended change detracts from 
emphasis on belief about consequences.  
21)  I have the information that I 
need to be able to order and 
collect my prescriptions with 
ease 
‘I have the information that I need to be 
able to easily order and collect my 
prescriptions’ 
‘I have the information that I 
need to be able to easily 
order and collect my 
prescriptions’ 
Recommend change improves flow of sentence 
slightly and was therefore implemented 
22)  I have difficulties telling my 
medicines apart from each 
other 
Needs amending as only applicable to 
patients who are taking more than one 
medicine 
‘Telling my medicines apart 
from each other would not be 
a problem for me’ 
Re-phrased to ease completion for patients who 
do not have more than one medicine 
24)  I worry about what other 
people would think of me if they 
knew I took medicines 
‘...took medicines for an illness or 
condition’ 
No changes necessary Suggested change adds unnecessary 
complexity to statement 
25)  My Pharmacy or surgery 
provides an efficient service for 
ordering and collecting my 
medicines 
‘Pharmacy’ should not have a capital ‘P’ ‘My pharmacy or surgery 
provides an efficient service 
for ordering and collecting my 
medicines’ 
A well spotted genuine typographic error 
26)  Taking my medicines as 
prescribed is a burden to me 
‘Necessary burden’? No change necessary  Inappropriate and unnecessary addition  
